{"meta":{"query_hash":"6de10d7fb825","filters":{"venue":"Journal for ImmunoTherapy of Cancer"},"cohort_total":261,"direct_labels_cover":0,"predictions_cover":261,"exported":261,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/6de10d7fb825","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+for+ImmunoTherapy+of+Cancer"},"results":[{"id":"W1517732299","doi":"10.1186/s40425-015-0066-0","title":"Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute","keywords":"Ipilimumab; Medicine; Liver transplantation; Melanoma; Transplantation; Metastatic melanoma; Oncology; Internal medicine; Cancer; Immunotherapy; Cancer research","score_opus":0.020230095732515482,"score_gpt":0.3295934070659579,"score_spread":0.3093633113334424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1517732299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814464,0.016169209,0.00044231126,0.0010094126,0.00013717555,0.00058753206,0.00003632912,0.0000027834596,0.00016885354],"genre_scores_gemma":[0.9836422,0.014903114,0.0010085248,0.0002607754,0.00005924974,0.000016566773,0.0000037093812,0.000016080736,0.000089773945],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989262,0.000055914734,0.0005477499,0.00009259601,0.000246198,0.00013130707],"domain_scores_gemma":[0.9991751,0.00017467127,0.0003092165,0.00012711145,0.00017506257,0.000038881626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069591845,0.00010508849,0.00035452683,0.0001356492,0.000034850837,0.0000057140915,0.00010145815,0.00004991657,0.000031951215],"category_scores_gemma":[0.000025215919,0.00006860367,0.00013419645,0.00019702587,0.00006107279,0.00008075929,0.0000032641224,0.00009690248,8.1234965e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12052128,0.0002035777,0.00694514,0.0003411545,0.00024534846,0.000005206236,0.02171,0.00024390059,0.2835704,0.000029405845,0.000159284,0.5660253],"study_design_scores_gemma":[0.075836964,0.0069531538,0.6948488,0.0020642264,0.00032926898,0.000300286,0.0032531864,0.00013931753,0.19953966,0.00013473057,0.016313538,0.0002868712],"about_ca_topic_score_codex":0.0003325869,"about_ca_topic_score_gemma":0.00013482846,"teacher_disagreement_score":0.68790364,"about_ca_system_score_codex":0.000089379784,"about_ca_system_score_gemma":0.0001584405,"threshold_uncertainty_score":0.27975768},"labels":[],"label_agreement":null},{"id":"W1924107806","doi":"10.1186/s40425-015-0085-x","title":"Immune monitoring technology primer: flow and mass cytometry","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Single-cell and spatial transcriptomics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Flow cytometry; Mass cytometry; Fluorescence; Immune system; Antibody; Fluorescent labelling; Cytometry; Multiplex; Computational biology; Molecular biology; Chemistry; Immunology; Biology; Bioinformatics; Biochemistry; Physics","score_opus":0.021556233595377113,"score_gpt":0.30390766704808864,"score_spread":0.2823514334527115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1924107806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9006755,0.0840676,0.013535982,0.00027516045,0.0012490661,0.00012373972,0.000012114552,0.000007517955,0.000053322467],"genre_scores_gemma":[0.9755425,0.011555033,0.01174257,0.000050005212,0.0005374101,0.000019488642,0.0000033965362,0.00003661326,0.0005130125],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99934417,0.000013832992,0.00024644958,0.00012155321,0.000102137376,0.0001718347],"domain_scores_gemma":[0.99945855,0.0000067233464,0.00014133005,0.00014062207,0.00020039079,0.000052404543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021044334,0.00011033928,0.00018658096,0.000097277574,0.000071536546,0.000020563364,0.00015490403,0.00014782604,0.000005753302],"category_scores_gemma":[0.000022738766,0.00009710327,0.00009283474,0.000086850545,0.00007797313,0.0000063541524,0.000013919689,0.00011731155,2.3181748e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053523266,0.00002623674,0.019115938,0.000012302592,0.00016369646,5.286617e-7,0.00005895804,0.000055668574,0.9212587,0.0000054907055,0.00011741464,0.058649853],"study_design_scores_gemma":[0.0024199039,0.000635559,0.0011468452,0.000044682813,0.00002044077,0.000029668774,0.00011985154,0.000069999114,0.93026567,0.0003586862,0.06474873,0.00013998461],"about_ca_topic_score_codex":0.000017370956,"about_ca_topic_score_gemma":0.0000018038696,"teacher_disagreement_score":0.07486697,"about_ca_system_score_codex":0.000028488193,"about_ca_system_score_gemma":0.00011017021,"threshold_uncertainty_score":0.39597565},"labels":[],"label_agreement":null},{"id":"W2010401950","doi":"10.1186/2051-1426-1-s1-p27","title":"ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors","year":2013,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Anaplastic lymphoma kinase; Cancer research; Tyrosine kinase; Lymphoma; Neuroblastoma; Anaplastic large-cell lymphoma; Medicine; Pathology; Biology; Internal medicine; Cell culture; Receptor","score_opus":0.045372139869788504,"score_gpt":0.35913235344989697,"score_spread":0.31376021358010847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010401950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.914506,0.079018265,0.000933958,0.0012084802,0.0009752995,0.003206579,0.000084921216,0.00001800706,0.000048476373],"genre_scores_gemma":[0.8829298,0.10705494,0.0008567886,0.000279068,0.0012482225,0.00082649756,0.000011517183,0.00014393576,0.006649241],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797773,0.000041221687,0.0007212117,0.00022885471,0.00049035286,0.00054064975],"domain_scores_gemma":[0.9979968,0.00045591148,0.00052800134,0.0004014507,0.00042640124,0.0001914298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012490134,0.00030963751,0.00065821287,0.00025305164,0.00023052587,0.000054379103,0.00025929973,0.0000751844,0.00064669043],"category_scores_gemma":[0.000018534336,0.00018419225,0.0006929083,0.0002469141,0.00010949159,0.0001378454,0.000009138665,0.00009018595,0.0000100081525],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012021763,0.0024131539,0.004094098,0.00017480085,0.004965435,0.000021030655,0.0012984804,0.00015891551,0.070523135,0.00004710109,0.014668753,0.88961333],"study_design_scores_gemma":[0.1010323,0.046621736,0.18704137,0.00055052544,0.0018213888,0.00032053515,0.000613855,0.0008499796,0.16350028,0.001558028,0.49539578,0.0006942171],"about_ca_topic_score_codex":0.00043331017,"about_ca_topic_score_gemma":0.000023115726,"teacher_disagreement_score":0.8889191,"about_ca_system_score_codex":0.0004186403,"about_ca_system_score_gemma":0.00064497016,"threshold_uncertainty_score":0.7511142},"labels":[],"label_agreement":null},{"id":"W2030838608","doi":"10.1186/2051-1426-2-s3-o3","title":"Toward cell transfer immunotherapy against patient-specific mutations in gastrointestinal cancers","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Immunotherapy; Medicine; Somatic cell; Cancer research; Melanoma; Metastatic melanoma; Gastrointestinal cancer; Cancer; Colorectal cancer; Immunology; Internal medicine; Biology; Gene; Genetics","score_opus":0.02094606342333718,"score_gpt":0.2891011124387091,"score_spread":0.26815504901537196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030838608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9617922,0.021323148,0.011938663,0.0015248721,0.0010670152,0.0011287467,0.00007898693,0.00003953329,0.0011068387],"genre_scores_gemma":[0.9794901,0.013641935,0.003977693,0.0017417823,0.00036439495,0.00019492561,0.00002303943,0.000117980526,0.000448128],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99742657,0.0000953791,0.0011267258,0.0003144235,0.00047446467,0.00056241197],"domain_scores_gemma":[0.9986994,0.00015259271,0.00034172132,0.00032332703,0.00035892095,0.00012402379],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052928686,0.00035364483,0.00068732246,0.0004155356,0.00017255565,0.00005395784,0.00025086908,0.00011256359,0.00060045964],"category_scores_gemma":[0.000015108866,0.0003045373,0.0006307262,0.00040757348,0.00021531903,0.00019684187,0.000006687594,0.00045587652,0.0000025999584],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016213527,0.00035917116,0.00466021,0.00014241404,0.00027816178,0.000011249705,0.00276671,0.0007648841,0.6090558,0.00005269798,0.0013767267,0.36431843],"study_design_scores_gemma":[0.07210882,0.010526521,0.045777712,0.004100943,0.00013974328,0.00065924745,0.0027643957,0.0011336807,0.23004621,0.0007626741,0.6305563,0.0014237516],"about_ca_topic_score_codex":0.00028818642,"about_ca_topic_score_gemma":0.000080820995,"teacher_disagreement_score":0.62917954,"about_ca_system_score_codex":0.00077254337,"about_ca_system_score_gemma":0.00059024605,"threshold_uncertainty_score":0.9999407},"labels":[],"label_agreement":null},{"id":"W2056397238","doi":"10.1186/2051-1426-2-s3-p17","title":"Tri-functional T cell receptor antigen coupler (Tri-TAC): a novel method to direct T cells against tumors","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Modular design; Antigen; Receptor; T cell; Cell biology; Cancer research; Biology; Immunology; Computer science; Chemistry; Immune system; Genetics","score_opus":0.034115129421557464,"score_gpt":0.360206308257852,"score_spread":0.3260911788362945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056397238","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7824463,0.009160543,0.18409541,0.0056853,0.0052565997,0.003931692,0.00033024882,0.00011946249,0.008974407],"genre_scores_gemma":[0.32305685,0.02952564,0.25156945,0.022847105,0.015666535,0.0012820225,0.00014897913,0.001421791,0.35448164],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970043,0.00013784552,0.00083277986,0.00038893643,0.0010015123,0.000634633],"domain_scores_gemma":[0.99749,0.00048670938,0.00043628732,0.00042649236,0.00081695535,0.00034358457],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002317004,0.0003342258,0.00088935153,0.00046535174,0.00023493895,0.00006982345,0.00031806255,0.00016316246,0.0064526163],"category_scores_gemma":[0.000082371786,0.00027281124,0.0006678148,0.00047641006,0.00008348015,0.0001273796,0.00003015436,0.00054546434,0.00003000768],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070211613,0.00032093353,0.00056180515,0.00007673389,0.00045196296,0.0000016492413,0.00034627115,0.00078867766,0.8701937,0.0000119160795,0.020690387,0.099534765],"study_design_scores_gemma":[0.006448164,0.0009987215,0.0013397725,0.00016764343,0.00003536367,0.000022049899,0.000051132218,0.00052167854,0.4689899,0.000023155582,0.52119917,0.00020324583],"about_ca_topic_score_codex":0.00013594932,"about_ca_topic_score_gemma":0.000012335201,"teacher_disagreement_score":0.5005088,"about_ca_system_score_codex":0.0004759136,"about_ca_system_score_gemma":0.00064025586,"threshold_uncertainty_score":0.9999724},"labels":[],"label_agreement":null},{"id":"W2058130577","doi":"10.1186/2051-1426-2-s2-p36","title":"P62. Effectiveness of melatonin, IL-25 and siRNA IL-17B in growth control of breast cancer cell lines","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Melatonin; Proinflammatory cytokine; Cancer research; Cytokine; Medicine; Apoptosis; Breast cancer; Biology; Immunology; Cancer; Internal medicine; Inflammation","score_opus":0.006679934714977232,"score_gpt":0.25558503115788644,"score_spread":0.2489050964429092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058130577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.927644,0.07019625,0.00032344603,0.00010268723,0.00082446676,0.00032679277,0.0005093474,0.0000051139673,0.00006786354],"genre_scores_gemma":[0.9846331,0.014941334,0.00005476458,0.00003547421,0.00006662737,0.000068499656,0.000006083917,0.000025528423,0.0001686034],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99871045,0.0002963171,0.0005366664,0.00016097736,0.000056478646,0.00023908695],"domain_scores_gemma":[0.9984812,0.0004748523,0.0005800543,0.00013881945,0.00030520954,0.000019824045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065746735,0.00020117899,0.00073776033,0.00013340062,0.000073286414,0.000005643442,0.00016951209,0.0001934035,0.00016043043],"category_scores_gemma":[0.00001747939,0.00015363585,0.0002200241,0.000102620426,0.00016409531,0.00011335571,0.000011839725,0.00013031258,5.4738e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065953694,0.00022882214,0.066610366,0.00024057779,0.00096523145,4.6639263e-7,0.00036375897,0.000047682097,0.8698854,0.00020292054,0.000046652192,0.05481279],"study_design_scores_gemma":[0.017158829,0.0006842448,0.27658275,0.00049058924,0.00022842594,0.000030276984,0.000060903625,0.000013374391,0.70181054,0.00042487137,0.0023360737,0.00017914921],"about_ca_topic_score_codex":0.0012422651,"about_ca_topic_score_gemma":0.00019006417,"teacher_disagreement_score":0.20997237,"about_ca_system_score_codex":0.00007145927,"about_ca_system_score_gemma":0.00011563265,"threshold_uncertainty_score":0.6265088},"labels":[],"label_agreement":null},{"id":"W2060260809","doi":"10.1186/s40425-015-0055-3","title":"Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Immunotherapy; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; Phases of clinical research; Surgery; Urology; Gastroenterology; Overall survival; Clinical trial; Cancer","score_opus":0.023501342217022044,"score_gpt":0.31248380080424937,"score_spread":0.2889824585872273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060260809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99395704,0.0019807452,0.0003435468,0.00009852002,0.0001737055,0.0030567402,0.00011828791,0.00002483103,0.00024659667],"genre_scores_gemma":[0.99643165,0.00013788087,0.0025989315,0.000068279085,0.00004144094,0.00026668404,0.00012556795,0.00013299185,0.00019658654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964183,0.00044841532,0.0010016819,0.000499777,0.0010308381,0.00060097035],"domain_scores_gemma":[0.9970244,0.00018140805,0.001047076,0.0005706594,0.00093908753,0.00023736137],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010236352,0.00049886754,0.0009981671,0.00059281057,0.0001483569,0.000056504192,0.00025161894,0.00011572941,0.000026331443],"category_scores_gemma":[0.000022531241,0.0003371842,0.000105563835,0.0006250427,0.00014731941,0.0003955691,0.000010295264,0.0005983323,6.455901e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26589757,0.01912354,0.6802716,0.000111141824,0.00034257528,0.00037564524,0.0049099876,0.00914975,0.004592494,0.0000022947434,0.000035389185,0.015187989],"study_design_scores_gemma":[0.37442118,0.11669935,0.47929186,0.00050859276,0.00026753455,0.00003914521,0.0030525038,0.0004827555,0.024280826,0.000027094016,0.0003882447,0.0005408934],"about_ca_topic_score_codex":0.0020401364,"about_ca_topic_score_gemma":0.002243092,"teacher_disagreement_score":0.20097977,"about_ca_system_score_codex":0.0010253044,"about_ca_system_score_gemma":0.0012886266,"threshold_uncertainty_score":0.99990803},"labels":[],"label_agreement":null},{"id":"W2070037020","doi":"10.1186/2051-1426-2-s3-p5","title":"A clinical grade cell-based artificial APT, aAPC/mOKT3, for unbiased expansion of CD3+ T lymphocytes","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Adoptive cell transfer; CD3; Medicine; Tumor-infiltrating lymphocytes; T cell; Cancer research; Cancer; Immunology; Internal medicine; Immunotherapy; CD8; Immune system","score_opus":0.07337979631303736,"score_gpt":0.4284327000562539,"score_spread":0.3550529037432165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070037020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96418655,0.00483163,0.026013477,0.0016008872,0.0014270433,0.0016797207,0.00007393802,0.000026377837,0.00016038388],"genre_scores_gemma":[0.9826509,0.0031116523,0.008097893,0.0012398933,0.0019981372,0.00021170867,0.00002477784,0.00015882346,0.002506209],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970933,0.00017445054,0.0013385277,0.0002794811,0.00065753545,0.0004567115],"domain_scores_gemma":[0.99664176,0.0011868965,0.00077018084,0.0004424414,0.00077605975,0.00018269464],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002285467,0.00024000947,0.000948745,0.0002783183,0.00014770724,0.000027912132,0.00027885404,0.00022563573,0.0009820474],"category_scores_gemma":[0.00022507316,0.00019211274,0.0010813038,0.00021039828,0.000255563,0.00007444768,0.00001233524,0.00032411414,0.0000016427166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021866726,0.0005473862,0.0020265705,0.00029431682,0.00031583646,0.0000013673724,0.00017923617,0.00023878513,0.7469788,0.000042783304,0.002146795,0.22536135],"study_design_scores_gemma":[0.024790328,0.005938296,0.0022646878,0.0004962933,0.00017430776,0.000014556442,0.00010153513,0.006266706,0.8186038,0.0010015089,0.1401007,0.00024728215],"about_ca_topic_score_codex":0.000112626825,"about_ca_topic_score_gemma":0.000025924897,"teacher_disagreement_score":0.22511406,"about_ca_system_score_codex":0.00023170936,"about_ca_system_score_gemma":0.0011439882,"threshold_uncertainty_score":0.9999312},"labels":[],"label_agreement":null},{"id":"W2088712063","doi":"10.1186/2051-1426-1-s1-p146","title":"Development and stability of Th17 cells in ovarian cancer requires nitric oxide and endogenous NOS2 activity in cancer-associated CD4+ T cells","year":2013,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ovarian Cancer Canada","funders":"","keywords":"Ovarian cancer; Nitric oxide; Endogeny; Cancer; Cancer research; Nitric oxide synthase; Ascites; RAR-related orphan receptor gamma; Cancer cell; Medicine; Chemistry; Cell biology; Immunology; Biology; Internal medicine; Immune system","score_opus":0.03533179665720833,"score_gpt":0.2758429772357749,"score_spread":0.24051118057856657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088712063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615107,0.037151422,0.000009385244,0.000097660966,0.00043655385,0.00060948316,0.00015710885,0.0000054420957,0.000022229302],"genre_scores_gemma":[0.97882396,0.020472003,0.00021756871,0.0000383358,0.000018279961,0.0002482647,0.0000039575707,0.00002122764,0.0001564115],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853843,0.0001852969,0.0005931369,0.00023417966,0.0000676349,0.0003813254],"domain_scores_gemma":[0.9989429,0.00021437107,0.0005385027,0.00013015859,0.00014394749,0.000030118154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004831985,0.0002268701,0.0006129015,0.00021504865,0.00012689282,0.000015948643,0.00013983705,0.0002207182,0.00033672497],"category_scores_gemma":[0.000014769057,0.00018841751,0.00008919842,0.00019468856,0.00013076226,0.00020788782,0.000026920025,0.00020814824,8.1120464e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000938016,0.00030002705,0.057575967,0.00005747619,0.00049011724,0.0000013833859,0.0018572093,0.000012731927,0.8334671,0.0000028514855,0.000038787166,0.105258286],"study_design_scores_gemma":[0.004447088,0.00010941044,0.2575284,0.00014002757,0.000043144664,0.0000036922213,0.00017405149,0.0000029957566,0.73643446,0.00006016339,0.00090498617,0.00015159078],"about_ca_topic_score_codex":0.016393585,"about_ca_topic_score_gemma":0.0056815287,"teacher_disagreement_score":0.19995241,"about_ca_system_score_codex":0.00039796502,"about_ca_system_score_gemma":0.0004099889,"threshold_uncertainty_score":0.99015635},"labels":[],"label_agreement":null},{"id":"W2104319926","doi":"10.1186/s40425-014-0046-9","title":"CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Neuroinflammation and Neurodegeneration Mechanisms","field":"Neuroscience","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"L'Alliance Boviteq","funders":"Randy Shaver Cancer Research and Community Fund; National Institutes of Health; Morgan Adams Foundation; National Cancer Institute; American Brain Tumor Association","keywords":"Immunosuppression; Blockade; Immunotherapy; Medicine; Immunology; Cancer research; Immune system; Receptor; Internal medicine","score_opus":0.023796700130092264,"score_gpt":0.3004235208515833,"score_spread":0.27662682072149103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104319926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913302,0.0015728348,0.0015748848,0.001985208,0.0018704259,0.0014326811,0.000044393335,0.000038051352,0.00015129092],"genre_scores_gemma":[0.99387074,0.0012553383,0.0004492373,0.0028114805,0.000350863,0.00046328854,0.0000026865969,0.000095571515,0.00070080813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99720854,0.0004083097,0.0010547163,0.0003781592,0.0004404398,0.0005098624],"domain_scores_gemma":[0.99809206,0.0005907093,0.0006798545,0.00043525995,0.00014110644,0.00006098619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010302888,0.00030036332,0.00045505012,0.00032554282,0.00039370955,0.00012649591,0.00070970174,0.00010473562,0.00033579505],"category_scores_gemma":[0.00025225498,0.0002200165,0.0002978487,0.0004094328,0.00006874679,0.00030082295,0.000023728107,0.0004527704,0.0000039094048],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012136739,0.00011389332,0.00010946762,0.000012344507,0.000010884654,0.0000019680099,0.00064317154,0.0009405981,0.9668609,0.0015073922,0.00014175572,0.028443946],"study_design_scores_gemma":[0.005085451,0.00045406443,0.0006737414,0.000082717015,0.0000042662523,0.00003117178,0.00007493881,0.004823676,0.90829194,0.0042134807,0.07602904,0.00023554018],"about_ca_topic_score_codex":0.000038704027,"about_ca_topic_score_gemma":0.00006448015,"teacher_disagreement_score":0.075887285,"about_ca_system_score_codex":0.00010840491,"about_ca_system_score_gemma":0.00022244753,"threshold_uncertainty_score":0.8972013},"labels":[],"label_agreement":null},{"id":"W2105562405","doi":"10.1186/2051-1426-2-2","title":"Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Pfizer; Bristol-Myers Squibb; Genentech; Amgen","keywords":"Sorafenib; Medicine; Renal cell carcinoma; Pharmacokinetics; Pharmacodynamics; Pharmacology; Internal medicine; Rash; Oncology; Immunotherapy; Toxicity; Gastroenterology; Hepatocellular carcinoma; Cancer","score_opus":0.04145423578145745,"score_gpt":0.3631940069784667,"score_spread":0.32173977119700925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105562405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800443,0.0068960204,0.008378622,0.00054217444,0.0012287911,0.0026971532,0.000036683923,0.000016457581,0.00015980586],"genre_scores_gemma":[0.99032956,0.0002530279,0.0045735934,0.00024058984,0.00035525643,0.00054727774,0.000013631356,0.00009563811,0.0035914124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978115,0.000113100396,0.00091824547,0.0003060644,0.00041086684,0.00044024616],"domain_scores_gemma":[0.9979981,0.00024341235,0.00069077266,0.0003990627,0.0004959599,0.00017270302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008886141,0.0003296704,0.0009670747,0.00025307795,0.00018905014,0.00004564543,0.00022135823,0.000059538732,0.00018796154],"category_scores_gemma":[0.00004509285,0.00023619148,0.0006592181,0.0001359467,0.000064970285,0.00011494414,0.000017327922,0.00024663168,0.0000024960884],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09548707,0.0140248,0.0061722184,0.0014505133,0.0052085016,0.00015732142,0.01309434,0.00029553377,0.5437751,0.00013182842,0.013307175,0.30689558],"study_design_scores_gemma":[0.28826413,0.1012249,0.008427368,0.0006598341,0.0037452718,0.0005680901,0.0029940738,0.0021589715,0.44439736,0.0016941881,0.14491044,0.0009553862],"about_ca_topic_score_codex":0.00015597159,"about_ca_topic_score_gemma":0.00004219807,"teacher_disagreement_score":0.3059402,"about_ca_system_score_codex":0.00058700633,"about_ca_system_score_gemma":0.0004548087,"threshold_uncertainty_score":0.96316093},"labels":[],"label_agreement":null},{"id":"W2108739705","doi":"10.1186/2051-1426-1-s1-p58","title":"Reciprocal expression of tumour-associated carbohydrate antigens (Tn/sTn) and nuclear factor-B serves as an indicator of the prognosis of oral squamous cell carcinoma","year":2013,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Antigen; Basal cell; Medicine; Cancer research; Oncology; Pathology; Immunology","score_opus":0.01342541917021205,"score_gpt":0.29276383277377677,"score_spread":0.2793384136035647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108739705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953062,0.0040183524,0.00000252553,0.00005222006,0.00006864026,0.00040167908,0.00013072666,0.0000013666668,0.000018298286],"genre_scores_gemma":[0.9987153,0.0010324176,0.00009551692,0.000020111042,0.0000245224,0.000025422334,0.000006683875,0.000024535531,0.000055503948],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99907327,0.00007677272,0.00032717318,0.00013208839,0.00021317975,0.00017752676],"domain_scores_gemma":[0.9989819,0.000012692529,0.00053177215,0.00016128039,0.00024693937,0.00006542196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010630225,0.00011512484,0.0002493706,0.000047986916,0.00007450108,0.000012490782,0.00020663913,0.00009849101,0.00007573109],"category_scores_gemma":[0.00001861304,0.00007659261,0.00016287109,0.00006788463,0.00014405558,0.000015931786,0.000039906903,0.00008652862,1.139368e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006495476,0.00024770782,0.07774502,0.000056265784,0.00010940815,2.3935294e-7,0.00040745284,0.000004114467,0.9185881,0.0000012952888,0.00012152061,0.002069316],"study_design_scores_gemma":[0.0018864017,0.0016481691,0.14734308,0.000047527472,0.000021424154,0.0000018971276,0.00012678407,0.000011616964,0.8485378,0.000040869207,0.0002691739,0.00006524547],"about_ca_topic_score_codex":0.0019079836,"about_ca_topic_score_gemma":0.00013478886,"teacher_disagreement_score":0.07005031,"about_ca_system_score_codex":0.000027657834,"about_ca_system_score_gemma":0.00018557406,"threshold_uncertainty_score":0.31233558},"labels":[],"label_agreement":null},{"id":"W2157899115","doi":"10.1186/s40425-014-0041-1","title":"Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Retinal vasculitis; Extravasation; Pembrolizumab; Melanoma; Vasculitis; Metastasis; Retinal; Nivolumab; Optic nerve; Vitreous hemorrhage; Immune system; Immunotherapy; Pathology; Ophthalmology; Cancer research; Immunology; Retinal detachment; Internal medicine; Cancer; Disease","score_opus":0.013111459045823767,"score_gpt":0.301956724692727,"score_spread":0.2888452656469032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157899115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931362,0.003107204,0.0016878368,0.0012799733,0.000117896496,0.0006107367,0.000025337067,0.000006943209,0.000027829477],"genre_scores_gemma":[0.9885969,0.00022777494,0.010340257,0.000630073,0.000026548596,0.00007971582,0.000005325179,0.000028436783,0.000064978005],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877477,0.00021179936,0.00036633946,0.00017118976,0.00025482505,0.00022109461],"domain_scores_gemma":[0.9992935,0.00017938516,0.0001875452,0.00013916139,0.00010350753,0.00009691371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004968835,0.00015690118,0.0005107643,0.00021087368,0.00010966635,0.000016778717,0.0000312879,0.000042125386,0.00004606126],"category_scores_gemma":[0.0000640559,0.000114517024,0.00018002717,0.00013665658,0.000045675082,0.00006601652,0.0000085757865,0.00013946116,0.0000011211242],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19112399,0.0013999107,0.030044047,0.0003182536,0.0094666965,0.007922163,0.008676975,0.000614264,0.24704355,0.000095629715,0.00024376165,0.50305074],"study_design_scores_gemma":[0.1846426,0.14923981,0.17779933,0.00843455,0.007727438,0.06600525,0.0029206343,0.0012281829,0.15546434,0.0037673963,0.2406062,0.0021642847],"about_ca_topic_score_codex":0.00009475694,"about_ca_topic_score_gemma":0.00008817619,"teacher_disagreement_score":0.50088644,"about_ca_system_score_codex":0.0001865117,"about_ca_system_score_gemma":0.00010991604,"threshold_uncertainty_score":0.46698686},"labels":[],"label_agreement":null},{"id":"W2173070859","doi":"10.1186/2051-1426-3-s2-p259","title":"Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Université de Montréal; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Ipilimumab; Carboplatin; Medicine; Paclitaxel; Metastatic melanoma; Internal medicine; Oncology; Stage (stratigraphy); Melanoma; Biomarker; Nivolumab; Chemotherapy; Immunotherapy; Cancer; Cisplatin; Cancer research","score_opus":0.03410340619736896,"score_gpt":0.33195909338164753,"score_spread":0.2978556871842786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2173070859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98197407,0.015306121,0.00009994563,0.00010528908,0.000265175,0.001958613,0.0002392466,0.000011934316,0.000039606108],"genre_scores_gemma":[0.99753004,0.00071019767,0.0007014645,0.000074468764,0.000035660603,0.00012025366,0.000029650477,0.000077018325,0.0007212571],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99739337,0.00012233759,0.0010640537,0.00031389523,0.0007281774,0.0003781815],"domain_scores_gemma":[0.99781746,0.00018499499,0.00096138497,0.00038055924,0.00051449455,0.00014110893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071755395,0.00036605718,0.0011160002,0.00035289713,0.00013669538,0.000037427126,0.00018906809,0.000085963664,0.00035053],"category_scores_gemma":[0.00003324106,0.00021915945,0.00012340161,0.00050359755,0.00020609667,0.00028619712,0.000030898915,0.00028249063,1.4335997e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67901665,0.0076588574,0.19069134,0.00016874347,0.0072400826,0.000048613598,0.016364,0.00009147608,0.03314797,0.0000030003873,0.0002630528,0.06530621],"study_design_scores_gemma":[0.52905244,0.11956892,0.31930456,0.0021452704,0.0010531426,0.000052149517,0.015394424,0.00050635834,0.008979232,0.00006331206,0.003128497,0.00075169414],"about_ca_topic_score_codex":0.005229787,"about_ca_topic_score_gemma":0.0017642741,"teacher_disagreement_score":0.14996421,"about_ca_system_score_codex":0.0002690943,"about_ca_system_score_gemma":0.0006396037,"threshold_uncertainty_score":0.8937063},"labels":[],"label_agreement":null},{"id":"W2205469793","doi":"10.1186/s40425-015-0093-x","title":"A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial","year":2015,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"Medicine; Cancer vaccine; Clinical trial; Adjuvant; Cancer; Oncology; Phase (matter); Internal medicine; Immunotherapy","score_opus":0.1487543164012257,"score_gpt":0.5064022692511208,"score_spread":0.35764795284989503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2205469793","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0065933177,0.9861982,0.0002017701,0.00005110497,0.003200325,0.0022937593,0.0014326379,0.00001573002,0.000013140707],"genre_scores_gemma":[0.00022207705,0.99549305,0.000073694544,0.000060271002,0.0001153822,0.00084060314,0.00015530127,0.00012129376,0.0029183067],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943033,0.0012131279,0.0032095457,0.00044775734,0.00018520982,0.0006410486],"domain_scores_gemma":[0.99333405,0.0013257297,0.004001488,0.00058425934,0.00071732834,0.000037114674],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019585567,0.0007876533,0.006422919,0.0024263936,0.00016746615,0.00003585697,0.00093102787,0.0007699374,0.0030958136],"category_scores_gemma":[0.00014003234,0.00051691686,0.0027740826,0.0020645803,0.00030186347,0.00022920914,0.000034880683,0.00087503286,0.0000045599463],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25078994,0.0015589632,0.0000023455805,0.0009622198,0.0327473,0.0000038893945,0.00086823717,0.000016214059,0.0044389386,0.000039755294,0.00051449926,0.7080577],"study_design_scores_gemma":[0.12497327,0.007327666,0.000003588369,0.0041158195,0.008656112,0.000027604183,0.00024241327,0.000011470146,0.0007497739,0.000042932497,0.8533325,0.00051685475],"about_ca_topic_score_codex":0.000537084,"about_ca_topic_score_gemma":0.0002479217,"teacher_disagreement_score":0.852818,"about_ca_system_score_codex":0.00043053803,"about_ca_system_score_gemma":0.0034714649,"threshold_uncertainty_score":0.99972826},"labels":[],"label_agreement":null},{"id":"W2208379272","doi":"10.1186/2051-1426-3-s2-p160","title":"Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Pembrolizumab; Dexamethasone; Medicine; Multiple myeloma; Oncology; Internal medicine; Cancer research; Pharmacology; Immunotherapy; Cancer","score_opus":0.04112271902787046,"score_gpt":0.3538140881746188,"score_spread":0.31269136914674833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2208379272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852431,0.010167612,0.0016701688,0.0009174238,0.00024168914,0.0016347728,0.000055845558,0.000015214986,0.000054187305],"genre_scores_gemma":[0.9900669,0.0025202658,0.0056603197,0.00016235303,0.00015402687,0.0003236448,0.00002813849,0.00007162382,0.0010127573],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982783,0.000075911856,0.0004947622,0.0002386267,0.00048888905,0.0004234619],"domain_scores_gemma":[0.99817806,0.00040000177,0.00034533822,0.00021191023,0.00061166217,0.00025300714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006854989,0.00022823364,0.00056362955,0.00031919387,0.000115537885,0.00004041002,0.000113641676,0.00012116385,0.000036423175],"category_scores_gemma":[0.00030111131,0.00016588756,0.00014730664,0.00016965339,0.00012832614,0.00027069956,0.0000140493485,0.0002877748,0.0000011395446],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27546117,0.002219861,0.14391103,0.00058135553,0.0018241075,0.00009069261,0.0026392057,0.00024895137,0.076158606,0.0000910377,0.0018930957,0.49488088],"study_design_scores_gemma":[0.5021905,0.021157483,0.37380394,0.0021441448,0.00028842984,0.00043981106,0.0010106143,0.007554189,0.052251596,0.0020047477,0.03644019,0.00071436114],"about_ca_topic_score_codex":0.00039499084,"about_ca_topic_score_gemma":0.00033549085,"teacher_disagreement_score":0.49416652,"about_ca_system_score_codex":0.00051424466,"about_ca_system_score_gemma":0.00066939095,"threshold_uncertainty_score":0.6764698},"labels":[],"label_agreement":null},{"id":"W2221239533","doi":"10.1186/s40425-015-0099-4","title":"Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Terry Fox Foundation; Government of Ontario","keywords":"Chimeric antigen receptor; Antigen; Cytotoxic T cell; Degranulation; Ankyrin repeat; Tumor antigen; Antibody; Biology; Cancer research; Immunology; Cell biology; Receptor; Immunotherapy; Immune system; In vitro; Gene; Genetics","score_opus":0.04065385021059447,"score_gpt":0.38164280807278034,"score_spread":0.34098895786218586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2221239533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96111035,0.018914787,0.0091988575,0.0012058034,0.0015965841,0.0076261545,0.00005098226,0.00004468945,0.00025176583],"genre_scores_gemma":[0.77362645,0.02433199,0.11978056,0.0023622413,0.009364468,0.009163243,0.00014093594,0.0011237556,0.060106374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787754,0.00012819922,0.0006361029,0.00025822537,0.0005894487,0.0005105146],"domain_scores_gemma":[0.9977533,0.00015346768,0.0006384373,0.0002466671,0.0010072837,0.00020081739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018776647,0.00023220337,0.00061505847,0.00022888435,0.00019783805,0.000042584838,0.0002066288,0.000109838445,0.0007702549],"category_scores_gemma":[0.00028488005,0.00018511094,0.00040609,0.00025881536,0.000083138635,0.00014949104,0.000017841867,0.00028518782,0.0000021892777],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016317137,0.000207993,0.015485236,0.00014936627,0.0011169256,0.00000387996,0.0011422004,0.0000373054,0.7221398,0.000003823704,0.009799078,0.2335973],"study_design_scores_gemma":[0.020599548,0.006276421,0.0060597225,0.0006185612,0.00010131953,0.000043378473,0.00082051405,0.00021451122,0.554008,0.00038413674,0.41053686,0.0003369975],"about_ca_topic_score_codex":0.00009797011,"about_ca_topic_score_gemma":0.00001189453,"teacher_disagreement_score":0.4007378,"about_ca_system_score_codex":0.0006037886,"about_ca_system_score_gemma":0.00045832276,"threshold_uncertainty_score":0.843375},"labels":[],"label_agreement":null},{"id":"W2298802783","doi":"10.1186/s40425-016-0116-2","title":"Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"University of California, San Diego; U.S. Food and Drug Administration; Amgen","keywords":"Medicine; Oncolytic virus; Melanoma; Internal medicine; Oncology; Cancer research; Cancer","score_opus":0.02881937285232573,"score_gpt":0.35726615096828074,"score_spread":0.328446778115955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2298802783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926774,0.004855964,0.0011744997,0.000051868883,0.0002038544,0.00065171346,0.0003751427,0.0000050772596,0.000004472552],"genre_scores_gemma":[0.99854034,0.0006637297,0.00012944006,0.0000359147,0.00012261995,0.000159054,0.000027362563,0.000036899033,0.00028466218],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99858975,0.00017236138,0.0003981426,0.00026995986,0.0003011243,0.0002686714],"domain_scores_gemma":[0.999084,0.00005035643,0.00022209289,0.00026589006,0.00030905814,0.00006860594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030507307,0.00019911572,0.000279914,0.00012070021,0.00015257424,0.000015091139,0.0002542693,0.00009491019,0.00008815523],"category_scores_gemma":[0.000032549342,0.00012029802,0.00011593544,0.00010623887,0.00013965348,0.000013504209,0.000027536209,0.00008619888,0.0000010667453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21811853,0.0013801259,0.032855827,0.000005454401,0.0007220753,0.000010381682,0.00015085985,0.00012774885,0.6808147,4.533867e-7,0.000045560682,0.0657683],"study_design_scores_gemma":[0.1501964,0.08441024,0.0142917335,0.00026610523,0.000068700225,0.000017205228,0.00029591177,0.00007647051,0.7465612,0.0000057368547,0.0033887099,0.000421548],"about_ca_topic_score_codex":0.00024741815,"about_ca_topic_score_gemma":0.0015150612,"teacher_disagreement_score":0.08303012,"about_ca_system_score_codex":0.00020469155,"about_ca_system_score_gemma":0.000440311,"threshold_uncertainty_score":0.4905611},"labels":[],"label_agreement":null},{"id":"W2314244103","doi":"10.1186/s40425-016-0123-3","title":"Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Pembrolizumab; Medicine; Ipilimumab; Immunosuppression; Asymptomatic; Exacerbation; Bullous pemphigoid; Pemphigoid; Dermatology; Immunotherapy; Disease; Immunology; Internal medicine; Cancer; Antibody","score_opus":0.017347688674117994,"score_gpt":0.32649352927772024,"score_spread":0.30914584060360223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314244103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682765,0.017321885,0.0077206083,0.004510183,0.0001922366,0.0017747488,0.00016791504,0.00001578179,0.000020143518],"genre_scores_gemma":[0.99626064,0.0011387637,0.0015472363,0.00023219196,0.00008621572,0.00033129088,0.000011442102,0.00006405064,0.00032816618],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982228,0.00009714555,0.00074855244,0.00016981666,0.00043950506,0.00032212728],"domain_scores_gemma":[0.9979165,0.00047900985,0.0007434899,0.00035495366,0.00044650704,0.000059515634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006527419,0.00020362118,0.000544476,0.00017170778,0.0001229168,0.000018186705,0.0002524292,0.000038140384,0.00016212565],"category_scores_gemma":[0.00023319492,0.00010241954,0.00030931848,0.00019694734,0.00014772672,0.00015297953,0.000011322344,0.000100215824,3.3844586e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15148827,0.0033534332,0.2672611,0.003342909,0.0037537778,0.00006241828,0.012283065,0.0014924736,0.2589257,0.0014715075,0.0022971935,0.29426816],"study_design_scores_gemma":[0.052088503,0.004903505,0.9042556,0.0037837222,0.0012253746,0.00023935508,0.0014316066,0.0006621596,0.010533229,0.003068978,0.017291231,0.0005167336],"about_ca_topic_score_codex":0.00006255686,"about_ca_topic_score_gemma":0.000033546192,"teacher_disagreement_score":0.6369945,"about_ca_system_score_codex":0.00017742474,"about_ca_system_score_gemma":0.0007491228,"threshold_uncertainty_score":0.41765475},"labels":[],"label_agreement":null},{"id":"W2430573464","doi":"10.1186/s40425-016-0142-0","title":"Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Clinical trial; Common Rule; Medicine; Government (linguistics); Declaration; Cancer immunotherapy; Standardization; Cancer; Immunotherapy; Alternative medicine; Engineering ethics; Informed consent; Political science; Pathology; Law; Internal medicine","score_opus":0.03576900875414307,"score_gpt":0.36246891781178425,"score_spread":0.3266999090576412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2430573464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7196866,0.042926926,0.002276346,0.22623204,0.002319116,0.005662674,0.00077325315,0.000032500422,0.00009051025],"genre_scores_gemma":[0.7672882,0.15948956,0.0025280733,0.046954755,0.0028191635,0.0039355424,0.000017154296,0.00040451824,0.01656301],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99770683,0.00007713595,0.00084800285,0.0002580884,0.0006094353,0.00050052983],"domain_scores_gemma":[0.9974293,0.00047379214,0.00088565605,0.00057865353,0.00055807317,0.00007449139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015369246,0.00032903132,0.00064804876,0.00010124561,0.00042035608,0.00003977385,0.00052316114,0.000118520125,0.00080460374],"category_scores_gemma":[0.00002490441,0.00014149719,0.000991967,0.00025132837,0.00025956784,0.00008210238,0.000021414748,0.00020237154,0.0000014959413],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02351696,0.0002021942,0.0005920183,0.000101263475,0.002729637,2.7493724e-7,0.0021109988,0.000015601154,0.5523962,0.00012081953,0.045316212,0.37289786],"study_design_scores_gemma":[0.009877154,0.002951359,0.004234076,0.0010210124,0.00013223379,0.0000060332763,0.0005259054,0.000019529612,0.33279195,0.00033121213,0.6478982,0.00021136872],"about_ca_topic_score_codex":0.0005359559,"about_ca_topic_score_gemma":0.00050296815,"teacher_disagreement_score":0.602582,"about_ca_system_score_codex":0.00056154,"about_ca_system_score_gemma":0.0004999012,"threshold_uncertainty_score":0.88098466},"labels":[],"label_agreement":null},{"id":"W2528626295","doi":"10.1186/s40425-016-0168-3","title":"Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"Society for Immunotherapy of Cancer","keywords":"Immunotherapy; Medicine; Cancer immunotherapy; Melanoma; Immune system; Ipilimumab; Cancer; Renal cell carcinoma; Breast cancer; Oncology; Immunology; Cancer research; Internal medicine","score_opus":0.03410942348087324,"score_gpt":0.370393223925771,"score_spread":0.33628380044489775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528626295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7521126,0.21813616,0.0015310103,0.023674224,0.0020857095,0.0014996273,0.0001602549,0.000065938686,0.0007344556],"genre_scores_gemma":[0.8415075,0.14405236,0.0020749809,0.0034915996,0.0020910094,0.0003762839,0.000018377365,0.00031646775,0.006071449],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957543,0.00022634331,0.0017717262,0.0005893097,0.00085192855,0.00080639846],"domain_scores_gemma":[0.996037,0.0007755445,0.0013660633,0.0010201642,0.0006806978,0.00012052377],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020205677,0.00056791917,0.0010961558,0.0003032393,0.00036689875,0.00010558997,0.0006598484,0.00028280012,0.0018656263],"category_scores_gemma":[0.00015604791,0.0003202147,0.0010706985,0.00050681946,0.0005222421,0.00040964337,0.00003415985,0.0005269364,0.0000063359885],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030718757,0.0004489365,0.04473225,0.000028254894,0.003212087,0.00005712855,0.0058633396,0.000009431835,0.6126114,0.000067925524,0.021543387,0.2807071],"study_design_scores_gemma":[0.036306452,0.0011810837,0.32869953,0.0027009072,0.00015532544,0.0008336444,0.0020819225,0.000021418458,0.042893924,0.0021938956,0.5820542,0.0008776804],"about_ca_topic_score_codex":0.0036788643,"about_ca_topic_score_gemma":0.0007670326,"teacher_disagreement_score":0.56971747,"about_ca_system_score_codex":0.001007456,"about_ca_system_score_gemma":0.0009787502,"threshold_uncertainty_score":0.999925},"labels":[],"label_agreement":null},{"id":"W2529221862","doi":"10.1186/s40425-016-0171-8","title":"Antitumor activity of nivolumab on hemodialysis after renal allograft rejection","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Nivolumab; Hemodialysis; Ipilimumab; Transplantation; Immunosuppression; Internal medicine; Malignancy; Cancer; Intensive care medicine; Oncology; Immunotherapy","score_opus":0.015400382094347695,"score_gpt":0.31423989675110625,"score_spread":0.29883951465675856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529221862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908791,0.00393533,0.0020561407,0.0017587368,0.0007997385,0.0003743352,0.000052858664,0.000014187512,0.00012953277],"genre_scores_gemma":[0.9889188,0.007421188,0.0005050095,0.0003131049,0.00034535196,0.00006292084,0.0000010286055,0.000037924514,0.0023946862],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986412,0.000051044583,0.0005049908,0.0001854362,0.00037833434,0.00023901975],"domain_scores_gemma":[0.9986941,0.0000977685,0.00056883023,0.000278518,0.0003028569,0.00005792887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044520252,0.00017859912,0.00051211833,0.00025844976,0.00007946471,0.000011697854,0.00011077171,0.000108547334,0.000701312],"category_scores_gemma":[0.00002728804,0.0001103811,0.0006759212,0.00020259849,0.00016728685,0.0001531205,0.0000070242236,0.00013557565,9.2151856e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050138272,0.00019247849,0.0031856883,0.0000417012,0.00080362573,0.0000024497936,0.00008837605,0.00000250603,0.6707848,0.0000059319545,0.00096971984,0.2737845],"study_design_scores_gemma":[0.013474859,0.002918681,0.08670757,0.0010268091,0.00017979911,0.000046524146,0.000018842296,0.000010910573,0.83128464,0.0001237419,0.06401831,0.00018928676],"about_ca_topic_score_codex":0.00014590222,"about_ca_topic_score_gemma":0.000047125446,"teacher_disagreement_score":0.2735952,"about_ca_system_score_codex":0.00027898725,"about_ca_system_score_gemma":0.00024501095,"threshold_uncertainty_score":0.7678874},"labels":[],"label_agreement":null},{"id":"W2531271615","doi":"10.1186/s40425-016-0174-5","title":"High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Christie (Canada)","funders":"","keywords":"Medicine; Internal medicine; Clinical trial; Oncology; Renal cell carcinoma","score_opus":0.04813171222505309,"score_gpt":0.33063154148190993,"score_spread":0.28249982925685685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531271615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961677,0.0024917193,0.000119360266,0.00011949982,0.00023085729,0.0007747999,0.000064696724,0.000003932399,0.000027416378],"genre_scores_gemma":[0.9977176,0.00066419394,0.000851591,0.000025988576,0.0000693771,0.00011946225,0.0000076047677,0.00003055001,0.00051359355],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811727,0.00013467092,0.0008652355,0.0001988582,0.0004448201,0.00023914877],"domain_scores_gemma":[0.99843967,0.00012640357,0.0007260318,0.00028052364,0.00036300748,0.00006435773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001931228,0.00022605943,0.00061149464,0.00023241797,0.000048891707,0.0000099837625,0.00015039534,0.000047055713,0.00028111183],"category_scores_gemma":[0.000012680716,0.000113665956,0.0003272317,0.00016032677,0.00011269722,0.00014029501,0.00000690569,0.000066815104,7.402247e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013700599,0.0048270845,0.34024107,0.0001670011,0.00035877828,0.000013943569,0.02179153,0.00004326317,0.5692518,0.000007945134,0.000068608526,0.04952838],"study_design_scores_gemma":[0.020189162,0.023742946,0.3206993,0.00022016186,0.00025546507,0.000019265663,0.0011899921,0.000013216171,0.6313997,0.000038915707,0.0020793092,0.00015254195],"about_ca_topic_score_codex":0.00057102414,"about_ca_topic_score_gemma":0.000118171796,"teacher_disagreement_score":0.06214792,"about_ca_system_score_codex":0.0006856545,"about_ca_system_score_gemma":0.00012796624,"threshold_uncertainty_score":0.4635163},"labels":[],"label_agreement":null},{"id":"W2538528785","doi":"10.1186/s40425-016-0169-2","title":"Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Dalhousie University; University of Toronto; Sunnybrook Health Science Centre; Canada Research Chairs; Immunovaccine (Canada)","funders":"National Institutes of Health; Adaptive Biotechnologies; National Cancer Institute; University of Pittsburgh; University of Southern California","keywords":"ELISPOT; Immune system; Immunogenicity; Cytotoxic T cell; Immunology; CD8; Antigen; Medicine; Tumor antigen; Cancer vaccine; Spleen; Cancer research; Immunotherapy; Biology; In vitro","score_opus":0.016867753634658537,"score_gpt":0.27429946924626936,"score_spread":0.2574317156116108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2538528785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8025943,0.19591863,0.0002094368,0.0003362087,0.00034612353,0.00042337307,0.00015838449,0.000007651876,0.0000059001372],"genre_scores_gemma":[0.92464817,0.07499817,0.000120093035,0.000080351805,0.000030514864,0.000021936548,0.0000024827398,0.00003354627,0.00006471201],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978943,0.00043299978,0.0009979864,0.00023849278,0.00008923175,0.0003470319],"domain_scores_gemma":[0.9965288,0.0012920466,0.001584929,0.0003268076,0.00024497006,0.000022427632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013276472,0.00029875696,0.00091630983,0.00013734064,0.0003381698,0.000022193342,0.0002994655,0.00014018932,0.00016758016],"category_scores_gemma":[0.00008257939,0.00017480005,0.00026363757,0.00013293153,0.0004954105,0.00021218258,0.000046651694,0.00025787216,4.0208437e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006692123,0.0001836132,0.008376097,0.000028908446,0.0010906416,3.0701034e-7,0.0003791207,0.0000016080423,0.8715706,0.000028795452,0.00013518562,0.111513026],"study_design_scores_gemma":[0.0058338856,0.00069356273,0.16813312,0.00024839755,0.000028097684,0.00004197887,0.00023456068,0.0000011516479,0.8176513,0.00008060994,0.006877379,0.00017595278],"about_ca_topic_score_codex":0.0012603023,"about_ca_topic_score_gemma":0.000008792174,"teacher_disagreement_score":0.15975703,"about_ca_system_score_codex":0.00005456144,"about_ca_system_score_gemma":0.00018825672,"threshold_uncertainty_score":0.7128139},"labels":[],"label_agreement":null},{"id":"W2560342953","doi":"10.1186/s40425-016-0191-4","title":"31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College; University Health Network; Princess Margaret Cancer Centre; Université Laval","funders":"National Center for Advancing Translational Sciences; lékařská fakulta Univerzity Karlovy; Radboud Universitair Medisch Centrum; Université Paris Descartes; EMD Serono; Kindai University; Radboud Universiteit; Karolinska Institutet; Institut National de la Santé et de la Recherche Médicale; Université Pierre et Marie Curie; Dr. Ralph and Marian Falk Medical Research Trust; Sidra Medicine; Graduate School, University of Maryland; Pennsylvania Department of Health; University of Bern; Univerzita Karlova v Praze; National Cancer Institute; Alliance for Cancer Gene Therapy; National Institutes of Health; Keio University; National Science Foundation","keywords":"Durvalumab; Lung cancer; CD8; Immunotherapy; Cancer immunotherapy; Oncology; Medicine; Cancer research; Internal medicine; Cancer; Immunology; Immune system; Nivolumab","score_opus":0.017529416612312148,"score_gpt":0.31854342246694217,"score_spread":0.30101400585463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560342953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94011396,0.054026708,0.0002006987,0.0027597721,0.0009659839,0.0014062858,0.00044247144,0.0000189902,0.000065142434],"genre_scores_gemma":[0.9526955,0.042603713,0.001090202,0.0006012314,0.00035404455,0.00019154235,0.000005342661,0.0001175432,0.0023409133],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974928,0.000054202395,0.0012403161,0.00025070255,0.0004879397,0.00047402718],"domain_scores_gemma":[0.996195,0.0003022224,0.0021854774,0.00030309608,0.00094814686,0.00006601424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013323566,0.00030552165,0.0008152646,0.00009139876,0.0002514346,0.000025934998,0.00029794237,0.00023485067,0.00010405296],"category_scores_gemma":[0.000056846413,0.00017383999,0.0014040037,0.00025272387,0.00044041625,0.00021065534,0.000024669831,0.00021055863,8.294323e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008109531,0.0002222386,0.01538448,0.00023075966,0.004113358,2.7794528e-7,0.0019115814,0.0000133327685,0.61233884,0.00001144016,0.0013407915,0.3563234],"study_design_scores_gemma":[0.05568094,0.0036685145,0.27152008,0.013994185,0.0010408344,0.000049883223,0.0012301999,0.00008578471,0.47685063,0.00068095414,0.17435646,0.0008415534],"about_ca_topic_score_codex":0.0010477845,"about_ca_topic_score_gemma":0.00024385093,"teacher_disagreement_score":0.35548183,"about_ca_system_score_codex":0.00031670392,"about_ca_system_score_gemma":0.00074280007,"threshold_uncertainty_score":0.7088989},"labels":[],"label_agreement":null},{"id":"W2564318420","doi":"10.1186/s40425-016-0173-6","title":"31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Columbia College; Caprion (Canada)","funders":"National Institute of Neurological Disorders and Stroke; Stand Up To Cancer; National Institutes of Health; Knight Cancer Institute, Oregon Health and Science University; Cancer Research Society; European Commission; U.S. Department of Defense; Breast Cancer Research Foundation; Oregon Health and Science University; Prostate Cancer Foundation; Movember Foundation; Cancer League of Colorado; Harry J. Lloyd Charitable Trust; National Cancer Institute; Dendreon Pharmaceuticals; Melanoma Research Alliance; Susan G. Komen for the Cure; Pharmaceutical Research and Manufacturers of America Foundation; Amgen; Collins Medical Trust","keywords":"Prostate cancer; Immunotherapy; Cancer immunotherapy; Myeloid cells; Cancer; Medicine; Gerontology; Immunology; Oncology; Cancer research; Myeloid; Internal medicine","score_opus":0.019952623559447987,"score_gpt":0.3311051548978156,"score_spread":0.3111525313383676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564318420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89988714,0.091400534,0.00035133894,0.004167115,0.0015107943,0.0018932604,0.0007009511,0.000021814152,0.0000670273],"genre_scores_gemma":[0.8708895,0.11680655,0.0020311957,0.0014893578,0.0010398607,0.00064921135,0.000012905816,0.00022514455,0.0068562976],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975085,0.00007315964,0.0011729631,0.00026094288,0.0005080223,0.00047639798],"domain_scores_gemma":[0.99647254,0.00029025608,0.0017988053,0.00034682456,0.0010213739,0.000070185844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013129849,0.00031111165,0.0008677856,0.000083406485,0.0002491471,0.000021701648,0.00031616323,0.00019178921,0.00018194994],"category_scores_gemma":[0.00005574862,0.00017322678,0.0015685415,0.00027889266,0.00054769014,0.00018278218,0.000026130749,0.00019249598,9.1676924e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010848518,0.00029642868,0.026149144,0.00020623005,0.0051203384,1.9904527e-7,0.0017135028,0.0000048361367,0.5656192,0.000029348028,0.00601054,0.38400173],"study_design_scores_gemma":[0.07208356,0.004518243,0.056080986,0.010424612,0.0010560035,0.000039573417,0.0014510668,0.00006901456,0.42876703,0.00074239395,0.4239808,0.00078671786],"about_ca_topic_score_codex":0.00074414216,"about_ca_topic_score_gemma":0.0002509947,"teacher_disagreement_score":0.41797027,"about_ca_system_score_codex":0.00031723463,"about_ca_system_score_gemma":0.00083652046,"threshold_uncertainty_score":0.7063983},"labels":[],"label_agreement":null},{"id":"W2592274279","doi":"10.1186/s40425-017-0223-8","title":"Systematic evaluation of immune regulation and modulation","year":2017,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; U.S. National Library of Medicine; National Cancer Institute; National Institutes of Health; Trent University; Sidra Medicine; Nottingham Trent University","keywords":"Immune system; Immunotherapy; Medicine; Computational biology; Tumor microenvironment; Identification (biology); Cancer immunotherapy; Task force; Cancer; Bioinformatics; Computer science; Immunology; Data science; Biology; Internal medicine; Political science","score_opus":0.13558746605105143,"score_gpt":0.4619861904541074,"score_spread":0.32639872440305595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592274279","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047728184,0.9949139,0.00017725625,0.000046893463,0.0008906836,0.0033813568,0.00003918546,0.000006060495,0.0000674256],"genre_scores_gemma":[0.0011743386,0.9973506,0.00022212429,0.000009023798,0.00023186015,0.00028275495,0.000031448137,0.00006185883,0.00063599943],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9967859,0.0002151601,0.0019390874,0.00018647294,0.0007173183,0.00015606581],"domain_scores_gemma":[0.99340636,0.00014567775,0.004913772,0.0005037901,0.0009914662,0.00003892268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034733238,0.00029143278,0.0024755513,0.0003640582,0.00016298628,0.00004232297,0.0001719087,0.00027920518,0.00013058071],"category_scores_gemma":[0.00015446109,0.00020652736,0.0010965149,0.000113595444,0.00012432807,0.00016295545,0.000010847911,0.00019359814,3.1266262e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006669785,0.000040271665,0.00000524996,0.121361434,0.0025221389,1.6753769e-7,0.000121182755,0.0000056209374,0.0008346707,0.000013795302,0.000048926435,0.8743796],"study_design_scores_gemma":[0.010479258,0.00095150166,0.0015033612,0.55943865,0.013679828,0.000348894,0.000055575096,0.0009702118,0.00033402065,0.0005351903,0.41121352,0.0004899952],"about_ca_topic_score_codex":0.000055717912,"about_ca_topic_score_gemma":0.000005430567,"teacher_disagreement_score":0.87388957,"about_ca_system_score_codex":0.0004226062,"about_ca_system_score_gemma":0.00093358086,"threshold_uncertainty_score":0.84219414},"labels":[],"label_agreement":null},{"id":"W2594276295","doi":"10.1186/s40425-017-0225-6","title":"Immunotherapy biomarkers 2016: overcoming the barriers","year":2017,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"U.S. Food and Drug Administration; Society for Immunotherapy of Cancer","keywords":"Medicine; Immunotherapy; Data science; Computer science; Cancer; Internal medicine","score_opus":0.023611641771029142,"score_gpt":0.3512964664018322,"score_spread":0.32768482463080306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594276295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8230142,0.13148542,0.0017223064,0.029037444,0.008703107,0.0024403338,0.00014504029,0.00006930427,0.003382826],"genre_scores_gemma":[0.9029457,0.078319825,0.0017640588,0.0051703015,0.0016582248,0.00025252785,0.000006553052,0.00021890872,0.0096639125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977775,0.00006629289,0.00083393423,0.00026796907,0.0005259477,0.000528317],"domain_scores_gemma":[0.9968598,0.00016339452,0.0013162892,0.001134012,0.00037547795,0.00015101985],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014065771,0.00033953396,0.0006430007,0.00016546939,0.0019167748,0.00027257702,0.0008982688,0.000177002,0.0012890479],"category_scores_gemma":[0.00011769422,0.00021405914,0.0010464897,0.000113066046,0.0007009051,0.00037899666,0.000034068104,0.0003945692,0.0000028702298],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028217752,0.00009904475,0.0130962245,0.00008427801,0.005201976,0.000008455126,0.001152577,0.000008169856,0.4349012,0.00011487931,0.026364986,0.49075046],"study_design_scores_gemma":[0.019093841,0.0010467843,0.071722806,0.0007903501,0.00022431607,0.00022569828,0.00059662835,0.0000969289,0.055828184,0.00075571705,0.84918123,0.0004375049],"about_ca_topic_score_codex":0.0006380151,"about_ca_topic_score_gemma":0.000046794798,"teacher_disagreement_score":0.82281625,"about_ca_system_score_codex":0.00030050156,"about_ca_system_score_gemma":0.000846788,"threshold_uncertainty_score":0.9996239},"labels":[],"label_agreement":null},{"id":"W2612327959","doi":"10.1186/s40425-017-0243-4","title":"Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy","year":2017,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Immunotherapy; Immune system; Medicine; Tumor microenvironment; Cancer immunotherapy; Cancer; Immunology; Baseline (sea); Biomarker; Bioinformatics; Oncology; Internal medicine; Biology","score_opus":0.18568744673297063,"score_gpt":0.511312647124004,"score_spread":0.3256252003910334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612327959","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041970628,0.9856511,0.00076816237,0.000471054,0.007969339,0.0039194343,0.0005892358,0.000051872776,0.00016010174],"genre_scores_gemma":[0.00009598084,0.991942,0.0021599631,0.00033751942,0.000885103,0.00031581943,0.0000923618,0.0003824697,0.0037887879],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9882935,0.0005085017,0.008485507,0.0007904231,0.0010641123,0.0008579456],"domain_scores_gemma":[0.98745966,0.0007789173,0.008479897,0.001965761,0.0009871126,0.00032863545],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0073253596,0.0011334062,0.007537948,0.0012757813,0.00044133927,0.00013400918,0.0016228682,0.001140027,0.0011850558],"category_scores_gemma":[0.0004419902,0.0008554443,0.008517291,0.0006504387,0.0006248005,0.00027341963,0.00009931051,0.0013992252,0.000011139998],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009432679,0.00043244293,0.0007254312,0.008424779,0.018694798,0.000017263867,0.0001693201,0.0000013847787,0.0012384447,0.000008607319,0.0033992447,0.9574556],"study_design_scores_gemma":[0.011070272,0.0019929642,0.0009496042,0.047302507,0.002556729,0.00031187534,0.0000459119,0.000008028744,0.00022029314,0.000047795093,0.9347539,0.0007401335],"about_ca_topic_score_codex":0.0003548739,"about_ca_topic_score_gemma":0.00002417648,"teacher_disagreement_score":0.95671546,"about_ca_system_score_codex":0.0006711661,"about_ca_system_score_gemma":0.0021800841,"threshold_uncertainty_score":0.999728},"labels":[],"label_agreement":null},{"id":"W2766923414","doi":"10.1186/s40425-017-0290-x","title":"Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma","year":2017,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Hôpital Notre-Dame; Université du Québec à Montréal; Institute for Research in Immunology and Cancer; McGill University; Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"Bristol-Myers Squibb Canada; Réseau de cancérologie Rossy; Bristol-Myers Squibb","keywords":"Ipilimumab; Carboplatin; Medicine; Paclitaxel; Oncology; Melanoma; Internal medicine; Stage (stratigraphy); Blockade; Immune checkpoint; Chemotherapy; Immunotherapy; Cancer research; Cancer; Receptor; Cisplatin; Biology","score_opus":0.0230277490862044,"score_gpt":0.3553829253992408,"score_spread":0.3323551763130364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766923414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98132807,0.015156506,0.00038551664,0.0003114039,0.0006743197,0.0017578364,0.00018649155,0.000008494726,0.00019135648],"genre_scores_gemma":[0.9908253,0.0045322916,0.00021597723,0.00006679819,0.0001686918,0.0001538669,0.0000074842255,0.000054682267,0.003974893],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99759495,0.000087031214,0.0010951223,0.00030575562,0.0004934209,0.0004236988],"domain_scores_gemma":[0.9979107,0.00012724061,0.001170022,0.00047236026,0.00023548187,0.00008422995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010216548,0.00031012387,0.0010808539,0.00032827308,0.00030268787,0.00007220098,0.00030166018,0.00020319333,0.00046882217],"category_scores_gemma":[0.00006598277,0.0002152805,0.00023662695,0.00018293913,0.0005431052,0.00042466965,0.00004110079,0.0005052335,3.77492e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.786934,0.0010525263,0.0022378443,0.00021445222,0.00096216914,0.00005447149,0.0035480168,0.00016225876,0.1638057,0.000019388433,0.00007098018,0.040938184],"study_design_scores_gemma":[0.8331889,0.044850785,0.04752025,0.0025961443,0.00017984808,0.00006210901,0.003966191,0.0018629112,0.059502333,0.00009059368,0.005651886,0.0005280809],"about_ca_topic_score_codex":0.004946944,"about_ca_topic_score_gemma":0.0041285832,"teacher_disagreement_score":0.10430335,"about_ca_system_score_codex":0.0003898506,"about_ca_system_score_gemma":0.0008780247,"threshold_uncertainty_score":0.8778884},"labels":[],"label_agreement":null},{"id":"W2795166918","doi":"10.1186/s40425-017-0313-7","title":"Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Tumor microenvironment; Tumor progression; Cancer research; Angiogenesis; Macrophage; Population; Cancer; Medicine; Monocyte; Immunology; Chemistry; Internal medicine; Tumor cells; In vitro","score_opus":0.015898953830463896,"score_gpt":0.30018411644753457,"score_spread":0.28428516261707065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795166918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9481502,0.03985458,0.007623713,0.0013030664,0.0018517855,0.0005661065,0.000119872675,0.000016316202,0.00051435165],"genre_scores_gemma":[0.9908093,0.0020075687,0.0004737322,0.00033618076,0.00013152152,0.00012823472,0.000003760695,0.000054854667,0.0060548424],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878323,0.00009041887,0.0005493771,0.00016020988,0.000091278744,0.00032549832],"domain_scores_gemma":[0.9986165,0.00012976756,0.0006581581,0.00028716685,0.00029422453,0.000014157272],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041499015,0.00018655349,0.0003944767,0.00007441231,0.00032758646,0.00001509636,0.000415951,0.000084358726,0.0060704406],"category_scores_gemma":[0.00001740715,0.00011428225,0.0002068515,0.000109815104,0.0005519333,0.00009154786,0.000034653665,0.0003792845,0.000018667637],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002711714,0.00025127397,0.00022823308,0.000044088993,0.0020887868,7.560225e-7,0.00203849,0.0014981909,0.97394943,0.00007665171,0.004038624,0.013073771],"study_design_scores_gemma":[0.0062804124,0.0014605501,0.00059638824,0.0008896319,0.00036659688,0.0001333821,0.0009432575,0.0010709099,0.8457076,0.00061444327,0.14156963,0.00036723143],"about_ca_topic_score_codex":0.00015583416,"about_ca_topic_score_gemma":0.000091144604,"teacher_disagreement_score":0.137531,"about_ca_system_score_codex":0.00024470527,"about_ca_system_score_gemma":0.00016707301,"threshold_uncertainty_score":0.9948381},"labels":[],"label_agreement":null},{"id":"W2800200585","doi":"10.1186/s40425-018-0332-z","title":"Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Pembrolizumab; Medicine; Mucositis; Internal medicine; Esophagitis; Gastroenterology; Durvalumab; Oncology; Cancer; Radiation therapy; Surgery; Immunotherapy; Disease","score_opus":0.01402107771542368,"score_gpt":0.2911977492456359,"score_spread":0.27717667153021225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800200585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96577,0.03219998,0.000039224597,0.00083604857,0.00033867435,0.0005850488,0.00007302254,0.0000061412206,0.00015184825],"genre_scores_gemma":[0.996992,0.0016835316,0.000190407,0.00038260015,0.000084774256,0.000034728342,0.0000031504192,0.00004172603,0.00058707315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985416,0.00008218217,0.00060999894,0.00015303824,0.0003406233,0.0002725572],"domain_scores_gemma":[0.99861246,0.00013177816,0.0006018759,0.00024046379,0.00036938896,0.000044038778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043236004,0.00018832345,0.000566518,0.00015050852,0.00015263165,0.000019073103,0.00016727803,0.00007433666,0.00024634594],"category_scores_gemma":[0.000045325985,0.000117602154,0.00023385926,0.00035847406,0.00045021172,0.00011525628,0.000016390733,0.00021827375,1.378493e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07934641,0.001099238,0.4054796,0.0005376522,0.0049883425,0.000060492544,0.008797875,0.00003630474,0.29107386,0.00012485542,0.0015879917,0.20686737],"study_design_scores_gemma":[0.028763404,0.0035491807,0.9086361,0.0011450041,0.0002451251,0.0005816171,0.00031103293,0.00009768238,0.054189507,0.00019741165,0.0020722044,0.0002117383],"about_ca_topic_score_codex":0.0009119465,"about_ca_topic_score_gemma":0.00063749007,"teacher_disagreement_score":0.5031565,"about_ca_system_score_codex":0.00022068938,"about_ca_system_score_gemma":0.00042137792,"threshold_uncertainty_score":0.47956765},"labels":[],"label_agreement":null},{"id":"W2800568511","doi":"10.1186/s40425-018-0328-8","title":"Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Institutes of Health; National Cancer Institute; Melanoma Research Alliance","keywords":"Medicine; Immunotherapy; Melanoma; CTLA-4; Biomarker; Blockade; Oncology; Ipilimumab; Immune checkpoint; Predictive value; Immunology; Immune system; Internal medicine; T cell; Cancer research; Biology; Receptor","score_opus":0.015536892900585509,"score_gpt":0.32959102357534525,"score_spread":0.31405413067475973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800568511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98552555,0.007605517,0.0010747567,0.0018535594,0.0012192464,0.0021768329,0.0004535389,0.000023100463,0.00006792802],"genre_scores_gemma":[0.99346787,0.0030058275,0.0011431815,0.0010696277,0.00033167572,0.0002792783,0.000022543567,0.000104394705,0.0005755914],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975981,0.00011329704,0.00095010886,0.00040308444,0.00036981434,0.00056559325],"domain_scores_gemma":[0.99800223,0.0003248504,0.0004930537,0.00033556935,0.00069148163,0.00015281908],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001220328,0.0003673335,0.0008114344,0.00054929807,0.0002840548,0.000068723835,0.00023603602,0.00018188314,0.00022434875],"category_scores_gemma":[0.00013596739,0.0002929401,0.0003331938,0.00043731034,0.00032907038,0.00021311606,0.00002459281,0.00017821213,0.0000013906894],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21843538,0.00039648643,0.17336248,0.00009518983,0.0011433203,0.0000033167944,0.0019823643,0.0000017629922,0.48890355,0.0000044538674,0.0032881682,0.112383515],"study_design_scores_gemma":[0.026272012,0.0065555596,0.7948139,0.00068879017,0.000079466874,0.000036272697,0.0001457312,0.000121138495,0.052839924,0.000105852116,0.1179833,0.00035810936],"about_ca_topic_score_codex":0.00032094892,"about_ca_topic_score_gemma":0.00011966487,"teacher_disagreement_score":0.6214514,"about_ca_system_score_codex":0.00039939734,"about_ca_system_score_gemma":0.00041422257,"threshold_uncertainty_score":0.99995226},"labels":[],"label_agreement":null},{"id":"W2808122948","doi":"10.1186/s40425-018-0363-5","title":"Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Proteoglycans and glycosaminoglycans research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute; Royal Adelaide Hospital; Peter MacCallum Cancer Centre","keywords":"Medicine; Adverse effect; Pharmacology; Immune system; Toxicity; Clinical trial; Cancer; Immunology; Internal medicine","score_opus":0.031095811614531836,"score_gpt":0.39464869929133467,"score_spread":0.3635528876768028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808122948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915738,0.0065073497,0.0012482189,0.00014159056,0.00020064162,0.00025109618,0.00006214288,0.0000012402139,0.000013891435],"genre_scores_gemma":[0.99322575,0.0059229713,0.0005166564,0.000031384217,0.00021268427,0.000009141476,0.000011530093,0.0000147252085,0.000055125183],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887955,0.00009340549,0.00047524448,0.00022016455,0.00016963981,0.0001619918],"domain_scores_gemma":[0.99921423,0.000039056875,0.0002794701,0.00021424948,0.00020851866,0.000044493034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001020117,0.000101157944,0.00025227226,0.00007197444,0.0000828833,0.000017196138,0.00018582979,0.00011527096,0.000017119206],"category_scores_gemma":[0.00005021201,0.00008125176,0.000054548265,0.00005653347,0.00036350777,0.00002843166,0.00008594265,0.00017016912,3.6100978e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012544269,0.00041287692,0.076892614,0.00012008507,0.0005444844,0.0000019038448,0.0002853447,0.000009488169,0.61118454,0.000021991216,0.000257544,0.29772484],"study_design_scores_gemma":[0.020873047,0.012015897,0.45414507,0.00047043368,0.00009213359,0.00006557102,0.0006833483,0.00912694,0.48560122,0.0003850174,0.016001277,0.00054004684],"about_ca_topic_score_codex":0.00010261854,"about_ca_topic_score_gemma":0.00019408934,"teacher_disagreement_score":0.37725246,"about_ca_system_score_codex":0.000012411608,"about_ca_system_score_gemma":0.00022779933,"threshold_uncertainty_score":0.33133507},"labels":[],"label_agreement":null},{"id":"W2809418671","doi":"10.1186/s40425-018-0366-2","title":"Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Ontario Institute for Cancer Research","keywords":"Oncolytic virus; RNA interference; Virotherapy; Biology; Virology; Virus; Vesicular stomatitis virus; Interferon; Viral replication; Cancer research; RNA; Gene; Genetics","score_opus":0.016475318795310445,"score_gpt":0.361522493068755,"score_spread":0.34504717427344456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809418671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889081,0.0064577716,0.0026259841,0.00012843178,0.0002573491,0.0011903145,0.0003710854,0.000003700455,0.000057239147],"genre_scores_gemma":[0.9944094,0.003429931,0.00074962754,0.00013679633,0.00020140145,0.00020644406,0.00000536328,0.000060879385,0.00080016843],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99770546,0.00016619597,0.0009308742,0.00035614625,0.00046252314,0.00037880184],"domain_scores_gemma":[0.99727666,0.00004383159,0.00089493697,0.00060373155,0.0010670966,0.00011374124],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00062536687,0.00026544588,0.00060743355,0.00013629142,0.00007673139,0.000013441758,0.0007145872,0.0001957619,0.0010961434],"category_scores_gemma":[0.000049425504,0.00022217336,0.00032130754,0.00019987849,0.0004060569,0.000018006465,0.00006365467,0.00017909444,0.000001144015],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037038982,0.00034526063,0.00010615542,0.00014176365,0.00029645424,1.3917732e-7,0.00062302366,0.000069829024,0.93334234,0.0000016433949,0.001028652,0.027005767],"study_design_scores_gemma":[0.0029509005,0.014232466,0.00014183104,0.00048494505,0.0000179201,8.044299e-7,0.000080378086,0.000014445122,0.97901136,0.00008851121,0.0027663598,0.0002100625],"about_ca_topic_score_codex":0.00065308233,"about_ca_topic_score_gemma":0.0006990815,"teacher_disagreement_score":0.04566905,"about_ca_system_score_codex":0.00009511428,"about_ca_system_score_gemma":0.00059149996,"threshold_uncertainty_score":0.999817},"labels":[],"label_agreement":null},{"id":"W2886177168","doi":"10.1186/s40425-018-0381-3","title":"White paper on microbial anti-cancer therapy and prevention","year":2018,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovative Targeting Solutions (Canada)","funders":"National Cancer Institute","keywords":"Cancer therapy; Oncolytic virus; Medicine; Cancer; Cancer treatment; Commercialization; Intensive care medicine; Business; Internal medicine","score_opus":0.054621532462975804,"score_gpt":0.42136258989701986,"score_spread":0.36674105743404406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886177168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003661614,0.99451137,0.000030178497,0.00006340768,0.00055794476,0.00081829564,0.00030435028,0.0000029466319,0.000049910188],"genre_scores_gemma":[0.00003292176,0.99353546,0.00013555652,0.00013974073,0.0011812588,0.00028480732,0.00007298443,0.00007916284,0.0045381],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986952,0.000089278146,0.00043310795,0.00031589516,0.00017812895,0.00028838206],"domain_scores_gemma":[0.9989804,0.0000141450455,0.00051170756,0.00025091687,0.00017204245,0.00007080819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021335334,0.00031930587,0.00071628124,0.000106229534,0.00014290017,0.000059206835,0.0002245892,0.00024763535,0.00027575466],"category_scores_gemma":[0.000006020413,0.00022619934,0.0006466466,0.00007078108,0.00011046394,0.000009156854,0.00002544113,0.0001815489,0.0000017224276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083267444,0.00009686092,0.0000385793,0.0006821756,0.0019316562,5.331902e-7,0.000021585218,6.888562e-7,0.005511736,0.0000018797913,0.010640608,0.980241],"study_design_scores_gemma":[0.002225228,0.0016046356,0.000047674315,0.0026258356,0.000111285364,0.000019847232,0.0000028013853,1.2121467e-7,0.003532333,0.000029575955,0.9895808,0.00021982944],"about_ca_topic_score_codex":0.000049125727,"about_ca_topic_score_gemma":0.00007822342,"teacher_disagreement_score":0.9800212,"about_ca_system_score_codex":0.00008442285,"about_ca_system_score_gemma":0.00050798245,"threshold_uncertainty_score":0.9224141},"labels":[],"label_agreement":null},{"id":"W2888941300","doi":"10.1186/s40425-018-0398-7","title":"Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity","year":2018,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Natural Sciences and Engineering Research Council of Canada; Cancer Research Society","keywords":"Medicine; Immunosuppression; Immunotherapy; Perioperative; Cancer; Immune system; Surgical stress; Cancer immunotherapy; Intensive care medicine; Immunology; Bioinformatics; Surgery; Internal medicine","score_opus":0.0573483934805771,"score_gpt":0.39911118877289015,"score_spread":0.341762795292313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888941300","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010288428,0.9852351,0.000075149575,0.000111625835,0.0022026687,0.0019367795,0.000050702467,0.000058303463,0.000041268842],"genre_scores_gemma":[0.00046064475,0.9956501,0.00020520814,0.00032210365,0.0017019545,0.00046418363,0.00008209744,0.00036791433,0.0007457984],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99481857,0.0010163526,0.0021163346,0.00062615785,0.00063811394,0.0007844812],"domain_scores_gemma":[0.993146,0.0020834156,0.0028816452,0.00097036303,0.0005779822,0.0003406056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027197443,0.0010957648,0.0052267974,0.0008790283,0.0006677886,0.00022076693,0.0005380426,0.00068680034,0.00042126531],"category_scores_gemma":[0.00021878528,0.00080685265,0.0023493653,0.00039148398,0.0006351332,0.00041853837,0.00005018018,0.0012729944,0.0000028141028],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007135829,0.0001932048,0.000129703,0.009437033,0.00424814,0.000032831875,0.0012674439,4.8534804e-7,0.0010554414,0.0000053014983,0.000808424,0.9756862],"study_design_scores_gemma":[0.0038908706,0.003382008,0.00028176684,0.03595046,0.002001374,0.0022905848,0.00015035385,0.000012766655,0.00037276486,0.00008759194,0.95079213,0.00078729575],"about_ca_topic_score_codex":0.0002901795,"about_ca_topic_score_gemma":0.000013407353,"teacher_disagreement_score":0.9748989,"about_ca_system_score_codex":0.00051484996,"about_ca_system_score_gemma":0.0030173725,"threshold_uncertainty_score":0.9994382},"labels":[],"label_agreement":null},{"id":"W2895870246","doi":"10.1186/s40425-018-0420-0","title":"Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; University of Calgary; BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Pazopanib; Nivolumab; Sunitinib; Renal cell carcinoma; Tolerability; Discontinuation; Adverse effect; Internal medicine; Clinical endpoint; Oncology; Peripheral edema; Urology; Clinical trial; Cancer; Immunotherapy","score_opus":0.02981774737536692,"score_gpt":0.33283564118325626,"score_spread":0.30301789380788935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895870246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99506634,0.0025991092,0.000081102735,0.00026435588,0.00008855562,0.0017985274,0.0000124205335,0.0000037382376,0.00008581805],"genre_scores_gemma":[0.99763197,0.0007796071,0.0007122122,0.000055246335,0.000041316,0.000073612784,0.0000026314299,0.000034155804,0.00066923327],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99846697,0.00013351675,0.0006830574,0.00016689695,0.0003260175,0.00022354712],"domain_scores_gemma":[0.9986911,0.00026621285,0.0004902993,0.0002186604,0.0002876436,0.00004613096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006439441,0.00018272812,0.00057097676,0.00020316103,0.00008385169,0.000013220595,0.0001160807,0.00003162967,0.00013864627],"category_scores_gemma":[0.000035538753,0.000090260684,0.00007043352,0.0003211861,0.00015788824,0.00010578597,0.00001340064,0.00019499661,2.635915e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5002815,0.007814197,0.18787113,0.0006764894,0.0012644434,0.000280147,0.029534018,0.00029516828,0.11326576,0.00003771272,0.00009890672,0.15858051],"study_design_scores_gemma":[0.091949314,0.02702075,0.8177083,0.0005511792,0.0002654458,0.00014981402,0.0036059786,0.00013291217,0.057772294,0.00004098737,0.0006383928,0.00016461955],"about_ca_topic_score_codex":0.00044812373,"about_ca_topic_score_gemma":0.0015783393,"teacher_disagreement_score":0.6298372,"about_ca_system_score_codex":0.0002493974,"about_ca_system_score_gemma":0.00038170835,"threshold_uncertainty_score":0.3680724},"labels":[],"label_agreement":null},{"id":"W2901169611","doi":"10.1186/s40425-018-0433-8","title":"Immunoregulatory functions of innate lymphoid cells","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"IL-33, ST2, and ILC Pathways","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"Canada First Research Excellence Fund; Canada Research Chairs; Cancer Research Society","keywords":"Innate lymphoid cell; Innate immune system; Immunology; Medicine; Biology; Computational biology; Immune system","score_opus":0.013621574783314511,"score_gpt":0.2786182288879217,"score_spread":0.2649966541046072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901169611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9598263,0.026184434,0.0013656177,0.00010606745,0.009205379,0.00029922024,0.0015110486,0.00002659464,0.0014753235],"genre_scores_gemma":[0.9819771,0.0039404784,0.0002388928,0.00023056552,0.00038064376,0.000030516792,0.000017785384,0.000046803885,0.0131372195],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987512,0.00007614452,0.00061902555,0.00015180283,0.00006579423,0.00033603248],"domain_scores_gemma":[0.998396,0.00006190114,0.0005899963,0.0002800754,0.0006523003,0.00001975832],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003709439,0.0001812513,0.00041609534,0.0001849898,0.00034278532,0.000010259048,0.00030013066,0.00020947981,0.001254662],"category_scores_gemma":[0.000018678513,0.00015000007,0.00030375036,0.00017011393,0.0005279541,0.00013852291,0.000021806714,0.00019377435,0.000041046016],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014322611,0.00011798896,0.00044425493,0.000031665724,0.00073278794,2.481873e-7,0.001010265,0.000008618583,0.95089364,0.00016730546,0.017380312,0.027780626],"study_design_scores_gemma":[0.0022812246,0.00061050773,0.0014566687,0.0000642748,0.000040007144,0.000037530677,0.0001393837,0.0000014746423,0.54997045,0.0002543096,0.4450356,0.00010857735],"about_ca_topic_score_codex":0.00014706978,"about_ca_topic_score_gemma":0.00003464329,"teacher_disagreement_score":0.4276553,"about_ca_system_score_codex":0.000092043665,"about_ca_system_score_gemma":0.00040046583,"threshold_uncertainty_score":0.99965835},"labels":[],"label_agreement":null},{"id":"W2905817704","doi":"10.1186/s40425-018-0479-7","title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":571,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Canadian Institutes of Health Research","keywords":"Immune system; Immunotherapy; Medicine; Melanoma; Phenotype; Immune checkpoint; Immunology; Cancer research; Cancer; Biology; Internal medicine; Gene","score_opus":0.015517749621850001,"score_gpt":0.3085602037906005,"score_spread":0.2930424541687505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905817704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759296,0.017950699,0.00006930343,0.004497126,0.00077578425,0.0006848673,0.000048042275,0.000020995416,0.00002358389],"genre_scores_gemma":[0.99247515,0.003902081,0.0018085479,0.0005420653,0.0005199033,0.00007279949,0.0000037131535,0.000049441685,0.0006263084],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815613,0.00008035032,0.00077770953,0.00030473695,0.0003332834,0.00034778443],"domain_scores_gemma":[0.99856544,0.00027047584,0.0004121381,0.00019718731,0.0003926837,0.00016208779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010240142,0.0002786619,0.00058482133,0.0002704929,0.00031519812,0.000081646576,0.00011885209,0.00013323562,0.00022030504],"category_scores_gemma":[0.00014315828,0.00022135972,0.0001661119,0.00022253318,0.0006226259,0.00015441676,0.00004330808,0.00024407325,0.0000010929078],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1572043,0.00005530568,0.00038258475,0.000051071613,0.00055204955,0.000012308788,0.0015799609,0.0000033176016,0.79752576,0.00003760351,0.00019882157,0.04239691],"study_design_scores_gemma":[0.054383017,0.02263518,0.43643677,0.0021742487,0.00023040941,0.0008892004,0.00225591,0.000076902405,0.4389621,0.0004139387,0.040688075,0.0008542524],"about_ca_topic_score_codex":0.00037854037,"about_ca_topic_score_gemma":0.000025259073,"teacher_disagreement_score":0.43605417,"about_ca_system_score_codex":0.00022004051,"about_ca_system_score_gemma":0.0003591228,"threshold_uncertainty_score":0.9026787},"labels":[],"label_agreement":null},{"id":"W2905883696","doi":"10.1186/s40425-018-0480-1","title":"Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis","year":2018,"lang":"en","type":"letter","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Infliximab; Medicine; Immune system; Enterocolitis; Adverse effect; Immune dysregulation; Immune checkpoint; CTLA-4; Immunology; Intensive care medicine; Sepsis; Ipilimumab; Cancer; Oncology; Tumor necrosis factor alpha; Internal medicine; Immunotherapy; T cell","score_opus":0.051706465511070686,"score_gpt":0.3364134831832456,"score_spread":0.28470701767217493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905883696","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15142371,0.2162927,0.0007749204,0.61233,0.006263268,0.011028576,0.001811788,0.000024112214,0.00005088484],"genre_scores_gemma":[0.21138844,0.3274901,0.0012783086,0.3773631,0.044639047,0.010070033,0.0004376617,0.0013157069,0.026017636],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99605745,0.00021286745,0.002010948,0.0003137085,0.0008159369,0.00058909354],"domain_scores_gemma":[0.9922419,0.001590363,0.003978933,0.0012599669,0.00089455926,0.00003426762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012035505,0.0006111672,0.0012730379,0.0001243883,0.0006151536,0.0001112576,0.0009396288,0.00044845277,0.00047060096],"category_scores_gemma":[0.00007888168,0.00023523552,0.002359488,0.00022569961,0.000900184,0.000112114234,0.000034186865,0.0008491174,4.9674526e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025378864,0.00042127902,0.000111028196,0.00033240902,0.012414239,0.000003347245,0.00473645,0.0000087758135,0.20870097,0.000004933598,0.50900215,0.23888555],"study_design_scores_gemma":[0.009425483,0.004309738,0.0012983221,0.000925571,0.0009803306,0.00008692615,0.00031081363,0.00004936075,0.12792692,0.00004637791,0.85442144,0.0002187389],"about_ca_topic_score_codex":0.003458555,"about_ca_topic_score_gemma":0.00016569105,"teacher_disagreement_score":0.34541926,"about_ca_system_score_codex":0.000590358,"about_ca_system_score_gemma":0.0005452445,"threshold_uncertainty_score":0.9592626},"labels":[],"label_agreement":null},{"id":"W2906255446","doi":"10.1186/s40425-018-0457-0","title":"PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"PI3K/AKT/mTOR pathway; Tumor microenvironment; Immune system; CD8; Cancer research; T cell; Effector; Cytotoxic T cell; Immunosuppression; Immunotherapy; Biology; Chemistry; Pharmacology; Immunology; Medicine; Cell biology; In vitro; Signal transduction; Biochemistry","score_opus":0.015916303764539324,"score_gpt":0.30009173386688,"score_spread":0.28417543010234064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906255446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981578,0.006799478,0.0027808954,0.00012660008,0.006960285,0.0005209739,0.000027122212,0.000021848782,0.0011848309],"genre_scores_gemma":[0.99412984,0.0016839929,0.00014791895,0.0001409998,0.00015825873,0.0000543525,0.000018177061,0.000030469113,0.003635988],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864227,0.00023695451,0.0005679982,0.0001797599,0.00008308,0.00028995026],"domain_scores_gemma":[0.9981003,0.00015039422,0.0009490054,0.00025424393,0.0005325024,0.000013582246],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050625845,0.00021541819,0.0004936853,0.0001251968,0.00034645043,0.000018174705,0.00016028041,0.00014314135,0.002609612],"category_scores_gemma":[0.000044802026,0.00017736483,0.00032760025,0.0001418406,0.00027437563,0.0003532637,0.000024990644,0.000342919,0.000036641886],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032694137,0.0005735888,0.00025903367,0.00008865811,0.0004325936,2.4185474e-7,0.0007528128,0.0000015288397,0.9782678,0.000011110134,0.00501464,0.011328611],"study_design_scores_gemma":[0.0031712877,0.0024537267,0.0019290621,0.0002272981,0.00005817923,0.000021709046,0.00009593468,0.000004935124,0.9107976,0.0000546146,0.081023194,0.0001624633],"about_ca_topic_score_codex":0.00037656492,"about_ca_topic_score_gemma":0.00001635078,"teacher_disagreement_score":0.07600856,"about_ca_system_score_codex":0.00013923972,"about_ca_system_score_gemma":0.00013028024,"threshold_uncertainty_score":0.99830216},"labels":[],"label_agreement":null},{"id":"W2914393875","doi":"10.1186/s40425-018-0485-9","title":"Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; Swim Across America; National Institute of General Medical Sciences; KWF Kankerbestrijding; National Cancer Institute; National Institutes of Health; Cancer Prevention and Research Institute of Texas; National Institute of Allergy and Infectious Diseases; Deutsche Krebshilfe; Irving Medical Center, Columbia University; Owens Foundation; University of Texas MD Anderson Cancer Center","keywords":"Tumor microenvironment; Immune system; Head and neck squamous-cell carcinoma; Cancer research; Medicine; CD8; T cell; Mass cytometry; Myeloid; Antigen; Immunology; Cancer; Head and neck cancer; Biology; Internal medicine","score_opus":0.008691542132802798,"score_gpt":0.2691522417700022,"score_spread":0.26046069963719937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914393875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8870172,0.10837049,0.00033618035,0.00016508311,0.0033619548,0.00055341213,0.000045580084,0.000013042512,0.00013705154],"genre_scores_gemma":[0.9781321,0.014781529,0.0008536634,0.00020919324,0.00007457715,0.00006321082,0.000011606139,0.000053044623,0.0058210203],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998403,0.00006044688,0.00082756527,0.0002383186,0.000099490695,0.00037116287],"domain_scores_gemma":[0.99817455,0.00012160799,0.001125531,0.0003889949,0.00017692386,0.000012388338],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039030547,0.00025158533,0.0007095816,0.00015868079,0.000116544776,0.000012069311,0.00046485238,0.00018242524,0.0044735],"category_scores_gemma":[0.000008870602,0.00021135379,0.0003838645,0.00011656557,0.00024374956,0.00016405502,0.00002560298,0.000289004,0.000027691765],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018679807,0.00014463202,0.0033105817,0.0000705075,0.0007763828,2.2012551e-7,0.00043514828,0.00070985284,0.93875676,0.000088712964,0.00037341897,0.053465817],"study_design_scores_gemma":[0.004736022,0.00081909465,0.015563138,0.00017966224,0.000035874946,0.000035234447,0.00012257198,0.000017108454,0.9062225,0.0005091708,0.071534865,0.00022472505],"about_ca_topic_score_codex":0.00010821391,"about_ca_topic_score_gemma":0.000005513175,"teacher_disagreement_score":0.09358896,"about_ca_system_score_codex":0.00022616088,"about_ca_system_score_gemma":0.00010987413,"threshold_uncertainty_score":0.99643654},"labels":[],"label_agreement":null},{"id":"W2916703154","doi":"10.1186/s40425-019-0507-2","title":"Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital; Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Lung cancer; Cancer; Cancer research; Ligand (biochemistry); Medicine; Computational biology; Bioinformatics; Chemistry; Biology; Immunology; Oncology; Receptor; Internal medicine","score_opus":0.01122254260838088,"score_gpt":0.2874408932894919,"score_spread":0.276218350681111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916703154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92136526,0.025212016,0.012540047,0.0014555395,0.0359606,0.0018680493,0.00029276172,0.00007956103,0.0012261509],"genre_scores_gemma":[0.8882201,0.0030389826,0.00010370266,0.001201577,0.0001122052,0.00017781125,0.000057684378,0.000073979856,0.10701398],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99839807,0.00009426588,0.00059161417,0.00030677448,0.00013282096,0.00047646195],"domain_scores_gemma":[0.9984869,0.00006190608,0.0008310317,0.0002604503,0.00032426036,0.00003546633],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003079385,0.00031823348,0.0005528738,0.00015800296,0.0004010154,0.000051515803,0.00032493312,0.00028786523,0.013220611],"category_scores_gemma":[0.0000032457738,0.00027133146,0.00034709764,0.00009747179,0.000078599594,0.00029846595,0.000027736856,0.0005812519,0.000030164998],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022394962,0.00012374512,0.00008715215,0.00003507334,0.0010951692,2.4136938e-7,0.0011750251,0.00015716151,0.9563712,0.00007365342,0.036835004,0.0018070674],"study_design_scores_gemma":[0.0070526036,0.00056018465,0.00006871388,0.000117245756,0.0000688314,0.0000104997935,0.0004568806,0.000015376287,0.88990015,0.00023848508,0.10122114,0.00028991656],"about_ca_topic_score_codex":0.0015393528,"about_ca_topic_score_gemma":0.00015486623,"teacher_disagreement_score":0.10578783,"about_ca_system_score_codex":0.00038903803,"about_ca_system_score_gemma":0.00016172325,"threshold_uncertainty_score":0.9999739},"labels":[],"label_agreement":null},{"id":"W2921822469","doi":"10.1186/s40425-019-0521-4","title":"The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Inflammasome and immune disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"Associazione Italiana per la Ricerca sul Cancro; Worldwide Cancer Research","keywords":"Inflammasome; Signal transducing adaptor protein; Pancreatic cancer; Secretion; Cancer research; Cancer; Receptor; Medicine; Chemistry; Internal medicine","score_opus":0.0037357993382672663,"score_gpt":0.23353054729258363,"score_spread":0.22979474795431637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921822469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9554126,0.042812362,0.000011250573,0.0003454465,0.00048624355,0.00051687827,0.00038040648,0.0000041976205,0.00003058365],"genre_scores_gemma":[0.94837177,0.048800528,0.00003889531,0.00014247872,0.00011482329,0.00014573886,0.00004271343,0.00005895748,0.0022840737],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983917,0.00011008273,0.0006441392,0.00024473507,0.0002458223,0.00036356252],"domain_scores_gemma":[0.9983049,0.00005715202,0.0010075107,0.0002582893,0.00032093815,0.00005122191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039421994,0.00024295827,0.00042685933,0.000074931646,0.00013584546,0.000031152194,0.00024457774,0.00018146227,0.00010634026],"category_scores_gemma":[0.00005386614,0.00019023474,0.00021234762,0.00015122652,0.00012123336,0.000026667507,0.000028349816,0.00020502348,5.25123e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021396526,0.00005355201,0.038790856,0.0001047409,0.00034649772,1.6690245e-7,0.0002754465,0.0002686208,0.95080394,0.000004079283,0.0034686883,0.0037437903],"study_design_scores_gemma":[0.006017804,0.00085366226,0.046464246,0.0007129463,0.00006135941,0.0000018146131,0.0006148406,0.00019159481,0.8162353,0.00005788366,0.12838952,0.0003990115],"about_ca_topic_score_codex":0.0008608582,"about_ca_topic_score_gemma":0.0006868898,"teacher_disagreement_score":0.13456859,"about_ca_system_score_codex":0.00013961761,"about_ca_system_score_gemma":0.0003149688,"threshold_uncertainty_score":0.7757548},"labels":[],"label_agreement":null},{"id":"W2929415048","doi":"10.1186/s40425-019-0535-y","title":"Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; Toronto General Hospital","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; Center for AIDS Research, University of Washington; National Cancer Institute; National Institutes of Health; Kohlberg Foundation; Sarnoff Cardiovascular Research Foundation; American Heart Association","keywords":"Myocarditis; Vaccination; Medicine; Immunology; Immune system; Internal medicine","score_opus":0.02585979424590361,"score_gpt":0.3620537790854431,"score_spread":0.3361939848395395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2929415048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97909486,0.01853384,0.000024828298,0.00023088125,0.00075883983,0.00083622127,0.000014547958,0.000012500437,0.0004934496],"genre_scores_gemma":[0.98782694,0.010428685,0.0003436663,0.00033911585,0.00025878323,0.00006820831,0.0000031262973,0.000048442413,0.0006830114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984444,0.000038150487,0.00061872794,0.00015227373,0.0004639125,0.0002825544],"domain_scores_gemma":[0.99847794,0.00009332929,0.00043022537,0.00016694986,0.00076254096,0.00006903724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005918064,0.00015633265,0.00044770693,0.0002211811,0.00015507624,0.00003825618,0.0000840384,0.000087938766,0.00023462289],"category_scores_gemma":[0.00017688534,0.00012476814,0.00022733296,0.00014006824,0.00005947962,0.00031414998,0.00003461062,0.00030001398,0.0000031000343],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016970487,0.00008412513,0.7165814,0.00024583304,0.00076922955,8.446305e-7,0.0012881091,0.00003608958,0.049317546,0.000009803393,0.00069152366,0.22927846],"study_design_scores_gemma":[0.008073707,0.00080854486,0.9384501,0.00052597094,0.00004135393,0.000004977014,0.00014191537,0.000048089463,0.025854517,0.00010016808,0.025820965,0.00012968753],"about_ca_topic_score_codex":0.00013780837,"about_ca_topic_score_gemma":0.000009459761,"teacher_disagreement_score":0.22914878,"about_ca_system_score_codex":0.0002687019,"about_ca_system_score_gemma":0.000111860085,"threshold_uncertainty_score":0.5087897},"labels":[],"label_agreement":null},{"id":"W2933590268","doi":"10.1186/s40425-019-0519-y","title":"Correction to: 33rd Annual Meeting &amp; Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)","year":2019,"lang":"en","type":"erratum","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Council South Australia; Stand Up To Cancer; National Institutes of Health; Government of South Australia; Melanoma Research Alliance; South Australian Health and Medical Research Institute; Johns Hopkins University; Damon Runyon Cancer Research Foundation","keywords":"Cancer immunotherapy; Library science; Medicine; Immunotherapy; Cancer; Computer science; Internal medicine","score_opus":0.025540044931796076,"score_gpt":0.34468516163508495,"score_spread":0.3191451167032889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2933590268","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12813939,0.5297921,0.0058825053,0.007767302,0.29748008,0.023483392,0.0050809407,0.00014111343,0.0022331837],"genre_scores_gemma":[0.020449776,0.26074332,0.0069638146,0.0034103375,0.008947653,0.0028799449,0.00038019518,0.0009463919,0.6952786],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953401,0.00010650325,0.0021010302,0.00057050976,0.001125196,0.00075665046],"domain_scores_gemma":[0.9922647,0.0002651206,0.0039482773,0.00095694145,0.0024531463,0.000111810274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013516743,0.00074270816,0.0019758139,0.00025322803,0.0003119719,0.00006473967,0.00094720925,0.00075095793,0.00046123308],"category_scores_gemma":[0.00008485725,0.00052782486,0.0040684957,0.0006097275,0.00041715222,0.00019824396,0.00005910312,0.0011814898,7.01732e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023411438,0.00036658198,0.0017553286,0.0017076413,0.0071166055,1.4428241e-7,0.005086754,0.00008814106,0.11822059,0.0000052961177,0.59208024,0.25016123],"study_design_scores_gemma":[0.009058772,0.002844325,0.006168755,0.011831107,0.00073411316,0.000026818614,0.0006260947,0.00013579815,0.018943217,0.000069383444,0.94895816,0.0006034603],"about_ca_topic_score_codex":0.004013355,"about_ca_topic_score_gemma":0.0015765105,"teacher_disagreement_score":0.6930454,"about_ca_system_score_codex":0.0008769084,"about_ca_system_score_gemma":0.0035404016,"threshold_uncertainty_score":0.99971735},"labels":[],"label_agreement":null},{"id":"W2935816391","doi":"10.1186/s40425-019-0538-8","title":"Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Hyundai Hope On Wheels; National Cancer Institute; Stand Up To Cancer; U.S. Department of Health and Human Services; National Institutes of Health; University of Wisconsin Carbone Cancer Center; ECOG-ACRIN Cancer Research Group; Midwest Athletes Against Childhood Cancer; American College of Radiology Imaging Network; U.S. Public Health Service; St. Baldrick's Foundation; American Association for Cancer Research; University of Wisconsin-Madison","keywords":"Rituximab; Follicular lymphoma; Human leukocyte antigen; Follicular phase; Medicine; Immunology; Lymphoma; Internal medicine; Antigen","score_opus":0.00666545812998804,"score_gpt":0.2356607765638207,"score_spread":0.22899531843383267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935816391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763623,0.020509243,0.00023578474,0.0003269505,0.0020601752,0.00041472245,0.000018018789,0.000015385749,0.000057459034],"genre_scores_gemma":[0.9913491,0.0032100882,0.00012447154,0.00045050425,0.000044126693,0.000024872297,0.000018335362,0.000040554645,0.0047379555],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989904,0.00004917739,0.00041848587,0.00023207472,0.000046148834,0.00026370081],"domain_scores_gemma":[0.99909526,0.00010347804,0.00039730576,0.00016719062,0.000208175,0.000028590213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002550596,0.00023799132,0.00047249332,0.00013069704,0.00024895705,0.00006739495,0.00009719668,0.00017783561,0.000346663],"category_scores_gemma":[0.000017994975,0.00016091084,0.000102950864,0.000048983973,0.000118687014,0.00033783307,0.000028950775,0.00022092111,0.000002934659],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069176424,0.00027037843,0.18394719,0.000110902125,0.0014444643,4.1608243e-7,0.0022102832,0.0000021314568,0.6223994,0.000035701974,0.0012140127,0.18144746],"study_design_scores_gemma":[0.06149268,0.0050070793,0.40011224,0.00064258557,0.0002210567,0.00028454553,0.0015170078,0.00012821889,0.16234824,0.00031489512,0.36701274,0.0009187121],"about_ca_topic_score_codex":0.0001339893,"about_ca_topic_score_gemma":0.000022896145,"teacher_disagreement_score":0.46005118,"about_ca_system_score_codex":0.00006790545,"about_ca_system_score_gemma":0.000046453,"threshold_uncertainty_score":0.65617543},"labels":[],"label_agreement":null},{"id":"W2937370179","doi":"10.1186/s40425-019-0543-y","title":"Merger of dynamic two-photon and phosphorescence lifetime microscopy reveals dependence of lymphocyte motility on oxygen in solid and hematological tumors","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Advanced Fluorescence Microscopy Techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"National Institute of Biomedical Imaging and Bioengineering; National Institute of Neurological Disorders and Stroke; National Institutes of Health; National Cancer Institute; Canadian Institutes of Health Research; Victoria University; Cancer Prevention and Research Institute of Texas","keywords":"Motility; Bone marrow; Tumor microenvironment; Intravital microscopy; Immune system; Tumor hypoxia; Pathology; Hypoxia (environmental); Lymphocyte; Leukemia; Oxygen; Cancer research; Chemistry; Immunology; Medicine; Biology; Cell biology; Radiation therapy; Internal medicine; Microcirculation","score_opus":0.006129024459720525,"score_gpt":0.33289727716882284,"score_spread":0.3267682527091023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937370179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98352915,0.014983361,0.0009162451,0.0000316907,0.000077019795,0.00040579648,0.000045515724,0.0000029427401,0.00000828034],"genre_scores_gemma":[0.9757525,0.013539798,0.010525151,0.00007624736,0.000009300282,0.000018782763,0.0000027145043,0.000019818532,0.000055734105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988032,0.000045435645,0.0005463831,0.00026120737,0.00013726356,0.00020653226],"domain_scores_gemma":[0.99906844,0.000034893546,0.0004785992,0.00023403944,0.00014403136,0.00003999292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036278777,0.00016692646,0.00045580027,0.00006870134,0.000029676146,0.000006925689,0.00020580429,0.00012422993,0.000020486788],"category_scores_gemma":[0.000043477885,0.0001401239,0.00009360979,0.000072204784,0.00023779228,0.000012670774,0.000045498964,0.00012134168,1.0791613e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019450401,0.00006696605,0.0294274,0.00010562351,0.00004094364,7.445494e-7,0.00007734858,0.0000370696,0.96528107,0.000012462401,0.0000162786,0.0029890698],"study_design_scores_gemma":[0.001413853,0.0007868953,0.0272845,0.0004415747,0.00000720093,0.00002425594,0.000037283018,0.00015681134,0.96926445,0.0003686947,0.00009658033,0.000117879215],"about_ca_topic_score_codex":0.00007178711,"about_ca_topic_score_gemma":0.000018941771,"teacher_disagreement_score":0.009608906,"about_ca_system_score_codex":0.00004941402,"about_ca_system_score_gemma":0.00010729862,"threshold_uncertainty_score":0.5714087},"labels":[],"label_agreement":null},{"id":"W2937848504","doi":"10.1186/s40425-018-0488-6","title":"Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver Coastal Health; Canadian Centre for Applied Research in Cancer Control; Occupational Cancer Research Centre; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute","keywords":"Immune system; Tumor microenvironment; CD8; Cell; T cell; Cytotoxic T cell; Lung cancer; Biology; Cancer research; Adenocarcinoma; Pathology; Cancer; Medicine; Immunology; Internal medicine; In vitro","score_opus":0.013211437999701406,"score_gpt":0.320314737866742,"score_spread":0.3071032998670406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937848504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9491236,0.044366114,0.00030829853,0.0014103155,0.0026364853,0.0010529557,0.00012947425,0.000031053332,0.0009416733],"genre_scores_gemma":[0.98014706,0.008017587,0.00046688662,0.00097502634,0.00043852604,0.00015275284,0.000020971263,0.00008736027,0.009693819],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978736,0.0001024143,0.0007898615,0.00031779017,0.00037926988,0.0005370735],"domain_scores_gemma":[0.99770653,0.00020879344,0.0011170477,0.00031362657,0.00055636093,0.00009763333],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049904326,0.00032737738,0.0008194851,0.00020396146,0.00020921817,0.00003508914,0.0002585965,0.00014240379,0.0029875862],"category_scores_gemma":[0.000020204114,0.00025039862,0.00053082383,0.00023439167,0.00021169115,0.0002043675,0.000014678301,0.0006627574,0.000003841393],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017798416,0.0005270318,0.05039003,0.0002482467,0.001757125,0.0000091529855,0.002158483,0.00011698044,0.91108066,0.000013755806,0.0049752896,0.010924816],"study_design_scores_gemma":[0.08189479,0.011877272,0.29801694,0.0070192697,0.0018268637,0.00048859447,0.0026581108,0.0014218679,0.50359917,0.00037418664,0.08864154,0.0021814264],"about_ca_topic_score_codex":0.0010391179,"about_ca_topic_score_gemma":0.00018187979,"teacher_disagreement_score":0.40748152,"about_ca_system_score_codex":0.00089457806,"about_ca_system_score_gemma":0.00087223644,"threshold_uncertainty_score":0.9999948},"labels":[],"label_agreement":null},{"id":"W2943155654","doi":"10.1186/s40425-019-0542-z","title":"Radiotherapy enhances responses of lung cancer to CTLA-4 blockade","year":2019,"lang":"en","type":"letter","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Abscopal effect; Ipilimumab; Medicine; Radiation therapy; Immunotherapy; CTLA-4; Immune system; Lung cancer; Oncology; Clinical trial; Blockade; Immune checkpoint; Biological response modifiers; Immunology; Internal medicine; T cell; Receptor","score_opus":0.02045189570884703,"score_gpt":0.3664423344238244,"score_spread":0.34599043871497737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943155654","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10485345,0.29724178,0.00072102674,0.58368856,0.008424036,0.0036741823,0.0011525264,0.000048102578,0.00019634589],"genre_scores_gemma":[0.0037460527,0.23861152,0.003697912,0.661497,0.015468632,0.0009872977,0.000077271376,0.00069536467,0.07521895],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99551654,0.00016637813,0.001775642,0.0005689358,0.0011625208,0.00080998696],"domain_scores_gemma":[0.9955859,0.00053349807,0.0019768297,0.000825885,0.0009704651,0.000107430424],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008236044,0.00073935936,0.002215614,0.00092198775,0.00015673264,0.000062150335,0.00072989275,0.00090656034,0.0028016407],"category_scores_gemma":[0.000054793294,0.00059031503,0.0016113188,0.0005384806,0.0002610178,0.00015426647,0.00002551837,0.0014195632,0.0000019997563],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025888436,0.00008187284,0.00083587976,0.0011090075,0.0046576033,0.000014881135,0.0006376718,0.00002408191,0.3803986,0.0000010883784,0.55432963,0.032021224],"study_design_scores_gemma":[0.0072487546,0.0019613022,0.0010223379,0.0037305364,0.00048060433,0.00009440474,0.000033017477,0.000023328159,0.15050407,0.000024196444,0.8343296,0.0005478298],"about_ca_topic_score_codex":0.00081405824,"about_ca_topic_score_gemma":0.000027385757,"teacher_disagreement_score":0.27999994,"about_ca_system_score_codex":0.00095721975,"about_ca_system_score_gemma":0.002366094,"threshold_uncertainty_score":0.9996548},"labels":[],"label_agreement":null},{"id":"W2943665137","doi":"10.1186/s40425-019-0578-0","title":"Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Dental and Craniofacial Research","keywords":"Medicine; Cetuximab; Nivolumab; Pembrolizumab; Head and neck squamous-cell carcinoma; Internal medicine; Oncology; Docetaxel; Clinical trial; Immunotherapy; Head and neck cancer; Cancer","score_opus":0.06821629106114331,"score_gpt":0.4354250672816484,"score_spread":0.36720877622050513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943665137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783666,0.019301195,0.00004082142,0.00022834,0.0004850252,0.00131966,0.00018752963,0.000003142856,0.000067678346],"genre_scores_gemma":[0.992919,0.00634968,0.00017078078,0.00028931772,0.00005520437,0.000018631776,0.0000079916435,0.000023336985,0.0001660499],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964533,0.00037731818,0.0023179234,0.00025490363,0.00035873384,0.00023784551],"domain_scores_gemma":[0.99648046,0.0005532891,0.0022272605,0.00034080286,0.00032658954,0.00007157343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002299497,0.00024481452,0.002312767,0.0003784027,0.0000636783,0.00001655492,0.00017944293,0.00016160238,0.00018775927],"category_scores_gemma":[0.000045836325,0.00015675496,0.00091015594,0.00055575714,0.00028538847,0.00011222173,0.000020149822,0.00027359696,1.00668416e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06318129,0.0011610964,0.7103981,0.00018262755,0.002770033,6.8607307e-7,0.0028496836,0.000061220686,0.1872271,0.0000068805743,0.00017067253,0.031990655],"study_design_scores_gemma":[0.09768809,0.0035284965,0.8359793,0.0002799982,0.0009288666,0.0000035494154,0.00027981537,0.000867433,0.057440117,0.000040108185,0.0027774877,0.00018674337],"about_ca_topic_score_codex":0.00059529796,"about_ca_topic_score_gemma":0.000104743245,"teacher_disagreement_score":0.12978698,"about_ca_system_score_codex":0.00008548452,"about_ca_system_score_gemma":0.00024864843,"threshold_uncertainty_score":0.63922817},"labels":[],"label_agreement":null},{"id":"W2944068250","doi":"10.1186/s40425-019-0544-x","title":"Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Krembil Foundation; Université de Montréal; Institute for Research in Immunology and Cancer; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"Fonds de Recherche du Québec - Santé; Natural Sciences and Engineering Research Council of Canada; Mitacs; Canadian Cancer Society Research Institute; Institute of Cancer Research; Institut Du Cancer de Montréal; Terry Fox Research Institute; Canada Foundation for Innovation","keywords":"Multiplex; Medicine; Immune system; Immune checkpoint; Profiling (computer programming); Lung cancer; Oncology; Risk stratification; Immunology; Immunotherapy; Internal medicine; Bioinformatics; Biology; Computer science","score_opus":0.017285490871467562,"score_gpt":0.31139325831436837,"score_spread":0.2941077674429008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944068250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9226211,0.047777332,0.016829016,0.0011743994,0.0017041806,0.009219604,0.00061534817,0.000023238184,0.000035829464],"genre_scores_gemma":[0.96755385,0.0065398067,0.021101195,0.0001714213,0.00020025304,0.0030708404,0.00021623871,0.000111484485,0.0010348795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99710125,0.000041785417,0.00174439,0.00032540841,0.00035106047,0.00043608196],"domain_scores_gemma":[0.9958622,0.00040088565,0.0017132012,0.00038935008,0.0015632218,0.000071171446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009833039,0.00034014322,0.000832026,0.00028169848,0.00021517956,0.00003795873,0.00022809676,0.00015844377,0.00016496805],"category_scores_gemma":[0.00007649969,0.00028103785,0.0008567574,0.000267401,0.00009426424,0.00014925822,0.000016563072,0.00019829615,3.8764134e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011869898,0.0009985022,0.0074593853,0.0021342165,0.0011402103,2.0777769e-7,0.0011544655,0.00065319665,0.9349947,0.00005953911,0.0002383201,0.039297376],"study_design_scores_gemma":[0.026870003,0.0038399224,0.01348119,0.0015910818,0.0005248592,0.000009374395,0.0010330166,0.014103465,0.9325553,0.00010971306,0.0054872897,0.00039475854],"about_ca_topic_score_codex":0.0002721843,"about_ca_topic_score_gemma":0.000032808046,"teacher_disagreement_score":0.044932827,"about_ca_system_score_codex":0.00041721322,"about_ca_system_score_gemma":0.0008226202,"threshold_uncertainty_score":0.9999642},"labels":[],"label_agreement":null},{"id":"W2944392072","doi":"10.1186/s40425-019-0541-0","title":"An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Institute of Cancer Research; Ontario Institute for Cancer Research; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"Terry Fox Research Institute; Ontario Ministry of Research, Innovation and Science; Canada Research Chairs; Government of Ontario; Ontario Institute for Cancer Research; Ontario Ministry of Research and Innovation; Princess Margaret Cancer Foundation","keywords":"Pembrolizumab; Medicine; Internal medicine; Immunophenotyping; Oncology; Immune system; CD8; Tumor-infiltrating lymphocytes; Interim analysis; Clinical trial; Immunotherapy; Immunology; Antigen","score_opus":0.10289923724578354,"score_gpt":0.4450525707470737,"score_spread":0.3421533335012902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944392072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991771,0.0032561272,0.000023587252,0.0015169935,0.00092029775,0.0023665417,0.000021894297,0.000020003778,0.00010358029],"genre_scores_gemma":[0.99775666,0.000556526,0.000053334777,0.0010388055,0.000114279836,0.00016886716,0.000010469142,0.000043410644,0.0002576394],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99698615,0.0006248405,0.0010940759,0.00026526727,0.0007888728,0.00024077031],"domain_scores_gemma":[0.99702454,0.00030317745,0.0010846654,0.0007193447,0.0007847266,0.000083544764],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003830035,0.00023446965,0.0005841233,0.00022916713,0.00014695605,0.000033335706,0.00030421678,0.00012661616,0.0014473146],"category_scores_gemma":[0.0003089126,0.00014248077,0.00033099347,0.00028335137,0.0001803749,0.00015764235,0.000012480709,0.0003539011,0.0000018360473],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21472621,0.0022603034,0.0031880324,0.000026290385,0.0013342239,0.000014795244,0.001964664,0.000046243513,0.7282369,0.000014911379,0.00045991113,0.04772749],"study_design_scores_gemma":[0.16980983,0.15450533,0.2574072,0.0017746276,0.00091831625,0.0010305119,0.008747362,0.0016600471,0.3591464,0.00047257636,0.04374772,0.00078010076],"about_ca_topic_score_codex":0.00013151625,"about_ca_topic_score_gemma":0.000009164392,"teacher_disagreement_score":0.36909053,"about_ca_system_score_codex":0.0003469537,"about_ca_system_score_gemma":0.0009894568,"threshold_uncertainty_score":0.9994655},"labels":[],"label_agreement":null},{"id":"W2946884236","doi":"10.1186/s40425-019-0575-3","title":"CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Roche Innovation Center Zurich; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Sociedad Española de Oncología Médica; Cancer Research UK; Wellcome Trust","keywords":"Medicine; Colorectal cancer; Immunotherapy; Cancer immunotherapy; Organoid; Bispecific antibody; Cancer research; Antibody; Immunology; Cancer; Monoclonal antibody; Biology; Internal medicine; Genetics","score_opus":0.017888921491295666,"score_gpt":0.34024556078457385,"score_spread":0.3223566392932782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946884236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97030044,0.024430022,0.00022387886,0.002695833,0.0007578928,0.0013115826,0.00019030702,0.000013937698,0.0000761076],"genre_scores_gemma":[0.9822976,0.0152047165,0.00054299465,0.0007506951,0.00033497706,0.000097185104,0.000017874892,0.00007126783,0.00068268116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973552,0.00015571123,0.00079017796,0.00040521374,0.0006786899,0.0006149656],"domain_scores_gemma":[0.998482,0.00028769558,0.00038433878,0.00024084696,0.0004390656,0.00016606659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050408306,0.00033366427,0.0007175234,0.00021286475,0.0003308296,0.00008323494,0.0003107724,0.00014783537,0.000908101],"category_scores_gemma":[0.000053950676,0.00021493243,0.00023694821,0.00029607626,0.00017673113,0.00016436605,0.00007368249,0.00057983486,0.000007969147],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016334703,0.00014511068,0.078678966,0.00014203634,0.00025307483,0.0000093367935,0.001546975,0.00012779933,0.89360994,0.000014431891,0.0013581553,0.007779447],"study_design_scores_gemma":[0.006174091,0.0012174457,0.1770268,0.0010751857,0.000027586415,0.00003933626,0.00048175815,0.00022822997,0.70150197,0.000062474595,0.1118041,0.00036101794],"about_ca_topic_score_codex":0.00043938807,"about_ca_topic_score_gemma":0.0005206733,"teacher_disagreement_score":0.19210799,"about_ca_system_score_codex":0.00025772347,"about_ca_system_score_gemma":0.00037163406,"threshold_uncertainty_score":0.9943069},"labels":[],"label_agreement":null},{"id":"W2947794723","doi":"10.1186/s40425-019-0602-4","title":"Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop","year":2019,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Caprion (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; University of Toronto; University Health Network","funders":"National Center for Advancing Translational Sciences; Society for Immunotherapy of Cancer; National Cancer Institute; Celgene","keywords":"Premise; Cancer; Cancer immunotherapy; Immune escape; Immune system; Immunotherapy; Computational biology; Bioinformatics; Medicine; Immunology; Psychology; Biology; Genetics","score_opus":0.11245442319226147,"score_gpt":0.4196030258259771,"score_spread":0.30714860263371563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947794723","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008758338,0.98927665,0.00008067281,0.0016285112,0.0034292236,0.0032795235,0.0013749361,0.000019092004,0.00003557502],"genre_scores_gemma":[0.00008630256,0.9949322,0.00026322072,0.00093329506,0.00090058375,0.0005907569,0.00007910612,0.00022175354,0.001992806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950481,0.00041781034,0.0026278098,0.00051626447,0.0008175917,0.0005724203],"domain_scores_gemma":[0.9919796,0.0020406838,0.0036367476,0.0011191888,0.0011206189,0.00010317075],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007721254,0.0008581903,0.0051298765,0.000331256,0.00020321307,0.00006713803,0.0010032769,0.00059785496,0.0016418556],"category_scores_gemma":[0.00007510874,0.0005136753,0.0041079177,0.000785823,0.00040471874,0.0001339865,0.00007639491,0.0010714633,0.0000055372407],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011995067,0.0001453044,0.000032144653,0.011421816,0.013960815,0.000008342686,0.00081137166,0.000007131185,0.0025457928,0.000008232348,0.0047228844,0.9543411],"study_design_scores_gemma":[0.004921595,0.00052979257,0.0003400935,0.084829465,0.004191369,0.000094415955,0.0003134148,0.0000034399914,0.00039328643,0.000037099817,0.9038746,0.00047144585],"about_ca_topic_score_codex":0.002090258,"about_ca_topic_score_gemma":0.0001005984,"teacher_disagreement_score":0.95386964,"about_ca_system_score_codex":0.0007559713,"about_ca_system_score_gemma":0.003377965,"threshold_uncertainty_score":0.9997315},"labels":[],"label_agreement":null},{"id":"W2947924669","doi":"10.1186/s40425-019-0595-z","title":"Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"vaccines and immunoinformatics approaches","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Epitope; Antigen; Computational biology; Major histocompatibility complex; T cell; CD8; Cancer immunotherapy; Immunotherapy; MHC class I; Peptide; Biology; Epitope mapping; Immunology; Immune system; Biochemistry","score_opus":0.03674745316633686,"score_gpt":0.30496311464875525,"score_spread":0.2682156614824184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947924669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620414,0.002518132,0.0008212552,0.000027257835,0.00014841411,0.00017822317,0.000022290602,7.142203e-7,0.00007959396],"genre_scores_gemma":[0.9948891,0.0027830638,0.001732105,0.000016902046,0.000043778004,0.000004430723,0.000014665631,0.000012530613,0.0005034508],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99944806,0.000009578871,0.00032677146,0.000059022805,0.00007919545,0.00007738369],"domain_scores_gemma":[0.9991507,0.000015480531,0.0005160266,0.000096389376,0.00020909116,0.0000122914635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014991983,0.00007354247,0.00016341754,0.00005249611,0.000027545993,0.000009715739,0.00008408045,0.000059277634,0.00001864996],"category_scores_gemma":[0.000014454571,0.00006014125,0.00006830488,0.000047671096,0.000019197301,0.000019415167,0.000013396996,0.00003986768,1.2206809e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005710185,0.000026292275,0.0022508272,0.00016001026,0.00008993251,1.3464675e-8,0.00023718723,0.00025887656,0.9732235,0.000006761805,0.000079226505,0.023096344],"study_design_scores_gemma":[0.001440603,0.0008053749,0.005177782,0.000085797714,0.000015692125,0.00000503087,0.00021363296,0.0003793425,0.9894456,0.000041531144,0.002318906,0.00007066562],"about_ca_topic_score_codex":0.000022443273,"about_ca_topic_score_gemma":0.0000022320737,"teacher_disagreement_score":0.023025677,"about_ca_system_score_codex":0.000008998049,"about_ca_system_score_gemma":0.00006329505,"threshold_uncertainty_score":0.2452489},"labels":[],"label_agreement":null},{"id":"W2948662515","doi":"10.1186/s40425-019-0623-z","title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":438,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); Royal Ottawa Mental Health Centre","funders":"National Institute for Health and Care Research; Amgen","keywords":"Medicine; Oncolytic virus; Internal medicine; Melanoma; Confidence interval; Oncology; Hazard ratio; Randomized controlled trial; Cancer; Cancer research","score_opus":0.05177845107064362,"score_gpt":0.3877663574224503,"score_spread":0.3359879063518067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948662515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94316775,0.051560204,0.00047275395,0.000037106576,0.002311246,0.0020410037,0.00026322145,0.000012648145,0.00013409794],"genre_scores_gemma":[0.98980176,0.005408275,0.00029522186,0.0000274424,0.000053000902,0.00012655767,0.000030246829,0.00005522625,0.004202242],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959338,0.00082234864,0.0021870993,0.0003030399,0.00019775206,0.0005559775],"domain_scores_gemma":[0.9947825,0.0020994307,0.0022364445,0.00045561083,0.00039862405,0.00002736257],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017269354,0.00040065843,0.0024462652,0.00055381353,0.00016032238,0.00002274657,0.0005281803,0.00035270336,0.0042943363],"category_scores_gemma":[0.00025299954,0.00032178624,0.0010703144,0.00039485234,0.00041135596,0.0002560456,0.000042285126,0.00047120042,0.0000038176304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50032496,0.0004392762,0.0001172506,0.000053290765,0.0020264403,0.0000018299924,0.00074445544,0.00091491104,0.49086827,0.00002089162,0.00003223633,0.0044561843],"study_design_scores_gemma":[0.55701,0.003909777,0.00012504136,0.00019048492,0.00012876147,0.000007187029,0.00023899456,0.0001423824,0.4360845,0.000019831172,0.001942359,0.0002006585],"about_ca_topic_score_codex":0.0022626882,"about_ca_topic_score_gemma":0.00006267701,"teacher_disagreement_score":0.05668505,"about_ca_system_score_codex":0.0001644073,"about_ca_system_score_gemma":0.000574991,"threshold_uncertainty_score":0.9999234},"labels":[],"label_agreement":null},{"id":"W2948878352","doi":"10.1186/s40425-019-0619-8","title":"DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Southeastern Ontario Academic Medical Organization; Queen's University","keywords":"Immunoediting; Bladder cancer; Immune checkpoint; DNA repair; Immune system; Gene; Cancer; Cancer research; DNA mismatch repair; Immunotherapy; Tumor microenvironment; Medicine; Bioinformatics; Biology; Immunology; Genetics; Internal medicine","score_opus":0.010395492579599383,"score_gpt":0.275885229973412,"score_spread":0.26548973739381265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948878352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798083,0.018319596,0.00004231024,0.00047791566,0.0003565945,0.00079952,0.00009287269,0.000020102427,0.000082834755],"genre_scores_gemma":[0.9915912,0.0049490742,0.0010119185,0.0004162235,0.00020037698,0.00018710211,0.000015700247,0.00006128922,0.0015670988],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987871,0.000053260053,0.00041485668,0.00022073287,0.00027205312,0.0002519858],"domain_scores_gemma":[0.99883807,0.00010333988,0.0004731418,0.0002214993,0.0002972671,0.00006668422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027415677,0.00019958206,0.00045852814,0.00015494839,0.00011016185,0.000022249773,0.00007581437,0.000090037625,0.00035968274],"category_scores_gemma":[0.000018568164,0.00013747421,0.00015940148,0.00015470792,0.000047981106,0.00021797244,0.000012011342,0.00020343081,0.0000010786005],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018988356,0.00014409439,0.15472098,0.000075468655,0.00070738536,0.0000057999,0.00201382,0.0001518263,0.8363015,0.000003218892,0.0002527384,0.003724312],"study_design_scores_gemma":[0.007835858,0.00064210064,0.45520154,0.00048620143,0.000106183375,0.000021783288,0.00041734145,0.000040961706,0.5331228,0.00010079274,0.001876361,0.00014811497],"about_ca_topic_score_codex":0.0004082809,"about_ca_topic_score_gemma":0.00027061615,"teacher_disagreement_score":0.30317876,"about_ca_system_score_codex":0.0005049428,"about_ca_system_score_gemma":0.000576036,"threshold_uncertainty_score":0.56060356},"labels":[],"label_agreement":null},{"id":"W2952406594","doi":"10.1186/s40425-017-0215-8","title":"Gene expression markers of Tumor Infiltrating Leukocytes","year":2017,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":850,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Cancer Institute","keywords":"Immune system; Biology; Gene; Gene expression; Immunotherapy; Flow cytometry; Gene expression profiling; Computational biology; Genetics","score_opus":0.02844187749003703,"score_gpt":0.34877392438913074,"score_spread":0.3203320468990937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952406594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792354,0.017327879,0.0004146554,0.00075706636,0.0011088381,0.00044377957,0.000039697486,0.0000110396295,0.0006616112],"genre_scores_gemma":[0.98389083,0.0067924834,0.007371816,0.00034681862,0.00044783423,0.000042407908,0.000003045489,0.000051347837,0.0010534266],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985534,0.000026292011,0.00069215166,0.00014746339,0.00033768747,0.00024301666],"domain_scores_gemma":[0.99761957,0.000076361626,0.0014396938,0.00046654785,0.0003313131,0.00006649786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057170185,0.00017386777,0.0005128306,0.00012086677,0.00038695207,0.000051275612,0.00031525167,0.00007800613,0.0004571834],"category_scores_gemma":[0.00008526674,0.00013152618,0.00047237397,0.000051699364,0.00023707039,0.00023272658,0.00001942201,0.00018303143,3.3422455e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016123302,0.00007645488,0.013597809,0.00013421892,0.00048064117,0.000003546079,0.00021703659,0.000007828278,0.8709354,0.0000065917657,0.001504522,0.09691269],"study_design_scores_gemma":[0.007918112,0.0010919176,0.05380713,0.0011009371,0.000073592775,0.00009383353,0.0001565724,0.000035153033,0.91422725,0.000117040865,0.021228734,0.00014971847],"about_ca_topic_score_codex":0.00023396792,"about_ca_topic_score_gemma":0.000014461331,"teacher_disagreement_score":0.09676297,"about_ca_system_score_codex":0.0001183854,"about_ca_system_score_gemma":0.00036789197,"threshold_uncertainty_score":0.5363482},"labels":[],"label_agreement":null},{"id":"W2954038428","doi":"10.1186/s40425-019-0632-y","title":"Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Imperial Experimental Cancer Medicine Centre; National Institute for Health and Care Research; University of Leeds; Yorkshire Cancer Research; Kay Kendall Leukaemia Fund; Cancer Research UK; NHS Blood and Transplant","keywords":"Medicine; Oncolytic virus; Immune system; Immunology; Acquired immune system; Cancer; Immunotherapy; Internal medicine","score_opus":0.023023416088482497,"score_gpt":0.32839453528579615,"score_spread":0.30537111919731363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954038428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850974,0.0134518845,0.00009864751,0.00012115337,0.00039345145,0.00060511555,0.00012428434,0.00000496896,0.000103096434],"genre_scores_gemma":[0.98931843,0.008842987,0.00016892978,0.00040444345,0.00013326712,0.000049174538,0.000012539852,0.00006987684,0.0010003304],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840283,0.00016970489,0.0004409727,0.00028158384,0.00026940848,0.00043548632],"domain_scores_gemma":[0.9988335,0.000062172396,0.00033611836,0.0003338221,0.00031551626,0.0001188666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005929539,0.00025600253,0.0004018604,0.00009799014,0.00016609237,0.00006438691,0.00037543805,0.0001507967,0.00018650839],"category_scores_gemma":[0.000016679785,0.00023260158,0.00017848329,0.00012493593,0.00014012345,0.000021103453,0.00004911126,0.00037872125,0.000006848357],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071573365,0.00010157116,0.00036487167,0.000042370753,0.0004217332,0.000001549933,0.00010077972,0.000082474995,0.9832666,0.0000057046145,0.0005144436,0.007940593],"study_design_scores_gemma":[0.004438303,0.006311185,0.00041658856,0.000083574356,0.000023518354,0.00002765717,0.00014389628,0.00012297998,0.97799295,0.0000741117,0.0100832805,0.00028198192],"about_ca_topic_score_codex":0.00010067789,"about_ca_topic_score_gemma":0.00006719846,"teacher_disagreement_score":0.009568837,"about_ca_system_score_codex":0.000088893066,"about_ca_system_score_gemma":0.00050864666,"threshold_uncertainty_score":0.94852173},"labels":[],"label_agreement":null},{"id":"W2954377994","doi":"10.1186/s40425-019-0640-y","title":"Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada); Ontario Institute for Cancer Research; Jewish General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; Society for Immunotherapy of Cancer; National Cancer Institute; Celgene","keywords":"Library science; Computer science; Psychology","score_opus":0.03021381831505963,"score_gpt":0.3515596864330823,"score_spread":0.3213458681180226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954377994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8122178,0.17154235,0.00038987029,0.007567683,0.0066289897,0.0014124663,0.00015355504,0.00001657554,0.00007075937],"genre_scores_gemma":[0.9190523,0.06865584,0.0005908987,0.00499262,0.00071366195,0.0002882806,0.000016732787,0.000109938184,0.005579724],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978699,0.00012661406,0.00092257163,0.00026395568,0.0004911943,0.00032574573],"domain_scores_gemma":[0.99692935,0.0008370946,0.0007799043,0.0004897873,0.0008870702,0.000076766264],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044754436,0.00027945184,0.00090095936,0.00016043747,0.00013986269,0.000035989302,0.00034495423,0.00012713135,0.0017632501],"category_scores_gemma":[0.00006362971,0.00018691516,0.00072753016,0.00051829114,0.00013036796,0.0001239123,0.00003063201,0.00036748234,0.0000049465734],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049091093,0.00012186507,0.005945721,0.00012709145,0.002482066,0.0000018175492,0.0028608753,0.00024835495,0.6332858,0.0000059787412,0.0126927495,0.2931366],"study_design_scores_gemma":[0.011035202,0.0016943214,0.18773723,0.0062642065,0.00042078036,0.000048703,0.0027176186,0.00015325703,0.1360693,0.00008712486,0.65338665,0.00038562494],"about_ca_topic_score_codex":0.004660668,"about_ca_topic_score_gemma":0.0003295873,"teacher_disagreement_score":0.6406939,"about_ca_system_score_codex":0.0003707363,"about_ca_system_score_gemma":0.0006543428,"threshold_uncertainty_score":0.99914926},"labels":[],"label_agreement":null},{"id":"W2956407203","doi":"10.1186/s40425-019-0673-2","title":"Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Cancer Research UK; Richard M. Schulze Family Foundation; Mayo Foundation for Medical Education and Research; Hyundai Hope On Wheels; Mayo Clinic","keywords":"Medicine; Immunotherapy; Toxicity; Oncolytic virus; Immunology; Immune system; Brainstem; Cancer research; Internal medicine","score_opus":0.022841207930643707,"score_gpt":0.34046279427430043,"score_spread":0.3176215863436567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956407203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876729,0.009096428,0.00003464726,0.0006931489,0.000319193,0.0014503687,0.00004451535,0.000008446766,0.000680323],"genre_scores_gemma":[0.99064404,0.005050235,0.00008684834,0.00052169105,0.00013948651,0.000070534516,0.000002219713,0.000050248433,0.0034346979],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99792284,0.00019115445,0.00059217063,0.00021026129,0.0006981111,0.00038549246],"domain_scores_gemma":[0.99834895,0.00046403086,0.00040371765,0.0004400752,0.00028875167,0.000054463304],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011826089,0.0002304561,0.000705486,0.0002873723,0.00009238852,0.00002807167,0.0004206426,0.00010093566,0.0014387846],"category_scores_gemma":[0.000039488797,0.00014903733,0.00046482956,0.00037623692,0.0001930211,0.00012505913,0.000020640318,0.00041909073,0.0000022173656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006450941,0.00025099228,0.04481001,0.00021918229,0.0004733356,0.000008910583,0.00477706,0.000078407465,0.8493126,0.0000639041,0.0001997566,0.093354896],"study_design_scores_gemma":[0.02475063,0.0064588273,0.42949754,0.0019308303,0.000087446446,0.00028953727,0.005345263,0.00021624692,0.51124364,0.0005202527,0.019172044,0.00048774978],"about_ca_topic_score_codex":0.001246635,"about_ca_topic_score_gemma":0.0002530193,"teacher_disagreement_score":0.38468754,"about_ca_system_score_codex":0.00040122579,"about_ca_system_score_gemma":0.00040422642,"threshold_uncertainty_score":0.99947405},"labels":[],"label_agreement":null},{"id":"W2958648554","doi":"10.1186/s40425-019-0662-5","title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":738,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Center for Advancing Translational Sciences; University of Texas MD Anderson Cancer Center; National Institute for Health and Care Research; Cancer Research UK; Yale University; Society for Immunotherapy of Cancer; Università degli Studi di Milano; Brigham and Women's Hospital; Yale Cancer Center; Memorial Sloan-Kettering Cancer Center","keywords":"Pembrolizumab; Medicine; Nivolumab; Head and neck squamous-cell carcinoma; Oncology; Internal medicine; Immunotherapy; Cancer; Head and neck cancer; Population","score_opus":0.02314064955390921,"score_gpt":0.33343247864077485,"score_spread":0.31029182908686564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2958648554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.790246,0.19892289,0.00013313814,0.0037360727,0.0014492159,0.004876777,0.00059778476,0.0000064173696,0.00003172795],"genre_scores_gemma":[0.88735527,0.10700372,0.00060385844,0.00079288136,0.00024729135,0.0008251852,0.0000066181337,0.00012890917,0.003036241],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99692214,0.000086805616,0.0015719372,0.0003176359,0.00056975335,0.0005317052],"domain_scores_gemma":[0.99467266,0.001542063,0.0021019725,0.00085436594,0.0007753607,0.000053560638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009401458,0.00046185256,0.0010724323,0.00008809796,0.00047989291,0.00003376973,0.00047833283,0.00017585425,0.00013007197],"category_scores_gemma":[0.000014287259,0.000227224,0.0023758041,0.00023327266,0.00063578534,0.00005502466,0.000014781383,0.00019607155,1.2923817e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10086498,0.0012326423,0.011761172,0.0006887403,0.0061990824,2.3461318e-7,0.0064315167,0.00029657263,0.60567796,0.00015251918,0.0037661763,0.26292843],"study_design_scores_gemma":[0.0661817,0.019177442,0.041730758,0.00059860013,0.00059673353,0.000013093886,0.002135157,0.0004246919,0.4815457,0.00029506176,0.38692397,0.0003771151],"about_ca_topic_score_codex":0.0015838358,"about_ca_topic_score_gemma":0.00023429436,"teacher_disagreement_score":0.3831578,"about_ca_system_score_codex":0.00051309983,"about_ca_system_score_gemma":0.00095399586,"threshold_uncertainty_score":0.9265926},"labels":[],"label_agreement":null},{"id":"W2961644267","doi":"10.1186/s40425-019-0643-8","title":"Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer; Yale Cancer Center; Li Ka Shing Foundation; National Cancer Institute; National Institutes of Health; National Science Foundation; Yale University; AstraZeneca; Symphogen; Memorial Sloan-Kettering Cancer Center; National Center for Advancing Translational Sciences; Chugai Pharmaceutical","keywords":"Erlotinib; Infiltration (HVAC); Medicine; Immune system; Cancer research; Mutant; Lung; Oncology; Immunology; Internal medicine; Epidermal growth factor receptor; Biology; Receptor; Gene","score_opus":0.008928297133187109,"score_gpt":0.3020364498705301,"score_spread":0.293108152737343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961644267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97809285,0.019130934,0.000055118297,0.00030710682,0.00090834143,0.0013297674,0.00010293797,0.000018493034,0.000054454587],"genre_scores_gemma":[0.9916406,0.0063716513,0.0003853516,0.0002894345,0.00013268038,0.000057434776,0.000033716366,0.00008183295,0.0010072744],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99721307,0.000085948486,0.0015354627,0.0002448738,0.0005481679,0.00037250877],"domain_scores_gemma":[0.9976677,0.00022239966,0.0013642485,0.00031637895,0.00034443857,0.00008488878],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000813569,0.00031205348,0.00091618934,0.00034143365,0.00007344681,0.00002274199,0.00022848258,0.00015845078,0.0011997995],"category_scores_gemma":[0.000042165702,0.00021562011,0.00034599705,0.00040002025,0.00014129058,0.00025433395,0.000015222866,0.0003510663,0.000001916522],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04117475,0.00024540213,0.017209578,0.0003630371,0.0004884477,0.0000121076755,0.0008342642,0.00020637093,0.92820776,0.0000029666771,0.0007190978,0.010536204],"study_design_scores_gemma":[0.021677593,0.0023224968,0.021791589,0.0031360348,0.00007990761,0.00009003975,0.0004314618,0.0010111459,0.9382583,0.000019004621,0.01087062,0.0003118409],"about_ca_topic_score_codex":0.0003367716,"about_ca_topic_score_gemma":0.000063109284,"teacher_disagreement_score":0.01949716,"about_ca_system_score_codex":0.0004111368,"about_ca_system_score_gemma":0.00090839766,"threshold_uncertainty_score":0.99971324},"labels":[],"label_agreement":null},{"id":"W2961709931","doi":"10.1186/s40425-019-0641-x","title":"Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Cancer Institute, University of Pittsburgh; National Cancer Institute; National Institutes of Health; Ovarian Cancer Research Fund Alliance; Roswell Park Cancer Institute; Ovarian Cancer Research Fund","keywords":"Oncolytic virus; Medicine; Tumor microenvironment; Ovarian cancer; Immunotherapy; Immune checkpoint; Immune system; Blockade; CD8; Cancer research; Cancer immunotherapy; Immunology; Adjuvant; Cancer; Internal medicine; Receptor","score_opus":0.016154443909586744,"score_gpt":0.3142447476610089,"score_spread":0.29809030375142215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961709931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896852,0.007984183,0.00014638918,0.00084939075,0.00012025961,0.0011349545,0.000064951055,0.0000053635176,0.000009346242],"genre_scores_gemma":[0.9924468,0.0055370894,0.00027720587,0.0006212202,0.0001200761,0.00014177492,0.0000073926344,0.00008559379,0.0007628801],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982025,0.000203362,0.0004331419,0.00035994573,0.00033430682,0.00046671377],"domain_scores_gemma":[0.99884266,0.00006117409,0.00039281303,0.00037246308,0.00022522268,0.00010565362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008616986,0.0002876732,0.00046723353,0.00018222303,0.00011182781,0.000051644405,0.00029813146,0.00010250237,0.000255327],"category_scores_gemma":[0.000012340242,0.00021051962,0.00010335917,0.0001303337,0.000070072216,0.000022127108,0.000040189523,0.000267555,7.4357365e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14950615,0.0001055158,0.07199779,0.000057962898,0.0005497764,0.0000102689455,0.00045527262,0.00019158337,0.77022314,7.393272e-7,0.000031021496,0.006870781],"study_design_scores_gemma":[0.019190839,0.014157785,0.17369625,0.00049817015,0.000055741926,0.00006850426,0.00027909514,0.000070355025,0.78858095,0.000056894496,0.0029153596,0.00043006882],"about_ca_topic_score_codex":0.00037872806,"about_ca_topic_score_gemma":0.0020310918,"teacher_disagreement_score":0.13031532,"about_ca_system_score_codex":0.0001674552,"about_ca_system_score_gemma":0.000586485,"threshold_uncertainty_score":0.85847414},"labels":[],"label_agreement":null},{"id":"W2967093625","doi":"10.1186/s40425-019-0700-3","title":"PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"FujiFilm VisualSonics (Canada)","funders":"Leids Universitair Medisch Centrum; H2020 Marie Skłodowska-Curie Actions; KWF Kankerbestrijding; European Commission","keywords":"Tumor microenvironment; Immunotherapy; Cancer immunotherapy; Blockade; Immune system; Cancer research; Mass cytometry; Medicine; CD8; T cell; Immune checkpoint; Flow cytometry; In vivo; Colorectal cancer; Cancer; Immunology; Receptor; Biology; Internal medicine; Phenotype","score_opus":0.014173682057967981,"score_gpt":0.320614542574468,"score_spread":0.3064408605165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967093625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763529,0.019681007,0.0001038285,0.0007329245,0.0018036555,0.0008360367,0.000026622194,0.000030700423,0.00043234453],"genre_scores_gemma":[0.9816013,0.00499142,0.004906642,0.0019310771,0.0010248192,0.00011265473,0.0000068705504,0.00011928514,0.005305918],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981761,0.0000665792,0.00067614985,0.00027532395,0.00038868788,0.00041718475],"domain_scores_gemma":[0.99862564,0.00025554493,0.0005149512,0.00023687347,0.00023149497,0.00013548616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007946784,0.00026931494,0.0006029726,0.00021919383,0.00028290582,0.00007574925,0.00015592533,0.00010384044,0.0007983982],"category_scores_gemma":[0.0000678383,0.00022242557,0.00025974392,0.00020349643,0.00008622265,0.0002647751,0.00001861743,0.00033290355,0.0000027117608],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071950597,0.00006437599,0.01700647,0.00019261322,0.00050975545,0.0000017764289,0.001837826,0.00006210394,0.92355835,0.000005224562,0.0032663317,0.046300087],"study_design_scores_gemma":[0.007212264,0.0011234275,0.00803571,0.0010827242,0.000040113402,0.000097622666,0.0013256586,0.000058850917,0.70606697,0.000028570441,0.2746403,0.00028780184],"about_ca_topic_score_codex":0.00021012442,"about_ca_topic_score_gemma":0.0000074474697,"teacher_disagreement_score":0.27137396,"about_ca_system_score_codex":0.00033199615,"about_ca_system_score_gemma":0.0004007958,"threshold_uncertainty_score":0.90702516},"labels":[],"label_agreement":null},{"id":"W2968230578","doi":"10.1186/s40425-019-0698-6","title":"Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Center for Advancing Translational Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; National Institutes of Health; National Cancer Institute; Irving Medical Center, Columbia University; National Institute of Dental and Craniofacial Research; University of Texas MD Anderson Cancer Center","keywords":"Medicine; Tumor microenvironment; Cancer research; Immune checkpoint; Immune system; Cytotoxic T cell; T cell; Immunology; Immunotherapy; Biology","score_opus":0.012831285176136567,"score_gpt":0.28629095324417336,"score_spread":0.2734596680680368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968230578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9248024,0.07155423,0.0011456091,0.0010347144,0.00048753238,0.0008840531,0.000024748673,0.000009290394,0.000057391724],"genre_scores_gemma":[0.95562476,0.041333236,0.0013481906,0.0004465845,0.00013090279,0.00003524339,0.000009992323,0.000055687306,0.0010154183],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984366,0.000027716933,0.0008035895,0.00019520955,0.00031025417,0.00022659416],"domain_scores_gemma":[0.9987977,0.000049392274,0.00069922,0.00026220916,0.00014107255,0.000050383045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045096115,0.0002110185,0.00057603745,0.00018785475,0.000073862924,0.000018411374,0.000078687604,0.00012623407,0.00070036465],"category_scores_gemma":[0.0000029697476,0.00017100901,0.00039172583,0.00012910862,0.00013453414,0.00014790791,0.000008833323,0.0001684308,6.8193947e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008520571,0.00014375977,0.008062794,0.00016463874,0.0008705897,4.317529e-7,0.00056197273,0.00011787318,0.8310085,0.0000636566,0.00002632721,0.15045887],"study_design_scores_gemma":[0.022545217,0.0033956203,0.3137943,0.0009763866,0.0001706156,0.00014788524,0.00026800775,0.0007157206,0.6315638,0.0009105256,0.025175558,0.00033637145],"about_ca_topic_score_codex":0.00011656121,"about_ca_topic_score_gemma":0.0000062675476,"teacher_disagreement_score":0.30573153,"about_ca_system_score_codex":0.00028472007,"about_ca_system_score_gemma":0.00009862136,"threshold_uncertainty_score":0.7668502},"labels":[],"label_agreement":null},{"id":"W2973724679","doi":"10.1186/s40425-019-0734-6","title":"Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":187,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Qatar National Research Fund; Istituto Oncologico Veneto; Fondazione Italiana per la Ricerca sul Cancro; Università degli Studi di Verona; Università Cattolica del Sacro Cuore; Università degli Studi di Padova; Cancer Research Institute; Fondazione Italiana per la ricerca sulle Malattie del Pancreas; EuroNanoMed III; Associazione Italiana per la Ricerca sul Cancro; Agence Nationale de la Recherche","keywords":"CD14; Myeloid-derived Suppressor Cell; Immunosuppression; Medicine; Immune system; Cancer research; Myeloid; Flow cytometry; STAT3; Immunology; CD16; Suppressor; Biology; Internal medicine; Cancer; Apoptosis","score_opus":0.005649180257663867,"score_gpt":0.23961331054345023,"score_spread":0.23396413028578636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973724679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96258014,0.033697452,0.000050419698,0.0001300598,0.001791315,0.0010894509,0.0005795302,0.0000178742,0.00006374952],"genre_scores_gemma":[0.9916223,0.0022511713,0.00013726194,0.0002377141,0.000022386286,0.00009897552,0.00016077526,0.0001029757,0.0053664143],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976934,0.00018840152,0.0008555437,0.00039835676,0.00016734489,0.0006969441],"domain_scores_gemma":[0.9982671,0.00017028362,0.0007555269,0.00046106448,0.00031083147,0.000035158875],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025737222,0.00042202076,0.00079257356,0.00016952254,0.00016134705,0.000042323227,0.00053733005,0.00032914747,0.0027092674],"category_scores_gemma":[0.000009283452,0.000331097,0.0001926878,0.00019976417,0.00022823314,0.00032865859,0.000039975686,0.00064017426,0.000030566272],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007990941,0.0003265888,0.04945101,0.0000807255,0.00065317407,0.0000010012411,0.0011275308,0.00005024062,0.91862154,0.0000013021245,0.019511316,0.0021846062],"study_design_scores_gemma":[0.020783385,0.0016168081,0.034936823,0.0003147495,0.000081786435,0.0000095700525,0.00025926955,0.000012562245,0.9150389,0.000030468653,0.026456295,0.00045939782],"about_ca_topic_score_codex":0.0005698148,"about_ca_topic_score_gemma":0.0000065991853,"teacher_disagreement_score":0.03144628,"about_ca_system_score_codex":0.00040698383,"about_ca_system_score_gemma":0.00031592647,"threshold_uncertainty_score":0.9999141},"labels":[],"label_agreement":null},{"id":"W2981595408","doi":"10.1186/s40425-019-0762-2","title":"Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Pediatric Oncology Group","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; EMD Serono; Eisai; Servier; Amgen; Pfizer; Daiichi Sankyo Europe; Eli Lilly and Company; Eurostars; GlaxoSmithKline","keywords":"Medicine; T cell; Immunology; Fludarabine; Tumor microenvironment; Progressive disease; Synovial sarcoma; Cytotoxic T cell; Immune system; Cancer research; Internal medicine; Pathology; Sarcoma; Biology; Disease; Chemotherapy","score_opus":0.018535859971319776,"score_gpt":0.3255511113769634,"score_spread":0.3070152514056436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981595408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98067176,0.01659469,0.0007251451,0.00012910995,0.00057535945,0.0010043986,0.000025598625,0.0000062091844,0.00026772692],"genre_scores_gemma":[0.9928043,0.0051009767,0.00019122215,0.0000760481,0.00011000175,0.000019329316,0.0000018124839,0.000053422074,0.0016428734],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99819154,0.00012192855,0.0006834003,0.00017053835,0.00049219193,0.00034043333],"domain_scores_gemma":[0.9990917,0.00020772095,0.00014567316,0.00025756445,0.00021283026,0.0000845353],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009969873,0.00018578098,0.00078877265,0.00029865053,0.00005104053,0.00001686729,0.00018084125,0.0001387396,0.00094784424],"category_scores_gemma":[0.00001172552,0.00015444572,0.00039567752,0.00022058668,0.0001338428,0.00012843039,0.00001597374,0.0005375503,0.0000018270491],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00864249,0.00017409744,0.011090083,0.00038540812,0.00059718,0.000012242215,0.0022149382,0.00010133652,0.9219583,0.000019253837,0.00003717182,0.054767482],"study_design_scores_gemma":[0.049428657,0.0073127244,0.033210192,0.0054295114,0.00024075847,0.00039614463,0.005008857,0.00090430037,0.88506025,0.00022039736,0.012217852,0.00057038164],"about_ca_topic_score_codex":0.0005365323,"about_ca_topic_score_gemma":0.00005067927,"teacher_disagreement_score":0.054197103,"about_ca_system_score_codex":0.0003106876,"about_ca_system_score_gemma":0.00036033522,"threshold_uncertainty_score":0.9999654},"labels":[],"label_agreement":null},{"id":"W2991173919","doi":"10.1186/s40425-019-0783-x","title":"Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial","year":2019,"lang":"en","type":"letter","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"National Cancer Institute; Chemotherapy Foundation; Breast Cancer Research Foundation; U.S. Department of Defense","keywords":"Blockade; Medicine; Concomitant; Immunotherapy; Oncology; Cyclophosphamide; Immune system; Doxorubicin; Radiation therapy; Internal medicine; Cisplatin; Clinical trial; Chemotherapy; Immunology; Receptor","score_opus":0.04260303808485426,"score_gpt":0.39823958657665026,"score_spread":0.355636548491796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991173919","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18680817,0.04081974,0.00045313008,0.7566952,0.0105833,0.003908783,0.00059833203,0.000037452286,0.00009588768],"genre_scores_gemma":[0.02349484,0.037265588,0.0017663823,0.8396256,0.04175267,0.0018193397,0.00022380354,0.00059408054,0.05345767],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961154,0.00025429518,0.0014072793,0.0005694438,0.0009663634,0.0006872113],"domain_scores_gemma":[0.99637496,0.0008030693,0.0011099582,0.0010635336,0.00056559057,0.00008286914],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010517123,0.00061301555,0.0013439184,0.00038420944,0.0003458475,0.00025892493,0.00084233837,0.0007761515,0.0010861596],"category_scores_gemma":[0.00009980089,0.00041572025,0.0011493634,0.00047593497,0.0001549877,0.0002062945,0.00004755358,0.0020409469,0.000022209082],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.241466,0.00007349304,0.000011662427,0.00007431645,0.0023101796,0.000010448558,0.0012115734,0.000017051076,0.16565701,0.0000027800602,0.52039605,0.06876945],"study_design_scores_gemma":[0.020581858,0.0036408477,0.0011374445,0.0015373223,0.00036293187,0.00006926815,0.00041293848,0.000001215485,0.030638743,0.00013954398,0.94099367,0.00048423265],"about_ca_topic_score_codex":0.0017055896,"about_ca_topic_score_gemma":0.00012332048,"teacher_disagreement_score":0.4205976,"about_ca_system_score_codex":0.0007692403,"about_ca_system_score_gemma":0.0024624404,"threshold_uncertainty_score":0.9998295},"labels":[],"label_agreement":null},{"id":"W2992570001","doi":"10.1186/s40425-019-0559-3","title":"Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","year":2019,"lang":"en","type":"erratum","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; University of Calgary; BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Pazopanib; Sunitinib; Nivolumab; Renal cell carcinoma; Medicine; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.02364807024486524,"score_gpt":0.32243165102808974,"score_spread":0.2987835807832245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992570001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816694,0.00781455,0.00007864195,0.00026471136,0.0045068962,0.0052096928,0.00005136231,0.000006535399,0.00039817917],"genre_scores_gemma":[0.9258496,0.0045498786,0.00031517827,0.00009004038,0.00016926495,0.00025719317,0.000046908688,0.00012217565,0.06859973],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9974153,0.00022527724,0.0011175041,0.00032415884,0.0005977658,0.00031999568],"domain_scores_gemma":[0.9975254,0.00047890292,0.0011317867,0.0003696313,0.00042382703,0.00007048115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007923672,0.00039483863,0.0013021734,0.0005171228,0.000083824,0.00002621539,0.00019267661,0.0001102123,0.00012657308],"category_scores_gemma":[0.00008495514,0.00020996961,0.00015969458,0.00049975706,0.00007518715,0.000110732166,0.00002388425,0.0008281327,5.598857e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69093245,0.010075144,0.04071864,0.0035234992,0.003007601,0.00044598582,0.024866214,0.002739315,0.016803604,0.0000063955763,0.033297133,0.17358404],"study_design_scores_gemma":[0.1310944,0.060341164,0.7606519,0.006615684,0.0012735791,0.00041209543,0.006436768,0.00041495616,0.008852407,0.000015356845,0.023223309,0.00066837325],"about_ca_topic_score_codex":0.0011892214,"about_ca_topic_score_gemma":0.0036656174,"teacher_disagreement_score":0.7199333,"about_ca_system_score_codex":0.00083296467,"about_ca_system_score_gemma":0.0013316629,"threshold_uncertainty_score":0.8562312},"labels":[],"label_agreement":null},{"id":"W2995191565","doi":"10.1186/s40425-019-0777-8","title":"Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia model","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation; Leukemia and Lymphoma Society of Canada; Leukemia and Lymphoma Society","keywords":"Immunotherapy; Cancer research; CD8; Immune system; Immunology; Cancer; Cancer immunotherapy; Medicine; Interleukin 15; Leukemia; Cytotoxic T cell; Cancer cell; Interleukin 2; Cytokine; Interleukin; Biology; Internal medicine","score_opus":0.03037206175191861,"score_gpt":0.31059204252489875,"score_spread":0.28021998077298016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995191565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91988736,0.056338552,0.0003007996,0.0006391277,0.020623466,0.0011479297,0.00018032183,0.000067121226,0.0008153483],"genre_scores_gemma":[0.8960112,0.06161663,0.00028587607,0.0012141222,0.00025121024,0.00051477004,0.000112725975,0.00021716548,0.039776314],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99685454,0.00021220771,0.0013958436,0.00051798526,0.00017513365,0.00084426865],"domain_scores_gemma":[0.9979073,0.0001732351,0.00097075093,0.0004650572,0.00043775974,0.000045919307],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054028945,0.00053579913,0.0010151102,0.00043860386,0.00018511269,0.000060803803,0.0006182535,0.00047029427,0.020979673],"category_scores_gemma":[0.000015766003,0.00049700605,0.00049692474,0.00031958122,0.00015392365,0.0006504996,0.000063185915,0.0011135085,0.00008127936],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026135337,0.00037279804,0.0012605941,0.00008521323,0.00073780597,0.0000010868857,0.0028378505,0.011873248,0.89823663,0.000027629534,0.037621647,0.020810155],"study_design_scores_gemma":[0.047376473,0.0019403938,0.0028123362,0.00089009316,0.00007497045,0.000023524133,0.0021398566,0.0051831696,0.24378741,0.0000884381,0.69465774,0.0010256183],"about_ca_topic_score_codex":0.015323392,"about_ca_topic_score_gemma":0.0054240534,"teacher_disagreement_score":0.65703607,"about_ca_system_score_codex":0.0030154171,"about_ca_system_score_gemma":0.00087854074,"threshold_uncertainty_score":0.9997482},"labels":[],"label_agreement":null},{"id":"W2997299711","doi":"10.1186/s40425-019-0816-5","title":"High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Stromal cell; Tumor microenvironment; Immune system; Cancer research; Immune checkpoint; Biology; Granzyme B; Ovarian cancer; CD8; Immunology; Cancer; Immunotherapy","score_opus":0.014381859020029834,"score_gpt":0.28372799322185854,"score_spread":0.26934613420182874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997299711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99523324,0.0028803262,0.000018983217,0.00056575,0.00035275414,0.00073748315,0.00018497545,0.000007790398,0.00001869274],"genre_scores_gemma":[0.99652785,0.0023020646,0.00036046607,0.0003425483,0.00007737674,0.000044720382,0.000013660246,0.000040514293,0.00029080067],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99853647,0.000051263174,0.0005863176,0.00021799692,0.00035553778,0.00025242474],"domain_scores_gemma":[0.9987116,0.000120139426,0.00075727614,0.00016261463,0.00019427079,0.000054098593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027838323,0.00023090816,0.00066015066,0.00022265111,0.00007729325,0.000024377885,0.000084763466,0.00010240434,0.00024631235],"category_scores_gemma":[0.000009972999,0.00016732098,0.00011347036,0.0001826492,0.00010355272,0.00016752261,0.000012028561,0.0002047747,1.4753277e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037210044,0.000276511,0.054230325,0.000096007345,0.0005520957,0.000002149975,0.00053039077,0.00006209496,0.8977163,0.000010590135,0.000120497694,0.009192994],"study_design_scores_gemma":[0.02254075,0.0027155438,0.44975904,0.002268154,0.00006669283,0.000009135624,0.00015568345,0.00006857521,0.5215901,0.00002879413,0.00063744606,0.00016005177],"about_ca_topic_score_codex":0.0008874718,"about_ca_topic_score_gemma":0.000062468185,"teacher_disagreement_score":0.39552873,"about_ca_system_score_codex":0.00020564311,"about_ca_system_score_gemma":0.0001729431,"threshold_uncertainty_score":0.6823152},"labels":[],"label_agreement":null},{"id":"W3006887831","doi":"10.1136/jitc-2019-000186","title":"On the mechanism of anti-CD39 immune checkpoint therapy","year":2020,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Institute of Cancer Research; Terry Fox Research Institute","keywords":"Adenosinergic; Medicine; Immunotherapy; Adenosine; Mechanism of action; Cancer immunotherapy; Regulator; Adenosine receptor; Immune system; Targeted therapy; Pharmacology; Immunology; Cancer; Receptor; Cancer research; Biology; Internal medicine; In vitro; Gene","score_opus":0.03803198016739658,"score_gpt":0.34506916345052707,"score_spread":0.3070371832831305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006887831","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00066492415,0.99702746,0.000796983,0.00023681555,0.00055737735,0.000572032,0.00007878713,0.0000030026504,0.000062632666],"genre_scores_gemma":[0.0007070097,0.9977495,0.00011016228,0.00021164092,0.00068156095,0.00007935369,0.000021432863,0.00008417949,0.000355128],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983793,0.000111348694,0.0008771506,0.00021081399,0.00021883826,0.0002025382],"domain_scores_gemma":[0.99803525,0.00008565805,0.0013211174,0.00034926078,0.00017105973,0.00003767914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004284298,0.0003336005,0.0011076644,0.00006704464,0.00010481587,0.000020314654,0.00058232865,0.00024743102,0.00020599029],"category_scores_gemma":[0.000036891564,0.00019243348,0.0013905348,0.000117041105,0.000066784676,0.000002949171,0.000033106975,0.00031968285,0.0000011070107],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007244675,0.00015023226,7.683814e-7,0.0015666541,0.004211859,0.0000032499531,0.00013786179,0.000030251273,0.12109849,0.0015402497,0.0070380447,0.86349785],"study_design_scores_gemma":[0.00073924713,0.00079469103,6.5957573e-7,0.001962021,0.00012608519,0.000028503406,0.00001575256,0.0000023890846,0.06157186,0.00045564983,0.93410206,0.0002011043],"about_ca_topic_score_codex":0.0000146868915,"about_ca_topic_score_gemma":3.0210194e-7,"teacher_disagreement_score":0.927064,"about_ca_system_score_codex":0.000026664135,"about_ca_system_score_gemma":0.00041754168,"threshold_uncertainty_score":0.78472096},"labels":[],"label_agreement":null},{"id":"W3011282656","doi":"10.1136/jitc-2019-000282","title":"Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":175,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Vanderbilt Institute of Chemical Biology, School of Medicine, Vanderbilt University; Division of Chemical, Bioengineering, Environmental, and Transport Systems; National Institute of Diabetes and Digestive and Kidney Diseases; American Cancer Society; Vanderbilt University Medical Center; Vanderbilt University; Stand Up To Cancer; National Cancer Institute; Entertainment Industry Foundation; National Science Foundation; Canadian Institutes of Health Research; Alex's Lemonade Stand Foundation for Childhood Cancer; Vanderbilt Digestive Diseases Research Center, Vanderbilt University Medical Center; American Association for Cancer Research; National Institutes of Health","keywords":"Sting; Stimulator of interferon genes; Cancer research; Neuroblastoma; Immunogenic cell death; Immunotherapy; CD8; Programmed cell death; T cell; Cancer immunotherapy; Medicine; Apoptosis; Blockade; Interferon; Immune checkpoint; Immunogenicity; Immune system; Cell cycle checkpoint; Immunology; Biology; Cell cycle; Cell culture; Cancer; Innate immune system; Receptor; Internal medicine","score_opus":0.022959950127284797,"score_gpt":0.32842297215300525,"score_spread":0.30546302202572045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011282656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98607224,0.009380697,0.0019718423,0.0012527063,0.00074076955,0.00046241647,0.000025673015,0.000024246612,0.000069394606],"genre_scores_gemma":[0.99653524,0.0012087413,0.00034174792,0.0010712969,0.000056873043,0.0000359508,0.000006872214,0.000041852116,0.0007014303],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838376,0.00021188824,0.0007099643,0.00021607151,0.00006934631,0.0004089655],"domain_scores_gemma":[0.9989314,0.0002120276,0.0004120912,0.0001909558,0.00021926226,0.000034261342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033778118,0.0002326686,0.00045621465,0.00019776914,0.00022114751,0.000033704007,0.00041378578,0.0001250429,0.00038298394],"category_scores_gemma":[0.00013610571,0.00020892036,0.00023581117,0.00023272648,0.0000550893,0.0001972713,0.00005509885,0.00051989104,0.000025935553],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00847418,0.00013014382,0.0005810869,0.000038729777,0.00015775644,0.0000016552378,0.0016116975,0.000948207,0.9661118,0.000011436024,0.0003818671,0.021551454],"study_design_scores_gemma":[0.0023090534,0.0016004173,0.013066833,0.00021685229,0.000018031811,0.000019649848,0.00030530855,0.00006274321,0.96528006,0.000024744762,0.016878432,0.00021790674],"about_ca_topic_score_codex":0.00023483663,"about_ca_topic_score_gemma":0.000010396242,"teacher_disagreement_score":0.021333547,"about_ca_system_score_codex":0.0001329679,"about_ca_system_score_gemma":0.00018593388,"threshold_uncertainty_score":0.85195255},"labels":[],"label_agreement":null},{"id":"W3011361209","doi":"10.1136/jitc-2020-000530","title":"A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Nausea; Adverse effect; Internal medicine; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Gastroenterology; Tolerability; Antibody; Lung cancer; Oncology; Population; Monoclonal antibody; Toxicity; Phases of clinical research; Immunology","score_opus":0.021021986374473327,"score_gpt":0.3722325480268819,"score_spread":0.35121056165240855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011361209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651235,0.0011804987,0.00007924635,0.0002930291,0.00016005889,0.0017161599,0.00003017921,0.000012233846,0.000016243483],"genre_scores_gemma":[0.99890745,0.0004869748,0.00016897732,0.00020036775,0.00008709096,0.00005249611,0.000025955322,0.000054969885,0.000015705693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978291,0.0000611723,0.0010592064,0.0002725607,0.0004787766,0.00029919585],"domain_scores_gemma":[0.99861896,0.000029928658,0.00075186073,0.00024103338,0.00025730516,0.00010092376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027730782,0.00024694548,0.0008157981,0.00027768064,0.0000936764,0.000019933477,0.00018115428,0.00007273884,0.00016712146],"category_scores_gemma":[0.0000150308615,0.00019487496,0.00015455001,0.00048935384,0.00008675415,0.0003500672,0.000010433241,0.00024602696,1.6506154e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15045102,0.008734377,0.63543177,0.00029159378,0.0007297357,0.000025420217,0.009948977,0.0021148014,0.14299528,0.0000046683385,0.000048397702,0.04922396],"study_design_scores_gemma":[0.1167454,0.032971345,0.83898777,0.00089855545,0.0000784596,0.000005784772,0.0010408476,0.0004783582,0.007815571,0.000016646638,0.0006967652,0.00026450204],"about_ca_topic_score_codex":0.00041106564,"about_ca_topic_score_gemma":0.00052232103,"teacher_disagreement_score":0.203556,"about_ca_system_score_codex":0.0001921786,"about_ca_system_score_gemma":0.00018894672,"threshold_uncertainty_score":0.794677},"labels":[],"label_agreement":null},{"id":"W3011642937","doi":"10.1136/jitc-2019-000337","title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","year":2020,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":1061,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal; McMaster University","funders":"National Institute of General Medical Sciences; Associazione Italiana per la Ricerca sul Cancro; Rosetrees Trust; National Institute for Health and Care Research; Compagnia di San Paolo; National Cancer Institute; Cancer Research UK; Weill Cornell Medical College; U.S. Department of Defense","keywords":"Acquired immune system; Immune system; Programmed cell death; Immunogenic cell death; Antigenicity; Immunology; Medicine; Computer science; Biology; Antigen; Immunotherapy; Apoptosis","score_opus":0.10250403975799036,"score_gpt":0.38873547545808607,"score_spread":0.2862314357000957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011642937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002463493,0.98994094,0.0068493863,0.00016010665,0.0014482909,0.0011063025,0.00023135408,0.000007764966,0.000009490347],"genre_scores_gemma":[0.0023640967,0.9965812,0.00041386348,0.000055972105,0.00011307091,0.00022659835,0.000043452557,0.000047172496,0.00015459671],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981551,0.00014533599,0.001309497,0.00017023804,0.000049431823,0.00017036655],"domain_scores_gemma":[0.9964169,0.00072204886,0.0019346151,0.00017497908,0.0007406277,0.0000108196855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050969335,0.00026567178,0.0011261803,0.00012947703,0.0002515481,0.000020966858,0.00021936963,0.0002852022,0.00004110684],"category_scores_gemma":[0.0001360484,0.00017017532,0.0008279225,0.00010388263,0.00013071626,0.00005358975,0.000019450405,0.00024948633,0.0000010870099],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073556113,0.000023346602,0.0000012298636,0.0016299597,0.001459957,4.7859647e-8,0.00012784642,0.000009040971,0.035487697,0.0000476118,0.00052703393,0.9599507],"study_design_scores_gemma":[0.0018496545,0.0005303072,0.000019513665,0.002523416,0.0013762983,0.00010279251,0.00006889301,0.000087993525,0.011148528,0.00033761704,0.9817734,0.0001816047],"about_ca_topic_score_codex":0.000041106734,"about_ca_topic_score_gemma":0.0000072061057,"teacher_disagreement_score":0.98124635,"about_ca_system_score_codex":0.000084542284,"about_ca_system_score_gemma":0.0002962727,"threshold_uncertainty_score":0.6939548},"labels":[],"label_agreement":null},{"id":"W3015097837","doi":"10.1136/jitc-2019-000371","title":"Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Adverse effect; Internal medicine; Incidence (geometry); Cumulative incidence; Renal cell carcinoma; Cancer; Cohort; Oncology","score_opus":0.014567779285653172,"score_gpt":0.2799380632421677,"score_spread":0.2653702839565145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015097837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858917,0.009072083,0.00026299452,0.0032253324,0.00013485651,0.0011287295,0.00024161425,0.000017751945,0.00002492678],"genre_scores_gemma":[0.99513733,0.0024489101,0.0005173732,0.0012504583,0.00018802895,0.00016811215,0.00004530234,0.00007725312,0.00016721616],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99796784,0.0000766358,0.0008829102,0.00028684502,0.00043471926,0.00035104807],"domain_scores_gemma":[0.9986021,0.00006583827,0.0006751286,0.00015034234,0.00036975057,0.0001368708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003524236,0.00033154635,0.0007893421,0.00017408267,0.00014104781,0.000042586948,0.00011852633,0.00007670338,0.0006051922],"category_scores_gemma":[0.000019045046,0.00021877361,0.00022024344,0.00037814357,0.00027690068,0.00023807636,0.000012582848,0.00034867012,4.391474e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22564061,0.0007690844,0.14122862,0.00036369008,0.004421304,0.000030144141,0.0017347628,0.00037356175,0.5900525,0.000021023418,0.00043961304,0.03492511],"study_design_scores_gemma":[0.07493095,0.008223968,0.6730513,0.0013978268,0.00038680623,0.00003845761,0.00023013141,0.00014646088,0.23395441,0.000059256465,0.0070634154,0.00051699305],"about_ca_topic_score_codex":0.0005347729,"about_ca_topic_score_gemma":0.00009728699,"teacher_disagreement_score":0.5318227,"about_ca_system_score_codex":0.0002326182,"about_ca_system_score_gemma":0.00050093466,"threshold_uncertainty_score":0.8921329},"labels":[],"label_agreement":null},{"id":"W3015555708","doi":"10.1136/jitc-2019-000313","title":"Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck KGaA; Pfizer","keywords":"Avelumab; Merkel cell carcinoma; Medicine; Expanded access; Merkel cell polyomavirus; Progressive disease; Merkel cell; Internal medicine; Oncology; Clinical trial; Chemotherapy; Carcinoma; Immunotherapy; Cancer; Nivolumab","score_opus":0.024885778206527105,"score_gpt":0.3496780509239403,"score_spread":0.3247922727174132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015555708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98441875,0.0141680995,0.0000556853,0.00014287699,0.00006014003,0.00096194266,0.00015300796,0.000006027388,0.000033480872],"genre_scores_gemma":[0.9976805,0.0013593624,0.0007279386,0.00010056111,0.000026770342,0.00006687373,0.000009935481,0.000014099303,0.000013988538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991068,0.000023695535,0.00036822126,0.00013921082,0.00020901387,0.00015306276],"domain_scores_gemma":[0.999395,0.000027505494,0.0002724148,0.000091043614,0.000090646354,0.00012337808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000025543168,0.00013867093,0.00041865042,0.000033100154,0.00004073892,0.00001546953,0.00008299463,0.000033688604,0.0000674274],"category_scores_gemma":[0.000007838375,0.00008479076,0.000095577234,0.0001352934,0.00008068627,0.000099687626,0.000009802489,0.000065841166,8.9729504e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0703687,0.0029496779,0.6709992,0.0001333317,0.00088497536,0.000016682146,0.0052441335,0.00008278395,0.0026235443,0.000002476194,0.00004200052,0.24665245],"study_design_scores_gemma":[0.054496244,0.0049704313,0.93163455,0.0002333242,0.0003154311,0.0000025897427,0.0003034993,0.00010787539,0.007120462,0.000015602896,0.0006811219,0.000118882526],"about_ca_topic_score_codex":0.0007350325,"about_ca_topic_score_gemma":0.000019030917,"teacher_disagreement_score":0.2606353,"about_ca_system_score_codex":0.00011878053,"about_ca_system_score_gemma":0.00023899841,"threshold_uncertainty_score":0.34576666},"labels":[],"label_agreement":null},{"id":"W3017204401","doi":"10.1136/jitc-2019-000323","title":"Immune involvement of the contralateral hemisphere in a glioblastoma mouse model","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"H2020 European Research Council; Amsterdam University Medical Centers; Vanderbilt University Medical Center","keywords":"Immune system; Immunotherapy; Cancer research; Brain tumor; CD8; Myeloid; Immune checkpoint; Medicine; Immunology; Antigen; T cell; Glioma; Biology; Pathology","score_opus":0.02062743560339773,"score_gpt":0.2963018037683911,"score_spread":0.27567436816499336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017204401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856493,0.008373981,0.00006524885,0.005248555,0.00010558209,0.0004966249,0.000033815042,0.0000041189824,0.000022781313],"genre_scores_gemma":[0.9968006,0.001669946,0.00031940205,0.0009054145,0.00005339856,0.00006250937,6.792687e-7,0.000021895941,0.00016614828],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99901265,0.000016155846,0.00049460714,0.000092246926,0.00022193062,0.00016239687],"domain_scores_gemma":[0.9993504,0.000021961696,0.0003010049,0.00014116956,0.00013095576,0.00005448171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009874764,0.000117321266,0.00038676127,0.000034743796,0.000038049922,0.000008502628,0.00012485778,0.00004635768,0.0001427099],"category_scores_gemma":[0.0000106394755,0.00007109412,0.0003241125,0.000101155936,0.00004474401,0.00005008783,0.000013981596,0.00013355966,3.0008144e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047769384,0.00048780302,0.026888592,0.00012882882,0.00060087966,0.000004252221,0.0019515186,0.0048468374,0.95098794,0.00007234041,0.000799857,0.008454207],"study_design_scores_gemma":[0.01628844,0.0011053275,0.01058753,0.00040219218,0.000094063216,0.000010326785,0.00017782251,0.0057934,0.9633855,0.00019627916,0.001859427,0.00009968462],"about_ca_topic_score_codex":0.0001142998,"about_ca_topic_score_gemma":0.000050367544,"teacher_disagreement_score":0.016301062,"about_ca_system_score_codex":0.00011535625,"about_ca_system_score_gemma":0.00016058765,"threshold_uncertainty_score":0.2899134},"labels":[],"label_agreement":null},{"id":"W3034105569","doi":"10.1136/jitc-2019-000266","title":"Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Israel Science Foundation; Hebrew University of Jerusalem; Centre in Green Chemistry and Catalysis; Israel Cancer Research Fund","keywords":"TIGIT; Cancer research; Medicine; Computational biology; Computer science; Internal medicine; Biology; Immunotherapy; Cancer","score_opus":0.026157666394454025,"score_gpt":0.2801342962558834,"score_spread":0.2539766298614293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034105569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782988,0.010179821,0.001959677,0.005719346,0.0032274607,0.00027766917,0.000027800017,0.000026102569,0.0002833638],"genre_scores_gemma":[0.9916585,0.0025976151,0.00011451434,0.0028530587,0.00022016022,0.000021232006,0.00001417181,0.000029696897,0.0024910502],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991265,0.000029110652,0.0004531198,0.00016578719,0.000045947174,0.00017951625],"domain_scores_gemma":[0.9991252,0.000054619657,0.00039268797,0.000085614614,0.0003166792,0.00002519053],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001621285,0.00015105288,0.00029906028,0.000072485476,0.00022192945,0.000041301653,0.00007531491,0.00010071944,0.0012816616],"category_scores_gemma":[0.000046342335,0.00012827141,0.0001473619,0.00012179552,0.00007013768,0.00020214832,0.000016215936,0.00032899558,0.00001692601],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024404444,0.00009142907,0.0005160551,0.00003469473,0.00026250136,2.5461165e-7,0.0011648748,0.000006463745,0.97257847,0.00006373993,0.018823905,0.00401717],"study_design_scores_gemma":[0.0036754496,0.0006026565,0.0022097973,0.00007896831,0.000028000459,0.000093429524,0.0003233979,0.00003551145,0.66825163,0.000073363255,0.32450396,0.00012384313],"about_ca_topic_score_codex":0.00007185635,"about_ca_topic_score_gemma":0.000010380936,"teacher_disagreement_score":0.30568007,"about_ca_system_score_codex":0.00004720574,"about_ca_system_score_gemma":0.0000685755,"threshold_uncertainty_score":0.9996313},"labels":[],"label_agreement":null},{"id":"W3036508677","doi":"10.1136/jitc-2020-000840","title":"Chronic immune checkpoint inhibitor pneumonitis","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Pneumonitis; Immunosuppression; Hypersensitivity pneumonitis; Internal medicine; Bronchoalveolar lavage; Immunology; Gastroenterology; Lung","score_opus":0.024502063692747628,"score_gpt":0.3195411143344083,"score_spread":0.2950390506416607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036508677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6766221,0.2711462,0.0016851373,0.045319576,0.0028439204,0.0015065518,0.000113283946,0.00009242397,0.0006707999],"genre_scores_gemma":[0.9510534,0.038997702,0.0011287641,0.0032122834,0.0038706434,0.00011957217,0.000012443819,0.00012988178,0.001475337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981288,0.000029666575,0.00089735957,0.00021311565,0.00037246675,0.00035859205],"domain_scores_gemma":[0.9987502,0.00004529358,0.00053809537,0.00021346586,0.0002947982,0.00015814019],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030069656,0.00023937541,0.0006207691,0.000103904735,0.00016024827,0.00004058761,0.00020494046,0.00012250156,0.0014406474],"category_scores_gemma":[0.00003120873,0.00019448913,0.000819337,0.00026463057,0.00014034522,0.00015349133,0.0000168994,0.0003491159,0.000005834892],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007181028,0.00005811467,0.0005598075,0.00020605102,0.0008178901,0.000008050524,0.00058684754,0.000012564502,0.7806045,0.000013679897,0.0017717037,0.20817979],"study_design_scores_gemma":[0.013785027,0.0037046194,0.008996957,0.0006163263,0.00013413404,0.00016077473,0.00016595029,0.00011461263,0.50326455,0.00007981706,0.4687035,0.0002737308],"about_ca_topic_score_codex":0.00008457739,"about_ca_topic_score_gemma":0.000008741867,"teacher_disagreement_score":0.4669318,"about_ca_system_score_codex":0.0003774385,"about_ca_system_score_gemma":0.0006791555,"threshold_uncertainty_score":0.99947214},"labels":[],"label_agreement":null},{"id":"W3037575240","doi":"10.1136/jitc-2019-000467","title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"University Health Network","keywords":"Medicine; Acute kidney injury; Internal medicine; Creatinine; Incidence (geometry); Kidney disease; Adverse effect; Cancer; Gastroenterology; Oncology","score_opus":0.017823289581633112,"score_gpt":0.3066846269328215,"score_spread":0.2888613373511884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037575240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832516,0.009484472,0.00016796683,0.005257677,0.00051485404,0.0008211364,0.000416704,0.000049459824,0.00003616909],"genre_scores_gemma":[0.96005595,0.03525358,0.00040916665,0.0035040472,0.00023774632,0.000058190333,0.000025047426,0.00010299882,0.0003532787],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99789226,0.00007512316,0.0008532812,0.000288952,0.0005071212,0.00038328793],"domain_scores_gemma":[0.99800485,0.00011637219,0.001056495,0.00022433796,0.0003151848,0.00028273926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046617413,0.0003987457,0.0009761348,0.00015313193,0.00027172436,0.00006967401,0.00019704712,0.00017604308,0.0003396232],"category_scores_gemma":[0.0001480061,0.00024520763,0.0005404171,0.000358676,0.00024922544,0.0002584256,0.000021735297,0.0005041455,5.352261e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04223474,0.00025395732,0.4402691,0.00006907555,0.009997102,0.000010259121,0.003373517,0.0000026277348,0.4601774,0.0000051785923,0.0027495574,0.04085747],"study_design_scores_gemma":[0.029877784,0.008288154,0.63159406,0.00083314633,0.00063147076,0.000044212073,0.000397201,0.00006659229,0.27909708,0.000093183124,0.04844824,0.00062886014],"about_ca_topic_score_codex":0.0002692829,"about_ca_topic_score_gemma":0.0000109015655,"teacher_disagreement_score":0.19132496,"about_ca_system_score_codex":0.00020311236,"about_ca_system_score_gemma":0.00055917515,"threshold_uncertainty_score":0.99992764},"labels":[],"label_agreement":null},{"id":"W3039466405","doi":"10.1136/jitc-2020-001119","title":"BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy","year":2020,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune responses and vaccinations","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Ontario Ministry of Research, Innovation and Science; Queen's University","keywords":"Medicine; Vaccination; Immunotherapy; Immunology; Blockade; Immunity; Immune checkpoint; Tuberculosis; Pandemic; Immune system; Intensive care medicine; Internal medicine; Coronavirus disease 2019 (COVID-19); Disease","score_opus":0.04891834536234258,"score_gpt":0.413397048402426,"score_spread":0.36447870304008345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039466405","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019688444,0.98901844,0.003761761,0.0023550545,0.0010878033,0.0025625657,0.00096324476,0.000049525148,0.000004708542],"genre_scores_gemma":[0.00008818236,0.9957046,0.00019008695,0.0003544739,0.0002152158,0.00205116,0.00008301593,0.00014208355,0.0011712012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979064,0.00021568169,0.0010576941,0.00039902923,0.000042880605,0.00037831857],"domain_scores_gemma":[0.99729985,0.00071536173,0.0013065527,0.00027741218,0.00032652388,0.00007427863],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047788967,0.00047737846,0.0016596689,0.00037353995,0.0007032179,0.00007330892,0.0002612244,0.0005393539,0.00022338779],"category_scores_gemma":[0.00016693652,0.00037199399,0.0006904132,0.00027683817,0.000111767426,0.00014691535,0.000039768718,0.000543794,0.0000011545935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010046534,0.0000671725,0.00009728334,0.0030606978,0.0024212976,1.9517387e-7,0.0002551026,0.0000024798749,0.003010181,0.0003517268,0.003890891,0.9858383],"study_design_scores_gemma":[0.0040728054,0.0009417458,0.00048323284,0.0011191925,0.00060313975,0.00024611247,0.000019306872,0.0000017687823,0.000118398675,0.0004908671,0.9915234,0.0003800459],"about_ca_topic_score_codex":0.00037890917,"about_ca_topic_score_gemma":0.00007164626,"teacher_disagreement_score":0.9876325,"about_ca_system_score_codex":0.00034100068,"about_ca_system_score_gemma":0.001394623,"threshold_uncertainty_score":0.9998732},"labels":[],"label_agreement":null},{"id":"W3042095160","doi":"10.1136/jitc-2020-000891","title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Bristol-Myers Squibb; Ono Pharmaceutical; National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; University of Texas MD Anderson Cancer Center","keywords":"Nivolumab; Medicine; Sunitinib; Ipilimumab; Renal cell carcinoma; Internal medicine; Randomized controlled trial; Oncology; Clinical trial; Immunotherapy; Cancer","score_opus":0.04926157250532811,"score_gpt":0.3799343260798284,"score_spread":0.3306727535745003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042095160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934313,0.0015211764,0.00027661477,0.00046802286,0.00064600026,0.0035021168,0.00007404187,0.000009257091,0.000071421644],"genre_scores_gemma":[0.99734354,0.0003557891,0.0016870808,0.000085540574,0.000105642575,0.00017736152,0.00002132571,0.00006477988,0.00015894909],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99611056,0.00066435337,0.0015582398,0.00036548128,0.00096114137,0.00034021676],"domain_scores_gemma":[0.99636555,0.0012668543,0.001308708,0.00028445135,0.0005308514,0.00024361577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016934588,0.00036545465,0.0023661265,0.00019898431,0.000077300065,0.000024812622,0.00015719558,0.00012291035,0.00007246981],"category_scores_gemma":[0.00020035704,0.00022954271,0.0005433786,0.00019325891,0.00023883046,0.00015085882,0.000026603602,0.0004844054,1.5971634e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94228494,0.0013887497,0.04677108,0.00008493234,0.0013539308,0.000047212692,0.0008391219,0.00007328096,0.0009991027,0.000004025902,0.00001726354,0.0061363457],"study_design_scores_gemma":[0.8249253,0.051017817,0.120930225,0.00016681099,0.0006823579,0.000003937325,0.00034083895,0.00008956106,0.0014864664,0.0000040079276,0.00015643457,0.00019626338],"about_ca_topic_score_codex":0.00013828058,"about_ca_topic_score_gemma":0.000094676034,"teacher_disagreement_score":0.117359675,"about_ca_system_score_codex":0.00044962286,"about_ca_system_score_gemma":0.0014632066,"threshold_uncertainty_score":0.93604803},"labels":[],"label_agreement":null},{"id":"W3047494536","doi":"10.1136/jitc-2020-000883","title":"An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Institute of Cancer Research; Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Foundation; Canada Research Chairs; AstraZeneca; Celgene; Canadian Institutes of Health Research; AstraZeneca Canada","keywords":"Durvalumab; Medicine; Regimen; Hypomethylating agent; Internal medicine; Adverse effect; Breast cancer; Oncology; Gastroenterology; Immunology; DNA methylation; Cancer; Immunotherapy; Nivolumab; Biology","score_opus":0.0510288598174325,"score_gpt":0.42536665460349565,"score_spread":0.37433779478606316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047494536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932563,0.0053312117,0.00055632216,0.00006991144,0.00010944073,0.00063980767,0.000025165218,0.0000022687934,0.00000957505],"genre_scores_gemma":[0.9939547,0.0014345157,0.0043065418,0.00010672231,0.00009185578,0.00003804529,0.000014027464,0.000031767715,0.000021805796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876654,0.00011024837,0.00056198274,0.00023865026,0.00015460872,0.00016799642],"domain_scores_gemma":[0.99914116,0.000012558906,0.0004036433,0.00017771387,0.00016894983,0.00009597083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004913783,0.00013966991,0.00034036406,0.00005636467,0.00012013532,0.000033882094,0.00026005675,0.00006367041,0.000010050127],"category_scores_gemma":[0.000049022703,0.00012894874,0.000034501,0.0000987124,0.00003653126,0.000029579795,0.000055249096,0.00010349576,2.7743365e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019543797,0.002718042,0.0016536859,0.000014286422,0.00009299502,0.0000012157602,0.0012983377,0.0010640955,0.8184182,0.0000012468627,0.000002985769,0.17278054],"study_design_scores_gemma":[0.062385138,0.046375114,0.0074222535,0.000059927148,0.000046967758,0.0000028399506,0.0015138485,0.0056453594,0.8741875,0.00012217856,0.0019167135,0.00032211296],"about_ca_topic_score_codex":0.00014145952,"about_ca_topic_score_gemma":0.00017515465,"teacher_disagreement_score":0.17245844,"about_ca_system_score_codex":0.000019505665,"about_ca_system_score_gemma":0.000094776966,"threshold_uncertainty_score":0.5258377},"labels":[],"label_agreement":null},{"id":"W3047919807","doi":"10.1136/jitc-2020-000915","title":"Discovery and validation of surface <i>N</i>-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health; University of Toronto; Midwest Athletes Against Childhood Cancer","keywords":"Flow cytometry; Immunotherapy; Cell; Proteome; Medicine; Glycoprotein; Cell culture; Mass cytometry; Cancer research; Computational biology; Bioinformatics; Chemistry; Immunology; Biology; Molecular biology; Internal medicine; Cancer; Biochemistry","score_opus":0.02659038686089481,"score_gpt":0.3168505820342918,"score_spread":0.29026019517339696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047919807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626275,0.0347996,0.00046280609,0.0012245128,0.00008113338,0.00067061523,0.00010822255,0.000004171167,0.000021474549],"genre_scores_gemma":[0.9698471,0.027578479,0.0021752873,0.00022751716,0.000045759534,0.000020141955,0.000009567293,0.000025844956,0.00007033765],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893016,0.000043080654,0.00042046493,0.0001504312,0.00027019938,0.00018565252],"domain_scores_gemma":[0.9993025,0.000103902945,0.00027966374,0.00009457575,0.00013844503,0.000080930826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013455738,0.00014152518,0.00039616294,0.000075959964,0.000055104407,0.000027480753,0.0000547736,0.00005333118,0.000050157134],"category_scores_gemma":[0.000036331778,0.00010631304,0.00010123781,0.00011180392,0.00007918259,0.0002089003,0.00001374455,0.00013288569,1.4070747e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012005217,0.00027409018,0.14307176,0.00032984454,0.000407385,0.000008167965,0.0026734087,0.0003671712,0.77855074,0.000007489497,0.0002013467,0.062103402],"study_design_scores_gemma":[0.016120845,0.0031702658,0.048232738,0.00033243597,0.000036617075,0.000013213921,0.0005186644,0.00023234777,0.9238521,0.00014853178,0.0071872887,0.00015497628],"about_ca_topic_score_codex":0.00057384436,"about_ca_topic_score_gemma":0.000024067447,"teacher_disagreement_score":0.14530134,"about_ca_system_score_codex":0.00006536469,"about_ca_system_score_gemma":0.00016111013,"threshold_uncertainty_score":0.433532},"labels":[],"label_agreement":null},{"id":"W3048730325","doi":"10.1136/jitc-2020-000981","title":"Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; McMaster University","funders":"Terry Fox Foundation; Seerave Foundation; Ontario Institute for Cancer Research","keywords":"Medicine; Oncolytic virus; Immunology; Antigen; Vaccination; CD8; Melanoma; Cytotoxic T cell; Cancer; Cancer research; Cancer immunotherapy; Cyclophosphamide; Immunotherapy; Virus; Immune system; Chemotherapy; Biology; Internal medicine","score_opus":0.029711833246047814,"score_gpt":0.33559406518981433,"score_spread":0.3058822319437665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048730325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.853371,0.12725538,0.015652722,0.0004995788,0.0018320685,0.0010063185,0.000261302,0.00004428552,0.00007731031],"genre_scores_gemma":[0.98963475,0.0074432017,0.0008825796,0.0009088999,0.00012787247,0.00019623688,0.0000305763,0.00010066929,0.00067522307],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976506,0.0002492271,0.0012038646,0.0002874494,0.00014033003,0.00046847598],"domain_scores_gemma":[0.9972215,0.00031858258,0.0015993837,0.0002589581,0.0005688948,0.00003262469],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044027658,0.00034900793,0.000816154,0.00022912539,0.0003888097,0.000032479908,0.00046302675,0.0002719172,0.005218151],"category_scores_gemma":[0.00007200362,0.00031879664,0.00053009164,0.00037522826,0.0001773737,0.00033109693,0.000019775718,0.00042204058,0.000007057894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010260423,0.00017512112,0.00028640803,0.00015637347,0.0012904071,3.3330497e-7,0.0015642064,0.003025178,0.89953774,0.000044684406,0.00019357179,0.083465554],"study_design_scores_gemma":[0.00806234,0.00116776,0.004142268,0.00043697137,0.00016190503,0.000010871606,0.00020880777,0.00040740258,0.9673557,0.0000870155,0.017618898,0.00034000608],"about_ca_topic_score_codex":0.00036734436,"about_ca_topic_score_gemma":0.000017310933,"teacher_disagreement_score":0.13626371,"about_ca_system_score_codex":0.00025719986,"about_ca_system_score_gemma":0.0009296009,"threshold_uncertainty_score":0.9999264},"labels":[],"label_agreement":null},{"id":"W3090525098","doi":"10.1136/jitc-2020-001180","title":"Regulation of tumor growth by leukocyte-specific protein 1 in T cells","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Ministry of Education, Science and Technology; National Research Foundation of Korea; National Research Foundation","keywords":"Cancer research; Immunology; Computational biology; Biology; Medicine","score_opus":0.032812834537790075,"score_gpt":0.32360810513992944,"score_spread":0.2907952706021394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090525098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98268056,0.011456573,0.00061815983,0.0034755466,0.00016965238,0.0012585275,0.000028506105,0.000010430712,0.00030204552],"genre_scores_gemma":[0.9890655,0.004964843,0.0014739351,0.00047420955,0.0004103234,0.0000892391,0.00000661598,0.000078675235,0.0034366052],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984567,0.00005505122,0.00061747787,0.00015493503,0.0004829435,0.00023288414],"domain_scores_gemma":[0.9990304,0.000053298438,0.0003482656,0.00014637219,0.0003289628,0.000092668604],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040418355,0.00013017011,0.00045543362,0.00014679099,0.000035955327,0.000014719186,0.00015985109,0.00006426116,0.0027987822],"category_scores_gemma":[0.000024412939,0.00011100636,0.00021716642,0.00031011985,0.00008546861,0.00010268284,0.000009863174,0.0003047363,0.0000016816625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008666336,0.000108789245,0.0006449843,0.0001686914,0.00011036724,0.000002976994,0.0006139434,0.000028356653,0.95654386,0.000038916176,0.005809942,0.027262837],"study_design_scores_gemma":[0.005977863,0.0010854444,0.0020129692,0.00024078296,0.00000954138,0.000008201256,0.00008050973,0.00017200995,0.88406676,0.00020761593,0.10604733,0.00009095239],"about_ca_topic_score_codex":0.000081344486,"about_ca_topic_score_gemma":0.0000053348767,"teacher_disagreement_score":0.10023739,"about_ca_system_score_codex":0.00022046853,"about_ca_system_score_gemma":0.0002523905,"threshold_uncertainty_score":0.9981128},"labels":[],"label_agreement":null},{"id":"W3091948129","doi":"10.1136/jitc-2020-001006","title":"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Amgen","keywords":"Pembrolizumab; Medicine; Rash; Maculopapular rash; Internal medicine; Adverse effect; Refractory (planetary science); Gastroenterology; Lung cancer; Oncology; Cancer; Immunotherapy","score_opus":0.013646745651569215,"score_gpt":0.32535753150538355,"score_spread":0.31171078585381434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091948129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99503213,0.0023763725,0.00031115857,0.0010355847,0.00009262599,0.0010761931,0.000042443982,0.000012554366,0.000020924821],"genre_scores_gemma":[0.9944054,0.003779417,0.001413551,0.00023271322,0.00005847542,0.00001874599,0.000020344523,0.000050387982,0.000021001384],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983163,0.00005855971,0.00077835325,0.0002536701,0.00032640607,0.00026672502],"domain_scores_gemma":[0.9987758,0.00009907795,0.00065537327,0.00014463231,0.0002354913,0.000089634785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023353565,0.00022593595,0.0007686203,0.00020751674,0.00006799072,0.000016744,0.000115836425,0.00008385227,0.000093858725],"category_scores_gemma":[0.000034061668,0.00015318398,0.00009164485,0.00040831548,0.0001463506,0.0002944711,0.000008403355,0.00028129166,8.633439e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25724012,0.00049808336,0.18400042,0.00044278652,0.00032134808,0.00001084008,0.006748171,0.0015833885,0.41807255,0.000009589001,0.000008904576,0.1310638],"study_design_scores_gemma":[0.092506036,0.013618464,0.8586974,0.0040134015,0.000039984832,0.000046008314,0.0007821272,0.0019605397,0.027165862,0.000008115524,0.0008551357,0.0003068874],"about_ca_topic_score_codex":0.0002636773,"about_ca_topic_score_gemma":0.00016423306,"teacher_disagreement_score":0.67469704,"about_ca_system_score_codex":0.00017948056,"about_ca_system_score_gemma":0.00031510866,"threshold_uncertainty_score":0.62466615},"labels":[],"label_agreement":null},{"id":"W3092016117","doi":"10.1136/jitc-2020-001095","title":"Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences","keywords":"Durvalumab; Medicine; Tolerability; Response Evaluation Criteria in Solid Tumors; Pharmacodynamics; Internal medicine; Clinical endpoint; Oncology; Radiation therapy; Pharmacokinetics; Toxicity; Gastroenterology; Urology; Nivolumab; Adverse effect; Cancer; Phases of clinical research; Clinical trial; Immunotherapy","score_opus":0.020610346657450037,"score_gpt":0.33996781776810464,"score_spread":0.3193574711106546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092016117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355125,0.0037074143,0.00014124026,0.0015811896,0.00006710068,0.0009203891,0.000022648586,0.0000043147784,0.000004438958],"genre_scores_gemma":[0.9706731,0.028480453,0.00041345495,0.000344026,0.00003333073,0.00001977962,0.000005609066,0.000022515183,0.000007754358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987325,0.00008787707,0.00058315095,0.00019336489,0.00024922274,0.00015385977],"domain_scores_gemma":[0.998971,0.00013742091,0.00057828333,0.0000741478,0.00016834361,0.00007079875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040848862,0.00016123391,0.00064392114,0.00011223464,0.000045413602,0.000012402936,0.000045885023,0.00007272754,0.000018493987],"category_scores_gemma":[0.0000362582,0.00010422617,0.000047089,0.00022928223,0.00022705918,0.00023172384,0.000006700262,0.00024979236,1.1451345e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2359795,0.00029715215,0.44266364,0.00006873543,0.00026046718,0.0000021819972,0.0011912291,0.000012058261,0.0033517007,0.0000029231426,0.000005573562,0.31616485],"study_design_scores_gemma":[0.06624675,0.013177892,0.9159088,0.0004936821,0.000028260434,0.000005202567,0.0001416756,0.0002775034,0.003356561,0.00002041951,0.0002189447,0.00012429598],"about_ca_topic_score_codex":0.00009944392,"about_ca_topic_score_gemma":0.0002103442,"teacher_disagreement_score":0.47324517,"about_ca_system_score_codex":0.00010243432,"about_ca_system_score_gemma":0.00023253204,"threshold_uncertainty_score":0.425022},"labels":[],"label_agreement":null},{"id":"W3093348721","doi":"10.1136/jitc-2020-001154","title":"Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Pandemic; Medicine; Coronavirus disease 2019 (COVID-19); Outbreak; Family medicine; Cancer; Medical prescription; Internal medicine; Disease; Virology; Nursing; Infectious disease (medical specialty)","score_opus":0.15187442515706576,"score_gpt":0.5055723031600233,"score_spread":0.3536978780029576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093348721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9687188,0.019533763,0.0003256089,0.009359595,0.0004684355,0.0009937662,0.00052931684,0.000021483113,0.000049223694],"genre_scores_gemma":[0.9740123,0.020530121,0.00011365604,0.004925498,0.00019912359,0.000048514106,0.000010874258,0.00008098559,0.000078901474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725425,0.0002025232,0.0012968401,0.0002515009,0.00054893206,0.0004459448],"domain_scores_gemma":[0.9967673,0.00062917307,0.00124697,0.00030576746,0.0006873786,0.0003634171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012671786,0.00029515915,0.0013370784,0.00036216652,0.0000595701,0.000013554847,0.00028316316,0.00020726027,0.0005447501],"category_scores_gemma":[0.0008114803,0.00022218129,0.0006038502,0.00062429934,0.00016729471,0.00011856751,0.00001608522,0.00047522163,5.2107384e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056853842,0.00062376034,0.77326924,0.00080587185,0.0012763683,0.000016358159,0.006400316,0.0017790132,0.09733832,0.00001831281,0.003425279,0.058193322],"study_design_scores_gemma":[0.014571967,0.008287535,0.9646153,0.00059025263,0.000051112424,0.00002222251,0.0001324358,0.0001469001,0.0047086906,0.00008153961,0.006580098,0.00021196697],"about_ca_topic_score_codex":0.07450923,"about_ca_topic_score_gemma":0.0058922567,"teacher_disagreement_score":0.19134605,"about_ca_system_score_codex":0.0017339531,"about_ca_system_score_gemma":0.007271621,"threshold_uncertainty_score":0.9983562},"labels":[],"label_agreement":null},{"id":"W3095965358","doi":"10.1136/jitc-2020-001389","title":"Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Cancer Institute","keywords":"Immunotherapy; Cancer immunotherapy; Medicine; Data science; Volume (thermodynamics); Resource (disambiguation); Cancer; Computer science; Internal medicine","score_opus":0.13094875820765697,"score_gpt":0.413158312917038,"score_spread":0.282209554709381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095965358","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40114397,0.5584721,0.0016999097,0.033448,0.0014315265,0.0024735753,0.0011415496,0.00006130895,0.00012807774],"genre_scores_gemma":[0.17856513,0.7945893,0.012030061,0.009368754,0.0033415887,0.00037383204,0.00013213165,0.0003549045,0.0012443321],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965859,0.0000672352,0.0016526226,0.00070280203,0.00048579558,0.0005056629],"domain_scores_gemma":[0.9971897,0.00029031927,0.0011933019,0.0007389411,0.0003788398,0.00020887355],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001683966,0.00039017765,0.001190171,0.00009679737,0.00023362691,0.000053462438,0.0008547165,0.0002884355,0.00049958756],"category_scores_gemma":[0.00008058336,0.0003269208,0.0011046745,0.00022575587,0.00080775283,0.0003434751,0.00011781236,0.00040439627,3.8123304e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04981976,0.00024354068,0.01258546,0.00083154987,0.012638029,0.0000016500185,0.006110491,0.000014836818,0.076333374,0.00010710181,0.025327308,0.8159869],"study_design_scores_gemma":[0.031735197,0.0032971278,0.018312369,0.0010124432,0.00059166213,0.000024151837,0.002989289,0.0011451697,0.007921718,0.00022191991,0.93222487,0.0005241046],"about_ca_topic_score_codex":0.00026382497,"about_ca_topic_score_gemma":0.000046978355,"teacher_disagreement_score":0.90689754,"about_ca_system_score_codex":0.00013570463,"about_ca_system_score_gemma":0.0005304052,"threshold_uncertainty_score":0.9999183},"labels":[],"label_agreement":null},{"id":"W3101654075","doi":"10.1136/jitc-2020-001583","title":"Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee","year":2020,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Society for Immunotherapy of Cancer","keywords":"Medicine; Immunotherapy; Subspecialty; Clinical trial; Medical physics; Cancer immunotherapy; Cancer; Oncology; Intensive care medicine; Internal medicine; Pathology","score_opus":0.37732158310077407,"score_gpt":0.5774039456333534,"score_spread":0.20008236253257933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101654075","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000424419,0.9716055,0.0006135591,0.0076766587,0.0047118478,0.011326326,0.0036073176,0.000019444893,0.000014939775],"genre_scores_gemma":[0.000029649415,0.9847746,0.0055607385,0.0014921533,0.001849465,0.005445841,0.00024317623,0.00026264615,0.00034171177],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9876241,0.0014777177,0.008608534,0.00074872246,0.00073702104,0.0008039089],"domain_scores_gemma":[0.95462924,0.025574872,0.017900597,0.00070317637,0.0010532648,0.00013882208],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.018480966,0.0009414126,0.008359731,0.00023585004,0.000354622,0.000098580174,0.0007861464,0.0009172813,0.00036739325],"category_scores_gemma":[0.0018241759,0.0006116711,0.00844515,0.00048499167,0.00052236393,0.00013488572,0.000050740637,0.0012112476,8.6896074e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03468467,0.0007405344,0.00023872765,0.0065129385,0.024503604,0.000003650029,0.0011116226,0.0000040580035,0.001171232,0.000015363321,0.04050584,0.89050776],"study_design_scores_gemma":[0.018672394,0.003041146,0.0000463321,0.019227985,0.005062455,0.000028956993,0.0010018573,0.00002616828,0.0004995551,0.00009891233,0.9517248,0.00056939875],"about_ca_topic_score_codex":0.0033342005,"about_ca_topic_score_gemma":0.0009841769,"teacher_disagreement_score":0.911219,"about_ca_system_score_codex":0.001584474,"about_ca_system_score_gemma":0.010092995,"threshold_uncertainty_score":0.9996335},"labels":[],"label_agreement":null},{"id":"W3108323391","doi":"10.1136/jitc-2020-001128","title":"PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Centre for Drug Research and Development; University of British Columbia","funders":"Canadian Institutes of Health Research; Centre for Blood Research, University of British Columbia; National Research Foundation; Danmarks Grundforskningsfond; Stem Cell Network; Cancer Research Institute","keywords":"Podocalyxin; Cancer research; Epitope; Antigen; Cancer; Metastasis; Ovarian cancer; Antibody; Tumor microenvironment; Medicine; Biology; Kidney; Immunology; Internal medicine","score_opus":0.03868869120217639,"score_gpt":0.3684224076571678,"score_spread":0.32973371645499144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108323391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9147565,0.020941393,0.0012787975,0.061141983,0.0005625816,0.0009075957,0.0002556118,0.000023883575,0.00013167044],"genre_scores_gemma":[0.938386,0.019771297,0.0006420021,0.038879458,0.0015958182,0.0001429631,0.000008548931,0.00008984427,0.00048402118],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849796,0.000033222903,0.00047897288,0.00021932993,0.00044798508,0.00032251287],"domain_scores_gemma":[0.9987854,0.00010679337,0.00029131738,0.00022511519,0.0003393346,0.00025207212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015942084,0.00021171171,0.00047468318,0.00010950227,0.0001805301,0.00005338493,0.00026849177,0.000047338053,0.0005133731],"category_scores_gemma":[0.00015683469,0.00012492477,0.0003979117,0.00045152515,0.000062569045,0.00006960688,0.00002217428,0.0002845823,0.0000074125896],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010438569,0.00029077145,0.007994583,0.00015316861,0.0009199079,0.000028133052,0.0011489674,0.00045074706,0.903185,0.00025031992,0.022935422,0.05220441],"study_design_scores_gemma":[0.008281431,0.004420043,0.35317647,0.0019281098,0.00027850803,0.000070016795,0.00050726015,0.0007278989,0.05283003,0.00018559762,0.5771038,0.0004908613],"about_ca_topic_score_codex":0.00030992835,"about_ca_topic_score_gemma":0.00000869178,"teacher_disagreement_score":0.85035497,"about_ca_system_score_codex":0.0000917628,"about_ca_system_score_gemma":0.0004926866,"threshold_uncertainty_score":0.56210756},"labels":[],"label_agreement":null},{"id":"W3112961014","doi":"10.1136/jitc-2020-001849","title":"Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Galectins and Cancer Biology","field":"Immunology and Microbiology","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Faculty of Medicine and Dentistry, University of Alberta; Canadian Institutes of Health Research; University of Alberta; Alberta Cancer Foundation","keywords":"TIGIT; Cytotoxic T cell; T cell; Downregulation and upregulation; IL-2 receptor; Cancer research; Interleukin 21; Immunology; Galectin; CD8; Biology; Medicine; Immune system; In vitro","score_opus":0.010907829551133298,"score_gpt":0.2508194246248309,"score_spread":0.23991159507369764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112961014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938427,0.0048099975,0.000045270877,0.00013973191,0.0005621383,0.0004374347,0.00012355918,0.00001892425,0.000020226602],"genre_scores_gemma":[0.99764276,0.0014641527,0.00008152178,0.00044469096,0.000044769367,0.00004287105,0.000018162105,0.000037682203,0.0002234124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865645,0.00013297172,0.0005154786,0.000245863,0.000060387534,0.000388844],"domain_scores_gemma":[0.9990349,0.000078357705,0.00055121985,0.00010793913,0.00018672502,0.000040904808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017019972,0.00023119853,0.0005529953,0.000110670706,0.00017796461,0.000018169329,0.00017975338,0.00021277313,0.00035542052],"category_scores_gemma":[0.000018919807,0.00017057892,0.00011117361,0.00018835363,0.00013007848,0.000096362164,0.00002558524,0.00035425162,0.0000025032625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054417253,0.00017610002,0.039228316,0.000031752963,0.00024049298,0.0000011636884,0.0007638326,0.000052131745,0.94930315,0.0000011676098,0.0019070947,0.0028530783],"study_design_scores_gemma":[0.012095795,0.0029216844,0.103595644,0.00023787754,0.000036527963,0.0000062287454,0.00014656638,0.000007000692,0.8753477,0.000029055282,0.0053093266,0.00026660302],"about_ca_topic_score_codex":0.00014995404,"about_ca_topic_score_gemma":0.00013693854,"teacher_disagreement_score":0.073955454,"about_ca_system_score_codex":0.00009114926,"about_ca_system_score_gemma":0.00013667038,"threshold_uncertainty_score":0.6956006},"labels":[],"label_agreement":null},{"id":"W3124346768","doi":"10.1136/jitc-2020-001933","title":"Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research","keywords":"Blockade; Medicine; Lung cancer; Oncology; Cancer; Cancer research; Internal medicine; Receptor","score_opus":0.01249308043643551,"score_gpt":0.29473688144387794,"score_spread":0.28224380100744245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124346768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97833765,0.008810635,0.00016310722,0.00028520625,0.011293944,0.00058388803,0.00028782166,0.000027812046,0.00020991282],"genre_scores_gemma":[0.97614163,0.0055359025,0.00015451426,0.0025488052,0.00034350433,0.00016936682,0.00028467053,0.00009540277,0.014726219],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980715,0.0002232204,0.0007958856,0.0003449852,0.00013793775,0.00042645854],"domain_scores_gemma":[0.99769795,0.00015878474,0.00065771287,0.00026339476,0.0011727234,0.000049447957],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014477679,0.000319806,0.00056902366,0.00016176976,0.0004891035,0.00005520078,0.00021691636,0.00021312114,0.0070139547],"category_scores_gemma":[0.000037999387,0.00027927125,0.000395326,0.00018449101,0.00007987706,0.00026200098,0.00003333805,0.00046460787,0.000026470985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002902628,0.0004857692,0.007889184,0.000013812345,0.0012577482,0.0000011505288,0.00249894,0.00006448572,0.9417563,0.000007558188,0.023922656,0.019199744],"study_design_scores_gemma":[0.009392045,0.00063864695,0.03947612,0.00025395388,0.000057898746,0.0000032084115,0.00035143964,0.000004764009,0.8464154,0.000057433328,0.10303096,0.00031812311],"about_ca_topic_score_codex":0.0007187691,"about_ca_topic_score_gemma":0.000097460295,"teacher_disagreement_score":0.095340915,"about_ca_system_score_codex":0.0003461689,"about_ca_system_score_gemma":0.0002090243,"threshold_uncertainty_score":0.99996597},"labels":[],"label_agreement":null},{"id":"W3125964008","doi":"10.1136/jitc-2020-001642","title":"Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"University of Toronto","keywords":"Medicine; Neuroblastoma RAS viral oncogene homolog; Oncology; Internal medicine; Melanoma; Cohort; Proportional hazards model; Nivolumab; Immune checkpoint; Progression-free survival; Retrospective cohort study; Cancer; Immunotherapy; Cancer research; Overall survival; KRAS","score_opus":0.025299693950167255,"score_gpt":0.3139723413321364,"score_spread":0.2886726473819692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125964008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9372703,0.0567195,0.00022811405,0.0010093366,0.0036290796,0.00065721886,0.00018171473,0.000028198368,0.0002765346],"genre_scores_gemma":[0.947132,0.0511978,0.0005766956,0.000097793105,0.0003334439,0.000034316836,0.000061538165,0.00008525091,0.00048117604],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964136,0.00012690682,0.0019328587,0.00037529404,0.0006829535,0.0004683966],"domain_scores_gemma":[0.9960448,0.00025150954,0.001857317,0.0005420596,0.0012098943,0.00009440629],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001088692,0.00041939295,0.0015385199,0.00035814726,0.00016539927,0.000032222106,0.00033789696,0.00032405992,0.00072204246],"category_scores_gemma":[0.00007817578,0.00034652956,0.0011885327,0.0006479716,0.0003772139,0.0002214761,0.0000348956,0.00035479484,8.856976e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016315836,0.00083378184,0.044793952,0.00031467972,0.003182535,0.000009130191,0.00048513108,0.000074081,0.8885269,0.0001522035,0.00019352906,0.045118246],"study_design_scores_gemma":[0.02450763,0.0030076741,0.23914815,0.000815375,0.00023574442,0.00005470643,0.00041292087,0.00007528881,0.7229314,0.00022830616,0.008271294,0.00031151786],"about_ca_topic_score_codex":0.0005116377,"about_ca_topic_score_gemma":0.00004918821,"teacher_disagreement_score":0.1943542,"about_ca_system_score_codex":0.0002651003,"about_ca_system_score_gemma":0.0007119322,"threshold_uncertainty_score":0.9998987},"labels":[],"label_agreement":null},{"id":"W3125966940","doi":"10.1136/jitc-2020-001931","title":"Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University; Jewish General Hospital","funders":"National Health and Medical Research Council; Melanoma Institute Australia; University of Sydney; Cancer Institute NSW","keywords":"Coronavirus disease 2019 (COVID-19); Immune checkpoint; Medicine; Immune system; 2019-20 coronavirus outbreak; Cancer; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Cancer research; Bioinformatics; Immunology; Immunotherapy; Virology; Internal medicine; Biology; Disease","score_opus":0.06330711220933358,"score_gpt":0.46447215231227634,"score_spread":0.40116504010294274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125966940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99050266,0.0044639683,0.0002648145,0.0036792702,0.00019902454,0.00064368953,0.0001931557,0.0000138088235,0.000039600443],"genre_scores_gemma":[0.99032897,0.006700319,0.00026839212,0.0020131343,0.00023477264,0.000042206717,0.00004111236,0.000056033947,0.00031507903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979712,0.000092195216,0.0009097417,0.00021731821,0.0004979715,0.00031158904],"domain_scores_gemma":[0.9970225,0.00020803393,0.0009241839,0.00029096464,0.0012261589,0.0003281443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044703038,0.00022472185,0.0008186963,0.00016874228,0.00011698785,0.000016306278,0.00006490565,0.00013274576,0.0008388972],"category_scores_gemma":[0.00017450856,0.0001343649,0.0004624445,0.00031722855,0.0001314183,0.000107773776,0.0000074767604,0.0003859825,5.0747127e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07773375,0.0015672147,0.8280566,0.0006257223,0.0024204212,0.00004111867,0.00093381497,0.00064485875,0.020891784,0.000011903401,0.0011943153,0.06587854],"study_design_scores_gemma":[0.031487163,0.014964594,0.92198676,0.0020357536,0.00024848818,0.000047960482,0.0000954414,0.000020837238,0.02213136,0.000049222723,0.006728879,0.00020356046],"about_ca_topic_score_codex":0.003166783,"about_ca_topic_score_gemma":0.00042840902,"teacher_disagreement_score":0.09393018,"about_ca_system_score_codex":0.0010811314,"about_ca_system_score_gemma":0.00570654,"threshold_uncertainty_score":0.9999302},"labels":[],"label_agreement":null},{"id":"W3129135562","doi":"10.1136/jitc-2020-001580","title":"Immunotherapy for sarcomas: new frontiers and unveiled opportunities","year":2021,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research; University of Ottawa","keywords":"Medicine; Immunotherapy; Malignancy; Sarcoma; Radiation therapy; Disease; Cancer; Soft tissue sarcoma; Cancer immunotherapy; Oncology; Cancer research; Pathology; Internal medicine","score_opus":0.12473750641321807,"score_gpt":0.41549837843333776,"score_spread":0.2907608720201197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129135562","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037627186,0.9941427,0.00078509474,0.00097337784,0.0015707293,0.0021829484,0.0002439302,0.000016401053,0.0000471994],"genre_scores_gemma":[0.0000015540394,0.9851384,0.006905714,0.0004843152,0.0008134093,0.0007134418,0.00010217062,0.00018395767,0.0056570265],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997743,0.00007419685,0.0011565603,0.00032587364,0.0003023667,0.00039799666],"domain_scores_gemma":[0.99768543,0.00033786934,0.00106476,0.00037728617,0.00033526213,0.0001994197],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034654955,0.000557484,0.0033309564,0.00033521865,0.00019014157,0.000094461466,0.00019203819,0.0003058405,0.00031663774],"category_scores_gemma":[0.00003040388,0.0003992138,0.002013624,0.00013211933,0.00010239226,0.000098453915,0.000016244132,0.00029866368,3.707029e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004844082,0.00020863941,0.00007368271,0.0031461967,0.006847159,0.000018711238,0.00016054725,2.0020306e-7,0.000011695165,0.00011283942,0.039516155,0.94941974],"study_design_scores_gemma":[0.007384428,0.000762981,0.00003139417,0.015408538,0.0022845573,0.00034077824,0.00017150103,0.000002032702,0.000044020773,0.00027278333,0.97295886,0.00033810118],"about_ca_topic_score_codex":0.000062183135,"about_ca_topic_score_gemma":0.000006399159,"teacher_disagreement_score":0.94908166,"about_ca_system_score_codex":0.00036476084,"about_ca_system_score_gemma":0.0022011357,"threshold_uncertainty_score":0.999846},"labels":[],"label_agreement":null},{"id":"W3132046910","doi":"10.1136/jitc-2020-001387","title":"In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institute of Allergy and Infectious Diseases; Natural Sciences and Engineering Research Council of Canada; Institute of Cancer Research; NIH Clinical Center; National Institutes of Health; Institut Du Cancer de Montréal; Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada; Fondation du cancer du sein du Québec; U.S. Department of Energy","keywords":"Oncolytic virus; Vesicular stomatitis virus; In silico; Clinical trial; Medicine; Vaccinia; Enhancer; Immune system; Virus; Computational biology; Oncology; Bioinformatics; Immunology; Biology; Internal medicine","score_opus":0.031052805369189425,"score_gpt":0.3725765579536491,"score_spread":0.34152375258445966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132046910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9641275,0.03044757,0.0036202678,0.00036721717,0.00043078657,0.0007372847,0.0002548435,0.0000049945984,0.000009535119],"genre_scores_gemma":[0.99145293,0.0067320606,0.00028036904,0.00041879812,0.00028817946,0.0003813059,0.000051357303,0.000053392756,0.00034162187],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982408,0.00030093218,0.00060932647,0.0002468356,0.00028741956,0.0003146533],"domain_scores_gemma":[0.9984571,0.00016738776,0.0007096161,0.00023770401,0.0003700041,0.00005823694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014568086,0.00018601275,0.00052502507,0.00008903569,0.00013282629,0.00009634142,0.00022128185,0.00012406183,0.000086177715],"category_scores_gemma":[0.00024038796,0.00017065204,0.0003283748,0.000105338186,0.00006228332,0.0000347154,0.00001969285,0.0001375293,2.5232964e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046756696,0.00017442729,0.00027259582,0.00009349585,0.00027642172,0.0000055277624,0.00009853957,0.00019863529,0.978928,0.0000045809757,0.0022451896,0.013026905],"study_design_scores_gemma":[0.0064814165,0.002217906,0.0005153965,0.00022387734,0.000028928198,0.000019082012,0.00023125247,0.00018549564,0.9802979,0.00053786876,0.009080634,0.00018023435],"about_ca_topic_score_codex":0.000050761224,"about_ca_topic_score_gemma":0.001794146,"teacher_disagreement_score":0.027325416,"about_ca_system_score_codex":0.00013300346,"about_ca_system_score_gemma":0.0009363393,"threshold_uncertainty_score":0.69589883},"labels":[],"label_agreement":null},{"id":"W3134221665","doi":"10.1136/jitc-2020-001901","title":"Considerations for treatment duration in responders to immune checkpoint inhibitors","year":2021,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute; Society for Immunotherapy of Cancer","keywords":"Medicine; Immunotherapy; Clinical trial; Limiting; Oncology; Cancer; Internal medicine; Intensive care medicine","score_opus":0.08771796083704402,"score_gpt":0.4250182670291007,"score_spread":0.3373003061920567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134221665","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003894802,0.99117994,0.00026700873,0.0018394444,0.0017015028,0.0043337396,0.00024728465,0.000012877823,0.000028712762],"genre_scores_gemma":[0.000052344883,0.9925337,0.0025743076,0.00026906296,0.00058388105,0.0018937279,0.00009351979,0.00011757462,0.0018818931],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966056,0.000120582205,0.0022655851,0.00035595117,0.00027498437,0.00037733157],"domain_scores_gemma":[0.9974738,0.0004951104,0.0011173652,0.00037435573,0.00043716352,0.00010224133],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082814856,0.00047268835,0.0024861074,0.0006864109,0.00018308709,0.00007846495,0.000109464156,0.00032321466,0.00036589178],"category_scores_gemma":[0.000172692,0.0003603957,0.0022665623,0.00043522593,0.00006316089,0.00010058254,0.000010198075,0.0002111876,0.0000010830119],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036892886,0.00028112205,0.0000050677622,0.0024513388,0.0023714101,0.000010515026,0.00074155483,0.000010067961,0.006335633,0.00003375335,0.0020442926,0.982026],"study_design_scores_gemma":[0.0072327727,0.0018626334,0.000027299762,0.017865889,0.00072239735,0.00019432609,0.00016555985,0.000003674984,0.0033144993,0.00008378379,0.96819425,0.00033293027],"about_ca_topic_score_codex":0.00017510027,"about_ca_topic_score_gemma":0.00024380672,"teacher_disagreement_score":0.981693,"about_ca_system_score_codex":0.0020669785,"about_ca_system_score_gemma":0.0032421395,"threshold_uncertainty_score":0.9998848},"labels":[],"label_agreement":null},{"id":"W3135804634","doi":"10.1136/jitc-2020-002007","title":"Electrocardiographic features of immune checkpoint inhibitor associated myocarditis","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Myocarditis; Medicine; Mace; Internal medicine; QRS complex; Cardiology; PR interval; QT interval; Viral Myocarditis; Electrocardiography; Odds ratio; Heart rate; Blood pressure; Myocardial infarction; Percutaneous coronary intervention","score_opus":0.011009566007240729,"score_gpt":0.298156691801623,"score_spread":0.2871471257943823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135804634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7332996,0.2607484,0.0002768964,0.0020037864,0.0020056623,0.00052683306,0.00013134722,0.00003041354,0.0009770646],"genre_scores_gemma":[0.9339312,0.06207409,0.0007093252,0.0005489055,0.00050600833,0.000058416674,0.000034347806,0.0000674314,0.0020702772],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99775636,0.000085275795,0.0010415706,0.00021024099,0.0005362552,0.00037032395],"domain_scores_gemma":[0.99760795,0.000096103424,0.00084971293,0.00032321716,0.0010470663,0.00007596587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007072312,0.00023852647,0.0009498354,0.00025527112,0.00013769118,0.000029030307,0.00015119428,0.00019584937,0.0003563478],"category_scores_gemma":[0.00009493657,0.00020262293,0.0019125146,0.00065334537,0.00016133154,0.000106968684,0.000014675496,0.00037371082,3.2621244e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062020235,0.00025667003,0.0034651586,0.00013802883,0.0053991214,0.000014279012,0.00028229036,0.0000065702156,0.91120124,0.000034280114,0.003642941,0.06935742],"study_design_scores_gemma":[0.010408807,0.0012511814,0.17050457,0.0009190518,0.00033015493,0.0003063597,0.00018961608,0.000003889817,0.76797485,0.0002931922,0.047604002,0.00021432008],"about_ca_topic_score_codex":0.00015839815,"about_ca_topic_score_gemma":0.00003672135,"teacher_disagreement_score":0.20063159,"about_ca_system_score_codex":0.00023220347,"about_ca_system_score_gemma":0.0007639372,"threshold_uncertainty_score":0.8262723},"labels":[],"label_agreement":null},{"id":"W3136309976","doi":"10.1136/jitc-2020-002096","title":"Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Beatrice Hunter Cancer Research Institute; University of Calgary; Dalhousie University","funders":"Cancer Research Institute; Terry Fox Research Institute; Institute of Infection and Immunity; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Dalhousie University; Beatrice Hunter Cancer Research Institute","keywords":"Oncolytic virus; Vesicular stomatitis virus; Immunotherapy; Cancer research; Ovarian cancer; Natural killer T cell; Immunology; Virotherapy; Medicine; Antigen; Biology; Cancer; Virus; Virology; T cell; Immune system; Internal medicine","score_opus":0.016448385815238987,"score_gpt":0.30610441907018493,"score_spread":0.28965603325494593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136309976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968411,0.029924726,0.0002716198,0.00019250017,0.0002168007,0.00050739705,0.00045698686,0.0000053510335,0.000013603546],"genre_scores_gemma":[0.94377965,0.05349323,0.00075489527,0.00018546978,0.000092509756,0.00014921793,0.00004521281,0.000095403375,0.0014043947],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979899,0.00026747072,0.0005796148,0.00034673282,0.0004247533,0.0003915272],"domain_scores_gemma":[0.9986359,0.000058849062,0.00041305405,0.0003838985,0.0004125683,0.000095715746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003031808,0.0003326512,0.0006733301,0.00015538115,0.00012414853,0.000055142064,0.00027176682,0.00013313217,0.00026382477],"category_scores_gemma":[0.000008592824,0.0002437404,0.00022965332,0.00022049312,0.00015530069,0.00003591827,0.00004181026,0.0001946156,1.50668e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058361914,0.00071888143,0.0017436938,0.00007929434,0.00214329,0.000018607192,0.00019682542,0.0008695202,0.91477734,0.00000781838,0.000069365065,0.02101345],"study_design_scores_gemma":[0.020183561,0.0047937864,0.008044489,0.00019139255,0.00012533234,0.00007017571,0.00013506657,0.0003106841,0.9651271,0.00009579047,0.00053497433,0.00038765432],"about_ca_topic_score_codex":0.0019327436,"about_ca_topic_score_gemma":0.005855866,"teacher_disagreement_score":0.050349753,"about_ca_system_score_codex":0.00014551192,"about_ca_system_score_gemma":0.00093808316,"threshold_uncertainty_score":0.9939445},"labels":[],"label_agreement":null},{"id":"W3137265803","doi":"10.1136/jitc-2020-001803","title":"Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"Faculty of Medicine and Health, University of Leeds; University of Leeds; Kay Kendall Leukaemia Fund; Yorkshire Cancer Research; Cancer Research UK; NHS Blood and Transplant","keywords":"Bone marrow; Multiple myeloma; Immunity; Niche; Immunology; Medicine; Cancer research; Biology; Immune system; Ecology","score_opus":0.030523131196094705,"score_gpt":0.33210019707983307,"score_spread":0.30157706588373834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137265803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93071246,0.06645227,0.00019055717,0.0012503262,0.00040225327,0.0007623671,0.00020375142,0.0000034089571,0.000022601327],"genre_scores_gemma":[0.97131217,0.025630547,0.000371714,0.00029590138,0.00033144557,0.00031381287,0.00004114796,0.00006421353,0.0016390382],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99846786,0.00021792408,0.0005435282,0.00019634719,0.0002764357,0.000297906],"domain_scores_gemma":[0.9978273,0.0003447973,0.0004922541,0.0006620989,0.00062308024,0.000050500017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008469812,0.00019875061,0.0003147535,0.00004212997,0.0003936597,0.000032228676,0.00040087072,0.00012751573,0.000064790605],"category_scores_gemma":[0.000116217474,0.000114152026,0.00047637653,0.00015452207,0.00014758534,0.0000058622245,0.000024097986,0.00015592543,4.2029458e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021646056,0.00027620286,0.00019274013,0.000027046217,0.00080556184,0.0000012625616,0.0004947103,0.00017839001,0.9583929,0.000004460797,0.0006048757,0.017375752],"study_design_scores_gemma":[0.0050359885,0.005792147,0.0006563933,0.000026053753,0.000059478658,0.0000080436,0.00048139074,0.00013121018,0.92850536,0.00006559657,0.059112098,0.00012624227],"about_ca_topic_score_codex":0.00014446436,"about_ca_topic_score_gemma":0.0013986471,"teacher_disagreement_score":0.058507223,"about_ca_system_score_codex":0.00009263516,"about_ca_system_score_gemma":0.000756,"threshold_uncertainty_score":0.46549845},"labels":[],"label_agreement":null},{"id":"W3137963785","doi":"10.1136/jitc-2020-001831","title":"Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Dermatology; Immunosuppression; Adverse effect; Refractory (planetary science); Immune system; Ultraviolet b; Immunology; Internal medicine","score_opus":0.024746355654553263,"score_gpt":0.3409145376868956,"score_spread":0.31616818203234237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137963785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8374453,0.1518867,0.0004258233,0.005470237,0.0024368134,0.0017256687,0.00019144327,0.00005748417,0.00036052047],"genre_scores_gemma":[0.8393802,0.13943382,0.0018212663,0.008537756,0.0010480287,0.000729389,0.00015328133,0.00031016488,0.0085860845],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99669147,0.000121117344,0.0016452157,0.00046208742,0.00051326933,0.0005668154],"domain_scores_gemma":[0.9964841,0.0003300498,0.0012237666,0.00072017417,0.0010870412,0.00015486941],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010351083,0.0004712022,0.0010121667,0.0002559676,0.00048199066,0.00009290104,0.000212981,0.0003371814,0.001197422],"category_scores_gemma":[0.00009363791,0.00037483592,0.0013891486,0.0003687917,0.00019104224,0.00020760861,0.000009229332,0.0005256226,0.0000017104704],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027091984,0.0011030858,0.0006830003,0.00014669678,0.0044256398,0.0033240928,0.0020783274,0.0000230096,0.6288748,0.0000386236,0.01153001,0.32068077],"study_design_scores_gemma":[0.035898745,0.004174112,0.0051386342,0.0008004617,0.00014042814,0.04783794,0.0005353755,0.000030391391,0.35153535,0.0004323015,0.55293363,0.00054262095],"about_ca_topic_score_codex":0.00020249632,"about_ca_topic_score_gemma":0.000031674266,"teacher_disagreement_score":0.54140365,"about_ca_system_score_codex":0.00037591427,"about_ca_system_score_gemma":0.0011888073,"threshold_uncertainty_score":0.99987036},"labels":[],"label_agreement":null},{"id":"W3139360595","doi":"10.1136/jitc-2020-001965","title":"High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer","year":2021,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Heart, Lung, and Blood Institute; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Institute of Cancer Research; National Cancer Institute; National Institutes of Health; Université de Montréal; Terry Fox Research Institute","keywords":"Immune system; Ovarian cancer; Cancer research; Gene signature; Transcriptome; Tumor microenvironment; Cancer; CD8; Biology; Medicine; Microarray; Microarray analysis techniques; Immunology; Gene expression; Internal medicine; Gene","score_opus":0.02410786326807273,"score_gpt":0.33656913096828533,"score_spread":0.3124612677002126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139360595","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0110564865,0.9869039,0.00012777766,0.00016599422,0.000963734,0.00031457163,0.00046254968,0.0000016736784,0.0000032988369],"genre_scores_gemma":[0.0031190584,0.99468046,0.0002993024,0.00015291752,0.0006250879,0.00010051128,0.00015208748,0.00006059204,0.00081000844],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99787396,0.00019178573,0.0010487294,0.0003085276,0.00030963024,0.0002673638],"domain_scores_gemma":[0.99791837,0.000059186346,0.0012730738,0.00041833337,0.00028680268,0.00004421364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033850042,0.00033944342,0.001676917,0.00025322422,0.00008926228,0.000020337686,0.00047891343,0.00035053928,0.00029239847],"category_scores_gemma":[0.000024835852,0.00022422774,0.0014753648,0.0007746994,0.00007402014,0.000005507787,0.000068218185,0.00034315686,1.0864889e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006313247,0.000624374,0.0006595509,0.0034970483,0.040663764,0.000020067293,0.00019523788,0.022927778,0.035286363,0.00030910881,0.01387658,0.8813088],"study_design_scores_gemma":[0.0015135602,0.00015338331,0.0002980682,0.0046710134,0.0026541122,0.000028986891,0.00001191049,0.000015204074,0.008476862,0.00003523559,0.98176277,0.00037890894],"about_ca_topic_score_codex":0.0009344399,"about_ca_topic_score_gemma":0.0002230262,"teacher_disagreement_score":0.96788615,"about_ca_system_score_codex":0.00010399691,"about_ca_system_score_gemma":0.0011154966,"threshold_uncertainty_score":0.9143742},"labels":[],"label_agreement":null},{"id":"W3152586353","doi":"10.1136/jitc-2020-001955","title":"Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"National Institute of Dental and Craniofacial Research; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Cancer League of Colorado","keywords":"CD137; Cancer research; Immunotherapy; Medicine; CD8; CD80; Immune system; T cell; Dendritic cell; Immunology; IL-2 receptor; Cytotoxic T cell; Biology; In vitro; CD40","score_opus":0.00901117220919158,"score_gpt":0.27719306309205965,"score_spread":0.2681818908828681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152586353","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48111218,0.50942063,0.002235978,0.0036140212,0.002439067,0.00079020805,0.00014146097,0.000030125357,0.00021632855],"genre_scores_gemma":[0.906693,0.04567825,0.0013627498,0.0031981382,0.0002090505,0.00039675535,0.000055530552,0.0001715568,0.04223497],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970231,0.0005826997,0.0011852593,0.0003508839,0.0001558745,0.0007021492],"domain_scores_gemma":[0.9976625,0.00083768606,0.0006149999,0.00047637802,0.00037959695,0.00002885222],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011465264,0.00035130169,0.0006576816,0.00020642763,0.000697161,0.00009612617,0.0006013985,0.00025083218,0.0008960051],"category_scores_gemma":[0.00016272103,0.00028528398,0.00038091108,0.0005537068,0.00016186913,0.00023978335,0.000031969823,0.00061832566,0.0000133070425],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026433421,0.00020566928,0.0005811824,0.000036013895,0.00039233017,0.0000031509092,0.0024716263,0.00040488975,0.94203234,0.00012333074,0.018158272,0.032947846],"study_design_scores_gemma":[0.004263084,0.00018655192,0.0008655327,0.00017230444,0.00001716041,0.000017274167,0.0006687623,0.000012994763,0.5218388,0.00012150253,0.47158155,0.00025452193],"about_ca_topic_score_codex":0.00016228287,"about_ca_topic_score_gemma":0.00007036775,"teacher_disagreement_score":0.46374238,"about_ca_system_score_codex":0.00027761367,"about_ca_system_score_gemma":0.00043466734,"threshold_uncertainty_score":0.99995995},"labels":[],"label_agreement":null},{"id":"W3157675313","doi":"10.1136/jitc-2021-002535","title":"Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Canadian Cancer Society; ECOG-ACRIN Cancer Research Group; National Cancer Institute; National Institutes of Health; American College of Radiology Imaging Network; Bristol-Myers Squibb","keywords":"Ipilimumab; Medicine; Rash; Internal medicine; Adverse effect; Adjuvant; Melanoma; Oncology; Multivariate analysis; Proportional hazards model; Immunotherapy; Cancer","score_opus":0.024259388212844894,"score_gpt":0.3273518728818649,"score_spread":0.30309248466902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157675313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884503,0.009991237,0.00012292244,0.0002951139,0.0002200524,0.00080874655,0.00008641843,0.000011606641,0.000013609402],"genre_scores_gemma":[0.9928402,0.0050252806,0.0009456712,0.000121694546,0.000037758553,0.00007034118,0.000015667792,0.000059469985,0.0008839467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973347,0.00015602159,0.0011829933,0.00030295365,0.00067878974,0.0003444966],"domain_scores_gemma":[0.99751616,0.00017508268,0.0011966154,0.00040457165,0.00064173096,0.00006582036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078806514,0.0002896872,0.0012638273,0.00044999213,0.000106350984,0.000023783989,0.0001319643,0.00011776938,0.00017592008],"category_scores_gemma":[0.000045198154,0.00020690248,0.00038752463,0.0009105054,0.00007444124,0.0003259851,0.000023548668,0.00031191934,2.097976e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028307602,0.0009516537,0.9178069,0.00009059403,0.0114783915,0.000037939826,0.0015092423,0.0002879367,0.030505797,0.0000011470752,0.000030791107,0.008991976],"study_design_scores_gemma":[0.028407602,0.002625652,0.9507692,0.00044695887,0.0017460173,0.00005035563,0.0017930974,0.000060033748,0.012787913,0.000007153015,0.0010611445,0.0002448801],"about_ca_topic_score_codex":0.0017055757,"about_ca_topic_score_gemma":0.0025086002,"teacher_disagreement_score":0.032962263,"about_ca_system_score_codex":0.0004762414,"about_ca_system_score_gemma":0.00040037037,"threshold_uncertainty_score":0.8437238},"labels":[],"label_agreement":null},{"id":"W3158940958","doi":"10.1136/jitc-2020-002189","title":"Expanded antigen-experienced CD160<sup>+</sup>CD8<sup>+</sup>effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Calcium signaling and nucleotide metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; University of Alberta","keywords":"CD8; Chronic lymphocytic leukemia; Immunology; T cell; Cytokine; Receptor; Cytotoxic T cell; Proinflammatory cytokine; Leukemia; Medicine; Antigen; Chemistry; Biology; Immune system; Internal medicine; Inflammation; In vitro; Biochemistry","score_opus":0.010714209973224212,"score_gpt":0.2843837342926516,"score_spread":0.2736695243194274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158940958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9590784,0.037760887,0.0015670526,0.000064233405,0.0008594244,0.0004726061,0.00014154166,0.000022637465,0.000033224278],"genre_scores_gemma":[0.98826426,0.0077206283,0.00036277887,0.00033684433,0.0012766388,0.00019600405,0.00008569634,0.000108478846,0.0016486627],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973905,0.0002410197,0.00080043584,0.0005427276,0.00035709538,0.00066822267],"domain_scores_gemma":[0.9984974,0.000105189385,0.00034795774,0.00053827686,0.0003408352,0.00017031362],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005652388,0.0004187668,0.00069601886,0.00018717897,0.0002839359,0.00010198532,0.0003519517,0.00030674826,0.00065096765],"category_scores_gemma":[0.00008933384,0.00038645815,0.00073482376,0.00036114384,0.00015168254,0.000029808001,0.00005952375,0.0003029283,0.000013626604],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013526783,0.000066224886,0.00047628736,0.000085010346,0.00037288372,0.000011808937,0.0006137018,0.054514688,0.9300611,0.0000023369498,0.0026688238,0.009774456],"study_design_scores_gemma":[0.008891618,0.0008310213,0.00096010976,0.0002623297,0.00007700818,0.00008362418,0.00036440737,0.008438029,0.90230864,0.000018361307,0.077263944,0.00050092675],"about_ca_topic_score_codex":0.00031940412,"about_ca_topic_score_gemma":0.0000641103,"teacher_disagreement_score":0.074595116,"about_ca_system_score_codex":0.0014573329,"about_ca_system_score_gemma":0.003245159,"threshold_uncertainty_score":0.99985874},"labels":[],"label_agreement":null},{"id":"W3162235708","doi":"10.1136/jitc-2021-002449","title":"Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; NIH Clinical Center; National Institutes of Health","keywords":"Medicine; Melanoma; CD8; Tumor-infiltrating lymphocytes; Adoptive cell transfer; Antigen; Dendritic cell; Immunology; Immunotherapy; T cell; Population; Leukapheresis; Immune system; Cancer research; Biology; Stem cell","score_opus":0.01341338405052177,"score_gpt":0.2848127047442006,"score_spread":0.27139932069367884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162235708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748119,0.019276155,0.003642953,0.000031685675,0.00041968466,0.0016453244,0.000114883995,0.000008011375,0.00004937571],"genre_scores_gemma":[0.99568254,0.0018966597,0.001277366,0.000059889953,0.000017678087,0.00016811008,0.00005788138,0.000057357927,0.0007825291],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970055,0.00079384854,0.0014247051,0.00024091218,0.00018793788,0.0003470795],"domain_scores_gemma":[0.99714625,0.0006325276,0.001022289,0.00025404576,0.0009249412,0.000019934036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008745818,0.00032765616,0.0016010604,0.00030406483,0.00018861999,0.000016177668,0.00022455706,0.00011930304,0.0006686139],"category_scores_gemma":[0.00006520149,0.00021664794,0.00034198718,0.00035203868,0.00022699701,0.0002563202,0.000011468872,0.00022148447,4.182516e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.791915,0.0021848672,0.00036862955,0.0001557588,0.0011596882,0.000003473715,0.0026539622,0.00017533844,0.19698171,0.000021246218,0.000014918226,0.0043654395],"study_design_scores_gemma":[0.5738838,0.007581074,0.000286529,0.0002992453,0.00025443788,0.000031740437,0.0005493071,0.000023818522,0.41656548,0.000014467295,0.00033309855,0.00017703883],"about_ca_topic_score_codex":0.0001700724,"about_ca_topic_score_gemma":0.00006434756,"teacher_disagreement_score":0.21958378,"about_ca_system_score_codex":0.00021476301,"about_ca_system_score_gemma":0.0016581152,"threshold_uncertainty_score":0.8834647},"labels":[],"label_agreement":null},{"id":"W3169390234","doi":"10.1136/jitc-2021-002856","title":"IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; H2020 European Research Council; BC Cancer Agency; Horizon 2020 Framework Programme; Cancer Research UK","keywords":"Progenitor cell; Cancer research; Haematopoiesis; Bone marrow; Myeloid; Immune system; Monocyte; Dendritic cell; Metastasis; Biology; Immunology; Medicine; Cancer; Stem cell; Cell biology; Internal medicine","score_opus":0.014086607990613006,"score_gpt":0.3005891664180392,"score_spread":0.28650255842742617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169390234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7988756,0.16755496,0.023350412,0.0017440179,0.0068258117,0.0014904881,0.00012090687,0.000018864841,0.000018970766],"genre_scores_gemma":[0.99214596,0.0032790394,0.0018312039,0.00027484156,0.00006273567,0.00033636292,0.000026810876,0.00006497392,0.0019781038],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976514,0.00032727185,0.0011974506,0.00024031849,0.00014376665,0.0004397801],"domain_scores_gemma":[0.99721915,0.00051325635,0.00081661495,0.00045281497,0.00097316783,0.000025011654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069545297,0.00027630338,0.0007951637,0.00020049929,0.0003132643,0.000042629203,0.0005036857,0.000117297466,0.000669566],"category_scores_gemma":[0.0001189409,0.00019898647,0.00054291025,0.00041631554,0.00023756752,0.00012947433,0.000064493805,0.00037294687,0.000013716218],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008693747,0.00023469389,0.00018322056,0.00019152211,0.0033126005,0.0000016431047,0.0016766355,0.00017161478,0.95481926,0.00015255735,0.0008267077,0.0375602],"study_design_scores_gemma":[0.0037242617,0.00042267065,0.0012835155,0.00025813183,0.00048049688,0.00004660089,0.0006870763,0.0000255192,0.96438414,0.0024294662,0.026055926,0.00020219448],"about_ca_topic_score_codex":0.00017022397,"about_ca_topic_score_gemma":0.00004712844,"teacher_disagreement_score":0.19327037,"about_ca_system_score_codex":0.00025160008,"about_ca_system_score_gemma":0.00048021483,"threshold_uncertainty_score":0.81144327},"labels":[],"label_agreement":null},{"id":"W3171665778","doi":"10.1136/jitc-2020-002140","title":"Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Medical Research Council; Breast Cancer Now; Academy of Medical Sciences; Cancer Research UK","keywords":"Immunotherapy; Medicine; Antigen; Immunoglobulin E; Cancer immunotherapy; Immunology; Cancer research; Immune system; Antibody","score_opus":0.0655862087547177,"score_gpt":0.4044719527983389,"score_spread":0.3388857440436212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171665778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91266894,0.07230034,0.0074540144,0.0019539227,0.00289958,0.0022932757,0.00018839969,0.00003443174,0.00020712106],"genre_scores_gemma":[0.57735634,0.20230584,0.07370142,0.018675115,0.014483362,0.0019235895,0.00007822077,0.001974198,0.10950191],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971441,0.000137363,0.0008737571,0.00035882543,0.0007173494,0.0007685781],"domain_scores_gemma":[0.9970537,0.00045078518,0.000595892,0.00063392136,0.001123157,0.00014254413],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010305613,0.00034853778,0.00084758503,0.00018299463,0.0006722439,0.00017038705,0.00042262336,0.00013278934,0.0039398656],"category_scores_gemma":[0.00006541557,0.00022822642,0.0008627032,0.00041454154,0.00024823003,0.0002026545,0.00003057571,0.00050636264,0.000001003113],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009939585,0.000100513826,0.00037709097,0.00015258272,0.0012747452,0.000026886824,0.001506791,0.00051308714,0.9078522,0.000013416715,0.0023768398,0.07586629],"study_design_scores_gemma":[0.007427081,0.00057882065,0.0002878859,0.0005057537,0.00009439402,0.0002822567,0.0008889338,0.00096304703,0.6212004,0.00013404514,0.36740494,0.00023248367],"about_ca_topic_score_codex":0.00043853346,"about_ca_topic_score_gemma":0.000105527884,"teacher_disagreement_score":0.36502808,"about_ca_system_score_codex":0.00093935436,"about_ca_system_score_gemma":0.0033832178,"threshold_uncertainty_score":0.99697065},"labels":[],"label_agreement":null},{"id":"W3173127935","doi":"10.1136/jitc-2020-002157","title":"Follicular helper-T cells restore CD8<sup>+</sup>-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Ligue Contre le Cancer; Agence Nationale de la Recherche; Université de Franche-Comté; Fondation de France; Université Laval; Université de Bourgogne; Association pour la Recherche sur le Cancer","keywords":"Germinal center; Cytotoxic T cell; Immune system; CD8; Chemokine; Immunology; Cancer research; Biology; T cell; Adoptive cell transfer; Antibody; Flow cytometry; Cytokine; B cell; In vitro","score_opus":0.02059658743093797,"score_gpt":0.3176562006179244,"score_spread":0.2970596131869864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173127935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9002659,0.095366895,0.00029710127,0.0020426763,0.0010485942,0.0006678201,0.000098803386,0.00003443018,0.00017779753],"genre_scores_gemma":[0.90168685,0.0891996,0.0019170125,0.0018702227,0.0007679886,0.000059488288,0.000029851277,0.0001440766,0.004324885],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99725634,0.00015312064,0.00096248963,0.00040772965,0.00065742456,0.0005628753],"domain_scores_gemma":[0.99786305,0.00016495219,0.0005238455,0.00063168234,0.0006171595,0.00019929156],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00082147995,0.00040971866,0.00097382313,0.00022224014,0.0004515073,0.00012548243,0.00027727237,0.00022601969,0.00094316964],"category_scores_gemma":[0.000058641934,0.00034317622,0.0007384352,0.0003658817,0.00026058799,0.00023100243,0.00005121713,0.0005953106,0.0000034205873],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009754391,0.00063109695,0.003916485,0.0003177851,0.0022008119,0.00014089012,0.0014678459,0.0001623528,0.92276543,0.000032590866,0.0043179463,0.054292385],"study_design_scores_gemma":[0.030009419,0.0015702535,0.044982124,0.0017466482,0.0005401311,0.0014498828,0.0015186494,0.00021476705,0.5771221,0.00012611956,0.3399548,0.00076510716],"about_ca_topic_score_codex":0.00033722393,"about_ca_topic_score_gemma":0.000026552492,"teacher_disagreement_score":0.3456433,"about_ca_system_score_codex":0.00032051138,"about_ca_system_score_gemma":0.0008257376,"threshold_uncertainty_score":0.9999701},"labels":[],"label_agreement":null},{"id":"W3180594295","doi":"10.1136/jitc-2021-002642","title":"Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; National Human Genome Research Institute; Swim Across America; International Association for the Study of Lung Cancer; Mark Foundation For Cancer Research; LUNGevity Foundation; Commonwealth Foundation; National Cancer Institute; National Institutes of Health; Bloomberg Philanthropies","keywords":"Blockade; T-cell receptor; Immune system; Confounding; Immune checkpoint; T cell; Medicine; Cell; Immunology; Immunotherapy; Cancer research; Biology; Receptor; Internal medicine; Genetics","score_opus":0.0552863817777128,"score_gpt":0.405616804043211,"score_spread":0.3503304222654982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180594295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927028,0.0054652905,0.0007338165,0.00021254645,0.00015369996,0.00045012895,0.00002913981,0.0000064976043,0.0002460754],"genre_scores_gemma":[0.9941527,0.001094837,0.0014345144,0.000038636117,0.00006506004,0.000037979953,0.000012252758,0.000042189342,0.0031218259],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980525,0.00012301886,0.00078101654,0.00021634442,0.0005742843,0.0002528423],"domain_scores_gemma":[0.99790835,0.0004366148,0.0005638579,0.00021442912,0.0008052277,0.0000715289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010807656,0.0001586175,0.00052580965,0.0002006998,0.00009973431,0.00001165317,0.00009034746,0.00008680074,0.00074146513],"category_scores_gemma":[0.00017068001,0.00013492073,0.0002017102,0.00034679283,0.00015712154,0.00022729451,0.000020832016,0.00051428855,5.0660134e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036086203,0.00013162554,0.11402911,0.00015370075,0.0004286798,0.000009513548,0.0010894103,0.0017766287,0.8487166,0.000009276663,0.0000055423725,0.030041302],"study_design_scores_gemma":[0.01926024,0.0018872314,0.52281475,0.0021576327,0.00015111954,0.00021133684,0.00061302085,0.0018001779,0.4495127,0.00088806055,0.00044938046,0.00025437505],"about_ca_topic_score_codex":0.00017317447,"about_ca_topic_score_gemma":0.0000523485,"teacher_disagreement_score":0.40878564,"about_ca_system_score_codex":0.00045419848,"about_ca_system_score_gemma":0.001319345,"threshold_uncertainty_score":0.8118523},"labels":[],"label_agreement":null},{"id":"W3181256475","doi":"10.1136/jitc-2021-002552","title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Society for Immunotherapy of Cancer; Bladder Cancer Advocacy Network","keywords":"Medicine; Immunotherapy; Urothelial cancer; Guideline; Bladder cancer; Cancer; Atezolizumab; Intensive care medicine; Oncology; Cancer immunotherapy; Internal medicine; Pembrolizumab; Pathology","score_opus":0.06021223239992654,"score_gpt":0.45781727494001123,"score_spread":0.39760504254008466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181256475","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15659817,0.748272,0.026326474,0.039360374,0.011179304,0.011597816,0.0063054166,0.00006325889,0.00029719443],"genre_scores_gemma":[0.030817676,0.9018594,0.034837116,0.013431678,0.005702238,0.0049080392,0.00008458518,0.00045957876,0.007899692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99559546,0.0001235743,0.0024270338,0.00052210706,0.0007248884,0.0006069373],"domain_scores_gemma":[0.992161,0.0018037575,0.002103298,0.00079870934,0.0030094406,0.00012379028],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001096546,0.00057008374,0.0017251009,0.000105887906,0.0003727555,0.000041068703,0.00038093122,0.00031892327,0.0008814077],"category_scores_gemma":[0.000118599644,0.00036971926,0.0034785431,0.00029754944,0.00032186197,0.00017504679,0.000012661568,0.00029467465,5.524415e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074105255,0.004350498,0.002630909,0.00028657063,0.024894977,0.0000029708665,0.0028319496,0.0005466116,0.13674971,0.00018704502,0.020228023,0.73318547],"study_design_scores_gemma":[0.043150775,0.009829274,0.0020402842,0.00049774116,0.0016853181,0.000023355848,0.00059159775,0.00028728019,0.16022705,0.0003200457,0.7810333,0.00031399683],"about_ca_topic_score_codex":0.0017289203,"about_ca_topic_score_gemma":0.00023436124,"teacher_disagreement_score":0.76080525,"about_ca_system_score_codex":0.00070044096,"about_ca_system_score_gemma":0.0029822048,"threshold_uncertainty_score":0.9998755},"labels":[],"label_agreement":null},{"id":"W3184786167","doi":"10.1186/s40425-016-0172-7","title":"31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Centre Hospitalier de l’Université de Montréal; Université de Montréal; Trillium Therapeutics (Canada); Telesta Therapeutics (Canada); Campbell Scientific (Canada); Ontario Institute for Cancer Research; McMaster University","funders":"National Cancer Institute; Kite Pharma; Cancer Institute, University of Pittsburgh; Oregon Clinical and Translational Research Institute; Deutsches Zentrum für Lungenforschung; National Institutes of Health; M.J. Murdock Charitable Trust; Terry Fox Foundation; University of Pittsburgh; Midwest Athletes Against Childhood Cancer; National Institute of Allergy and Infectious Diseases; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Harry J. Lloyd Charitable Trust; Achievement Rewards for College Scientists Foundation; Dana-Farber/Harvard Cancer Center; National Science Foundation","keywords":"Cancer immunotherapy; Cancer; Immunotherapy; Medicine; Oncology; Immunology; Internal medicine","score_opus":0.01757493342482682,"score_gpt":0.28726839540413324,"score_spread":0.26969346197930644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184786167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89682674,0.09133429,0.0007901481,0.0021214671,0.0073238695,0.001169724,0.00030726247,0.00002287164,0.00010360442],"genre_scores_gemma":[0.9001506,0.061480246,0.0003615481,0.00062557386,0.00031623995,0.00036834495,0.00002596464,0.00011096132,0.03656054],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985214,0.000107064654,0.0007983837,0.00016756561,0.0000919999,0.00031357456],"domain_scores_gemma":[0.99731356,0.0002501484,0.0014610608,0.00019598086,0.0007652477,0.000013996827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007094439,0.00019051891,0.00050235476,0.000057377914,0.0002827621,0.000011985786,0.00023811322,0.00023844442,0.0005227071],"category_scores_gemma":[0.000055987075,0.00011384933,0.00079315255,0.00011134916,0.0003296917,0.00018714456,0.000022943597,0.00020478858,7.0016944e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00256671,0.00022393871,0.003729388,0.00004751514,0.0028882266,1.3883754e-8,0.0010982746,0.000004050866,0.85349476,0.000048348244,0.012894833,0.12300392],"study_design_scores_gemma":[0.009046126,0.0010422065,0.006979251,0.0012498097,0.0001774479,0.000006515996,0.00061909796,0.000004570895,0.5824772,0.00015952764,0.3980366,0.0002016442],"about_ca_topic_score_codex":0.0003521895,"about_ca_topic_score_gemma":0.00008360454,"teacher_disagreement_score":0.38514176,"about_ca_system_score_codex":0.00013932824,"about_ca_system_score_gemma":0.00024444138,"threshold_uncertainty_score":0.5723277},"labels":[],"label_agreement":null},{"id":"W3185017026","doi":"10.1136/jitc-2021-002673","title":"Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Oncolytics Biotech; King's College London; King's Health Partners; Cancer Research UK; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research","keywords":"Oncolytic virus; Medicine; Concomitant; Antibody; Neutralizing antibody; Docetaxel; Immunosuppression; Immunology; Virology; Gemcitabine; Cyclophosphamide; Virus; Pharmacology; Amantadine; Chemotherapy; Internal medicine","score_opus":0.022495464877330132,"score_gpt":0.41544805392018763,"score_spread":0.3929525890428575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185017026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842561,0.013576515,0.000797265,0.00025225055,0.00017223209,0.00045047546,0.00046249537,0.0000030318454,0.000029637793],"genre_scores_gemma":[0.9913499,0.007722128,0.000334516,0.00010088399,0.00020458981,0.000025890251,0.000015840431,0.000044466593,0.00020183326],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982233,0.00026807384,0.0006431569,0.0002093952,0.00038795016,0.00026811787],"domain_scores_gemma":[0.9979724,0.00008361454,0.00050019025,0.00046426314,0.0009129671,0.00006656024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009701489,0.00019015222,0.00047019933,0.00009313515,0.000106817744,0.000038057944,0.0003642041,0.0001056083,0.000107830034],"category_scores_gemma":[0.00008959822,0.00013244926,0.0003968729,0.00021306332,0.00019771274,0.000018480756,0.000024563986,0.0001304599,2.6489798e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053909715,0.00013662754,0.0011531181,0.000053432534,0.0008118834,0.0000024046847,0.00036597592,0.00023868779,0.9290821,0.0000067188744,0.00019035459,0.014049012],"study_design_scores_gemma":[0.0023767296,0.013743926,0.0032827156,0.00019592096,0.00003019274,0.00004181849,0.00031428118,0.000051903105,0.9787496,0.000063253676,0.0010027366,0.00014697337],"about_ca_topic_score_codex":0.00008396608,"about_ca_topic_score_gemma":0.00016988964,"teacher_disagreement_score":0.051532988,"about_ca_system_score_codex":0.00011208809,"about_ca_system_score_gemma":0.0021511144,"threshold_uncertainty_score":0.54011244},"labels":[],"label_agreement":null},{"id":"W3186632176","doi":"10.1136/jitc-2021-002968","title":"Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Neuroinflammation and Neurodegeneration Mechanisms","field":"Neuroscience","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Moonshot Research and Development Program; University of Texas MD Anderson Cancer Center","keywords":"Evasion (ethics); Mechanism (biology); Immune system; Stem cell; Immunology; Cancer research; Computational biology; Medicine; Biology; Cell biology","score_opus":0.04144192327952301,"score_gpt":0.3072220279034092,"score_spread":0.2657801046238862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186632176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925997,0.0028297317,0.002850748,0.00030796306,0.00091260526,0.0002899654,0.00005312308,0.00000822954,0.00014789739],"genre_scores_gemma":[0.9841156,0.013279797,0.0006680155,0.00037545266,0.00005487052,0.00001774903,9.540896e-7,0.0000363522,0.0014512276],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980166,0.0001637933,0.0009506959,0.00022192505,0.0004749569,0.00017205196],"domain_scores_gemma":[0.998405,0.00013222992,0.00090723176,0.00027717947,0.00024095677,0.000037450223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028712113,0.0001397787,0.00036277098,0.00019819799,0.00008528839,0.000022180539,0.00023357513,0.00007269755,0.00066817197],"category_scores_gemma":[0.000020966218,0.00012520286,0.00024871572,0.00030322792,0.000035277062,0.00019799065,0.000027991806,0.00017560381,0.000001186163],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004899756,0.00013966404,0.0000103613565,0.00006579009,0.000005908869,0.0000034172203,0.00060018856,0.00022249829,0.9903669,0.0028914458,0.00031830044,0.0048855566],"study_design_scores_gemma":[0.002384857,0.00024074476,0.0000954279,0.00026094614,0.0000048282395,0.000019835054,0.00008954959,0.00039226198,0.9905085,0.0015541003,0.004345344,0.00010359615],"about_ca_topic_score_codex":0.0000055274418,"about_ca_topic_score_gemma":0.0000014831504,"teacher_disagreement_score":0.010450065,"about_ca_system_score_codex":0.00004444629,"about_ca_system_score_gemma":0.00016698526,"threshold_uncertainty_score":0.7316015},"labels":[],"label_agreement":null},{"id":"W3190177153","doi":"10.1136/jitc-2020-002287","title":"Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Cytokine release syndrome; Tocilizumab; Leukopenia; Internal medicine; Neutropenia; Gastroenterology; Chimeric antigen receptor; Immunotherapy; Chemotherapy","score_opus":0.006887365602533204,"score_gpt":0.2905556143615081,"score_spread":0.2836682487589749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190177153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986212,0.012413909,0.0004502668,0.00014772807,0.00007774285,0.0003821468,0.00011463912,0.0000048823404,0.00019666227],"genre_scores_gemma":[0.9693585,0.025869437,0.0008089905,0.00013238144,0.00007877664,0.00002147509,0.00003619167,0.000048314923,0.0036459325],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984018,0.000060255283,0.00056844414,0.0002245056,0.00045816955,0.00028677963],"domain_scores_gemma":[0.9988142,0.000091296555,0.0003063655,0.0002634663,0.0004285694,0.00009608349],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033365484,0.00016984165,0.0007716248,0.00045894174,0.000060328024,0.000021414256,0.00011847236,0.00008999315,0.0015183554],"category_scores_gemma":[0.000015370842,0.00013318245,0.00028981472,0.0009144471,0.00010622547,0.00008185775,0.000018816318,0.00024323673,2.50627e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0228827,0.00023671487,0.1916203,0.00010856346,0.01282723,0.000038125778,0.001615838,0.0007357292,0.69644815,0.0000057586553,0.00010549582,0.07337536],"study_design_scores_gemma":[0.027727686,0.0013138159,0.8047592,0.000517835,0.0027263311,0.00033095558,0.00029679533,0.0015587801,0.15976462,0.000026188858,0.0007431938,0.00023459048],"about_ca_topic_score_codex":0.0006286047,"about_ca_topic_score_gemma":0.0005336102,"teacher_disagreement_score":0.6131389,"about_ca_system_score_codex":0.00043037345,"about_ca_system_score_gemma":0.0008402701,"threshold_uncertainty_score":0.9993944},"labels":[],"label_agreement":null},{"id":"W3190341154","doi":"10.1186/s40425-015-0078-9","title":"Pembrolizumab","year":2015,"lang":"id","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Pembrolizumab; Ipilimumab; Medicine; Melanoma; Oncology; Internal medicine; Lung cancer; Nivolumab; Cancer; Immunotherapy; Cancer research","score_opus":0.06837773108908334,"score_gpt":0.4185399310356333,"score_spread":0.35016219994654996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190341154","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025175625,0.9819048,0.00020078248,0.0006267632,0.012239202,0.002833716,0.0004822625,0.000030885098,0.0014298555],"genre_scores_gemma":[0.0000670943,0.9631194,0.000337382,0.00061048474,0.0041317614,0.00036422478,0.00007079106,0.00036137216,0.030937532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99316406,0.00031512612,0.0033932189,0.00062066177,0.0013993917,0.0011075353],"domain_scores_gemma":[0.99221957,0.00030832321,0.0041760406,0.0009433979,0.0019184018,0.0004342696],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027139075,0.0012031596,0.0049776738,0.0007121284,0.00037382418,0.00015245509,0.0010355593,0.00096739625,0.0041538193],"category_scores_gemma":[0.00009385208,0.00090507296,0.00436433,0.0007122168,0.00046897834,0.00026207743,0.00004952221,0.0014394667,0.000041468124],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017773023,0.00035651907,0.000036546142,0.009335047,0.009563198,0.000018392624,0.0005486885,0.000003839438,0.0009640816,0.000029741952,0.052544426,0.9088265],"study_design_scores_gemma":[0.01926395,0.003299314,0.000069344205,0.029110536,0.0031593335,0.0007541437,0.00014315474,0.000008605199,0.00028787742,0.0001494502,0.94289696,0.00085733645],"about_ca_topic_score_codex":0.00020460617,"about_ca_topic_score_gemma":0.000024916937,"teacher_disagreement_score":0.9079692,"about_ca_system_score_codex":0.002357351,"about_ca_system_score_gemma":0.008113945,"threshold_uncertainty_score":0.99934},"labels":[],"label_agreement":null},{"id":"W3192736776","doi":"10.1136/jitc-2021-002863","title":"First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis","keywords":"Medicine; Tolerability; Adverse effect; Pharmacokinetics; Pharmacodynamics; Internal medicine; Pharmacology; Toxicity; Oncology; Gastroenterology","score_opus":0.0333281760727157,"score_gpt":0.38328785776998303,"score_spread":0.3499596816972673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192736776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99676234,0.0016489889,0.000009078856,0.0003116702,0.000044038734,0.0011581257,0.000013125012,0.000002159627,0.000050452803],"genre_scores_gemma":[0.9985268,0.0009522583,0.00021925513,0.000052926865,0.000013789101,0.000050887757,0.000016367869,0.00002470948,0.00014300298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985306,0.00006503141,0.00055233197,0.00021563588,0.00041410417,0.00022229001],"domain_scores_gemma":[0.9991741,0.000056471377,0.00030141178,0.00011725907,0.0002854255,0.00006532422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024746105,0.00015681125,0.0005622052,0.00025219083,0.000093018185,0.00004092596,0.000087504384,0.00004036378,0.000044038185],"category_scores_gemma":[0.000019257413,0.00011582378,0.00002391849,0.00029644155,0.00008676216,0.00024825393,0.00003499725,0.00016017607,7.8625945e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027684605,0.012165752,0.9067755,0.00023833403,0.0002459605,0.00009257409,0.002915851,0.00033287337,0.02418888,0.00004186798,0.000009710887,0.025308106],"study_design_scores_gemma":[0.10146398,0.010807565,0.87863785,0.0013397186,0.000025596364,0.00003231455,0.0006284361,0.00033758194,0.0062742825,0.000107442465,0.00020428577,0.00014094262],"about_ca_topic_score_codex":0.00076333596,"about_ca_topic_score_gemma":0.0021955285,"teacher_disagreement_score":0.073779374,"about_ca_system_score_codex":0.00015625755,"about_ca_system_score_gemma":0.00018972666,"threshold_uncertainty_score":0.47231567},"labels":[],"label_agreement":null},{"id":"W3194210289","doi":"10.1136/jitc-2021-003188","title":"Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EUSA Pharma; Ipsen; Pharmacyclics; Eisai; Incyte; Genentech; Les Laboratories Pierre Fabre; AstraZeneca; Pfizer; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Discontinuation; Adjuvant; Ipilimumab; Adverse effect; Oncology; Internal medicine; Proportional hazards model; Melanoma; Cancer; Immunotherapy","score_opus":0.03369585980913195,"score_gpt":0.35122985655377575,"score_spread":0.3175339967446438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194210289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9560984,0.0358874,0.0018865515,0.002906984,0.0012928635,0.0012291708,0.00042000652,0.000009999052,0.00026861535],"genre_scores_gemma":[0.9558552,0.028012164,0.005034252,0.00055292196,0.00047394718,0.00029308847,0.000083634804,0.00010741728,0.009587362],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99800205,0.000098471224,0.00066675077,0.00018349044,0.0008275417,0.00022172122],"domain_scores_gemma":[0.99669033,0.00028190258,0.0009227663,0.0002529088,0.0018044645,0.000047649006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022490316,0.00016699675,0.00064715877,0.00009820655,0.00013533127,0.000024475185,0.000103866245,0.00011321243,0.0003496663],"category_scores_gemma":[0.00020414354,0.00012484149,0.00028518523,0.00016511756,0.00006514484,0.0001417383,0.000011106742,0.00014345799,5.7360747e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06903238,0.0005327454,0.19367895,0.00057057774,0.007442035,0.000002895819,0.0022386054,0.00010451287,0.1136142,0.00021339483,0.00344473,0.60912496],"study_design_scores_gemma":[0.17164087,0.0051765516,0.62132436,0.0016168627,0.002152529,0.000071155315,0.0023167105,0.001252809,0.09345902,0.001198719,0.099150725,0.0006396712],"about_ca_topic_score_codex":0.00017425702,"about_ca_topic_score_gemma":0.00046985815,"teacher_disagreement_score":0.6084853,"about_ca_system_score_codex":0.0005698089,"about_ca_system_score_gemma":0.0010933978,"threshold_uncertainty_score":0.5090888},"labels":[],"label_agreement":null},{"id":"W3195751328","doi":"10.1136/jitc-2021-002973","title":"Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; National Center for Advancing Translational Sciences; AstraZeneca; National Cancer Institute; Foundation for the National Institutes of Health","keywords":"Durvalumab; Tremelimumab; Medicine; Lung cancer; PD-L1; Internal medicine; Oncology; Squamous cell cancer; Cancer; Immunotherapy; Nivolumab","score_opus":0.016859926611319694,"score_gpt":0.3365914877365322,"score_spread":0.3197315611252125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195751328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9142769,0.076970674,0.00011518814,0.0003454409,0.0009489424,0.0066454853,0.0005954667,0.000045496694,0.000056381745],"genre_scores_gemma":[0.97876096,0.014178917,0.000239404,0.00040287973,0.00027021227,0.0009655195,0.00009364951,0.0002458221,0.0048426283],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950354,0.0002266205,0.0018725483,0.00074961846,0.0012386434,0.00087713054],"domain_scores_gemma":[0.99454635,0.0002403029,0.0018657267,0.0008848711,0.002243899,0.00021887365],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00074981333,0.0007603263,0.0018789887,0.00037705497,0.0006617508,0.000085480446,0.00044570287,0.00023074518,0.0011506474],"category_scores_gemma":[0.00003825071,0.00056464056,0.0008466098,0.0007054278,0.00018944565,0.0002994328,0.00003653026,0.00042816324,3.5203456e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5794823,0.03741722,0.080912754,0.0017593218,0.011776492,0.00008401699,0.018468097,0.00031963072,0.21419667,0.0000075373614,0.004895318,0.050680645],"study_design_scores_gemma":[0.61313194,0.12513939,0.06576171,0.0021318793,0.0030215846,0.00003498203,0.005752743,0.0005245071,0.13083808,0.000019852918,0.052021507,0.0016218312],"about_ca_topic_score_codex":0.0018087917,"about_ca_topic_score_gemma":0.00081368245,"teacher_disagreement_score":0.08772217,"about_ca_system_score_codex":0.0011481426,"about_ca_system_score_gemma":0.0023248317,"threshold_uncertainty_score":0.9997624},"labels":[],"label_agreement":null},{"id":"W3198525580","doi":"10.1136/jitc-2021-002876","title":"Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute","keywords":"Tumor microenvironment; Cancer research; Immune system; Pancreatic cancer; Medicine; Cancer; Immunotherapy; TLR9; Immunology; Internal medicine; Biology","score_opus":0.014385650407572545,"score_gpt":0.3010974693788345,"score_spread":0.28671181897126197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198525580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98558813,0.012417121,0.00018854403,0.0008695541,0.00015230088,0.00071550015,0.00005560552,0.00000481481,0.000008397979],"genre_scores_gemma":[0.98138523,0.017961139,0.00028148518,0.00012384255,0.000040425763,0.00009018827,0.000016696942,0.00002821241,0.00007277009],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987719,0.00012340603,0.00047639417,0.00021855383,0.00021117528,0.00019856954],"domain_scores_gemma":[0.99921274,0.000039004164,0.00035447662,0.00013313348,0.00021974415,0.00004088612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027634177,0.00018982358,0.00056460855,0.0001831186,0.00009250905,0.00003295744,0.00005076692,0.000078295714,0.00008290227],"category_scores_gemma":[0.000009886398,0.00015388046,0.000082081,0.00030502485,0.00020326262,0.00035097892,0.0000052592036,0.0002331179,3.5261767e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013148651,0.0008538845,0.040030707,0.0002442123,0.00039430233,0.000020997802,0.003217109,0.00024967344,0.9194234,0.0000072837015,0.000008532342,0.022401238],"study_design_scores_gemma":[0.011180942,0.0025251335,0.43690553,0.0014131129,0.00009467987,0.00020358167,0.0008740141,0.00025464693,0.54624814,0.000028049948,0.00011540547,0.00015673295],"about_ca_topic_score_codex":0.0022174348,"about_ca_topic_score_gemma":0.0022381903,"teacher_disagreement_score":0.39687485,"about_ca_system_score_codex":0.00038797728,"about_ca_system_score_gemma":0.0005475415,"threshold_uncertainty_score":0.6275063},"labels":[],"label_agreement":null},{"id":"W3200807512","doi":"10.1136/jitc-2021-003032","title":"Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy","year":2021,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"Hope Against Cancer","keywords":"Blockade; Immunotherapy; Medicine; Immune checkpoint; Tumor microenvironment; Mesothelioma; Clinical trial; Oncology; Cancer; PD-L1; Immune system; Cancer research; CTLA-4; Internal medicine; T cell; Immunology; Pathology; Receptor","score_opus":0.024857341948631193,"score_gpt":0.35853161334454514,"score_spread":0.33367427139591394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200807512","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004515384,0.99250597,0.000056271812,0.00077251304,0.00008112079,0.0012472244,0.00080307235,0.000001726273,0.000016697702],"genre_scores_gemma":[0.00024645284,0.99760765,0.0006119268,0.00010983597,0.00012708202,0.0002339734,0.00007379698,0.00005361717,0.0009356681],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99855375,0.000037873742,0.0009411631,0.00015458907,0.00016985727,0.0001427871],"domain_scores_gemma":[0.99829364,0.00023575594,0.0010673129,0.00029163685,0.00006391497,0.000047751822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019602219,0.00021739145,0.0011864424,0.00008617854,0.0000807761,0.000007939069,0.00015741376,0.00007085197,0.0005429905],"category_scores_gemma":[0.000014752461,0.00013294577,0.000977479,0.00007642465,0.00020221781,0.000026040532,0.000029080456,0.00012438401,0.0000014973567],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010274494,0.00097469235,0.0011218673,0.013519074,0.0044496763,8.166374e-7,0.00014345866,0.000013975237,0.046285734,0.000032457407,0.0024548022,0.929976],"study_design_scores_gemma":[0.0021627077,0.00041146702,0.024297595,0.009365276,0.0024796703,0.00015534315,0.00002084953,0.0000019821202,0.003479191,0.000083380764,0.95737576,0.00016678363],"about_ca_topic_score_codex":0.000011571489,"about_ca_topic_score_gemma":3.339735e-7,"teacher_disagreement_score":0.95492095,"about_ca_system_score_codex":0.000110688314,"about_ca_system_score_gemma":0.00018367596,"threshold_uncertainty_score":0.59453654},"labels":[],"label_agreement":null},{"id":"W3201513519","doi":"10.1136/jitc-2021-002954","title":"Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Japan Society for the Promotion of Science; Ono Pharmaceutical; Secom Science and Technology Foundation","keywords":"mTORC1; Mitochondrial ROS; Cancer research; Glutaminolysis; Reactive oxygen species; Mitochondrion; Metformin; Chemistry; Biology; Cell biology; Cancer cell; Cancer; Signal transduction; PI3K/AKT/mTOR pathway; Endocrinology","score_opus":0.01487345650998473,"score_gpt":0.29098705614444154,"score_spread":0.2761135996344568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201513519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87533283,0.12218691,0.0010183641,0.000029809877,0.0009263418,0.000256842,0.00007320231,0.0000032266937,0.00017248461],"genre_scores_gemma":[0.9141299,0.08174496,0.0014629281,0.00026029,0.0013093714,0.000101282196,0.0000707581,0.00006450971,0.00085599633],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831957,0.000119837874,0.000720555,0.00023696548,0.0003104017,0.00029265945],"domain_scores_gemma":[0.99828076,0.000059505055,0.0007393694,0.00029796164,0.00057268864,0.000049708437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039813426,0.00021620948,0.00051012216,0.00011770947,0.0001225727,0.000035668134,0.00024252561,0.00012612675,0.00022372673],"category_scores_gemma":[0.00014385098,0.00019719802,0.00032661908,0.0001806058,0.00008756081,0.00004386568,0.000033692722,0.00018630597,3.2211298e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015326696,0.00013356881,0.0006724082,0.000053001255,0.00035661753,0.0000018597276,0.00033857592,0.00013295417,0.9493672,0.00003074452,0.0002689266,0.04711143],"study_design_scores_gemma":[0.003573777,0.0002484305,0.0027353747,0.00012939303,0.000037201753,0.000020465815,0.0004877885,0.000017145134,0.92424655,0.00025323976,0.06804982,0.00020084194],"about_ca_topic_score_codex":0.0002896893,"about_ca_topic_score_gemma":0.00015266148,"teacher_disagreement_score":0.0677809,"about_ca_system_score_codex":0.00016676928,"about_ca_system_score_gemma":0.0007525802,"threshold_uncertainty_score":0.80415016},"labels":[],"label_agreement":null},{"id":"W3201611853","doi":"10.1136/jitc-2021-003122","title":"Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Ovarian Cancer Academy; Merck Sharp and Dohme; U.S. Department of Defense","keywords":"Carboplatin; Medicine; Ovarian cancer; Pembrolizumab; Fallopian tube cancer; Oncology; Fallopian tube; Internal medicine; Gynecology; Cancer; Chemotherapy; Immunotherapy; Cisplatin","score_opus":0.017180304316084676,"score_gpt":0.3050659985256309,"score_spread":0.2878856942095462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201611853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8404892,0.15335935,0.00014913,0.0033105596,0.0010859338,0.0010544201,0.00035399644,0.000015352187,0.00018204025],"genre_scores_gemma":[0.92470026,0.06763851,0.0044472646,0.00037546598,0.00067456136,0.00069407263,0.00007208242,0.00013457047,0.0012632427],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983259,0.000041133837,0.00060339767,0.0003517916,0.0003191096,0.0003586771],"domain_scores_gemma":[0.9985617,0.00020361143,0.0003962326,0.00022207916,0.0004601433,0.000156237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022791895,0.00030868954,0.0008463828,0.000089732996,0.00025882365,0.00008273354,0.00007115864,0.00011498478,0.00013547046],"category_scores_gemma":[0.000019696694,0.00023271763,0.00018212866,0.00012989444,0.00012820245,0.000120437,0.000022157135,0.0002460689,9.3989534e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11198822,0.0016755296,0.11124402,0.003093885,0.00993054,0.00020031391,0.0039784103,0.00021073257,0.1392294,0.001978509,0.0013173517,0.6151531],"study_design_scores_gemma":[0.090949416,0.010542542,0.8099701,0.005650613,0.0018256134,0.00075058104,0.0008771074,0.0006647842,0.031096295,0.0005936215,0.046142675,0.00093666406],"about_ca_topic_score_codex":0.0003476645,"about_ca_topic_score_gemma":0.00054125796,"teacher_disagreement_score":0.69872606,"about_ca_system_score_codex":0.00036408255,"about_ca_system_score_gemma":0.0010281778,"threshold_uncertainty_score":0.948995},"labels":[],"label_agreement":null},{"id":"W3202631322","doi":"10.1136/jitc-2021-003272","title":"Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Princess Margaret Cancer Centre; Université Laval","funders":"National Cancer Institute; Ministry of Science and ICT, South Korea; UVA Cancer Center; University of Virginia","keywords":"Medicine; Clinical endpoint; Melanoma; Placebo; Internal medicine; Adverse effect; Adjuvant; Randomized controlled trial; Gastroenterology; Phases of clinical research; Clinical trial; Oncology; Surgery; Pathology","score_opus":0.011307735804506116,"score_gpt":0.2810383951323538,"score_spread":0.2697306593278477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202631322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611537,0.033494785,0.000057238918,0.00013458627,0.0023009812,0.0026580505,0.00017441844,0.0000075390076,0.000018687906],"genre_scores_gemma":[0.9888156,0.009351173,0.00013884786,0.000033523345,0.00005141558,0.00026151116,0.00006105923,0.00004475313,0.001242092],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970039,0.0006389326,0.0014941522,0.00027870748,0.00018706788,0.0003972444],"domain_scores_gemma":[0.9959936,0.00048699067,0.002051966,0.00040516292,0.0010397881,0.000022494725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008363895,0.00032150804,0.001231148,0.0003645127,0.00018543264,0.0000134307065,0.000322929,0.0002698635,0.0008913654],"category_scores_gemma":[0.00012287153,0.00023700726,0.00048208816,0.00027330214,0.00013514693,0.00020599223,0.000040553216,0.00043419734,0.0000024638532],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79224336,0.0014492666,0.02637213,0.00006566886,0.002639507,0.0000011366427,0.00057799096,0.000060938764,0.16308211,0.000012806131,0.000040700827,0.013454385],"study_design_scores_gemma":[0.62964094,0.007542115,0.037512366,0.00036275815,0.00017786433,0.00001242052,0.000095766394,0.0000028817233,0.32281226,0.0000130798935,0.0016418482,0.00018569228],"about_ca_topic_score_codex":0.00059572636,"about_ca_topic_score_gemma":0.00027025686,"teacher_disagreement_score":0.16260241,"about_ca_system_score_codex":0.00019789996,"about_ca_system_score_gemma":0.00039067777,"threshold_uncertainty_score":0.9759826},"labels":[],"label_agreement":null},{"id":"W3202872245","doi":"10.1136/jitc-2021-003467","title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Thomas Hospital; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Acute kidney injury; Renal function; Internal medicine; Creatinine; Odds ratio; Proportional hazards model; Biopsy; Urology; Gastroenterology","score_opus":0.008752036805244228,"score_gpt":0.2927027088432207,"score_spread":0.28395067203797647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202872245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99184155,0.004872741,0.00003424947,0.00169748,0.0006644105,0.00054410414,0.00012745328,0.000016545675,0.00020147074],"genre_scores_gemma":[0.9797334,0.013234575,0.0010271595,0.0019963966,0.00030584924,0.00012213108,0.00009639234,0.00012313109,0.0033609765],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99813217,0.00004422669,0.00086530624,0.00022425561,0.0003873276,0.00034668724],"domain_scores_gemma":[0.99854076,0.000019633726,0.00047749403,0.00028235494,0.0005593964,0.00012036346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027921965,0.00024561418,0.0006195684,0.00022899786,0.00009700307,0.00003391327,0.00011776532,0.00012869436,0.0005789162],"category_scores_gemma":[0.000025542808,0.00018064764,0.0004122997,0.0005049664,0.000106389496,0.00016741462,0.000013052433,0.00030720865,9.617399e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.070373304,0.0009173158,0.19003473,0.0001297705,0.002849006,0.000039154827,0.00058322167,0.0000032727937,0.623093,0.0000062447225,0.0034653794,0.108505584],"study_design_scores_gemma":[0.03318033,0.0031179502,0.27045336,0.0014427861,0.00020644865,0.000084436506,0.000076071985,0.000008673601,0.6188357,0.000034195866,0.072251655,0.000308436],"about_ca_topic_score_codex":0.00017966068,"about_ca_topic_score_gemma":0.000015433396,"teacher_disagreement_score":0.108197145,"about_ca_system_score_codex":0.0004319788,"about_ca_system_score_gemma":0.0008593223,"threshold_uncertainty_score":0.7366597},"labels":[],"label_agreement":null},{"id":"W3202999930","doi":"10.1136/jitc-2021-003476","title":"Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Genentech; Astellas Pharma; Eisai; National Cancer Institute; Natera; MacroGenics; Mirati Therapeutics; Regeneron Pharmaceuticals; Array BioPharma; MorphoSys; Celgene; Symphogen; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Agios Pharmaceuticals; GlaxoSmithKline","keywords":"Nivolumab; Medicine; Oncology; Cancer; Tumor microenvironment; Internal medicine; Gastroenterology; Immunotherapy; Pathology","score_opus":0.01924529420777987,"score_gpt":0.3262464013921124,"score_spread":0.30700110718433254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202999930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92578834,0.07261681,0.000061042454,0.000097075055,0.0007567784,0.00060322706,0.000056070345,0.000003957588,0.000016726372],"genre_scores_gemma":[0.99191654,0.007432695,0.0000812646,0.00002747731,0.000021543785,0.000053407213,0.000012062592,0.000019051666,0.00043596895],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833447,0.00034686804,0.0008171897,0.00017958059,0.00007937915,0.0002425249],"domain_scores_gemma":[0.9983663,0.00021700794,0.00074095244,0.00020498665,0.00044979953,0.00002097385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005549893,0.00018202572,0.00082775956,0.00013678659,0.00012867143,0.000011095032,0.00015236561,0.0001243168,0.00021451717],"category_scores_gemma":[0.00011602699,0.00015712042,0.00016966272,0.00020338313,0.00019410036,0.00019711223,0.000036315585,0.00027908653,1.8247596e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013504912,0.0007808019,0.0889115,0.0001375065,0.00085158204,0.0000030371239,0.0025955515,0.00003860746,0.86194056,0.000028322118,0.00005603958,0.04330602],"study_design_scores_gemma":[0.006223589,0.000856284,0.42666432,0.000324775,0.00007016239,0.000015683067,0.00044266868,0.0000058591854,0.5649163,0.00005136698,0.0003302691,0.00009871118],"about_ca_topic_score_codex":0.0016419977,"about_ca_topic_score_gemma":0.00061790994,"teacher_disagreement_score":0.33775282,"about_ca_system_score_codex":0.00008948292,"about_ca_system_score_gemma":0.00061495847,"threshold_uncertainty_score":0.64071846},"labels":[],"label_agreement":null},{"id":"W3203166965","doi":"10.1136/jitc-2021-003329","title":"CXCR6 by increasing retention of memory CD8<sup>+</sup> T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; NIH Office of the Director","keywords":"Immunosurveillance; Ovarian cancer; Tumor microenvironment; CD8; Cytotoxic T cell; Cancer research; Medicine; Biology; Cancer; Immunology; Internal medicine; Tumor cells; Immune system","score_opus":0.008352878838006181,"score_gpt":0.24650940341765806,"score_spread":0.2381565245796519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203166965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78810126,0.20957538,0.0003985194,0.00064775866,0.00040669338,0.0005314945,0.00031451622,0.0000048191714,0.000019557478],"genre_scores_gemma":[0.9737093,0.025042728,0.0002220778,0.0002959856,0.00003855164,0.00008458629,0.000020635505,0.000040730938,0.0005454234],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99693155,0.0011196183,0.0011500983,0.00026209184,0.00013581412,0.00040084647],"domain_scores_gemma":[0.99773496,0.00059428555,0.0010475636,0.00038819696,0.00021907678,0.000015940093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018347264,0.00028624886,0.0008166974,0.00015130272,0.0002227936,0.00002889135,0.00037802572,0.00018811936,0.0005266924],"category_scores_gemma":[0.00007534557,0.00021939584,0.00031615276,0.00020541789,0.0004418483,0.00016335299,0.000029954515,0.00041660073,7.7946424e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008466449,0.0003285129,0.003167332,0.00012240572,0.0010555057,0.0000028188067,0.0024918169,0.00010623791,0.96366775,0.00002609351,0.00026774034,0.020297343],"study_design_scores_gemma":[0.011557498,0.00061471004,0.024553627,0.000576014,0.000109987915,0.00020591138,0.0013905,0.00003249622,0.93964815,0.00011529236,0.020943183,0.000252621],"about_ca_topic_score_codex":0.0013715952,"about_ca_topic_score_gemma":0.000035229627,"teacher_disagreement_score":0.18560801,"about_ca_system_score_codex":0.00010805675,"about_ca_system_score_gemma":0.0003014258,"threshold_uncertainty_score":0.89467025},"labels":[],"label_agreement":null},{"id":"W3208136450","doi":"10.1136/jitc-2020-001219","title":"Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Institute of Dental and Craniofacial Research; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Imiquimod; Pembrolizumab; Mucosal melanoma; Melanoma; Biopsy; Temozolomide; Dermatology; Hard palate; Surgery; Adjuvant therapy; Adjuvant; Oncology; Internal medicine; Cancer; Radiation therapy; Chemotherapy; Immunotherapy; Cancer research","score_opus":0.03045542805732991,"score_gpt":0.315627695618274,"score_spread":0.28517226756094405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208136450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900433,0.007476255,0.00024152649,0.0014368473,0.00035309457,0.00028673606,0.000018811665,0.000004033439,0.00013939408],"genre_scores_gemma":[0.9939434,0.0036305625,0.0009872598,0.000063189495,0.0000611478,0.000012778702,0.0000018539644,0.000010683506,0.0012891452],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99927,0.000054923803,0.00029219655,0.00010509953,0.00017959697,0.00009814929],"domain_scores_gemma":[0.99934036,0.000030343288,0.00028074507,0.00016576904,0.00014447693,0.000038283102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007079351,0.00009868077,0.00035684745,0.00003879054,0.000069703754,0.000005240879,0.000048621176,0.000039607177,0.000104594015],"category_scores_gemma":[0.000010746667,0.00005303861,0.00016059328,0.00005715658,0.00009597578,0.000018666342,0.000013404098,0.000078223406,5.489352e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017844237,0.0009313271,0.02486918,0.0003031718,0.00059405627,0.000060781444,0.0010830556,0.000024512321,0.4728661,0.00028138128,0.00023175258,0.48091045],"study_design_scores_gemma":[0.029012535,0.023576949,0.43079722,0.00085052627,0.0008921003,0.0056163664,0.00065499917,0.00040466292,0.2240371,0.00050717226,0.28332332,0.00032706384],"about_ca_topic_score_codex":0.000052781917,"about_ca_topic_score_gemma":0.000062515224,"teacher_disagreement_score":0.4805834,"about_ca_system_score_codex":0.00014504461,"about_ca_system_score_gemma":0.00013804222,"threshold_uncertainty_score":0.21628517},"labels":[],"label_agreement":null},{"id":"W3216739419","doi":"10.1136/jitc-2021-003101","title":"Immunization with short peptide particles reveals a functional CD8<sup>+</sup> T-cell neoepitope in a murine renal carcinoma model","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; McGill University; Roswell Park Cancer Institute; National Institutes of Health; American Cancer Society","keywords":"Cancer vaccine; Immunology; Adjuvant; Major histocompatibility complex; Immunotherapy; Cytotoxic T cell; Medicine; Immune system; Immunization; Vaccination; CD8; Cancer immunotherapy; Cancer; Cancer research; Biology; Internal medicine","score_opus":0.019522419006735285,"score_gpt":0.2667006303931691,"score_spread":0.2471782113864338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216739419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9292829,0.06403894,0.0052634645,0.0005105674,0.00032024743,0.00036682852,0.00005264563,0.000021829817,0.00014256417],"genre_scores_gemma":[0.98108625,0.005983668,0.0016126664,0.00040121208,0.00008538851,0.00013364664,0.000067769055,0.00007511078,0.010554288],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997752,0.00032380183,0.0009140124,0.0003138367,0.00014440823,0.0005519178],"domain_scores_gemma":[0.99848044,0.00022009021,0.00035027412,0.00040146845,0.0005171258,0.000030589723],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062062143,0.00032570516,0.0006244335,0.00025923835,0.00034517885,0.00005089174,0.00028569653,0.0002271596,0.00090197026],"category_scores_gemma":[0.00004653049,0.00027008244,0.00029740538,0.00037059592,0.0002046078,0.00029107876,0.000036308116,0.000522861,0.0000065719573],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012145748,0.00044206512,0.009210132,0.00004599517,0.0005523402,0.000012771466,0.0014377739,0.029433858,0.9312902,0.000111521644,0.0013665414,0.013951014],"study_design_scores_gemma":[0.014082867,0.0011605071,0.021641199,0.00047210118,0.00012586785,0.0005824331,0.00093890063,0.0019551956,0.92428833,0.00060485635,0.033551984,0.00059578],"about_ca_topic_score_codex":0.00012306782,"about_ca_topic_score_gemma":0.00005085417,"teacher_disagreement_score":0.05805527,"about_ca_system_score_codex":0.00018949568,"about_ca_system_score_gemma":0.00083690917,"threshold_uncertainty_score":0.99997514},"labels":[],"label_agreement":null},{"id":"W4200325010","doi":"10.1136/jitc-2021-003439","title":"Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"Medizinischen Fakultät, Eberhard Karls Universität Tübingen; Klaus Tschira Stiftung; Eberhard Karls Universität Tübingen; Merck Sharp and Dohme; Bristol-Myers Squibb","keywords":"Medicine; Peripheral blood; Melanoma; Antigen; Peripheral; Metastatic melanoma; Immunology; Oncology; Internal medicine; Cancer research","score_opus":0.02305420118363625,"score_gpt":0.33290988309969516,"score_spread":0.3098556819160589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200325010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96202564,0.035257116,0.00015805254,0.00073748385,0.0010288825,0.0005865183,0.000148013,0.000013559045,0.000044745146],"genre_scores_gemma":[0.9725142,0.024746321,0.0011916774,0.0008425134,0.0002008539,0.000039089435,0.0000093389035,0.00008157499,0.00037444234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734324,0.00014229283,0.0012690941,0.00037778245,0.00046827344,0.00039928767],"domain_scores_gemma":[0.99801695,0.0003017418,0.00075200986,0.0004015576,0.0004286932,0.00009906527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043140716,0.00034963488,0.0013794106,0.00013491047,0.00009628305,0.000044799315,0.00022858812,0.00017546095,0.000758199],"category_scores_gemma":[0.00001982085,0.00024698544,0.00076066144,0.00032186203,0.00036766467,0.00022262224,0.000014819756,0.0004996821,7.7837433e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022286113,0.0009993768,0.598716,0.000028674798,0.0033174779,0.00005408924,0.0010741266,0.00003283101,0.3610592,0.000009798589,0.000040776686,0.01238154],"study_design_scores_gemma":[0.02464601,0.0021595317,0.7596884,0.0006624263,0.00012797867,0.00007342067,0.0006379785,0.000017428778,0.20942634,0.000090389534,0.002202237,0.0002678928],"about_ca_topic_score_codex":0.0011303975,"about_ca_topic_score_gemma":0.00024655016,"teacher_disagreement_score":0.16097236,"about_ca_system_score_codex":0.00012184243,"about_ca_system_score_gemma":0.0008632545,"threshold_uncertainty_score":0.9999982},"labels":[],"label_agreement":null},{"id":"W4205273215","doi":"10.1136/jitc-2021-003497","title":"Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; University of Manitoba","funders":"","keywords":"Blockade; Esophageal squamous cell carcinoma; Chemotherapy; Basal cell; Cell; Neoadjuvant therapy; Programmed cell death","score_opus":0.01985469544806639,"score_gpt":0.3174916672448145,"score_spread":0.2976369717967481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205273215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9244317,0.0666513,0.00059812964,0.0025350286,0.0004120703,0.0047932235,0.00025760967,0.00004232058,0.00027866533],"genre_scores_gemma":[0.983456,0.0007211199,0.0038796896,0.000536663,0.00031584917,0.0025033967,0.00004741898,0.00013889243,0.0084009785],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974561,0.00007055938,0.0005216958,0.00034163677,0.0008242794,0.0007857308],"domain_scores_gemma":[0.99835765,0.00015802073,0.00043658642,0.000358714,0.00042814488,0.0002608996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000508029,0.00031748763,0.0006796337,0.00022150401,0.0006291719,0.00005201813,0.00030292696,0.00006666492,0.00077494903],"category_scores_gemma":[0.00000936604,0.00023595398,0.00043300944,0.00027524904,0.00008075519,0.00009245326,0.000028515857,0.00048383782,6.5516656e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51624626,0.013270194,0.16093346,0.002959342,0.0027576538,0.00076166063,0.0058476455,0.0019212684,0.1393543,0.00022741496,0.024740541,0.13098024],"study_design_scores_gemma":[0.17429215,0.11592824,0.017359098,0.00011373385,0.00051913643,0.00041661575,0.0008661304,0.0009697431,0.59809834,0.0007766407,0.089975744,0.0006844406],"about_ca_topic_score_codex":0.00040703322,"about_ca_topic_score_gemma":0.000036571553,"teacher_disagreement_score":0.45874405,"about_ca_system_score_codex":0.00081264775,"about_ca_system_score_gemma":0.0012495844,"threshold_uncertainty_score":0.9621924},"labels":[],"label_agreement":null},{"id":"W4205297406","doi":"10.1136/jitc-2021-003687","title":"Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Pathological; Medicine; Oncology; Soft tissue sarcoma; Sarcoma; Multivariate analysis; Internal medicine; Stage (stratigraphy); Immunohistochemistry; Metastasis; Immune system; Pathology; Cancer; Immunology; Biology","score_opus":0.01768678517388356,"score_gpt":0.3139879048871727,"score_spread":0.29630111971328915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205297406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6877852,0.3023931,0.00002126224,0.008665732,0.00029625784,0.0007307821,0.00007482917,0.0000063499338,0.000026466869],"genre_scores_gemma":[0.9845543,0.013821535,0.0002659693,0.00087878114,0.00006151048,0.00016189365,0.0000047613617,0.00002177166,0.00022951592],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99894226,0.000075019445,0.00038239083,0.00014518604,0.00027830066,0.00017686664],"domain_scores_gemma":[0.9990525,0.0002374029,0.00036590308,0.00016600426,0.00015367176,0.000024478064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003569083,0.00014020316,0.0003878461,0.0001258431,0.00022429369,0.000012331383,0.000114728995,0.000077118464,0.0005163084],"category_scores_gemma":[0.00003737416,0.0000879542,0.0001423308,0.00021394016,0.00011743697,0.0000445638,0.000026075653,0.0004536755,1.4631247e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075600306,0.0015122168,0.15929918,0.00020499888,0.0014697689,0.00007799385,0.0054252897,0.00019319885,0.23770906,0.00023000572,0.010638553,0.5756797],"study_design_scores_gemma":[0.027592123,0.011037839,0.596655,0.0013803801,0.0006974216,0.0017211775,0.0050234743,0.00032944206,0.06659642,0.007817861,0.2806035,0.0005453455],"about_ca_topic_score_codex":0.00025945224,"about_ca_topic_score_gemma":0.000053645115,"teacher_disagreement_score":0.57513434,"about_ca_system_score_codex":0.00013859295,"about_ca_system_score_gemma":0.00015611744,"threshold_uncertainty_score":0.5653215},"labels":[],"label_agreement":null},{"id":"W4205349336","doi":"10.1136/jitc-2021-003779","title":"Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"Cancer Prevention and Research Institute of Texas","keywords":"Medicine; Lung cancer; Internal medicine; Adverse effect; Cancer; Retrospective cohort study; Adverse Event Reporting System; Antibiotics; Pharmacovigilance; Logistic regression; Oncology","score_opus":0.008027828496329797,"score_gpt":0.2762625650620914,"score_spread":0.2682347365657616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205349336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98550814,0.011477524,0.000022985438,0.0006657346,0.00069254974,0.0014239429,0.00013605105,0.000014776546,0.00005831756],"genre_scores_gemma":[0.9876534,0.009152978,0.00027069132,0.00017001602,0.000048099908,0.00018487776,0.000031532585,0.00009372537,0.0023947202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99738723,0.0001384438,0.0010209006,0.00025552075,0.00078869803,0.00040920635],"domain_scores_gemma":[0.9974495,0.00009399276,0.0017248827,0.0002907238,0.00039089067,0.00005001422],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065787195,0.00030756555,0.000832186,0.0003776132,0.0002344852,0.0000060442453,0.00019069777,0.0000976273,0.0010765463],"category_scores_gemma":[0.000007997855,0.00022120142,0.00038551714,0.0006352392,0.000069669644,0.00017718374,0.0000133056465,0.00032674012,2.463586e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06311891,0.0013446804,0.8346685,0.000074796386,0.0047507323,0.0000028768843,0.0017856639,0.0010660833,0.03147571,0.000002435576,0.00008099417,0.061628576],"study_design_scores_gemma":[0.06325807,0.01067425,0.906132,0.00090789853,0.0002916498,0.000015992866,0.00042526316,0.000046274516,0.009276228,0.00001898,0.0086282855,0.00032510102],"about_ca_topic_score_codex":0.0015043374,"about_ca_topic_score_gemma":0.0002367707,"teacher_disagreement_score":0.07146347,"about_ca_system_score_codex":0.002931121,"about_ca_system_score_gemma":0.00074139546,"threshold_uncertainty_score":0.9998366},"labels":[],"label_agreement":null},{"id":"W4205941875","doi":"10.1136/jitc-2021-003155","title":"Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hospital for Sick Children","keywords":"Pharmacology; Immune system; Medicine; Interleukin 2; IL-2 receptor; Immunotherapy; T cell; CD8; In vivo; Cancer immunotherapy; Cancer research; Pharmacodynamics; Immunology; Pharmacokinetics; Biology","score_opus":0.01714246827524964,"score_gpt":0.360369119108195,"score_spread":0.3432266508329454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205941875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97552913,0.02321513,0.00008198658,0.0005153334,0.00027414528,0.0003088946,0.000045777684,0.0000041074322,0.000025484123],"genre_scores_gemma":[0.9943925,0.0031903028,0.00015002252,0.00013391372,0.00011306392,0.00011434137,0.00002342235,0.00005368252,0.0018287642],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985902,0.00015567109,0.00046862217,0.00022598304,0.00021879467,0.0003407588],"domain_scores_gemma":[0.99932885,0.00003964778,0.0002536284,0.0002054509,0.00012850914,0.000043894877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010095335,0.00016478208,0.0002752921,0.00018767721,0.00035915786,0.000047039997,0.00032278697,0.000058025107,0.00026380274],"category_scores_gemma":[0.000028551012,0.00015959905,0.00015252543,0.00013626907,0.0000794667,0.000014267723,0.00010402699,0.00028305678,2.5914886e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01604781,0.00009324988,0.0039922716,0.00003702165,0.00022031239,0.0000061659593,0.0002828432,0.00028700725,0.9683922,0.0000012998828,0.00018870897,0.010451134],"study_design_scores_gemma":[0.0043128515,0.003843008,0.006123119,0.00006029563,0.0000127299,0.000056883193,0.00026381155,0.000052709758,0.9770169,0.00006940826,0.007984328,0.00020393633],"about_ca_topic_score_codex":0.00019414007,"about_ca_topic_score_gemma":0.00051422615,"teacher_disagreement_score":0.020024827,"about_ca_system_score_codex":0.00009853918,"about_ca_system_score_gemma":0.00019415945,"threshold_uncertainty_score":0.65082604},"labels":[],"label_agreement":null},{"id":"W4206536750","doi":"10.1136/jitc-2021-003289","title":"CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McMaster University","funders":"Mitacs; Terry Fox Research Institute; McMaster University","keywords":"Glioblastoma; Tumor microenvironment; Immunotherapy; Medicine; Cancer research; Computer science; Computational biology; Internal medicine; Cancer; Biology; Tumor cells","score_opus":0.012045329031695294,"score_gpt":0.29424844497210195,"score_spread":0.28220311594040665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206536750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77007735,0.22543572,0.000035555862,0.00058687263,0.0032069846,0.0005099368,0.00007926414,0.000013372789,0.00005492023],"genre_scores_gemma":[0.9599272,0.029719116,0.0002065561,0.00092196144,0.00009687438,0.0005798163,0.000025286172,0.00009919033,0.008423973],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99828696,0.00025089414,0.0006079155,0.00028650873,0.00011706426,0.00045067485],"domain_scores_gemma":[0.99914014,0.00007953627,0.00045542332,0.00023600581,0.00006528185,0.000023611574],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006553803,0.00023577343,0.0004107758,0.00026105455,0.0005231371,0.000021662549,0.00038434897,0.00011281992,0.0070079993],"category_scores_gemma":[0.000008321494,0.00021172033,0.0001576155,0.00015457056,0.000120324155,0.00021685794,0.000076248114,0.0006674884,0.00000971506],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008539329,0.0004666659,0.00048903434,0.000033545086,0.00047095737,0.0000030730675,0.001809656,0.0008850366,0.91827345,0.00011439262,0.0008160741,0.0680988],"study_design_scores_gemma":[0.006145448,0.003252113,0.0019278094,0.00005918802,0.000033529104,0.00028997043,0.00082030846,0.000044408283,0.27690563,0.0010316448,0.7091897,0.0003002637],"about_ca_topic_score_codex":0.0000989322,"about_ca_topic_score_gemma":0.000022851278,"teacher_disagreement_score":0.7083736,"about_ca_system_score_codex":0.00058807747,"about_ca_system_score_gemma":0.00021539656,"threshold_uncertainty_score":0.9938997},"labels":[],"label_agreement":null},{"id":"W4206897023","doi":"10.1136/jitc-2021-003777","title":"Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":322,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of Calgary; Université de Montréal; McGill University Health Centre","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Medicine; Cohort; Endometrial cancer; Internal medicine; Microsatellite instability; Interim analysis; Interim; Oncology; Adverse effect; Cancer; Clinical trial; Biology; Microsatellite","score_opus":0.033581488453805174,"score_gpt":0.3416970790202096,"score_spread":0.3081155905664045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206897023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850208,0.005663228,0.000033058626,0.0001565875,0.001346044,0.003964665,0.0037688357,0.000026887014,0.000019862817],"genre_scores_gemma":[0.99639034,0.002233248,0.0005480464,0.00007528935,0.00010263244,0.0002959307,0.000107292864,0.00006292974,0.00018427815],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99595004,0.00028650416,0.0015301561,0.00067594094,0.0010285112,0.00052882044],"domain_scores_gemma":[0.996969,0.00051859755,0.0013801125,0.00046883643,0.00050057116,0.00016291265],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096643687,0.0004191127,0.0014439892,0.00052589946,0.0002894636,0.000038805538,0.00025214156,0.00007145872,0.0007884262],"category_scores_gemma":[0.000263028,0.0002758975,0.00025867054,0.0014491905,0.00015816953,0.00026470787,0.00011268389,0.0005096911,1.5565412e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73008275,0.023393566,0.03693705,0.00019132104,0.00101693,0.000025581048,0.0027481585,0.00019876263,0.014766998,0.0000012498766,0.000029381823,0.19060823],"study_design_scores_gemma":[0.5854995,0.16859192,0.14007762,0.002078507,0.0009887732,0.000025237608,0.0032188725,0.00010455148,0.07855256,0.000045229568,0.019868033,0.0009491899],"about_ca_topic_score_codex":0.0026537068,"about_ca_topic_score_gemma":0.0008908769,"teacher_disagreement_score":0.18965904,"about_ca_system_score_codex":0.0015662587,"about_ca_system_score_gemma":0.00073387084,"threshold_uncertainty_score":0.9999693},"labels":[],"label_agreement":null},{"id":"W4206944818","doi":"10.1136/jitc-2021-003024","title":"Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies","year":2022,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Medicine; Oncology; Adverse effect; Immunotherapy; Internal medicine; Cancer; Immune system; Quality of life (healthcare); Intensive care medicine; Immunology","score_opus":0.10129871765778996,"score_gpt":0.45823394637188564,"score_spread":0.35693522871409566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206944818","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049849114,0.9924239,0.0013055266,0.0006071017,0.0022145303,0.0028339662,0.00048622716,0.000023736548,0.00005518368],"genre_scores_gemma":[0.000014315498,0.985294,0.010598755,0.0004292867,0.0007452099,0.0017724943,0.00026283917,0.0002179472,0.00066518923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99593914,0.00033677273,0.0024772792,0.00038526847,0.00042301914,0.00043850264],"domain_scores_gemma":[0.9951706,0.0015849215,0.0023437815,0.00051172875,0.00025768566,0.0001312729],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029223596,0.0005647253,0.0034365295,0.00029619917,0.00032645283,0.000048254504,0.00030676145,0.0003333348,0.0013165716],"category_scores_gemma":[0.000156231,0.00038945567,0.0050716363,0.00019916448,0.00013339431,0.000056468954,0.000028834855,0.00096257497,0.0000011545842],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019893204,0.00050047535,0.000021763171,0.0063237557,0.0055189845,0.000011651848,0.000066156455,0.000005782481,0.000011905318,0.00014975634,0.0012378488,0.9841626],"study_design_scores_gemma":[0.008089601,0.0035384854,0.00002628864,0.010475859,0.0025826483,0.00012237109,0.000055397442,0.000011974938,0.000068228794,0.000165773,0.97453094,0.00033240768],"about_ca_topic_score_codex":0.00004786031,"about_ca_topic_score_gemma":0.000006638337,"teacher_disagreement_score":0.9838302,"about_ca_system_score_codex":0.0005753782,"about_ca_system_score_gemma":0.0025538683,"threshold_uncertainty_score":0.99985576},"labels":[],"label_agreement":null},{"id":"W4207039879","doi":"10.1136/jitc-2021-004310","title":"Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; ECOG-ACRIN Cancer Research Group; University of Pittsburgh; American College of Radiology Imaging Network; Canadian Cancer Society Research Institute; Moffitt Cancer Center; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Internal medicine; Oncology; Melanoma; Proportional hazards model; Adjuvant; Immune system; Population; Primary tumor; Immunotherapy; Hazard ratio; FOXP3; Immunology; Gastroenterology; Metastasis; Cancer; Cancer research; Confidence interval","score_opus":0.008562596039694056,"score_gpt":0.25557831900032485,"score_spread":0.2470157229606308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4207039879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206036,0.00659786,0.00029536596,0.000077458026,0.00013143285,0.00081214396,0.00001500878,0.000003495726,0.0000068916056],"genre_scores_gemma":[0.9974907,0.0017423976,0.00056259177,0.00005208704,0.000014682313,0.00007705731,0.0000017702793,0.000014049952,0.000044664353],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990896,0.00004779436,0.0004135389,0.000118424534,0.00023374152,0.000096892174],"domain_scores_gemma":[0.9989929,0.000060757106,0.0006477309,0.00009899411,0.00017504916,0.000024522367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029362983,0.00008743728,0.00032797444,0.00015230797,0.00007272171,0.0000054435877,0.00004977348,0.000018788625,0.000053483833],"category_scores_gemma":[0.000021264164,0.00007087212,0.00005721567,0.00014043527,0.00005672228,0.00007493579,0.000024427634,0.00013005943,9.367124e-9],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02594743,0.0004876519,0.2832546,0.000721096,0.00066506653,0.000002381974,0.0012053116,0.00027141228,0.4856694,0.00001459846,0.000012381277,0.20174868],"study_design_scores_gemma":[0.009349407,0.005225997,0.9370706,0.00048581252,0.0001664881,0.000035072677,0.00016737118,0.0001934192,0.04685026,0.00008191748,0.00026270523,0.00011093024],"about_ca_topic_score_codex":0.00047104518,"about_ca_topic_score_gemma":0.00006429565,"teacher_disagreement_score":0.65381604,"about_ca_system_score_codex":0.00014165508,"about_ca_system_score_gemma":0.00009380671,"threshold_uncertainty_score":0.2890081},"labels":[],"label_agreement":null},{"id":"W4210690867","doi":"10.1136/jitc-2021-003551","title":"Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition","year":2022,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Canadian Cancer Society; McGill University Health Centre; McGill University","keywords":"Janus kinase; Immune system; Monoclonal antibody; Medicine; Kinase; Cancer research; STAT protein; Immunology; Proinflammatory cytokine; Antibody; Tyrosine kinase; Signal transduction; Inflammation; Biology; STAT3; Cytokine; Cell biology; Receptor; Internal medicine","score_opus":0.03088694924051371,"score_gpt":0.3364963500272145,"score_spread":0.3056094007867008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210690867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027020015,0.9624004,0.00043242107,0.00059200596,0.0022121472,0.004699033,0.002552351,0.00006582978,0.000025835176],"genre_scores_gemma":[0.0014498949,0.99147296,0.0009905028,0.0002796214,0.0005427653,0.0016927221,0.0019101705,0.00031178692,0.0013495521],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99468607,0.0002511263,0.0028098486,0.00063757197,0.0009220863,0.0006932819],"domain_scores_gemma":[0.9952115,0.00028011686,0.0032321662,0.0005348491,0.0005817596,0.0001596452],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012764388,0.00093787315,0.0031949996,0.0006911682,0.00070339424,0.000051113064,0.00031909958,0.0005003617,0.002467151],"category_scores_gemma":[0.00008007875,0.00071951735,0.0035813674,0.0006981711,0.00019650233,0.00026733548,0.00006147279,0.00092270237,0.0000028317431],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03151489,0.0010829527,0.000044684628,0.0033397714,0.024451733,0.00006435719,0.0014155458,0.000063123116,0.024784528,0.000014443903,0.0009463151,0.91227764],"study_design_scores_gemma":[0.022464292,0.0043399762,0.0010262821,0.034383092,0.0039654244,0.0002591202,0.00044488904,0.000015160804,0.0026886882,0.00032128158,0.9289377,0.0011541058],"about_ca_topic_score_codex":0.00031154204,"about_ca_topic_score_gemma":0.000036213394,"teacher_disagreement_score":0.9279914,"about_ca_system_score_codex":0.0016441661,"about_ca_system_score_gemma":0.0014746065,"threshold_uncertainty_score":0.9995256},"labels":[],"label_agreement":null},{"id":"W4210910593","doi":"10.1136/jitc-2021-003534","title":"Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novelis (Canada)","funders":"High-level Hospital Construction Project of Guangdong Provincial People's Hospital; National Natural Science Foundation of China","keywords":"Immunotherapy; Cancer research; Epidermal growth factor receptor; Tumor microenvironment; CD8; Adenocarcinoma; Immune system; Lung cancer; Biology; Cell; Cytotoxic T cell; Immune checkpoint; Medicine; Cancer; Immunology; Pathology; Internal medicine","score_opus":0.01319586278171577,"score_gpt":0.27630196322931394,"score_spread":0.2631061004475982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210910593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8757089,0.120656446,0.0002636269,0.0014525166,0.0006356816,0.0009786271,0.00020745919,0.000013193083,0.00008355091],"genre_scores_gemma":[0.9921131,0.0043822606,0.00045212012,0.0010062383,0.000119354154,0.00034739665,0.000031289732,0.00007583702,0.0014723842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99707633,0.00016401695,0.0012443458,0.00035451932,0.0006358681,0.000524919],"domain_scores_gemma":[0.998512,0.00008222175,0.0008039322,0.00041189196,0.00009256498,0.000097370415],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00075884763,0.00031618716,0.0010152039,0.0007815657,0.00029108,0.000033203258,0.00035756797,0.000067242196,0.0045257453],"category_scores_gemma":[0.0000073083265,0.00028678676,0.0012425544,0.00091880176,0.00012922577,0.00012276905,0.0000320668,0.00054635474,5.200551e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021899309,0.0009058975,0.026143935,0.00013717225,0.00314689,0.000082150626,0.0024940523,0.0005351159,0.9376552,0.000002109018,0.00055595976,0.006442191],"study_design_scores_gemma":[0.059635554,0.006075537,0.28532904,0.0005364327,0.0036537927,0.00078840094,0.0041688336,0.0010376596,0.5328885,0.00008013952,0.10472414,0.0010819898],"about_ca_topic_score_codex":0.0003975378,"about_ca_topic_score_gemma":0.000040688188,"teacher_disagreement_score":0.40476674,"about_ca_system_score_codex":0.0016459017,"about_ca_system_score_gemma":0.00030041876,"threshold_uncertainty_score":0.99995846},"labels":[],"label_agreement":null},{"id":"W4212834341","doi":"10.1136/jitc-2021-003490","title":"Oncolytic adenovirus decreases the proportion of TIM-3<sup>+</sup> subset of tumor-infiltrating CD8<sup>+</sup> T cells with correlation to improved survival in patients with cancer","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Galectins and Cancer Biology","field":"Immunology and Microbiology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Etelä-Savon Rahasto; Novo Nordisk Fonden; K. Albin Johanssons Stiftelse; Syöpäjärjestöt; Päivikki ja Sakari Sohlbergin Säätiö; Novo Nordisk; Jane ja Aatos Erkon Säätiö; Suomen Kulttuurirahasto; Suomen Lääketieteen Säätiö; Suomalais-Norjalainen Lääketieteen Säätiö; Helsingin Yliopisto","keywords":"Oncolytic virus; Oncolytic adenovirus; Immunotherapy; Medicine; CD8; Immune checkpoint; Melanoma; Cancer; Immune system; Cancer research; Cytotoxic T cell; Cancer immunotherapy; Tumor-infiltrating lymphocytes; T cell; Immunology; Oncology; Internal medicine; Biology","score_opus":0.009075243039969082,"score_gpt":0.25476948698413565,"score_spread":0.24569424394416656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212834341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99480784,0.0028445078,0.00026523863,0.00014034264,0.00041670026,0.0011522442,0.00033203946,0.000008412587,0.00003265307],"genre_scores_gemma":[0.9987031,0.00021473519,0.00013791361,0.00017678957,0.000049416656,0.00031309098,0.000046361863,0.000040787952,0.0003177536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805737,0.0002601519,0.00084841845,0.00025825913,0.00019743248,0.00037839063],"domain_scores_gemma":[0.99786556,0.00016359158,0.0012100942,0.00024624146,0.00048549686,0.000028988774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006155395,0.00024181127,0.00060230825,0.00019867526,0.0002878109,0.0000107173755,0.00032039735,0.00009513978,0.0008937742],"category_scores_gemma":[0.000027756525,0.00015865955,0.00013921826,0.00040382368,0.00020565459,0.000109619396,0.000035980567,0.0004663735,5.6694716e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0369782,0.000905513,0.5035728,0.00012868491,0.0013895269,0.0000019317843,0.0051868814,0.14380705,0.27623355,0.000051548584,0.0007773501,0.030966965],"study_design_scores_gemma":[0.053169247,0.039841786,0.4774841,0.001309368,0.0008385862,0.00015402802,0.011125247,0.0026499159,0.3777794,0.00016698329,0.03383645,0.0016448824],"about_ca_topic_score_codex":0.0028490752,"about_ca_topic_score_gemma":0.00064623705,"teacher_disagreement_score":0.14115714,"about_ca_system_score_codex":0.00032516854,"about_ca_system_score_gemma":0.0007965679,"threshold_uncertainty_score":0.9786201},"labels":[],"label_agreement":null},{"id":"W4214685750","doi":"10.1136/jitc-2021-003776","title":"Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation; American Society of Clinical Oncology; Novartis","keywords":"Medicine; Adverse effect; Dosing; Internal medicine; Oncology; Cancer; Gastroenterology","score_opus":0.011892139948701776,"score_gpt":0.30239322763100274,"score_spread":0.290501087682301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214685750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98965967,0.0066455295,0.000008952424,0.00043354524,0.0010754352,0.002009497,0.00012982248,0.000010061316,0.000027481137],"genre_scores_gemma":[0.9981884,0.00057571445,0.00008424517,0.00033820354,0.00007594601,0.00024177047,0.0000074582217,0.000056628454,0.00043164744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975748,0.00011563532,0.00087611214,0.00023866969,0.0008544578,0.00034029403],"domain_scores_gemma":[0.9983341,0.00004606361,0.0008452661,0.00042246413,0.0003062267,0.000045890123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000456055,0.00024915134,0.0006628272,0.00022706436,0.00044273754,0.000014785337,0.00033043325,0.000048706323,0.00036846453],"category_scores_gemma":[0.000016001613,0.0001625462,0.00029077497,0.0006054202,0.00014374964,0.00015562058,0.000060222526,0.00036939143,8.4361616e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23353723,0.03178137,0.28625506,0.0002692523,0.0029038643,0.000017515207,0.016697401,0.0013339032,0.19222936,0.000015535341,0.002115649,0.23284385],"study_design_scores_gemma":[0.29953027,0.08939952,0.49278253,0.0009764119,0.00035749128,0.000050895684,0.0077197547,0.00004265583,0.050218925,0.000053199416,0.058239575,0.0006287693],"about_ca_topic_score_codex":0.00019035442,"about_ca_topic_score_gemma":0.0001268162,"teacher_disagreement_score":0.23221508,"about_ca_system_score_codex":0.00040681902,"about_ca_system_score_gemma":0.00043373372,"threshold_uncertainty_score":0.6628442},"labels":[],"label_agreement":null},{"id":"W4214902204","doi":"10.1136/jitc-2021-003923","title":"Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Beatrice Hunter Cancer Research Institute; Dalhousie University","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Beatrice Hunter Cancer Research Institute; Cancer Research Institute","keywords":"Oncolytic virus; Immunotherapy; Blockade; Medicine; Virotherapy; Cancer research; Pancreatic cancer; Immunology; Immune system; Oncology; Tumor cells; Internal medicine; Cancer; Receptor","score_opus":0.009588304409269253,"score_gpt":0.2990606469923034,"score_spread":0.2894723425830341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214902204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9268612,0.07091694,0.00012794712,0.00062685466,0.0005774456,0.0007902417,0.000049876995,0.000014351987,0.000035131663],"genre_scores_gemma":[0.97836834,0.015570283,0.0010516278,0.0010432524,0.000388169,0.0004423379,0.00003724315,0.00018197406,0.0029167617],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997603,0.00027880777,0.00054213667,0.00041292395,0.00062588806,0.0005372268],"domain_scores_gemma":[0.9985601,0.000095917436,0.0005892356,0.0004455465,0.00019247577,0.000116737065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006870132,0.0003849048,0.0005336156,0.00019101906,0.0007427358,0.000087111985,0.00051599834,0.0000896996,0.0004267338],"category_scores_gemma":[0.0000126501545,0.00028957677,0.0002444727,0.00020408494,0.00023713587,0.000024008368,0.00007164064,0.00049831544,4.8136104e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047759544,0.00022357695,0.0010264666,0.000044713157,0.00052035385,0.0000066235484,0.00047838534,0.0004458825,0.932585,0.0000024697958,0.0011909745,0.015716022],"study_design_scores_gemma":[0.016458955,0.017867124,0.0010074629,0.0001552584,0.000052296833,0.00012481512,0.0004439117,0.00034889914,0.8925306,0.00018974896,0.07024338,0.00057754957],"about_ca_topic_score_codex":0.000044443193,"about_ca_topic_score_gemma":0.000040522904,"teacher_disagreement_score":0.069052406,"about_ca_system_score_codex":0.00014780153,"about_ca_system_score_gemma":0.00047923543,"threshold_uncertainty_score":0.99995565},"labels":[],"label_agreement":null},{"id":"W4220702214","doi":"10.1136/jitc-2021-003569","title":"Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"Research and Development; National Cancer Institute; Sanofi; Merck","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Aflibercept; Melanoma; Adverse effect; Population; Cancer; Gastroenterology; Bevacizumab; Immunotherapy; Cancer research; Chemotherapy","score_opus":0.013439187549297058,"score_gpt":0.339573802387077,"score_spread":0.32613461483777995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220702214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360263,0.0038101713,0.000033930177,0.00014523164,0.00050864974,0.0017375828,0.000086307875,0.000011232006,0.00006423794],"genre_scores_gemma":[0.99827856,0.0004668615,0.00015088485,0.00027211016,0.000060823153,0.00027615222,0.000012828946,0.000066696964,0.00041509612],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976606,0.00008842608,0.00094337517,0.00022959962,0.00074940076,0.0003286468],"domain_scores_gemma":[0.99845177,0.000048051716,0.00083968707,0.00031123057,0.00028508613,0.00006420283],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003951978,0.00023229512,0.00080035185,0.00037202696,0.00019478901,0.0000115447665,0.00024857692,0.00003946442,0.00091947307],"category_scores_gemma":[0.000009416158,0.00018400357,0.00023750232,0.00046908177,0.00008982604,0.00014686839,0.000026804524,0.00037379633,1.5857653e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.550506,0.016016802,0.05947073,0.00018358282,0.0023073175,0.000026385964,0.016118754,0.0030517012,0.045333594,0.0000059939985,0.00079042674,0.30618867],"study_design_scores_gemma":[0.5367376,0.111699075,0.31027082,0.00066624675,0.00030071207,0.00007617026,0.009320028,0.00018058537,0.0076815886,0.000053524047,0.022362698,0.0006509265],"about_ca_topic_score_codex":0.0002624963,"about_ca_topic_score_gemma":0.00008402885,"teacher_disagreement_score":0.30553776,"about_ca_system_score_codex":0.00070617354,"about_ca_system_score_gemma":0.00056346506,"threshold_uncertainty_score":0.9999938},"labels":[],"label_agreement":null},{"id":"W4220720824","doi":"10.1136/jitc-2021-004335","title":"Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Natural Sciences and Engineering Research Council of Canada; Ontario Veterinary College, University of Guelph; Terry Fox Research Institute; Cancer Research Society","keywords":"Oncolytic virus; Ovarian cancer; Cancer research; Immunotherapy; Biology; Innate immune system; Immune system; Cancer; Virotherapy; Immunology","score_opus":0.027000529465359756,"score_gpt":0.3315976207972424,"score_spread":0.3045970913318827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220720824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905844,0.0049622967,0.003155056,0.00020005359,0.00018964257,0.0004765796,0.0004091984,0.0000030867575,0.000019733461],"genre_scores_gemma":[0.98751867,0.00985188,0.0010285302,0.000304949,0.00006206857,0.00016856454,0.000004337517,0.00005657253,0.0010044405],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986115,0.00012030367,0.00038160261,0.0002797155,0.00028748185,0.0003193669],"domain_scores_gemma":[0.9992547,0.000026827207,0.00026722645,0.00019708868,0.00016283046,0.00009130247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006277523,0.00019230052,0.00037086586,0.00020092505,0.00014971574,0.000020113897,0.0002282318,0.0000664578,0.00012020028],"category_scores_gemma":[0.000007150919,0.00018281826,0.0000935353,0.00018119958,0.0000763802,0.000014612921,0.00011909426,0.00023081318,7.853657e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02013703,0.00011361607,0.00007988568,0.000038087557,0.00024714944,0.0000036924139,0.00037961768,0.035887424,0.9290549,0.000024528621,0.000029375795,0.014004665],"study_design_scores_gemma":[0.0037160532,0.0044696643,0.00033747722,0.00004880181,0.000018036346,0.0000057785605,0.0001475862,0.0080684135,0.9812279,0.00031913,0.0014152605,0.00022590181],"about_ca_topic_score_codex":0.0007884903,"about_ca_topic_score_gemma":0.0013587078,"teacher_disagreement_score":0.05217297,"about_ca_system_score_codex":0.000114667986,"about_ca_system_score_gemma":0.00036350676,"threshold_uncertainty_score":0.74551123},"labels":[],"label_agreement":null},{"id":"W4220847549","doi":"10.1136/jitc-2021-004233","title":"Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; Pharmacyclics; Genentech; PharmaMar; Eisai; Syndax Pharmaceuticals; Clovis Oncology; BeiGene; Conquer Cancer Foundation; Merck KGaA; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Princess Margaret Cancer Foundation; Pfizer; Mersana Therapeutics","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Immunotherapy; Cabozantinib; Clinical endpoint; Endometrial cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Cancer; Clinical trial; Gastroenterology; Phases of clinical research; Chemotherapy","score_opus":0.04021511302289515,"score_gpt":0.3943897692277361,"score_spread":0.35417465620484095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220847549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754911,0.017370284,0.0003773099,0.0009599251,0.0014654541,0.003958285,0.00030548696,0.000006195437,0.00006594722],"genre_scores_gemma":[0.9888441,0.0072051487,0.0011780519,0.00010016473,0.00016706885,0.0019758868,0.00004181888,0.000037179925,0.0004506044],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972825,0.0002725717,0.0012346089,0.00019895077,0.0007622365,0.00024910632],"domain_scores_gemma":[0.99799335,0.0007331028,0.0008760064,0.000116831485,0.00022369166,0.00005699487],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012939437,0.000192319,0.001367334,0.0008530146,0.00011999989,0.000007872304,0.00013092427,0.00003715753,0.0019682709],"category_scores_gemma":[0.00018423655,0.0001313594,0.0003769098,0.001294324,0.00009187385,0.00015158969,0.0000117089,0.0003321974,6.221952e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81436527,0.003843774,0.0003643979,0.000078394434,0.00069302705,0.000008133894,0.00065956014,0.00060121005,0.0017257851,0.00006509598,0.000024998217,0.17757037],"study_design_scores_gemma":[0.9704422,0.020407746,0.00025105837,0.00028027268,0.00030100864,0.00001828552,0.00016118452,0.00022341403,0.0020976204,0.0004989465,0.005181697,0.00013659263],"about_ca_topic_score_codex":0.0006438865,"about_ca_topic_score_gemma":0.00041860473,"teacher_disagreement_score":0.17743377,"about_ca_system_score_codex":0.00035644326,"about_ca_system_score_gemma":0.00093251874,"threshold_uncertainty_score":0.99894404},"labels":[],"label_agreement":null},{"id":"W4221060919","doi":"10.1136/jitc-2021-004191","title":"Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Labex Immuno-Oncology; Horizon 2020 Framework Programme; Institut Carnot Santé Animale; Institut Universitaire de France; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; Institut National Du Cancer; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche; Université de Paris; Association pour la Recherche sur le Cancer; Seerave Foundation; Institut Gustave-Roussy; Fondation Leducq; European Commission; Centre National de la Recherche Scientifique; National Institutes of Health; Equipex","keywords":"Prostate cancer; Medicine; Akkermansia; Immune system; Androgen deprivation therapy; Immunology; Cancer; Internal medicine; Cancer research; Biology","score_opus":0.01269978521263206,"score_gpt":0.29391935045288975,"score_spread":0.2812195652402577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221060919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93413895,0.06466001,0.000097680175,0.0001845984,0.00033165127,0.00044003868,0.000134277,0.0000038127002,0.00000895318],"genre_scores_gemma":[0.9805116,0.0183007,0.00053914555,0.00017028284,0.00012464619,0.00007896592,0.000034388242,0.000033919936,0.00020636062],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99901664,0.000060679246,0.0004685197,0.00016552952,0.00009747614,0.00019115103],"domain_scores_gemma":[0.99905336,0.000016854981,0.0005532678,0.00015943413,0.000181588,0.00003549532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032010349,0.000134804,0.00025989924,0.000073698015,0.0002227413,0.000013954682,0.00017548195,0.000048995276,0.000026820457],"category_scores_gemma":[0.000007407411,0.00011947125,0.00013507222,0.000084674466,0.000065649176,0.000006042631,0.000044141234,0.00012613216,5.15442e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021374964,0.00007262718,0.003945689,0.00009614419,0.00018864643,5.25435e-7,0.0002720504,0.00015337064,0.93091387,0.000005923824,0.0002364196,0.061977245],"study_design_scores_gemma":[0.0065462007,0.001368998,0.019981867,0.00017844138,0.000026544521,0.0001293081,0.00022978871,0.000056578152,0.9033345,0.000008240575,0.06793239,0.00020714234],"about_ca_topic_score_codex":0.000114634204,"about_ca_topic_score_gemma":0.000012544352,"teacher_disagreement_score":0.067695975,"about_ca_system_score_codex":0.000078441604,"about_ca_system_score_gemma":0.0003129599,"threshold_uncertainty_score":0.48718962},"labels":[],"label_agreement":null},{"id":"W4221112390","doi":"10.1136/jitc-2021-004241","title":"MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Chromosomal and Genetic Variations","field":"Agricultural and Biological Sciences","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Endogenous retrovirus; Medicine; Lung cancer; Oncology; Clinical endpoint; Transcriptome; Proportional hazards model; Internal medicine; Cancer; Gene expression; Immunology; Gene; Biology; Randomized controlled trial; Genetics","score_opus":0.018719100877234055,"score_gpt":0.24922115197429534,"score_spread":0.2305020510970613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221112390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987926,0.010161157,0.000011722413,0.0006614947,0.00041686025,0.00052988715,0.00018215347,0.000007187749,0.0001035583],"genre_scores_gemma":[0.99489385,0.004066976,0.00012714903,0.00033673586,0.00017323611,0.000121329,0.000012040434,0.000005255129,0.00026343673],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99874324,0.000073536845,0.00044818237,0.0001823349,0.00027727196,0.00027545908],"domain_scores_gemma":[0.99914646,0.0001332605,0.00047097265,0.000070506176,0.00013493345,0.000043883367],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022781502,0.00015840228,0.000336997,0.000040364852,0.00028985707,0.000021465963,0.0003280256,0.0000574495,0.0021443292],"category_scores_gemma":[0.0000031571356,0.0000684633,0.00019119198,0.0004111867,0.000045088,0.000053082033,0.000024552652,0.00025618364,2.8514052e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001180226,0.00033099903,0.06463918,0.0000101509995,0.00016585834,0.0000031886111,0.0008721823,0.0024974896,0.86674553,0.000003727484,0.00015362952,0.06339782],"study_design_scores_gemma":[0.008650817,0.0038896222,0.82752746,0.00013239823,0.000083089886,0.000046835634,0.00039896194,0.00046020094,0.12919822,0.00012222328,0.02901707,0.00047310416],"about_ca_topic_score_codex":0.0020320334,"about_ca_topic_score_gemma":0.00047307706,"teacher_disagreement_score":0.76288825,"about_ca_system_score_codex":0.00010926896,"about_ca_system_score_gemma":0.00009533669,"threshold_uncertainty_score":0.99876785},"labels":[],"label_agreement":null},{"id":"W4221119237","doi":"10.1136/jitc-2022-004560","title":"Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University; Mount Sinai Hospital; Vancouver General Hospital; University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; H&E stain; Pathology; Biopsy; Internal medicine; Immunohistochemistry","score_opus":0.03298784563646882,"score_gpt":0.36664944114517334,"score_spread":0.3336615955087045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221119237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9576839,0.024825545,0.00440457,0.008543568,0.0017110325,0.0014447534,0.0012537435,0.000023048533,0.00010981839],"genre_scores_gemma":[0.9872275,0.0054126177,0.005780509,0.000424849,0.00013952992,0.0004264794,0.00009326956,0.000039281316,0.00045596325],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835795,0.00008253056,0.0008729005,0.00015495632,0.00031382585,0.00021782161],"domain_scores_gemma":[0.99838436,0.00014506883,0.0009246936,0.00012763278,0.00037247702,0.000045790955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013165931,0.00013833567,0.0005190039,0.0001692309,0.00043619671,0.000018100809,0.00009178702,0.000068337955,0.0007536627],"category_scores_gemma":[0.000030039122,0.00012380711,0.00043607166,0.00017800779,0.000112328846,0.0000817699,0.000023946217,0.00021198433,1.7855879e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019353174,0.00063968863,0.0034664539,0.00020831077,0.0020010953,0.0000026118892,0.00091193407,0.000033082106,0.8698322,0.00030624383,0.004115947,0.09912926],"study_design_scores_gemma":[0.072790846,0.018753922,0.25299034,0.0015643095,0.0008766738,0.00060801744,0.004342996,0.00091781415,0.11055015,0.0029416054,0.5328274,0.00083593384],"about_ca_topic_score_codex":0.00012340202,"about_ca_topic_score_gemma":0.000008256036,"teacher_disagreement_score":0.75928205,"about_ca_system_score_codex":0.0009744797,"about_ca_system_score_gemma":0.00043542785,"threshold_uncertainty_score":0.8252078},"labels":[],"label_agreement":null},{"id":"W4225128983","doi":"10.1136/jitc-2021-004151","title":"Local anesthetics elicit immune-dependent anticancer effects","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Labex Immuno-Oncology; High-end Foreign Experts Recruitment Plan of China; European Research Area Network on Cardiovascular Diseases; Chancellerie des Universités de Paris; Cancéropôle Ile de France; Institut Universitaire de France; China Scholarship Council; Ligue Contre le Cancer; Fondation pour la Recherche Médicale; Institut National Du Cancer; Institut National de la Santé et de la Recherche Médicale; Université Paris-Saclay; Agence Nationale de la Recherche; E-Rare; Fondation Philanthropia; Bristol-Myers Squibb; Association pour la Recherche sur le Cancer; Seerave Foundation; Institut Gustave-Roussy; Fondation Leducq; European Commission","keywords":"Unfolded protein response; Autophagy; Endoplasmic reticulum; ATG5; Immunogenic cell death; Integrated stress response; Medicine; Phosphorylation; Cancer research; Pharmacology; Cell biology; Immunology; Immune system; Chemistry; Biology; Immunotherapy; Apoptosis; Biochemistry; Translation (biology)","score_opus":0.010377446770517789,"score_gpt":0.30995109416371,"score_spread":0.2995736473931922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225128983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.830658,0.15857469,0.002799652,0.0030140695,0.0032424808,0.0013235576,0.00004481818,0.000055200693,0.0002874971],"genre_scores_gemma":[0.97037214,0.02088246,0.00034278168,0.0016276177,0.0007561397,0.0003878538,0.000009446768,0.00014383387,0.005477729],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975061,0.00015179266,0.0007592408,0.00025248728,0.00082915253,0.0005012209],"domain_scores_gemma":[0.99840516,0.00021119797,0.0005456741,0.00043534292,0.0002816353,0.000120965036],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007134415,0.00028688455,0.0008031959,0.0002649712,0.00048808966,0.000036325793,0.00033943067,0.00008900142,0.0010247704],"category_scores_gemma":[0.00003324442,0.00025278272,0.00065805315,0.00026316984,0.0002100272,0.000102847436,0.00004376091,0.000603625,0.0000031442353],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041963317,0.0011480025,0.0037320144,0.00060675247,0.0016994543,0.00017360633,0.002270205,0.002656725,0.24540299,0.00020769083,0.0073169665,0.6928223],"study_design_scores_gemma":[0.017577969,0.005982682,0.023502408,0.0005451578,0.00046045316,0.0032905396,0.0011650258,0.0005408998,0.11485629,0.00032648456,0.8311669,0.000585151],"about_ca_topic_score_codex":0.00026531,"about_ca_topic_score_gemma":0.000012033859,"teacher_disagreement_score":0.82385,"about_ca_system_score_codex":0.0006560148,"about_ca_system_score_gemma":0.0007957575,"threshold_uncertainty_score":0.99999243},"labels":[],"label_agreement":null},{"id":"W4234138863","doi":"10.1186/s40425-017-0297-3","title":"32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Late-Breaking Abstracts","year":2017,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cancer immunotherapy; Immunotherapy; Cancer; Medicine; Internal medicine","score_opus":0.03271945670655681,"score_gpt":0.35928972632851763,"score_spread":0.32657026962196084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234138863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94891703,0.045801673,0.00020109939,0.0019093935,0.0010966674,0.0016574106,0.000237264,0.000011936574,0.00016754253],"genre_scores_gemma":[0.96779597,0.027928343,0.0020305628,0.0002891648,0.0003614332,0.00018923351,0.0000042583297,0.000075391436,0.0013256146],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99767625,0.000034283228,0.0011027418,0.00027694818,0.00047004767,0.000439743],"domain_scores_gemma":[0.99539405,0.00013543028,0.0028651436,0.00060704234,0.0009286392,0.00006969522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011188599,0.00031743787,0.0008232576,0.000070915805,0.00061863585,0.00009268355,0.00058487826,0.0002210027,0.00008261336],"category_scores_gemma":[0.00004764681,0.00021604294,0.0012104412,0.00009779071,0.00068044255,0.00031710352,0.000044554316,0.0003110174,5.242787e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014118845,0.00024425937,0.025685789,0.0006990186,0.0037781463,5.65977e-7,0.0058068456,0.000054732227,0.5097948,0.000036333568,0.00089736807,0.4388833],"study_design_scores_gemma":[0.030434411,0.0028066714,0.53269666,0.00738701,0.0008106897,0.00006806348,0.0013772637,0.0003600296,0.31575426,0.00078411493,0.106820956,0.0006998785],"about_ca_topic_score_codex":0.0028150955,"about_ca_topic_score_gemma":0.00047916398,"teacher_disagreement_score":0.5070109,"about_ca_system_score_codex":0.00014917432,"about_ca_system_score_gemma":0.00077631715,"threshold_uncertainty_score":0.8809976},"labels":[],"label_agreement":null},{"id":"W4234912275","doi":"10.1136/jitc-2020-001472","title":"Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II—practical challenges","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Cancer Institute; Society for Immunotherapy of Cancer","keywords":"Data sharing; Clinical trial; Medicine; Resource (disambiguation); Biomarker; Data science; Biomarker discovery; Data collection; Computer science; Medical physics; Alternative medicine; Pathology","score_opus":0.08466978870647565,"score_gpt":0.4076963484725098,"score_spread":0.3230265597660341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234912275","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5538451,0.4048139,0.006355,0.031066399,0.0011198933,0.0010878736,0.0016230689,0.000011230054,0.00007756057],"genre_scores_gemma":[0.15054211,0.82605994,0.0155966,0.0041218423,0.002853298,0.00014522663,0.00013828067,0.0001561521,0.00038653548],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983633,0.000028991031,0.00072352606,0.0004515986,0.00016246058,0.00027012033],"domain_scores_gemma":[0.9985297,0.00010794098,0.00057856005,0.00045684367,0.00021293754,0.000114040304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007462177,0.00019424873,0.0004300127,0.00002397478,0.0001692553,0.000039242193,0.00053080963,0.00019336258,0.00006038348],"category_scores_gemma":[0.00013814335,0.0001799193,0.0004178052,0.000053298598,0.00021817996,0.000021501355,0.00021016526,0.00016729224,1.006575e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014668044,0.00026634525,0.006062893,0.00039012742,0.0066945413,0.0000010431684,0.0013513108,0.00016420471,0.34305158,0.00028696473,0.08464349,0.5424195],"study_design_scores_gemma":[0.005675917,0.001559846,0.001794938,0.000094245835,0.00014709613,0.000006795005,0.00030486283,0.00085240445,0.020297332,0.00029625895,0.9687076,0.00026269475],"about_ca_topic_score_codex":0.00008692511,"about_ca_topic_score_gemma":0.00006211888,"teacher_disagreement_score":0.88406414,"about_ca_system_score_codex":0.000029334293,"about_ca_system_score_gemma":0.0003357405,"threshold_uncertainty_score":0.7336896},"labels":[],"label_agreement":null},{"id":"W4243956777","doi":"10.1136/jitc-2020-0485-9corr","title":"Correction: <i>Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy</i>","year":2020,"lang":"en","type":"erratum","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Tumor microenvironment; Chemoradiotherapy; Medicine; Cancer research; Oncology; Tumor cells; Overall survival","score_opus":0.014953348568983692,"score_gpt":0.2911113908260646,"score_spread":0.2761580422570809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243956777","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06397599,0.7509421,0.0021288518,0.006806362,0.16764764,0.004294294,0.00061333633,0.00011860572,0.0034728358],"genre_scores_gemma":[0.03481848,0.6687502,0.0033861392,0.0050314907,0.010009389,0.00050298136,0.0003766202,0.0005860214,0.27653867],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967107,0.000051143146,0.0016335287,0.000456092,0.00071924314,0.00042927422],"domain_scores_gemma":[0.99616104,0.00009108532,0.0027587248,0.0004887507,0.00039759974,0.000102803984],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003745694,0.00059545285,0.0018483712,0.00030010272,0.0001859373,0.00004035607,0.0004202598,0.00051177654,0.001507286],"category_scores_gemma":[0.000028593107,0.00049972517,0.0013898251,0.00034123397,0.00033043046,0.00014755526,0.000024236935,0.0010585748,0.0000021295207],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016821109,0.00029296483,0.00023435347,0.0006681845,0.0032145712,0.0000058620717,0.0004541357,0.00006715869,0.44422024,0.0000031928487,0.4054186,0.12859963],"study_design_scores_gemma":[0.006962391,0.003245523,0.004522739,0.0023596208,0.00038979884,0.00018591824,0.000120774435,0.00024559782,0.10637091,0.000096465796,0.8750292,0.00047104625],"about_ca_topic_score_codex":0.0002305046,"about_ca_topic_score_gemma":0.000027357,"teacher_disagreement_score":0.46961063,"about_ca_system_score_codex":0.0007269883,"about_ca_system_score_gemma":0.00079290464,"threshold_uncertainty_score":0.9997454},"labels":[],"label_agreement":null},{"id":"W4280488168","doi":"10.1136/jitc-2021-003487","title":"Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?","year":2022,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Innovative Medicines Initiative; European Commission; European Federation of Pharmaceutical Industries and Associations","keywords":"T-cell receptor; Cancer immunotherapy; Medicine; Immunotherapy; Translational research; Chimeric antigen receptor; T cell; Cancer research; Immune system; Computational biology; Immunology; Bioinformatics; Biology; Pathology","score_opus":0.05417610846829858,"score_gpt":0.3756960139525929,"score_spread":0.3215199054842943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280488168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006766527,0.9925498,0.00003785933,0.001727372,0.0011554898,0.0028408528,0.0008438219,0.000018293995,0.0001498965],"genre_scores_gemma":[0.000018635448,0.9861544,0.00014396278,0.00030620286,0.0014836276,0.000283801,0.000066034794,0.00021065431,0.0113326805],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99613,0.0003790526,0.0012309619,0.00035378282,0.0013840285,0.00052219955],"domain_scores_gemma":[0.9934682,0.0034720085,0.0015469072,0.0010716576,0.00033662794,0.000104587],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019235625,0.00052467594,0.002269962,0.00022651065,0.00037149753,0.00007986027,0.0012794067,0.00026685162,0.019103756],"category_scores_gemma":[0.00017801514,0.00027852377,0.0025081118,0.0005778147,0.00027043978,0.000076517914,0.00010239677,0.0018979325,0.0000045188967],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069495966,0.00012505347,0.0000059309286,0.0013279645,0.005620873,0.000004350858,0.0014960063,0.000021246791,0.008023157,0.0000024632209,0.02128132,0.9613967],"study_design_scores_gemma":[0.0027935572,0.00058979646,0.00002026915,0.004493461,0.0014857678,0.00006830269,0.00019002386,0.00009457572,0.0011908511,0.000022240247,0.9888198,0.00023140581],"about_ca_topic_score_codex":0.0002414264,"about_ca_topic_score_gemma":0.000007102639,"teacher_disagreement_score":0.9675384,"about_ca_system_score_codex":0.00051732204,"about_ca_system_score_gemma":0.0014310507,"threshold_uncertainty_score":0.9999667},"labels":[],"label_agreement":null},{"id":"W4280541127","doi":"10.1136/jitc-2021-004076","title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Foundation Medicine; Takeda Oncology; Chugai Pharmaceutical; Novartis Pharma; Genentech; Daiichi Sankyo Europe; National Cancer Institute; Servier; Eisai; Basilea Pharmaceutica; AstraZeneca; Institut National Du Cancer; Seagen; Agios Pharmaceuticals; Eisai Canada; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Boston Pharmaceuticals; Taiho Pharmaceutical; F. Hoffmann-La Roche; Yale University; Bayer HealthCare; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atezolizumab; Blockade; Solid tumor; Medicine; Immune checkpoint; Immune system; Oncology; Cancer research; Internal medicine; Immunology; Immunotherapy; Pembrolizumab; Cancer; Receptor","score_opus":0.014477426203594235,"score_gpt":0.32528427437223195,"score_spread":0.31080684816863774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280541127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99010825,0.0048000095,0.00027425864,0.00092445844,0.000990004,0.0027507434,0.0001038205,0.000021669293,0.000026813941],"genre_scores_gemma":[0.99460816,0.0020871374,0.0010270552,0.00044403638,0.00007301005,0.0013826087,0.000045271252,0.00010150665,0.00023123574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969502,0.000074621435,0.00133763,0.00038246796,0.0006521847,0.00060289813],"domain_scores_gemma":[0.9981076,0.00010138537,0.0010191548,0.00031450816,0.0003818225,0.000075496886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006289083,0.00035950076,0.0010029393,0.0005488593,0.00032744167,0.000041526306,0.00032992876,0.00008301668,0.00045833059],"category_scores_gemma":[0.000054750366,0.00028070758,0.00037485114,0.000692623,0.00014186613,0.0003227,0.000035473127,0.000454386,2.5535968e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23319407,0.0033755575,0.01682321,0.00044990407,0.0008348254,0.000053591764,0.010228373,0.00308418,0.6592176,0.000029427552,0.000115776245,0.07259351],"study_design_scores_gemma":[0.22667712,0.022972047,0.25135398,0.0022615525,0.00013370924,0.00034068077,0.0068158917,0.00089195045,0.46870372,0.00047220816,0.018295437,0.00108172],"about_ca_topic_score_codex":0.0003946761,"about_ca_topic_score_gemma":0.000121790465,"teacher_disagreement_score":0.23453076,"about_ca_system_score_codex":0.0018777178,"about_ca_system_score_gemma":0.0011244374,"threshold_uncertainty_score":0.99996454},"labels":[],"label_agreement":null},{"id":"W4281940442","doi":"10.1136/jitc-2022-004885","title":"Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Université de Paris; Unicancer; Bristol-Myers Squibb; Sorbonne Université; Ligue Contre le Cancer; Institut National de la Santé et de la Recherche Médicale; Institute of Cancer Research; Institut National Du Cancer","keywords":"Nivolumab; Medicine; Renal cell carcinoma; Internal medicine; Oncology; Flow cytometry; Immune system; Clear cell renal cell carcinoma; Immunotherapy; B cell; Prospective cohort study; Immunology; Antibody","score_opus":0.013715196003064773,"score_gpt":0.23272666965966934,"score_spread":0.21901147365660456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281940442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550813,0.0013841438,0.000013931334,0.000079428544,0.00017859065,0.002611542,0.00007210506,0.000037673934,0.00011443996],"genre_scores_gemma":[0.99766904,0.00003649103,0.00013163636,0.00007483418,0.000037254238,0.00011271717,0.00005680365,0.00021304628,0.0016682044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99616754,0.0005242184,0.0009350648,0.00054677506,0.0012546087,0.00057181314],"domain_scores_gemma":[0.99692327,0.00026559923,0.0016824782,0.00046636723,0.00049307325,0.00016920608],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010016654,0.00056906167,0.0010390665,0.0002887928,0.0005754257,0.00006519488,0.00025714058,0.00010954105,0.00016159583],"category_scores_gemma":[0.000012744181,0.0003336464,0.00017697613,0.0005533357,0.00013300832,0.00017613167,0.000051891417,0.0009876902,3.6159554e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022264415,0.0031200068,0.94439346,0.00008414173,0.00090363616,0.00014851124,0.0066475244,0.008628609,0.01355292,2.9004124e-7,0.00009163665,0.0001648675],"study_design_scores_gemma":[0.07655302,0.02178963,0.86669445,0.00026800155,0.0009037188,0.00002820056,0.008723957,0.00096241175,0.023464724,0.0000055538526,0.00004331961,0.0005630052],"about_ca_topic_score_codex":0.002393472,"about_ca_topic_score_gemma":0.00078779395,"teacher_disagreement_score":0.077698976,"about_ca_system_score_codex":0.0011145545,"about_ca_system_score_gemma":0.0005643051,"threshold_uncertainty_score":0.99991155},"labels":[],"label_agreement":null},{"id":"W4282947288","doi":"10.1136/jitc-2021-004378","title":"Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Vagus Nerve Stimulation Research","field":"Neuroscience","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation; Merck","keywords":"Pembrolizumab; Medicine; Choline; Internal medicine; Cohort; Phosphocholine; Oncology; Choline acetyltransferase; Cancer; Gastroenterology; Acetylcholine; Immunotherapy; Biology","score_opus":0.031134015736450533,"score_gpt":0.36052166816713554,"score_spread":0.329387652430685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282947288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462026,0.0004819957,0.00026742913,0.00068816607,0.0006921234,0.0023278205,0.0008715039,0.000017284729,0.00003341758],"genre_scores_gemma":[0.9973604,0.0001482523,0.00083059946,0.00025104804,0.000078333585,0.000954849,0.000007588427,0.00007340774,0.00029549052],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99726105,0.00025231217,0.00067792536,0.00038035747,0.00084068516,0.0005876744],"domain_scores_gemma":[0.9982696,0.00045074662,0.0005676047,0.00033112493,0.00028321042,0.000097676064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009841167,0.00021165647,0.0004113252,0.00042781336,0.00037073932,0.000037624584,0.00068986503,0.000051164297,0.00026098188],"category_scores_gemma":[0.0006312101,0.0001805653,0.00011864599,0.0006624803,0.00008296258,0.00041098884,0.0001057226,0.0005202562,9.728769e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.090065576,0.0011946126,0.27691576,0.00023158487,0.00011937738,0.000009780935,0.0016035584,0.16133057,0.1434322,0.00007055878,0.00034448077,0.32468194],"study_design_scores_gemma":[0.10753484,0.0063664378,0.8244192,0.0006023429,0.000019625239,0.000009978515,0.0001872445,0.027740361,0.024913719,0.00090374594,0.0066126264,0.00068988337],"about_ca_topic_score_codex":0.00022877843,"about_ca_topic_score_gemma":0.00049401046,"teacher_disagreement_score":0.5475034,"about_ca_system_score_codex":0.0011410884,"about_ca_system_score_gemma":0.00088855263,"threshold_uncertainty_score":0.7363239},"labels":[],"label_agreement":null},{"id":"W4283022888","doi":"10.1136/jitc-2022-004849","title":"iRECIST and atypical patterns of response to immuno-oncology drugs","year":2022,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Oncology; Precision oncology; Internal medicine; Bioinformatics; Cancer; Biology","score_opus":0.0556000296636933,"score_gpt":0.43022200263523774,"score_spread":0.3746219729715444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283022888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052461657,0.99028796,0.00006762914,0.00063361315,0.0016566275,0.0016136564,0.00043189264,0.000011634534,0.00005080351],"genre_scores_gemma":[0.000105562765,0.99634576,0.00042001533,0.00048757278,0.00031047262,0.00039634263,0.00002260103,0.00012536571,0.0017863008],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99664026,0.00039739208,0.0017351928,0.00034165537,0.0005017335,0.0003837611],"domain_scores_gemma":[0.9967687,0.0009484616,0.0014657094,0.00046937837,0.00019909622,0.00014866985],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019313653,0.000446815,0.0028988854,0.0006009659,0.00018064621,0.000023977793,0.0003924482,0.00032756175,0.0022701062],"category_scores_gemma":[0.00009282244,0.00034394336,0.0014546132,0.00035675042,0.00015781385,0.0000585983,0.0000738378,0.00062769384,8.205018e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08088003,0.00017873185,0.000029606701,0.0038710106,0.0023019293,0.00001077508,0.0007809831,3.4844226e-7,0.0015465948,0.0000064065753,0.0015037323,0.90888983],"study_design_scores_gemma":[0.005166192,0.0042076437,0.00033784323,0.008067806,0.0008315763,0.0005373188,0.00022883803,4.647882e-7,0.00012814476,0.000015009031,0.9801723,0.0003068592],"about_ca_topic_score_codex":0.00010237926,"about_ca_topic_score_gemma":0.000012617842,"teacher_disagreement_score":0.9786686,"about_ca_system_score_codex":0.0010388492,"about_ca_system_score_gemma":0.0019722409,"threshold_uncertainty_score":0.99990124},"labels":[],"label_agreement":null},{"id":"W4283319121","doi":"10.1136/jitc-2021-004458","title":"Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medical Research Council; National Cancer Institute; National Research, Development and Innovation Office; Radiumhemmets Forskningsfonder; Cancerföreningen i Stockholm; Vetenskapsrådet; Karolinska Institutet; Cancerfonden; Knut och Alice Wallenbergs Stiftelse; Kommunfullmäktige, Stockholms Stad; Stiftelsen Tornspiran","keywords":"Auranofin; Cytotoxic T cell; Oxidative stress; Degranulation; Chemistry; Cancer research; CD19; Reactive oxygen species; Flow cytometry; Immunology; Pharmacology; Cell biology; Biology; In vitro; Biochemistry; Receptor","score_opus":0.007982904849460928,"score_gpt":0.2779203625517257,"score_spread":0.2699374577022648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283319121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97999483,0.018227639,0.00008810563,0.00003652692,0.00025699942,0.0001977088,0.0011819404,0.0000024260642,0.000013820922],"genre_scores_gemma":[0.994281,0.0042511104,0.00041120482,0.00005069859,0.00016068619,0.000031498304,0.000048358463,0.000033253535,0.0007322129],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989741,0.00007972156,0.00037906304,0.00020723302,0.00014458274,0.00021530899],"domain_scores_gemma":[0.9991489,0.000020912064,0.0005001379,0.00014210083,0.0001436025,0.000044321758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021326504,0.00015317119,0.0002640283,0.000053129992,0.00028562374,0.000018303845,0.0002231842,0.000051311068,0.000045339657],"category_scores_gemma":[0.000012154903,0.0001508362,0.00013189529,0.00004185549,0.00013898431,0.00000913305,0.000083758336,0.00015510828,4.2519314e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011801288,0.00007866339,0.0011140495,0.00007291511,0.00017747373,6.5332836e-7,0.00036743056,0.00014449403,0.9953559,0.0000033017527,0.00094598706,0.0005590063],"study_design_scores_gemma":[0.0014573247,0.00054594217,0.0007197998,0.000028302495,0.000018913212,0.0000036229019,0.00070927566,0.00000670463,0.9872785,0.000048823178,0.009017917,0.0001648556],"about_ca_topic_score_codex":0.00005217636,"about_ca_topic_score_gemma":0.000005162,"teacher_disagreement_score":0.014286143,"about_ca_system_score_codex":0.00003816026,"about_ca_system_score_gemma":0.00008157772,"threshold_uncertainty_score":0.6150922},"labels":[],"label_agreement":null},{"id":"W4292103594","doi":"10.1136/jitc-2022-004761","title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Hôtel-Dieu de Québec","funders":"Foundation Medicine; National Center for Advancing Translational Sciences; Ono Pharmaceutical; Clovis Oncology; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Prostate cancer; Nivolumab; Internal medicine; Oncology; Cohort; Progression-free survival; Cancer; Urology; Chemotherapy; Androgen receptor; Immunotherapy","score_opus":0.07347743674206077,"score_gpt":0.4234544933584976,"score_spread":0.34997705661643685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292103594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9094368,0.053191833,0.00025017717,0.016136775,0.0025519722,0.0064611463,0.011888783,0.000024910127,0.000057591777],"genre_scores_gemma":[0.9357943,0.027613532,0.002246888,0.00132044,0.002353568,0.010107608,0.00094790047,0.00020176683,0.019414008],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975715,0.0001226769,0.00088260695,0.00027922177,0.0006934016,0.0004505693],"domain_scores_gemma":[0.99802536,0.0004154944,0.0007217198,0.0003131067,0.00041865543,0.00010568712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010355604,0.00022572302,0.00057749206,0.00010435645,0.00090465567,0.000082420825,0.00027690828,0.000037383823,0.0005810683],"category_scores_gemma":[0.00007381844,0.00014425645,0.0004389505,0.00022877757,0.0001280725,0.0001297954,0.000026789356,0.00038292015,5.0866026e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.815492,0.0006151149,0.00003844797,0.000086076056,0.0024987033,0.00001996059,0.0053833947,0.0006558246,0.081662305,0.000043865108,0.020181166,0.07332315],"study_design_scores_gemma":[0.58750266,0.010590245,0.00021170259,0.00023715387,0.0007293828,0.000030078461,0.0025456196,0.0013213248,0.026691921,0.0013131003,0.36854607,0.0002807626],"about_ca_topic_score_codex":0.002132175,"about_ca_topic_score_gemma":0.0002993369,"teacher_disagreement_score":0.34836492,"about_ca_system_score_codex":0.0009724737,"about_ca_system_score_gemma":0.0024599964,"threshold_uncertainty_score":0.69579715},"labels":[],"label_agreement":null},{"id":"W4292241648","doi":"10.1136/jitc-2022-004660","title":"Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Universitätsklinikum Hamburg-Eppendorf; Natural Sciences and Engineering Research Council of Canada; Bundesministerium für Bildung und Forschung; Deutsche Forschungsgemeinschaft; Université Laval","keywords":"Adenosine; Cancer research; Ceritinib; Cancer cell; Pharmacology; Kinase; Chemistry; Adenosine kinase; Cancer; Medicine; Lung cancer; Biochemistry; Anaplastic lymphoma kinase; Adenosine deaminase; Internal medicine","score_opus":0.013038133883040717,"score_gpt":0.301313983630451,"score_spread":0.2882758497474103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292241648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92201364,0.07077366,0.0035232475,0.0009764556,0.0008786541,0.0014032965,0.00038256997,0.000019864345,0.000028630078],"genre_scores_gemma":[0.98090184,0.0022729218,0.006186858,0.00102128,0.0024884383,0.0028514392,0.00007227979,0.00024761213,0.0039573405],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983619,0.00007575994,0.0005646736,0.0003112411,0.0002652999,0.00042113208],"domain_scores_gemma":[0.99881923,0.000026683152,0.00053731573,0.00024667193,0.00029883985,0.00007123407],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005117991,0.00025892525,0.0003545849,0.000101693106,0.0005288653,0.00005208739,0.00034921686,0.00009783547,0.00055805664],"category_scores_gemma":[0.000025971995,0.00024555583,0.00045099834,0.00012800528,0.000066060515,0.000014318035,0.00005034254,0.00023731952,1.0433744e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004738776,0.00017468967,0.00025996045,0.000060770082,0.0004604222,0.0000024130966,0.0002525872,0.0018816153,0.9625152,0.000023176492,0.012551493,0.017078906],"study_design_scores_gemma":[0.0040513473,0.0013429156,0.000028529488,0.000070036265,0.00002242655,0.000022960168,0.00013026618,0.00013720588,0.49324304,0.00024388211,0.5004551,0.00025230923],"about_ca_topic_score_codex":0.00011033068,"about_ca_topic_score_gemma":0.000007919328,"teacher_disagreement_score":0.4879036,"about_ca_system_score_codex":0.00011285289,"about_ca_system_score_gemma":0.0004903886,"threshold_uncertainty_score":0.99999964},"labels":[],"label_agreement":null},{"id":"W4294958749","doi":"10.1136/jitc-2022-004913","title":"Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Foundation Medicine; Pfizer; G1 Therapeutics; York University; NYU Grossman School of Medicine; Genentech; AstraZeneca; Bristol-Myers Squibb","keywords":"Immune system; CD8; Cancer research; Medicine; Immunotherapy; Immunology; Cytotoxic T cell; Chemotherapy; Tumor microenvironment; Cisplatin; Biology; Internal medicine","score_opus":0.01763794552398114,"score_gpt":0.3215746549365428,"score_spread":0.3039367094125617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294958749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91248447,0.082924046,0.00019190315,0.0018804895,0.00037091257,0.001833108,0.00023306774,0.000019146297,0.00006288748],"genre_scores_gemma":[0.9764324,0.01918903,0.0010926368,0.00038913198,0.00025290198,0.0013171786,0.000008238118,0.00008339961,0.0012351176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99797636,0.00009082979,0.0006129405,0.00027857145,0.00052831095,0.00051296764],"domain_scores_gemma":[0.9988025,0.00009631979,0.0003858985,0.00021776767,0.0003790403,0.00011850807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080786465,0.00027017525,0.0006523636,0.00043210253,0.00042850742,0.00003701777,0.0002587829,0.000045219982,0.0002880739],"category_scores_gemma":[0.00007882145,0.00023197809,0.00018996294,0.00047748434,0.00013143195,0.00016077302,0.00016892106,0.00087315496,1.5523784e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044573643,0.000470034,0.021128142,0.0010723346,0.00042375308,0.000024885872,0.0030583635,0.00023600964,0.96258044,0.0000470072,0.0010312311,0.0054704193],"study_design_scores_gemma":[0.062936254,0.0053281602,0.18938346,0.0044059926,0.00040112398,0.00041732242,0.0034905649,0.003400292,0.68161243,0.00043328365,0.04684684,0.0013442462],"about_ca_topic_score_codex":0.0021834665,"about_ca_topic_score_gemma":0.00031196148,"teacher_disagreement_score":0.280968,"about_ca_system_score_codex":0.0008897514,"about_ca_system_score_gemma":0.0008761881,"threshold_uncertainty_score":0.9459792},"labels":[],"label_agreement":null},{"id":"W4296661760","doi":"10.1136/jitc-2022-005646","title":"Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"School of Medicine, Stanford University; Universitätsklinikum Heidelberg; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; University of Washington; University of Miami; Universitair Medisch Centrum Groningen; University of Texas MD Anderson Cancer Center; Northwestern University; National Cancer Institute; University of Toronto; National Institute of General Medical Sciences; Massachusetts General Hospital; University of California, Los Angeles; Memorial Sloan-Kettering Cancer Center; Ohio State University; Leonard M. Miller School of Medicine; University of Pennsylvania","keywords":"Medicine; Corticosteroid; Creatinine; Internal medicine; Cohort; Acute kidney injury; Adverse effect; Confounding; Duration (music)","score_opus":0.02640980364461186,"score_gpt":0.32402318233306016,"score_spread":0.2976133786884483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296661760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94852614,0.04445251,0.000079715304,0.0023587313,0.0037136886,0.00068746135,0.00007287161,0.000021622709,0.000087227134],"genre_scores_gemma":[0.9891114,0.00878835,0.0001136682,0.00044401994,0.00029649006,0.00019715891,0.000035531742,0.000056463843,0.0009569084],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797994,0.0000761096,0.0009752511,0.00020409904,0.0004742965,0.0002903159],"domain_scores_gemma":[0.9987054,0.00007447762,0.0007582819,0.00019470965,0.00019416674,0.000072975],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007803213,0.0002014649,0.0004518587,0.0001718773,0.0003831831,0.00004467472,0.000114363254,0.00007358376,0.0010952384],"category_scores_gemma":[0.000033245902,0.0001761999,0.00037318678,0.00020991395,0.00009708412,0.0001386966,0.000033588494,0.00038592922,4.5107984e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082839526,0.0005656996,0.003073294,0.000085202875,0.0022260805,0.000010329202,0.0021768296,0.000022435497,0.70312357,0.000011838562,0.0023392397,0.20352595],"study_design_scores_gemma":[0.123421565,0.02859857,0.21722394,0.0011475284,0.0011048468,0.0006876669,0.0029393996,0.0007912775,0.20735589,0.00034812928,0.4150037,0.0013774912],"about_ca_topic_score_codex":0.000089841364,"about_ca_topic_score_gemma":0.0000431217,"teacher_disagreement_score":0.49576768,"about_ca_system_score_codex":0.0006860534,"about_ca_system_score_gemma":0.00026514573,"threshold_uncertainty_score":0.9998179},"labels":[],"label_agreement":null},{"id":"W4297141578","doi":"10.1136/jitc-2022-004725","title":"TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Cancer Institute; National Institutes of Health; National Center for Advancing Translational Sciences; University of Minnesota","keywords":"Stromal cell; Tumor microenvironment; Cancer research; Lymphokine-activated killer cell; Biology; Interleukin 21; Degranulation; Cytokine; T cell; Immunology; Immune system; Tumor cells; Receptor","score_opus":0.03057813303820549,"score_gpt":0.3280423464682694,"score_spread":0.2974642134300639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297141578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797854,0.012236766,0.00015174311,0.002009928,0.003227748,0.0018347487,0.000104096864,0.00004645452,0.000603137],"genre_scores_gemma":[0.96828437,0.0020939407,0.0011817566,0.0014631924,0.0011030856,0.0003015415,0.000008504698,0.00021541158,0.025348186],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957072,0.00048180023,0.0008551344,0.0006162963,0.0014543324,0.00088524807],"domain_scores_gemma":[0.99763227,0.0004915616,0.0005324774,0.00061527593,0.00032317566,0.00040524974],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002190273,0.0004855866,0.0011182525,0.00065250543,0.00096418004,0.0001491669,0.00051419076,0.00006858202,0.0124114435],"category_scores_gemma":[0.000066441986,0.00041114644,0.0006175292,0.0006216087,0.0001967814,0.00023315256,0.0001468135,0.0024891368,0.000007035099],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014452739,0.00064476224,0.0017355516,0.00009998504,0.00042099482,0.0001874142,0.0010886563,0.00006088609,0.9301697,0.000027575014,0.02085136,0.030260375],"study_design_scores_gemma":[0.014781913,0.0033620915,0.05135899,0.00013962733,0.00007098372,0.00079421804,0.0010807381,0.00014019576,0.11805802,0.000049040656,0.809571,0.0005931602],"about_ca_topic_score_codex":0.00008260419,"about_ca_topic_score_gemma":0.0000107777105,"teacher_disagreement_score":0.8121117,"about_ca_system_score_codex":0.000866042,"about_ca_system_score_gemma":0.0006186201,"threshold_uncertainty_score":0.99983406},"labels":[],"label_agreement":null},{"id":"W4297322118","doi":"10.1136/jitc-2021-004450","title":"Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Hyundai Hope On Wheels; National Cancer Institute; American Association for Cancer Research; Children's Hospital of Philadelphia; Alex's Lemonade Stand Foundation for Childhood Cancer; Damon Runyon Cancer Research Foundation; Kortney Rose Foundation","keywords":"Chimeric antigen receptor; Medulloblastoma; Neuroblastoma; Cancer research; Glioma; Pediatric cancer; Medicine; Flow cytometry; Brain tumor; Cancer; Immunotherapy; Cell culture; Biology; Immunology; Pathology; Internal medicine","score_opus":0.046226171553148024,"score_gpt":0.37651339021005625,"score_spread":0.33028721865690824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297322118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98609143,0.01022418,0.0008921219,0.0004106023,0.0010324083,0.0012225871,0.00004771366,0.000022268894,0.00005669968],"genre_scores_gemma":[0.70865566,0.018912513,0.22694127,0.0020702146,0.0048574284,0.001773799,0.00015693573,0.0010021633,0.035630018],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977265,0.00008210912,0.0008630094,0.00019944807,0.00071454246,0.00041439742],"domain_scores_gemma":[0.9984114,0.00018234686,0.0006908939,0.00019950718,0.00041756863,0.000098288765],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012671233,0.0001868249,0.0006004173,0.0005110023,0.00041682832,0.000014632594,0.0002587602,0.00005202628,0.004459669],"category_scores_gemma":[0.0000623605,0.00017116574,0.0003963376,0.00063644326,0.00005690523,0.00006948576,0.000037173995,0.00032556007,3.0309826e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006385172,0.00025558315,0.0073154443,0.0001898512,0.0007285712,0.0000020071193,0.002453852,0.00022587417,0.82618177,0.0000045593006,0.003084469,0.15317287],"study_design_scores_gemma":[0.015294295,0.0025391942,0.015380766,0.00020157167,0.00016330488,0.0001647714,0.0011617218,0.0012393183,0.28695834,0.00013873276,0.6762574,0.0005006176],"about_ca_topic_score_codex":0.00007208594,"about_ca_topic_score_gemma":0.000008157348,"teacher_disagreement_score":0.6731729,"about_ca_system_score_codex":0.0006276277,"about_ca_system_score_gemma":0.0017475178,"threshold_uncertainty_score":0.99645036},"labels":[],"label_agreement":null},{"id":"W4297387081","doi":"10.1136/jitc-2022-005187","title":"GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"Mark Hughes Foundation; Medical Research Council; Flinders Foundation; Tour de Cure; Australian Cancer Research Foundation; Fay Fuller Foundation; Cancer Australia; Cancer Council South Australia; Neurosurgical Research Foundation; National Health and Medical Research Council; Hospital Research Foundation","keywords":"Chimeric antigen receptor; Medicine; Glioma; Flow cytometry; Cancer research; Brain tumor; Antigen; Immune system; Immunotherapy; Tumor antigen; Pathology; Oncology; Immunology","score_opus":0.02121667910910916,"score_gpt":0.3714376681463423,"score_spread":0.35022098903723314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297387081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762477,0.016567545,0.0024037587,0.0005433706,0.00074053055,0.0031086307,0.0003258284,0.000031435542,0.000031150033],"genre_scores_gemma":[0.974937,0.016708659,0.0017190848,0.0008869673,0.0006907419,0.001742134,0.00002659523,0.00020247021,0.0030863124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972492,0.0002970839,0.00079333247,0.00043443544,0.0006821115,0.0005438334],"domain_scores_gemma":[0.99783736,0.000566735,0.0006180159,0.00030757696,0.00045470896,0.00021557251],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017420605,0.00029860935,0.00078638096,0.00019960274,0.00062394666,0.000056452744,0.0003013448,0.00013395815,0.002008677],"category_scores_gemma":[0.000041901847,0.0002505281,0.00054252543,0.00022318258,0.00012811535,0.00018236623,0.000027391685,0.0006759699,3.471185e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040014494,0.00040391245,0.000432482,0.00009575854,0.00041325597,0.0000012839179,0.0016582067,0.00009074553,0.79727316,0.000001059218,0.0031789674,0.15643668],"study_design_scores_gemma":[0.018698853,0.013908248,0.0006554515,0.00015938233,0.000053771848,0.000018369055,0.001010906,0.0001529794,0.8631942,0.00017750927,0.10170798,0.00026230598],"about_ca_topic_score_codex":0.00003990449,"about_ca_topic_score_gemma":0.000013021698,"teacher_disagreement_score":0.15617438,"about_ca_system_score_codex":0.00031473098,"about_ca_system_score_gemma":0.00027358407,"threshold_uncertainty_score":0.9999947},"labels":[],"label_agreement":null},{"id":"W4304608290","doi":"10.1136/jitc-2022-004653","title":"Mast cell-T cell axis alters development of colitis-dependent and colitis-independent colorectal tumours: potential for therapeutically targeting via mast cell inhibition","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo; Universidade de São Paulo; Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Colorectal cancer; Colitis; Cancer research; Medicine; CD8; Cytotoxic T cell; Mast cell; Immune system; Population; Carcinogenesis; Immunology; T cell; Cancer; Biology; Internal medicine; In vitro","score_opus":0.007699038656310319,"score_gpt":0.23714430713305956,"score_spread":0.22944526847674923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304608290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702936,0.015038996,0.010664819,0.0001788769,0.0018248503,0.0011507968,0.0006010595,0.000015105963,0.00023190647],"genre_scores_gemma":[0.9939421,0.000802219,0.0020427979,0.00014500355,0.00009233177,0.00024031049,0.00011962061,0.000060710827,0.0025549033],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997801,0.00015556715,0.0009746094,0.00032541837,0.00019697823,0.0005464404],"domain_scores_gemma":[0.99854517,0.0001062152,0.0008852111,0.00012508758,0.0002841496,0.000054190103],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00079400046,0.00028029093,0.0005373013,0.00018546252,0.00075787154,0.00003283967,0.00023587974,0.00014689313,0.0020067166],"category_scores_gemma":[0.000003748644,0.00027644515,0.00026570144,0.00008078564,0.00016561216,0.00009144359,0.00008486083,0.0004017717,0.000002029425],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076486627,0.0005501013,0.00022966563,0.00023866953,0.00025748048,0.000004753972,0.0022259254,0.0002933361,0.97757757,0.000045002696,0.0008447663,0.01008409],"study_design_scores_gemma":[0.011866621,0.0021951976,0.0026503063,0.00006048447,0.00012348438,0.00011937119,0.0023418455,0.00008296559,0.92119,0.00018951681,0.058768813,0.0004113961],"about_ca_topic_score_codex":0.00014937362,"about_ca_topic_score_gemma":0.00008969938,"teacher_disagreement_score":0.057924047,"about_ca_system_score_codex":0.00031067518,"about_ca_system_score_gemma":0.00040696925,"threshold_uncertainty_score":0.99996877},"labels":[],"label_agreement":null},{"id":"W4308026783","doi":"10.1136/jitc-2022-005780","title":"FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Université Laval; Juravinski Cancer Centre; Université du Québec à Montréal","funders":"National Center for Advancing Translational Sciences; Foundation Medicine; EMD Serono; Genentech; European Society for Medical Oncology; Shionogi; Natera; Seagen; Pfizer; Incyte; Jounce Therapeutics; Astellas Pharma; Eisai; Ono Pharmaceutical; Eli Lilly and Company; National Comprehensive Cancer Network; National Cancer Institute; Gilead Sciences; Calithera Biosciences; Celldex Therapeutics; Ipsen; Array BioPharma; Karyopharm Therapeutics; Exelixis; Sanofi; Memorial Sloan-Kettering Cancer Center; Dana-Farber/Harvard Cancer Center; Bristol-Myers Squibb; AstraZeneca; American Society of Clinical Oncology; GlaxoSmithKline; Amgen; Dana-Farber Cancer Institute","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Oncology; Tolerability; Renal cell carcinoma; Discontinuation; Combination therapy; Hazard ratio; Clinical endpoint; Progression-free survival; Adverse effect; Clinical trial; Cancer; Immunotherapy; Chemotherapy; Confidence interval","score_opus":0.024101134792033473,"score_gpt":0.3518191333851835,"score_spread":0.32771799859315004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308026783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.945512,0.048121214,0.00048295857,0.0011768513,0.0015273757,0.0026495766,0.00011716122,0.00002723467,0.00038564426],"genre_scores_gemma":[0.98481697,0.0029118496,0.0034219727,0.00095005444,0.0005491144,0.0037537378,0.000047043723,0.00013500602,0.003414275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975361,0.00013216483,0.0007713675,0.00038199124,0.0006668594,0.0005114764],"domain_scores_gemma":[0.9979675,0.00023548093,0.0008340382,0.0004285444,0.00040666942,0.00012779904],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000478919,0.00035349836,0.00078560726,0.00029285438,0.00056897453,0.00002702532,0.00024024586,0.00012889525,0.0012878003],"category_scores_gemma":[0.000013285889,0.00027738622,0.0007652726,0.000182433,0.00008410978,0.000138512,0.000031374704,0.0005265323,0.0000019003578],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2146422,0.0014843974,0.0018015901,0.0001255786,0.00062670547,0.00006069792,0.0010809214,0.0006995324,0.3618798,0.000015163806,0.0034085554,0.41417485],"study_design_scores_gemma":[0.067645386,0.04545395,0.012558811,0.00018879518,0.00022368127,0.0003276401,0.00071134296,0.00022123347,0.28917286,0.00036050598,0.5826867,0.0004490933],"about_ca_topic_score_codex":0.000050343526,"about_ca_topic_score_gemma":0.000006591273,"teacher_disagreement_score":0.5792782,"about_ca_system_score_codex":0.0027760987,"about_ca_system_score_gemma":0.0010949705,"threshold_uncertainty_score":0.9999678},"labels":[],"label_agreement":null},{"id":"W4310549999","doi":"10.1136/jitc-2022-005732","title":"Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"NIHR Imperial Biomedical Research Centre; European Society for Medical Oncology; Cancer Treatment and Research Trust; National Institute for Health and Care Research","keywords":"Medicine; Cancer; Immune system; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Immune checkpoint; Immunotherapy; Immunology; Oncology; Intensive care medicine; Internal medicine","score_opus":0.050141232009651975,"score_gpt":0.37359630881688566,"score_spread":0.3234550768072337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310549999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783204,0.017909609,0.000029848468,0.002614447,0.0002490108,0.00057318545,0.00029248156,0.000007593536,0.0000033817428],"genre_scores_gemma":[0.98254615,0.016180802,0.000103667975,0.00096439203,0.000050734798,0.00008287177,0.000020354722,0.000027168768,0.000023863005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984327,0.00007009187,0.000701198,0.00019308027,0.00040290266,0.00020001932],"domain_scores_gemma":[0.99864745,0.00010340039,0.00072353147,0.00019343932,0.00027829205,0.000053871827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003783529,0.00018174748,0.00091072026,0.0005489071,0.00016330027,0.000020246629,0.000055631863,0.000061370505,0.0001086135],"category_scores_gemma":[0.000042382533,0.00013437556,0.00021850438,0.0004946718,0.00009839642,0.00012431484,0.000023594617,0.0003078599,1.5975274e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009026335,0.00021163102,0.9151403,0.000102671125,0.002130058,0.0000016427636,0.0032920826,0.000069906964,0.016243996,0.0000028067464,0.000049689548,0.053728938],"study_design_scores_gemma":[0.011368755,0.002165831,0.96931916,0.00024998715,0.00033083782,0.000002095561,0.0002045708,0.000038501283,0.012576344,0.00005523128,0.0035576525,0.00013102476],"about_ca_topic_score_codex":0.037622336,"about_ca_topic_score_gemma":0.0042100847,"teacher_disagreement_score":0.054178927,"about_ca_system_score_codex":0.0005435306,"about_ca_system_score_gemma":0.0005635886,"threshold_uncertainty_score":0.96878624},"labels":[],"label_agreement":null},{"id":"W4310747261","doi":"10.1136/jitc-2022-005360","title":"Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Division of Chemical, Bioengineering, Environmental, and Transport Systems; York University; New York University; Leukemia and Lymphoma Society; AstraZeneca; National Institute of General Medical Sciences; Cancer Research Institute; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Chimeric antigen receptor; CD19; Medicine; T cell; Immunotherapy; Clinical trial; Leukemia; Oncology; Internal medicine; Antigen; Immunology; Cancer; Immune system","score_opus":0.020053779762780204,"score_gpt":0.31615903936231066,"score_spread":0.29610525959953043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310747261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95115995,0.04657307,0.00024552442,0.0006321145,0.00018514412,0.00070570706,0.0002094568,0.000011523874,0.00027751346],"genre_scores_gemma":[0.93907183,0.020687042,0.004105726,0.00044418455,0.000074851596,0.00015539968,0.000022199587,0.00010775303,0.035331033],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778444,0.00014688513,0.0006844961,0.00025663478,0.00084641896,0.00028111224],"domain_scores_gemma":[0.9983884,0.00032176203,0.00050949317,0.000257722,0.00038496943,0.00013761701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069969456,0.00020039271,0.00051339954,0.00026886156,0.00044611565,0.000018852204,0.00014294553,0.00007592208,0.0007548997],"category_scores_gemma":[0.00003808342,0.00017414037,0.00018619724,0.00018926381,0.00021860359,0.000088914734,0.00006921101,0.0003931541,8.884756e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056111697,0.00018607058,0.0027755185,0.00023072305,0.00039759706,0.000009523184,0.0041528447,0.008330196,0.9015805,0.000053386306,0.0057741837,0.020397728],"study_design_scores_gemma":[0.08264099,0.0154927755,0.025465155,0.0017755,0.00039075754,0.0010303404,0.0031105804,0.048229977,0.36775807,0.010587334,0.44206902,0.001449504],"about_ca_topic_score_codex":0.00004117941,"about_ca_topic_score_gemma":0.000008254236,"teacher_disagreement_score":0.5338225,"about_ca_system_score_codex":0.00070655916,"about_ca_system_score_gemma":0.0008747673,"threshold_uncertainty_score":0.8265622},"labels":[],"label_agreement":null},{"id":"W4315780755","doi":"10.1136/jitc-2022-006136","title":"Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Pharmacodynamics; Colorectal cancer; Response Evaluation Criteria in Solid Tumors; Cohort; Pancreatic cancer; Gastroenterology; Cancer; Phases of clinical research; Pharmacokinetics; Clinical trial; Immunotherapy","score_opus":0.03232948702170655,"score_gpt":0.3487401860462075,"score_spread":0.3164106990245009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315780755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99257356,0.005327567,0.00003930967,0.000043008677,0.00011894947,0.0018145236,0.000071887946,0.000007349657,0.000003862378],"genre_scores_gemma":[0.99857104,0.00070231175,0.00024638057,0.000019188583,0.000005794478,0.00026588683,0.00002276707,0.00004609927,0.000120543715],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99803424,0.00043452653,0.0008564376,0.00023042326,0.00011556384,0.00032879555],"domain_scores_gemma":[0.99840623,0.0002235705,0.0009501598,0.00017130298,0.00022717967,0.000021562531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075903896,0.00023478833,0.0008545719,0.00051537604,0.00010611126,0.000030140269,0.0002518916,0.000057427664,0.00008178996],"category_scores_gemma":[0.000029195784,0.0001765568,0.000037520127,0.00050179486,0.00018556704,0.00052872475,0.000028378598,0.0002228595,5.426902e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047214862,0.0037394774,0.06381855,0.00018492053,0.0012385508,0.000013066331,0.014022,0.00026952414,0.86553705,0.0000132821715,0.000011821315,0.00393691],"study_design_scores_gemma":[0.113285355,0.021334935,0.10660805,0.00096457225,0.00029146834,0.00006329171,0.010859051,0.0006019982,0.7454869,0.00006736198,0.0000932937,0.00034368763],"about_ca_topic_score_codex":0.0042107804,"about_ca_topic_score_gemma":0.0024978383,"teacher_disagreement_score":0.120050095,"about_ca_system_score_codex":0.00012959362,"about_ca_system_score_gemma":0.00035042377,"threshold_uncertainty_score":0.71997774},"labels":[],"label_agreement":null},{"id":"W4317500300","doi":"10.1136/jitc-2022-006397","title":"Next-generation ctDNA-driven clinical trials in precision immuno-oncology","year":2023,"lang":"en","type":"letter","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Precision oncology; Clinical Oncology; Medicine; Immunotherapy; Clinical trial; Oncology; Precision medicine; Targeted therapy; Cancer immunotherapy; Computational biology; Cancer; Internal medicine; Bioinformatics; Biology; Pathology","score_opus":0.18044064665614404,"score_gpt":0.465082961907514,"score_spread":0.28464231525136996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317500300","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30634928,0.17753719,0.0067395996,0.43032122,0.07012237,0.006026724,0.0025444904,0.000042203003,0.0003169133],"genre_scores_gemma":[0.004890398,0.6527373,0.0034076215,0.25170407,0.07749433,0.00081045507,0.00202484,0.0004977632,0.0064331866],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957073,0.0007752416,0.0024444656,0.0004254606,0.0002612852,0.00038629846],"domain_scores_gemma":[0.99620384,0.0010134456,0.0019485917,0.0004269119,0.00035657047,0.00005065563],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004714173,0.00031685364,0.0013312316,0.00023429557,0.00009613319,0.00008880392,0.00048429045,0.0014501702,0.00009057408],"category_scores_gemma":[0.0013088596,0.00028160223,0.0010902786,0.000112394635,0.00010081321,0.000008839624,0.000065794164,0.0009124524,0.0000033279894],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009367806,0.00005332038,0.00020842458,0.00003204476,0.00047026464,0.000011241352,0.00004186965,0.00034252257,0.16951223,0.0000022173967,0.7145608,0.11382827],"study_design_scores_gemma":[0.0036726678,0.001472225,0.00024291158,0.00015939372,0.00009608472,0.000016167653,0.00001756336,0.00017171755,0.008994056,0.00023133909,0.9846228,0.00030309483],"about_ca_topic_score_codex":0.00012616863,"about_ca_topic_score_gemma":0.00039329703,"teacher_disagreement_score":0.47520015,"about_ca_system_score_codex":0.00022256761,"about_ca_system_score_gemma":0.0012281301,"threshold_uncertainty_score":0.99996364},"labels":[],"label_agreement":null},{"id":"W4318773806","doi":"10.1136/jitc-2022-006127","title":"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital du Sacré-Cœur de Montréal","funders":"EMD Serono; Ipsen; Universiteit Gent; Astellas Pharma; Eisai; G1 Therapeutics; Sanofi; Apollomics; Agios Pharmaceuticals; University of Texas Southwestern Medical Center; BeiGene; GlaxoSmithKline; Tizona Therapeutics; Les Laboratories Pierre Fabre; Daiichi Sankyo Europe; National Cancer Institute; Servier; Calithera Biosciences; AstraZeneca; Novocure; MacroGenics; Celldex Therapeutics; Cilag; Puma Biotechnology; Regeneron Pharmaceuticals; Pfizer; Incyte; Grifols; F. Hoffmann-La Roche; Celgene; PTC Therapeutics; Genentech; Aeglea BioTherapeutics; Amgen; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Oncology; Internal medicine; Lung cancer; Metastatic melanoma; First line; Cancer; Immunotherapy","score_opus":0.041473298833537224,"score_gpt":0.33657208283311646,"score_spread":0.29509878399957923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318773806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838194,0.010585225,0.0009719791,0.0003979054,0.0015536811,0.0021513323,0.000421287,0.000035481542,0.0000636534],"genre_scores_gemma":[0.94322246,0.042916834,0.005400174,0.0009551566,0.0020335151,0.0010970993,0.00010143753,0.000311169,0.0039621266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789006,0.000023339993,0.0007757352,0.0003057832,0.00038862176,0.00061648194],"domain_scores_gemma":[0.9983826,0.00011534369,0.00071886665,0.0002323147,0.00042553415,0.00012532712],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042480507,0.0003401087,0.0006842556,0.00034086552,0.0005313795,0.000067340596,0.00015552256,0.000092294154,0.0002841538],"category_scores_gemma":[0.000018599536,0.00026308434,0.0002598192,0.00040614186,0.00011214414,0.00024062897,0.000024239378,0.00021553031,8.797103e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13579561,0.00084846106,0.52626354,0.005836526,0.005279087,0.000006705133,0.009907742,0.0096271075,0.010111478,0.00003380215,0.009888788,0.28640118],"study_design_scores_gemma":[0.19022073,0.008783668,0.51473624,0.0059095486,0.0019163351,0.000036795864,0.00102733,0.04016334,0.012335754,0.0003435608,0.22280636,0.0017203573],"about_ca_topic_score_codex":0.0005272491,"about_ca_topic_score_gemma":0.0006290249,"teacher_disagreement_score":0.28468084,"about_ca_system_score_codex":0.00064121775,"about_ca_system_score_gemma":0.0005659518,"threshold_uncertainty_score":0.9999821},"labels":[],"label_agreement":null},{"id":"W4318826747","doi":"10.1136/jitc-2022-005545","title":"Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec; University of Toronto; McGill University","funders":"Canadian Institutes of Health Research; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Canada Foundation for Innovation; Fonds de Recherche du Québec - Santé; Brain Tumor Funders' Collaborative","keywords":"Immunotherapy; Immune system; Tumor microenvironment; Mass cytometry; Immune checkpoint; Immunology; Cancer research; Medicine; Cancer immunotherapy; T cell; Cancer; Biology; Internal medicine; Phenotype","score_opus":0.02469995268454188,"score_gpt":0.31953550746252946,"score_spread":0.29483555477798756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318826747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777859,0.013289684,0.0054362565,0.0006497346,0.0013790515,0.000993508,0.00021251377,0.00004946905,0.00020390034],"genre_scores_gemma":[0.9810425,0.014416532,0.0016998022,0.00028054442,0.0001780643,0.000069435824,0.000022245993,0.000116728595,0.0021741474],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965603,0.00024870285,0.001675944,0.000275557,0.00072782417,0.0005117167],"domain_scores_gemma":[0.9961984,0.00046987092,0.0017608558,0.0006531488,0.00082269456,0.000094986004],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023523353,0.00036952028,0.0012662908,0.00068877434,0.00017644688,0.000023624152,0.0004491875,0.00023036989,0.0010142042],"category_scores_gemma":[0.000102676706,0.00030967884,0.0009775021,0.000848173,0.00026160106,0.00016615713,0.000032885877,0.0003466759,0.0000028447664],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09150323,0.0004769707,0.0005333484,0.00031709464,0.00097384705,0.000005079503,0.0011703934,0.000031552918,0.8571971,0.000022001523,0.0009732386,0.046796143],"study_design_scores_gemma":[0.016386444,0.0052102655,0.01830235,0.0011350156,0.00012397049,0.000043024786,0.0006115566,0.00005182652,0.9504879,0.0007774436,0.0065693213,0.0003008718],"about_ca_topic_score_codex":0.00034735317,"about_ca_topic_score_gemma":0.000023430306,"teacher_disagreement_score":0.09329081,"about_ca_system_score_codex":0.0001799945,"about_ca_system_score_gemma":0.00064135593,"threshold_uncertainty_score":0.9999355},"labels":[],"label_agreement":null},{"id":"W4319316777","doi":"10.1136/jitc-2022-005691","title":"Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Vetenskapsrådet; Karolinska Institutet; Cancerfonden; Barncancerfonden; Memorial Sloan-Kettering Cancer Center","keywords":"CD28; Mesothelin; Cancer research; T cell; Ovarian cancer; Flow cytometry; Tumor microenvironment; Chimeric antigen receptor; CD19; Immunotherapy; Cytotoxic T cell; Cancer; Biology; Immune system; Immunology; Medicine; In vitro; Antibody; Tumor cells; Internal medicine","score_opus":0.07222553027337288,"score_gpt":0.39572200909368005,"score_spread":0.3234964788203072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319316777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377775,0.002569244,0.0001379552,0.0020106432,0.00052669575,0.00078156346,0.0000739888,0.000016838414,0.00010532894],"genre_scores_gemma":[0.97452813,0.01846738,0.0003242875,0.00018668038,0.00030089726,0.0001493233,0.0000060300663,0.00007553053,0.0059617325],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998011,0.000107598564,0.00069013564,0.00019977045,0.0006064821,0.0003850491],"domain_scores_gemma":[0.99864733,0.00024569334,0.0003236683,0.00025772766,0.00044733853,0.000078210534],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010016043,0.00017793773,0.0006016576,0.00076230936,0.00008577728,0.000026494228,0.0002103679,0.0001297052,0.0015758567],"category_scores_gemma":[0.00005332337,0.00015017277,0.0002616877,0.00077512895,0.00011545477,0.00027860492,0.000019886287,0.0003622059,0.0000013139596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01327943,0.0001159697,0.0023116365,0.00015277007,0.00033236586,0.000008092171,0.0018285996,0.00087781687,0.95346165,0.00002816611,0.0005202325,0.027083253],"study_design_scores_gemma":[0.006698237,0.0006171984,0.01837935,0.00075217994,0.00003186726,0.000011444002,0.00044525947,0.0009036959,0.9645422,0.00046974912,0.0069965078,0.00015230125],"about_ca_topic_score_codex":0.0013564222,"about_ca_topic_score_gemma":0.000091207505,"teacher_disagreement_score":0.026930952,"about_ca_system_score_codex":0.00032906543,"about_ca_system_score_gemma":0.000978523,"threshold_uncertainty_score":0.99933684},"labels":[],"label_agreement":null},{"id":"W4320914885","doi":"10.1136/jitc-2022-005854","title":"Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review","year":2023,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Meta-analysis; Circulating tumor DNA; Subgroup analysis; Clinical trial; Cancer","score_opus":0.024404445784671096,"score_gpt":0.3410580362663591,"score_spread":0.316653590481688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320914885","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0064172246,0.991001,0.000004608566,0.00007443066,0.00016075715,0.0022370098,0.00009574398,0.0000042791476,0.0000049267146],"genre_scores_gemma":[0.00036184766,0.9981804,0.000043022897,0.00010832117,0.00014297653,0.0009087629,0.000035993486,0.00010950913,0.00010918304],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9976044,0.00010233376,0.0015314177,0.00029440047,0.00015990192,0.00030754428],"domain_scores_gemma":[0.99787307,0.00011366064,0.0015563151,0.00029405273,0.00011312736,0.000049757018],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007900576,0.00040215504,0.0027609873,0.000249916,0.00004623536,0.00003977457,0.00022141504,0.00014278777,0.0000056243716],"category_scores_gemma":[0.00019371214,0.00028082472,0.00041670084,0.00025455328,0.00005221671,0.00000525683,0.000045004093,0.00023564977,3.6361195e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015983057,0.00011477494,0.00039094427,0.93821466,0.0016149888,0.000051933148,0.0001551635,0.000022062155,0.003407913,0.000004788203,0.000060258644,0.05580267],"study_design_scores_gemma":[0.0020593675,0.00068228994,0.0001286597,0.97156477,0.00083036826,0.000233166,0.00007935447,0.0000072343096,0.0011201187,0.000021865666,0.02263075,0.00064208294],"about_ca_topic_score_codex":0.00017830364,"about_ca_topic_score_gemma":0.0008174374,"teacher_disagreement_score":0.055160586,"about_ca_system_score_codex":0.00017833461,"about_ca_system_score_gemma":0.00042760055,"threshold_uncertainty_score":0.9999644},"labels":[],"label_agreement":null},{"id":"W4327560927","doi":"10.1136/jitc-2022-005301","title":"First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Internal medicine; FOXP3; Pharmacodynamics; Tolerability; Adverse effect; Granzyme; Gastroenterology; Pharmacokinetics; Immunology; Pharmacology; CD8; Oncology; Immunotherapy; Immune system; Cancer","score_opus":0.012898636780171113,"score_gpt":0.3175022932758785,"score_spread":0.30460365649570736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327560927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954862,0.0020350881,0.000013359723,0.000105010855,0.00041106285,0.0018620229,0.00004541963,0.000028239041,0.000013617571],"genre_scores_gemma":[0.9973326,0.0004548757,0.000026256006,0.000047646743,0.000016368995,0.00023956524,0.000015549069,0.00008197156,0.0017852169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975213,0.0004276067,0.0009911531,0.00028988675,0.00018466338,0.0005854263],"domain_scores_gemma":[0.9980073,0.00023120624,0.00090169406,0.00045797724,0.00038366526,0.000018179304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000532248,0.00036032428,0.00092048355,0.00045175868,0.0005474468,0.000024790923,0.00058882503,0.00013657799,0.00020849564],"category_scores_gemma":[0.000053355023,0.00020357936,0.00013682613,0.0011812501,0.00030896763,0.00021556426,0.000034972498,0.00067944615,0.0000016127434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31067285,0.00693133,0.34712797,0.00015592953,0.0024612122,0.000014685466,0.018143501,0.0027022618,0.29310018,0.000015232316,0.00025153655,0.01842331],"study_design_scores_gemma":[0.14737782,0.02395586,0.7515235,0.0012148287,0.00010309875,0.000040555155,0.0034633724,0.000024736051,0.06649313,0.00002289621,0.0052449317,0.0005352989],"about_ca_topic_score_codex":0.00044967807,"about_ca_topic_score_gemma":0.0017547674,"teacher_disagreement_score":0.4043955,"about_ca_system_score_codex":0.00017881018,"about_ca_system_score_gemma":0.00046365854,"threshold_uncertainty_score":0.83017254},"labels":[],"label_agreement":null},{"id":"W4360613262","doi":"10.1136/jitc-2022-006408","title":"Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; McMaster University; University of Toronto; Children's Hospital of Eastern Ontario; University of Ottawa","funders":"Natural Sciences and Engineering Research Council of Canada; Lundbeckfonden; Canadian Cancer Society; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society; Terry Fox Research Institute; University of Ottawa; Novo Nordisk Fonden; Kræftens Bekæmpelse","keywords":"Oncolytic virus; Translation (biology); Transgene; Adaptation (eye); Messenger RNA; Cancer research; Biology; Medicine; Computational biology; Bioinformatics; Virology; Gene; Genetics; Neuroscience; Tumor cells","score_opus":0.05014852488167118,"score_gpt":0.38372096737177036,"score_spread":0.3335724424900992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360613262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979554,0.016532598,0.0025118166,0.00064597285,0.00022279324,0.00043896242,0.000060037943,0.0000038453113,0.000029964422],"genre_scores_gemma":[0.97866,0.020562468,0.00025329556,0.000052874726,0.00017960118,0.000035543813,0.000015813652,0.000033204335,0.00020722089],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883467,0.00008310903,0.00045628657,0.000120493314,0.00031570985,0.00018975796],"domain_scores_gemma":[0.9990683,0.00008448593,0.00031179984,0.00021783663,0.00028865627,0.00002892721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066385046,0.000106892796,0.00021984552,0.000100077275,0.0000805529,0.000007825415,0.00025584278,0.00008095681,0.00006530096],"category_scores_gemma":[0.00002110916,0.000079235244,0.00027308404,0.00024721125,0.00013306852,0.0000075631247,0.000005983711,0.00009513023,4.797405e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006850638,0.000050520957,0.00014743756,0.000038164788,0.0002889081,1.3888263e-7,0.0004904908,0.0066883736,0.7772608,0.0000069738726,0.00015549795,0.20802206],"study_design_scores_gemma":[0.0038763662,0.0028778426,0.0038298315,0.00007684075,0.000042146614,0.0000026696644,0.00013449421,0.0010918071,0.9739583,0.00012086955,0.013888606,0.0001002379],"about_ca_topic_score_codex":0.000049445214,"about_ca_topic_score_gemma":0.00014205347,"teacher_disagreement_score":0.20792182,"about_ca_system_score_codex":0.000023357106,"about_ca_system_score_gemma":0.00032877908,"threshold_uncertainty_score":0.32311195},"labels":[],"label_agreement":null},{"id":"W4362549334","doi":"10.1136/jitc-2022-006170","title":"Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Ottawa; Queen's University","funders":"Canadian Institutes of Health Research; Queen's University; Institute of Cancer Research; Canada Foundation for Innovation","keywords":"PTEN; Cancer research; Tumor microenvironment; Ovarian cancer; Medicine; Immune system; Biology; Cancer; Immunology; Internal medicine; PI3K/AKT/mTOR pathway; Apoptosis","score_opus":0.01799954787856017,"score_gpt":0.28620840698745886,"score_spread":0.2682088591088987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362549334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788947,0.01510435,0.00020048964,0.0018605932,0.0027550189,0.000929879,0.00019762578,0.000048972153,0.000008336803],"genre_scores_gemma":[0.988566,0.0038333295,0.000034457764,0.00054592843,0.00010922215,0.00048152733,0.000034214518,0.00009812847,0.0062972107],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99709517,0.00065086136,0.0009802193,0.00034705532,0.00015347099,0.00077321724],"domain_scores_gemma":[0.9983948,0.00037958287,0.0007385846,0.00028416197,0.00016233086,0.000040569274],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009433838,0.00037296175,0.0006900267,0.00038155727,0.00035266203,0.00004716158,0.0004137905,0.0002487708,0.0017534557],"category_scores_gemma":[0.00006246361,0.00032754132,0.00027711326,0.00038304893,0.00008989506,0.00017458425,0.00006768703,0.0005186465,0.000025471805],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021942299,0.00026745495,0.0013376344,0.0000307274,0.000642493,0.0000034080722,0.0021769893,0.00056155113,0.9532504,0.0000094044035,0.0005907881,0.019186813],"study_design_scores_gemma":[0.0067554135,0.0007155837,0.1756648,0.00048140684,0.00004910824,0.0000075093017,0.0003716272,0.00002161061,0.80343765,0.000036210193,0.012116201,0.00034287],"about_ca_topic_score_codex":0.0034932324,"about_ca_topic_score_gemma":0.0005554675,"teacher_disagreement_score":0.17432716,"about_ca_system_score_codex":0.0011547751,"about_ca_system_score_gemma":0.00044873942,"threshold_uncertainty_score":0.9999177},"labels":[],"label_agreement":null},{"id":"W4366339464","doi":"10.1136/jitc-2022-005839","title":"Ectopic expression of cGAS in <i>Salmonella typhimurium</i> enhances STING-mediated IFN-β response in human macrophages and dendritic cells","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Cancer Center Amsterdam; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Eidgenössische Technische Hochschule Zürich; Albert-Ludwigs-Universität Freiburg; Université de Fribourg; University of Oxford; Imperial College London","keywords":"Sting; Stimulator of interferon genes; Secretion; Immune system; Interferon; Ectopic expression; Cytotoxic T cell; Gene knockdown; Downregulation and upregulation; Microbiology; Innate immune system; In vitro; Cytokine; Biology; Cell biology; Cytotoxicity; Chemistry; Cell culture; Immunology; Gene; Biochemistry","score_opus":0.0141963607539722,"score_gpt":0.3486339116966563,"score_spread":0.3344375509426841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366339464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877961,0.011775893,0.000010429768,0.00006991165,0.00010248377,0.00018522552,0.000043531003,0.0000023027123,0.000014094155],"genre_scores_gemma":[0.9876907,0.011698081,0.000060560833,0.000021069814,0.000050078408,0.000041770898,0.000008945511,0.000016227845,0.00041259997],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991651,0.00008403221,0.0002814064,0.00013690075,0.0001264844,0.00020604744],"domain_scores_gemma":[0.9996001,0.00006841907,0.00013123445,0.000103057784,0.000060971353,0.000036208214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033684462,0.00009179438,0.00018555223,0.00015697745,0.000044249555,0.000011627901,0.00010590439,0.00006687651,0.000022868046],"category_scores_gemma":[0.000036989797,0.000078974,0.00006014541,0.00014239534,0.00006701063,0.000006702681,0.0000249013,0.00008638529,3.1229771e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032867782,0.000059396985,0.006294059,0.000049566832,0.00003798985,0.0000103121165,0.00017521014,0.00007537941,0.9878617,5.556487e-7,0.0001961895,0.0019528519],"study_design_scores_gemma":[0.003001146,0.00071269396,0.028257076,0.00017878345,0.000003726854,0.0000036162269,0.00007827745,0.00000859174,0.96618783,0.00009844425,0.0013986381,0.00007116784],"about_ca_topic_score_codex":0.00021561669,"about_ca_topic_score_gemma":0.00031400198,"teacher_disagreement_score":0.021963015,"about_ca_system_score_codex":0.000032467302,"about_ca_system_score_gemma":0.00010167435,"threshold_uncertainty_score":0.3220466},"labels":[],"label_agreement":null},{"id":"W4378473295","doi":"10.1136/jitc-2022-006595","title":"CD71<sup>+</sup> erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; University of Alberta; Alberta Cancer Foundation","keywords":"Medicine; Avelumab; Immunotherapy; Melanoma; Immune system; Cancer; Effector; T cell; Immunology; Internal medicine; Cancer research; Oncology; Pembrolizumab","score_opus":0.009519084047119179,"score_gpt":0.27464340871007614,"score_spread":0.265124324662957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378473295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963635,0.0010562413,0.000057608628,0.00025139708,0.0008320827,0.00096563355,0.0003532513,0.00006338582,0.000056857727],"genre_scores_gemma":[0.99060464,0.0036743633,0.000110122026,0.0006964609,0.00018203034,0.00017264383,0.0001306673,0.00011999193,0.0043090694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810946,0.00012294258,0.00065733085,0.00027671902,0.0003721511,0.000461412],"domain_scores_gemma":[0.99862707,0.0002707964,0.0004286475,0.0002583525,0.00030361628,0.00011151894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035087563,0.00031103395,0.0008719967,0.0004041577,0.00021245412,0.000029694509,0.00012428538,0.00017347127,0.00038001803],"category_scores_gemma":[0.000030357633,0.00022568584,0.00025697768,0.00039833845,0.00014445624,0.00016498331,0.00001788761,0.00043534883,0.000012351309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02328463,0.0017894114,0.6422501,0.00029704333,0.0019703475,0.000016512608,0.0023768912,0.0029917741,0.30433688,0.0000023518521,0.011306278,0.009377749],"study_design_scores_gemma":[0.038581807,0.0065088524,0.93127316,0.0005023612,0.000144858,0.000010871089,0.00042612126,0.000766382,0.012268974,0.0000367703,0.009081423,0.00039839125],"about_ca_topic_score_codex":0.00012794777,"about_ca_topic_score_gemma":0.000040358434,"teacher_disagreement_score":0.2920679,"about_ca_system_score_codex":0.00018762551,"about_ca_system_score_gemma":0.00019656468,"threshold_uncertainty_score":0.92032015},"labels":[],"label_agreement":null},{"id":"W4379645119","doi":"10.1136/jitc-2023-006802","title":"Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"Medizinischen Fakultät, Eberhard Karls Universität Tübingen; Klaus Tschira Stiftung; Eberhard Karls Universität Tübingen; Merck Sharp and Dohme; Bristol-Myers Squibb","keywords":"Medicine; Melanoma; Biomarker; Oncology; Myeloid-derived Suppressor Cell; Immune checkpoint; Immune system; Flow cytometry; Myeloid; Internal medicine; Cancer; Immunotherapy; Cohort; Immunology; Cancer research; Suppressor; Biology","score_opus":0.01955512069351003,"score_gpt":0.2874628456149711,"score_spread":0.2679077249214611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379645119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97714776,0.02051405,0.00004734107,0.00024261308,0.0012528102,0.0005214143,0.00019497426,0.000025051864,0.000053981687],"genre_scores_gemma":[0.9910722,0.006109596,0.00029268098,0.0000911874,0.000025972608,0.00013769457,0.000019595856,0.000065459695,0.0021856278],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978924,0.00017333729,0.0010384176,0.0002553506,0.000114992836,0.0005255322],"domain_scores_gemma":[0.99848026,0.000180109,0.0007647514,0.00030402798,0.00023753096,0.00003334826],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069135294,0.00025715458,0.0006513937,0.000517927,0.00015350884,0.000020942009,0.0002745086,0.00018062806,0.0018472805],"category_scores_gemma":[0.000044184104,0.0002342816,0.00037326556,0.0004459591,0.00021650837,0.00021382484,0.000048466292,0.00033330187,0.000021643646],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027125904,0.00020602842,0.0006904461,0.00020424875,0.0012553424,0.000012050677,0.002381406,0.00007964456,0.9892871,0.00000872395,0.0007433248,0.002419127],"study_design_scores_gemma":[0.010100212,0.00033141515,0.019347815,0.0004391561,0.00014433789,0.000048034162,0.00033094,0.000010369458,0.9658812,0.00032644733,0.0028092237,0.00023080337],"about_ca_topic_score_codex":0.0006936369,"about_ca_topic_score_gemma":0.000039425482,"teacher_disagreement_score":0.02340582,"about_ca_system_score_codex":0.00011418426,"about_ca_system_score_gemma":0.00028574973,"threshold_uncertainty_score":0.99906516},"labels":[],"label_agreement":null},{"id":"W4380077943","doi":"10.1136/jitc-2022-006624","title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Society for Immunotherapy of Cancer","keywords":"Medicine; Guideline; Immunotherapy; Cancer; Cervical cancer; Endometrial cancer; Clinical Practice; Ovarian cancer; Intensive care medicine; Oncology; Multidisciplinary approach; Clinical trial; Quality of life (healthcare); Internal medicine; Biomarker; Disease; Gynecology; Family medicine; Nursing; Pathology","score_opus":0.07599925134873417,"score_gpt":0.46799917507606126,"score_spread":0.39199992372732706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380077943","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4304497,0.48321685,0.0085285455,0.0474985,0.012435916,0.014303193,0.0032818187,0.00014848968,0.00013698297],"genre_scores_gemma":[0.027705105,0.93780184,0.011533839,0.009325568,0.0027771532,0.005120858,0.0000826494,0.00034611364,0.0053068916],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945695,0.0001384434,0.003137178,0.0005634669,0.00077249133,0.00081895874],"domain_scores_gemma":[0.9893841,0.0042582857,0.0031860208,0.00086505234,0.0021960882,0.000110415145],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003120759,0.0006408197,0.0018857978,0.00025792836,0.00050909224,0.000044146916,0.00062040676,0.00044627528,0.00073966244],"category_scores_gemma":[0.00019508184,0.00040588024,0.00426603,0.00069820136,0.0005617337,0.00020123365,0.000016812392,0.0003450679,0.0000010414554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.097348236,0.0017912702,0.0019150482,0.00027352935,0.017392691,0.0000013305754,0.002065206,0.0007629977,0.14486893,0.00008831831,0.052172635,0.68131983],"study_design_scores_gemma":[0.039884046,0.014645718,0.007956631,0.00052074983,0.0010070407,0.000012559318,0.0010873841,0.0010803898,0.0488682,0.0002966058,0.88421804,0.00042261335],"about_ca_topic_score_codex":0.0015043081,"about_ca_topic_score_gemma":0.00022332754,"teacher_disagreement_score":0.83204544,"about_ca_system_score_codex":0.00087732746,"about_ca_system_score_gemma":0.0017249963,"threshold_uncertainty_score":0.9998393},"labels":[],"label_agreement":null},{"id":"W4381548535","doi":"10.1136/jitc-2022-006589","title":"G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Astellas Pharma; Daiichi-Sankyo; Genentech; Coherus Biosciences; Servier; Moderna; Revolution Medicines; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Foghorn Therapeutics; Mallinckrodt Pharmaceuticals; Boston Scientific Corporation; Pharmavite; Ludwig Center at Harvard; GlaxoSmithKline; Pfizer; Break Through Cancer; National Institute of Allergy and Infectious Diseases; Celgene","keywords":"FOLFIRINOX; Pegfilgrastim; Medicine; Filgrastim; Gemcitabine; Immunology; Pancreatic cancer; Neutropenia; Granulocyte colony-stimulating factor; Chemotherapy; Cancer research; Internal medicine; Cancer; Irinotecan","score_opus":0.02184843116684437,"score_gpt":0.32327058491701505,"score_spread":0.3014221537501707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381548535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9548092,0.04088762,0.00003172879,0.00044295276,0.0030789233,0.00061636616,0.00004109335,0.000021343141,0.00007080327],"genre_scores_gemma":[0.98993844,0.00686651,0.00007365008,0.00009842075,0.00006225151,0.00010232201,0.000009048398,0.000056631437,0.002792731],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99805284,0.00015217463,0.000989099,0.0002537236,0.000090935944,0.00046121338],"domain_scores_gemma":[0.99879664,0.00019368621,0.00043258976,0.00031674965,0.00023639642,0.000023918412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008269027,0.0002277298,0.0007087917,0.00046454318,0.00016276486,0.000018043173,0.0004611068,0.00025093879,0.00022051092],"category_scores_gemma":[0.000046950314,0.0001965096,0.00019347266,0.00036554414,0.000120612676,0.00014989394,0.00008807012,0.00041733778,0.00001644284],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023696197,0.000049253707,0.0020279498,0.00015105378,0.00021733883,0.0000021801973,0.001895665,0.00021378239,0.9767694,0.0000469691,0.0021004328,0.014156342],"study_design_scores_gemma":[0.0055673,0.00065046863,0.030374072,0.001177989,0.000039004182,0.000054729822,0.00044268812,0.0000055705677,0.9459298,0.000095502066,0.015427249,0.00023559187],"about_ca_topic_score_codex":0.00049733673,"about_ca_topic_score_gemma":0.00011767565,"teacher_disagreement_score":0.035129268,"about_ca_system_score_codex":0.00015308098,"about_ca_system_score_gemma":0.00017277592,"threshold_uncertainty_score":0.8013429},"labels":[],"label_agreement":null},{"id":"W4383561245","doi":"10.1136/jitc-2023-006863","title":"BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Ovarian Cancer Research Alliance; McMaster University; Roswell Park Cancer Institute","keywords":"Cancer research; T cell; Medicine; Tumor microenvironment; Ovarian cancer; Adoptive cell transfer; Chimeric antigen receptor; Cytotoxic T cell; Immunology; Cancer; Biology; Immune system; Internal medicine; In vitro","score_opus":0.026223649595796015,"score_gpt":0.3397886489431468,"score_spread":0.31356499934735077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383561245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9451866,0.032524873,0.005814755,0.008087504,0.003630067,0.0031844648,0.0011133861,0.00014168886,0.00031662293],"genre_scores_gemma":[0.76722014,0.11023648,0.00034984917,0.0037765915,0.0021235214,0.0011336571,0.00007542203,0.00043732362,0.114646986],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974862,0.00010543612,0.00070384616,0.0003056727,0.00076090964,0.0006379526],"domain_scores_gemma":[0.99848497,0.00017907731,0.00029705727,0.0002827613,0.0005522041,0.00020395436],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00086469646,0.00029336312,0.00071620697,0.00034923264,0.00021104126,0.0000706472,0.00025335737,0.0002021216,0.0028046658],"category_scores_gemma":[0.00000844352,0.00024163605,0.00054963457,0.0005116344,0.00014535768,0.00019426663,0.000009395839,0.0005254922,0.000008128845],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007981193,0.000090064794,0.00038323767,0.00012657698,0.0011204556,0.0000065824133,0.0007722836,0.00009999679,0.80136955,0.000008695153,0.013741758,0.17429964],"study_design_scores_gemma":[0.029105632,0.0023546226,0.004280762,0.00056915934,0.00026578858,0.0000364151,0.00045593467,0.0024565319,0.32869834,0.0001471452,0.6311827,0.00044701074],"about_ca_topic_score_codex":0.0005300586,"about_ca_topic_score_gemma":0.00006322333,"teacher_disagreement_score":0.61744094,"about_ca_system_score_codex":0.00041595905,"about_ca_system_score_gemma":0.00060680445,"threshold_uncertainty_score":0.9981069},"labels":[],"label_agreement":null},{"id":"W4385215055","doi":"10.1136/jitc-2023-006994","title":"Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Royal College of Physicians and Surgeons of Canada; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Canadian Institutes of Health Research; V Foundation for Cancer Research","keywords":"Blockade; Medicine; PD-L1; Chemotherapy; Oncology; Cohort; Internal medicine; First line; Lung; Pharmacology; Immunotherapy; Cancer; Receptor","score_opus":0.01725263915675259,"score_gpt":0.3307501556499867,"score_spread":0.31349751649323415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385215055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742334,0.01658337,0.0003954474,0.002108959,0.0006203112,0.0057569616,0.000117377145,0.000098785444,0.000085407],"genre_scores_gemma":[0.9790704,0.017156715,0.00068674417,0.0005122405,0.00040537692,0.00066846696,0.000042517077,0.00024578127,0.001211762],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99506646,0.00016231298,0.0019626392,0.0007348641,0.0011326021,0.00094114087],"domain_scores_gemma":[0.99645877,0.00046438904,0.0013982073,0.00081544125,0.0006596536,0.00020356133],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012023473,0.0007583399,0.0021478857,0.0009813736,0.00029162088,0.000056597684,0.00059120177,0.0002592397,0.00040434216],"category_scores_gemma":[0.000037796104,0.0006062912,0.00074204186,0.0017891931,0.0003676668,0.00026033647,0.00003428733,0.0006919684,0.0000021870003],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38974598,0.0036761474,0.3690831,0.0004942713,0.010729513,0.00013166547,0.017364124,0.008114342,0.15003355,0.000007759334,0.001165652,0.04945389],"study_design_scores_gemma":[0.12147393,0.007669477,0.8118827,0.0020119643,0.00046578606,0.00013064366,0.00205688,0.001918308,0.04575085,0.00004748585,0.0058118366,0.00078013685],"about_ca_topic_score_codex":0.0010048957,"about_ca_topic_score_gemma":0.00056738564,"teacher_disagreement_score":0.4427996,"about_ca_system_score_codex":0.0010475,"about_ca_system_score_gemma":0.00088468415,"threshold_uncertainty_score":0.99963886},"labels":[],"label_agreement":null},{"id":"W4385532450","doi":"10.1136/jitc-2022-006500","title":"Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review","year":2023,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"McMaster University","keywords":"Medicine; Adverse effect; Pembrolizumab; Nivolumab; Internal medicine; Endocrine system; Cancer; Immunotherapy","score_opus":0.023318942090214626,"score_gpt":0.34530797997758805,"score_spread":0.32198903788737343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385532450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005233836,0.98543227,0.0000051445413,0.00022565282,0.002226095,0.011350867,0.00016288484,0.000056929475,0.000016784918],"genre_scores_gemma":[0.00005272234,0.9937165,0.000043326912,0.00011053553,0.00033914193,0.0030236454,0.0001222798,0.00040305915,0.0021888057],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9910677,0.00038560256,0.006013996,0.00060409924,0.0010826773,0.0008458908],"domain_scores_gemma":[0.99174887,0.00024807762,0.0062924125,0.00093354133,0.00063460146,0.00014249426],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002538908,0.001070482,0.007227145,0.0008812201,0.00018988439,0.00001995811,0.0006476959,0.0005534446,0.0005484314],"category_scores_gemma":[0.00015101398,0.00070619077,0.0033326203,0.0017077301,0.00014694949,0.00026854337,0.000057027544,0.0013378125,0.000013225096],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017035431,0.00024118251,0.00022583996,0.8135688,0.009405874,0.000010457061,0.00018452604,0.0000063431107,0.00005632281,8.6843124e-7,0.00016295316,0.17443334],"study_design_scores_gemma":[0.010769306,0.0011057368,0.00095360324,0.90162665,0.005221219,0.000062959705,0.000027976555,0.0000027110725,0.000025673835,0.0000070852834,0.07948599,0.00071110384],"about_ca_topic_score_codex":0.00053076586,"about_ca_topic_score_gemma":0.00011902416,"teacher_disagreement_score":0.17372222,"about_ca_system_score_codex":0.004300883,"about_ca_system_score_gemma":0.0030674075,"threshold_uncertainty_score":0.9995389},"labels":[],"label_agreement":null},{"id":"W4386295527","doi":"10.1136/jitc-2023-006770","title":"Location of CD39<sup>+</sup> T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EPSRC Centre for Doctoral Training in Medical Imaging; Engineering and Physical Sciences Research Council; Institute of Genetics; Cancer Research UK; GlaxoSmithKline","keywords":"Flow cytometry; Tumor microenvironment; CD8; Cancer research; Lung cancer; Multiplex; Cell; Immunofluorescence; Biology; Stromal cell; Pathology; T cell; Medicine; Immunology; Antigen; Immune system; Bioinformatics; Tumor cells; Antibody","score_opus":0.012809677577280291,"score_gpt":0.2850960522620882,"score_spread":0.2722863746848079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386295527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98780996,0.005431896,0.0013273513,0.00020525746,0.004572506,0.0005130635,0.000032144075,0.000026805774,0.00008101298],"genre_scores_gemma":[0.9819612,0.0017535766,0.00004290631,0.00006974071,0.000075056276,0.0001335218,0.000061008326,0.000039849423,0.01586313],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998393,0.000104781975,0.00092958024,0.00018573011,0.00008542801,0.00030146143],"domain_scores_gemma":[0.99856293,0.000121654506,0.00074663246,0.00019450847,0.0003552355,0.000019024512],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029760972,0.00020719953,0.00047107326,0.00045488967,0.00017402202,0.000017583503,0.00021688126,0.0001913169,0.0009403993],"category_scores_gemma":[0.000025037625,0.00017708675,0.00024257453,0.00038475118,0.00007419604,0.00018198339,0.000020690604,0.00039946495,0.000011036682],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017545923,0.00036894603,0.14397195,0.00033896414,0.00046208515,6.697106e-7,0.0045179254,0.033800792,0.80656433,0.000024761002,0.0062531526,0.0019418317],"study_design_scores_gemma":[0.0137370955,0.0007969554,0.3026124,0.001014371,0.00023744236,0.000013708132,0.0025655439,0.0108629735,0.66061175,0.00009534098,0.006914937,0.0005374746],"about_ca_topic_score_codex":0.0012209063,"about_ca_topic_score_gemma":0.00016709749,"teacher_disagreement_score":0.15864044,"about_ca_system_score_codex":0.00018233231,"about_ca_system_score_gemma":0.00024468452,"threshold_uncertainty_score":0.9999729},"labels":[],"label_agreement":null},{"id":"W4386496099","doi":"10.1136/jitc-2023-007277","title":"Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; T cell; Cancer research; Immunology; Immune system","score_opus":0.06099437135282873,"score_gpt":0.3805189673241266,"score_spread":0.3195245959712979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386496099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866644,0.009342513,0.0005659674,0.00059606344,0.0013100217,0.00099722,0.000044543947,0.000053391093,0.0004258777],"genre_scores_gemma":[0.830801,0.07260696,0.009760436,0.0012741169,0.003546351,0.00029341178,0.000034880213,0.00055230956,0.081130505],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99762464,0.00006846612,0.00067564717,0.00026022582,0.00070169487,0.00066932413],"domain_scores_gemma":[0.9982863,0.00021710093,0.0004325437,0.00027050223,0.00064916763,0.00014436833],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010700105,0.0002579722,0.0006006729,0.00040407566,0.00029576963,0.00006322653,0.00026294368,0.00014164622,0.0026319732],"category_scores_gemma":[0.000026623416,0.00021456245,0.00048990315,0.0006071365,0.00015376405,0.00015062034,0.000038484843,0.00041673705,0.000013446961],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040744473,0.00008215935,0.0013705639,0.00020844875,0.00051143114,0.000021784146,0.0013013756,0.0019255605,0.97948486,0.000007335046,0.002991818,0.008020217],"study_design_scores_gemma":[0.008902804,0.0005673803,0.00042074337,0.00029052785,0.00008681051,0.00004234482,0.00075321243,0.0010596081,0.91835546,0.00022381119,0.0690609,0.00023641597],"about_ca_topic_score_codex":0.00023047913,"about_ca_topic_score_gemma":0.000009222812,"teacher_disagreement_score":0.15586337,"about_ca_system_score_codex":0.0003880445,"about_ca_system_score_gemma":0.0006116625,"threshold_uncertainty_score":0.99827975},"labels":[],"label_agreement":null},{"id":"W4387784546","doi":"10.1136/jitc-2023-007354","title":"Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Decipher Biosciences (Canada)","funders":"Boehringer Ingelheim Fonds","keywords":"Prostate cancer; Transcriptome; Medicine; Oncology; Internal medicine; Cancer; Cancer research; Biology; Gene; Gene expression","score_opus":0.04261554050152196,"score_gpt":0.3952922527049947,"score_spread":0.35267671220347274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387784546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611273,0.03199116,0.00004705875,0.00474301,0.0004608439,0.0013779913,0.00018399967,0.000017452854,0.000051190756],"genre_scores_gemma":[0.94861287,0.047974046,0.00013503047,0.00028038435,0.00026691367,0.00023395008,0.000008981294,0.000059636128,0.0024281717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99805725,0.00005987064,0.0006888569,0.00017425184,0.0006369942,0.0003827934],"domain_scores_gemma":[0.99846935,0.00015602227,0.00040026446,0.0002847485,0.000587496,0.0001020907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006916612,0.00018381239,0.00062838587,0.00037527859,0.00013822572,0.000017790553,0.00025766724,0.000047730173,0.00024174912],"category_scores_gemma":[0.000027858656,0.000103359474,0.00048533987,0.00094740203,0.00018783768,0.00008599944,0.000012411195,0.00021948494,8.058741e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018926285,0.000246148,0.02421968,0.00025074565,0.0025431174,0.0000077675795,0.006577862,0.0008385781,0.7557225,0.000010664391,0.0027939233,0.18786268],"study_design_scores_gemma":[0.025360081,0.00398656,0.1956867,0.0017316069,0.00038461603,0.000024309178,0.0014252167,0.00037565938,0.71725506,0.00021270914,0.053303696,0.00025378773],"about_ca_topic_score_codex":0.00037397564,"about_ca_topic_score_gemma":0.000028140154,"teacher_disagreement_score":0.1876089,"about_ca_system_score_codex":0.00015205365,"about_ca_system_score_gemma":0.0006502036,"threshold_uncertainty_score":0.42148772},"labels":[],"label_agreement":null},{"id":"W4388019704","doi":"10.1136/jitc-2023-007047","title":"Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Concordance; Internal medicine; Lung cancer; Adjuvant; Immunohistochemistry; Oncology; PD-L1; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.05075007968482245,"score_gpt":0.45012553697261176,"score_spread":0.39937545728778934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388019704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9236028,0.068698026,0.0003562055,0.00089974614,0.0018572276,0.0037601215,0.0007550351,0.000013727767,0.000057064222],"genre_scores_gemma":[0.9368282,0.060986206,0.00045438646,0.00013804548,0.0006656367,0.00032988377,0.00009586848,0.00006994825,0.00043182957],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99511206,0.0001975359,0.003484271,0.00036721752,0.00042921756,0.00040967096],"domain_scores_gemma":[0.99269086,0.0036231817,0.0027054593,0.00049361,0.00039673393,0.0000901444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003892299,0.00033960192,0.0024933543,0.00017476869,0.00014193488,0.000024221923,0.00039051467,0.0002975878,0.00009727552],"category_scores_gemma":[0.00037096566,0.00023178302,0.0013392417,0.00033847714,0.0004998316,0.00007052506,0.000035939964,0.00053328363,1.4037998e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74944437,0.0007592718,0.0009981244,0.00018900674,0.0015676584,0.0000017571481,0.0023365763,0.000035485304,0.19997251,0.0000018046177,0.004374261,0.040319156],"study_design_scores_gemma":[0.90734214,0.0020872308,0.004311617,0.0013820312,0.0007185215,0.0000041741373,0.000566922,0.0020513071,0.07642165,0.000055085613,0.004815993,0.0002433382],"about_ca_topic_score_codex":0.002139684,"about_ca_topic_score_gemma":0.000087470326,"teacher_disagreement_score":0.15789776,"about_ca_system_score_codex":0.00022014703,"about_ca_system_score_gemma":0.00089471915,"threshold_uncertainty_score":0.94518375},"labels":[],"label_agreement":null},{"id":"W4389130660","doi":"10.1136/jitc-2023-007353","title":"Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Rash; Adverse effect; Internal medicine; Cohort; Colorectal cancer; Lung cancer; Monoclonal antibody; Gastroenterology; Antibody; Cancer; Oncology; Immunology","score_opus":0.016048132750075172,"score_gpt":0.35549619980918673,"score_spread":0.33944806705911157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389130660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981936,0.00029595417,0.00006263239,0.000048652837,0.00014014209,0.0012112746,0.00004054117,0.000003453432,0.0000037283235],"genre_scores_gemma":[0.99939996,0.00015285799,0.00017401179,0.000041585314,0.000019089042,0.000093894894,0.000057515063,0.000030652976,0.00003043693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988348,0.00007984501,0.0004414788,0.00019037309,0.00027462823,0.00017891255],"domain_scores_gemma":[0.9989405,0.000019753728,0.00049178384,0.00020009174,0.00032109028,0.000026743608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000170068,0.00014314952,0.00023781002,0.00010978161,0.000080283535,0.000025318348,0.00032001545,0.00004506426,0.0000062806484],"category_scores_gemma":[0.000026921456,0.0000977947,0.000036631565,0.00027645903,0.00005969165,0.00003125474,0.000040948198,0.00009802521,1.17753416e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016975319,0.009503549,0.61604637,0.00005850501,0.0002579077,0.0000028355637,0.0008771053,0.008495185,0.33500156,0.0000050183494,0.000056024557,0.012720618],"study_design_scores_gemma":[0.1056363,0.007120544,0.7865084,0.00058488915,0.00003329472,0.0000015236404,0.00048118745,0.0008367042,0.098336965,0.000018820241,0.00022130023,0.00022010012],"about_ca_topic_score_codex":0.00012420204,"about_ca_topic_score_gemma":0.00046926105,"teacher_disagreement_score":0.23666458,"about_ca_system_score_codex":0.00004526602,"about_ca_system_score_gemma":0.00015934999,"threshold_uncertainty_score":0.39879522},"labels":[],"label_agreement":null},{"id":"W4389130677","doi":"10.1136/jitc-2023-007479","title":"TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Chromatin immunoprecipitation; mTORC1; Cancer research; Immunotherapy; Hepatocellular carcinoma; PI3K/AKT/mTOR pathway; PD-L1; Biology; Transcription factor; Immune system; Flow cytometry; Small hairpin RNA; Immunology; Signal transduction; Gene knockdown; Cell culture; Promoter; Cell biology; Gene expression; Gene","score_opus":0.02587258318433669,"score_gpt":0.30907782748007884,"score_spread":0.2832052442957421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389130677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786442,0.018796692,0.00013412404,0.0006757337,0.0009946126,0.0006072747,0.00004592647,0.000032436164,0.00006899405],"genre_scores_gemma":[0.9894069,0.0087589165,0.000246534,0.000092889706,0.0002237175,0.00006289472,0.00005987161,0.000054741708,0.0010935591],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99791247,0.00006141273,0.0010092547,0.00019972259,0.00048793436,0.00032922378],"domain_scores_gemma":[0.9985772,0.00014317447,0.0005987365,0.00024210468,0.00037999553,0.000058811216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009213055,0.00020035954,0.00057380623,0.0006499441,0.00010294806,0.000013449073,0.00013971822,0.00016908621,0.0004740079],"category_scores_gemma":[0.000051562198,0.00017124752,0.00045295715,0.00086749386,0.00011598197,0.00014681273,0.000013342397,0.00021536427,0.0000027637338],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011026931,0.00012882864,0.08540897,0.00014478932,0.00035491693,0.0000046105415,0.00047789773,0.00025308988,0.8828248,0.000013600813,0.0007883154,0.018573303],"study_design_scores_gemma":[0.009056379,0.0007099363,0.63753164,0.0006190406,0.000056743975,0.000035206303,0.00015104386,0.0045987684,0.33539099,0.00037928091,0.011288266,0.00018270763],"about_ca_topic_score_codex":0.0006943379,"about_ca_topic_score_gemma":0.00003100493,"teacher_disagreement_score":0.55212265,"about_ca_system_score_codex":0.00035197407,"about_ca_system_score_gemma":0.00038745024,"threshold_uncertainty_score":0.6983271},"labels":[],"label_agreement":null},{"id":"W4389219114","doi":"10.1136/jitc-2023-007631","title":"Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"LAVA Therapeutics; Medical Research Council; National Health and Medical Research Council; Vrije Universiteit Amsterdam","keywords":"CD1D; Antigen presentation; Cell biology; Phosphatidylserine; Biology; Antibody; Immune system; Chemistry; T cell; Immunology; Biochemistry; T-cell receptor; Phospholipid","score_opus":0.03603972794639646,"score_gpt":0.36809400577456336,"score_spread":0.3320542778281669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389219114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752889,0.012354697,0.008587575,0.00029909203,0.0027435515,0.0005585356,0.000043873046,0.000063818006,0.000059905204],"genre_scores_gemma":[0.9953307,0.0016161096,0.00064390665,0.000057242167,0.00015491393,0.00006716967,0.000109821776,0.000059996706,0.0019601288],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983663,0.00013688374,0.0007725987,0.00022584469,0.00009763692,0.00040071842],"domain_scores_gemma":[0.99851364,0.00013346023,0.00077397615,0.00021624536,0.00034129104,0.00002140915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004280181,0.00023426948,0.0004486926,0.00033352716,0.0004594938,0.00005096344,0.00023610749,0.00013735659,0.00059492583],"category_scores_gemma":[0.000040292263,0.00021024644,0.00033762015,0.00038095273,0.00013961733,0.000557758,0.00003417321,0.0002557058,0.000019788687],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000961423,0.00017253662,0.00037337522,0.0000383743,0.00078853464,5.9036694e-7,0.0010802861,0.0005496611,0.96584374,0.00006410235,0.00048026585,0.029647093],"study_design_scores_gemma":[0.0035235698,0.00042793693,0.015034901,0.00028445598,0.00006967607,0.00004952538,0.00039010047,0.00039204315,0.95815194,0.0006933234,0.020732442,0.00025006765],"about_ca_topic_score_codex":0.00013540132,"about_ca_topic_score_gemma":0.000014704816,"teacher_disagreement_score":0.029397026,"about_ca_system_score_codex":0.00021657691,"about_ca_system_score_gemma":0.00015203212,"threshold_uncertainty_score":0.85736006},"labels":[],"label_agreement":null},{"id":"W4392244637","doi":"10.1136/jitc-2023-008155","title":"CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Bundesministerium für Bildung und Forschung; Deutsche Forschungsgemeinschaft","keywords":"Downregulation and upregulation; ICAM-1; Immune system; Immune escape; Medicine; Cancer research; Immunology; Biology; Gene; Cell adhesion molecule","score_opus":0.007697019596176288,"score_gpt":0.26784176051490316,"score_spread":0.26014474091872686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392244637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73737967,0.23777539,0.0027985303,0.00057828304,0.020407548,0.0005513554,0.00015077087,0.000084006475,0.0002744185],"genre_scores_gemma":[0.97743917,0.007757618,0.000100825426,0.00015818636,0.00014147384,0.000038362406,0.0001619589,0.00006164258,0.014140788],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984867,0.0001129885,0.00086552015,0.00017810935,0.00008460785,0.00027210006],"domain_scores_gemma":[0.99877596,0.00024640825,0.0005328619,0.00015356953,0.0002747104,0.000016475507],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004590517,0.00019970682,0.00042804185,0.00022367944,0.00016558239,0.000036143534,0.00016902524,0.000164395,0.0038167217],"category_scores_gemma":[0.000035318848,0.00016502933,0.00038011276,0.00018474167,0.000108990556,0.0002824327,0.000013988925,0.0003791306,0.000029223866],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008666106,0.000074923104,0.00008461713,0.000098571356,0.00064765447,5.9716564e-7,0.0005225811,0.000087300876,0.93483096,0.00004372541,0.056747694,0.0059947423],"study_design_scores_gemma":[0.001418433,0.00026761618,0.0004850972,0.00020088551,0.00005229959,0.000013993474,0.00021283078,0.00012026207,0.650296,0.000033137323,0.34677255,0.0001269124],"about_ca_topic_score_codex":0.00018831421,"about_ca_topic_score_gemma":0.0000044042695,"teacher_disagreement_score":0.29002485,"about_ca_system_score_codex":0.00014518721,"about_ca_system_score_gemma":0.00014706304,"threshold_uncertainty_score":0.9970939},"labels":[],"label_agreement":null},{"id":"W4392303061","doi":"10.1136/jitc-2023-008735","title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","year":2024,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Iovance Biotherapeutics; Gilead Sciences; Servier; National Cancer Institute; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Swedish Orphan Biovitrum; Pfizer; Moderna; Incyte; Ipsen; BeiGene; Sun Pharma; Sanofi; Moffitt Cancer Center; Exelixis; Seagen; Agios Pharmaceuticals; Society for Immunotherapy of Cancer; Bristol-Myers Squibb; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Medicine; Context (archaeology); Intensive care medicine; Clinical trial; Cell therapy; Best practice; Internal medicine; Stem cell","score_opus":0.26030052746488336,"score_gpt":0.5246172299582877,"score_spread":0.2643167024934044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392303061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014449976,0.99183226,0.000038852682,0.000911978,0.0014690142,0.004261209,0.00013490031,0.000027599714,0.0011796709],"genre_scores_gemma":[0.0000011028455,0.9491868,0.004467408,0.0007347612,0.001843226,0.0010798584,0.000017157063,0.00026795565,0.04240175],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965638,0.00011116425,0.0015749778,0.0005320225,0.000692888,0.0005251685],"domain_scores_gemma":[0.99603516,0.0007288034,0.0019463848,0.0004700342,0.0006691275,0.0001504732],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013649064,0.0006504909,0.002073346,0.0005401865,0.00022590575,0.00020712962,0.00031405006,0.00023029392,0.00045656893],"category_scores_gemma":[0.00009870923,0.00043027033,0.0012551509,0.00025544077,0.00013235593,0.000069500114,0.000032318625,0.00058225973,0.0000050565136],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032378368,0.00018210498,8.8905244e-7,0.015361357,0.0031020774,0.00003938691,0.0001618553,0.0000023597527,0.0016735175,0.000026885446,0.017265212,0.9589465],"study_design_scores_gemma":[0.005394632,0.0025009436,2.4641878e-7,0.025074815,0.0009996322,0.00046256644,0.00025084658,0.000046996614,0.00093369395,0.00006797629,0.9638933,0.00037438],"about_ca_topic_score_codex":0.00013524784,"about_ca_topic_score_gemma":0.000008195481,"teacher_disagreement_score":0.95857215,"about_ca_system_score_codex":0.00056803634,"about_ca_system_score_gemma":0.0011321958,"threshold_uncertainty_score":0.9998149},"labels":[],"label_agreement":null},{"id":"W4392820515","doi":"10.1136/jitc-2023-008409","title":"Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Oxaliplatin; Nivolumab; Oncology; Colorectal cancer; Clinical endpoint; Irinotecan; Randomized controlled trial; Progression-free survival; Phases of clinical research; Clinical trial; Cancer; Chemotherapy; Immunotherapy","score_opus":0.08274832123584072,"score_gpt":0.43882121467788904,"score_spread":0.3560728934420483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392820515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8936414,0.09442472,0.0010593452,0.0031439855,0.0012043129,0.00481585,0.0016601267,0.00001866888,0.000031602256],"genre_scores_gemma":[0.9169016,0.07855006,0.0009374176,0.00007504555,0.00076112826,0.0019406443,0.000042409363,0.000055885706,0.0007358173],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977259,0.000117643984,0.0012680702,0.00032499694,0.0003045397,0.00025884804],"domain_scores_gemma":[0.9967537,0.0020112644,0.00066379394,0.00018506208,0.00030530055,0.00008091318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086919294,0.00031303405,0.0018631924,0.00007632459,0.00022610555,0.00005035992,0.00009381356,0.000071174996,0.000044373868],"category_scores_gemma":[0.00014144587,0.0001498894,0.0007684783,0.00012229089,0.00035886967,0.00007792454,0.000010696687,0.00013762701,1.1569753e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8182841,0.0005794413,0.00008846042,0.00008435381,0.011685108,0.0000055311457,0.0027913712,0.00010996691,0.00025966467,0.000022381839,0.0003385009,0.16575114],"study_design_scores_gemma":[0.94736576,0.024242694,0.00023790354,0.0006999504,0.0045330995,0.000023863635,0.00022622521,0.006805096,0.0022000992,0.0003961865,0.013097691,0.00017146058],"about_ca_topic_score_codex":0.0017298397,"about_ca_topic_score_gemma":0.0015483163,"teacher_disagreement_score":0.16557969,"about_ca_system_score_codex":0.00039547417,"about_ca_system_score_gemma":0.00080749806,"threshold_uncertainty_score":0.6112312},"labels":[],"label_agreement":null},{"id":"W4392846645","doi":"10.1136/jitc-2023-008295","title":"Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Rutgers Cancer Institute of New Jersey; National Institutes of Health; New Jersey Health Foundation","keywords":"CD16; Cancer research; Antibody-dependent cell-mediated cytotoxicity; Interleukin 12; Ovarian cancer; Cancer cell; Immune system; Metastasis; Immunology; NK-92; Cancer; Interleukin 21; Antibody; Cytotoxic T cell; Medicine; Biology; T cell; In vitro; Monoclonal antibody; CD3; Internal medicine","score_opus":0.014263035926557486,"score_gpt":0.29593898391096224,"score_spread":0.28167594798440476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392846645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7294524,0.267017,0.000086646825,0.00036878034,0.0027027954,0.00027611296,0.000038745184,0.0000075651305,0.000049968836],"genre_scores_gemma":[0.87355244,0.12373135,0.000060243696,0.00006775037,0.000047595906,0.0000690041,0.000003144455,0.00002837044,0.0024400884],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985265,0.00026537062,0.0005997752,0.00024951805,0.000069502945,0.00028930214],"domain_scores_gemma":[0.99888414,0.000491908,0.00035194083,0.00014163382,0.00011765057,0.00001269725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076418987,0.00022702437,0.0005321043,0.00031225698,0.0001742198,0.000056924877,0.00016764586,0.0001421705,0.00088152406],"category_scores_gemma":[0.000015912847,0.00015903408,0.0001688508,0.00023143,0.00028777428,0.00028885377,0.000031175936,0.00065318984,0.000002461917],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029554244,0.00010754612,0.000086162254,0.00021746162,0.00033869004,0.0000016102107,0.0019405422,0.000014131326,0.91644,0.000020132444,0.00042572548,0.07745257],"study_design_scores_gemma":[0.002217689,0.0002057639,0.0031418498,0.00032166258,0.00007703226,0.000016703703,0.00071878877,0.00006029566,0.9547608,0.00004411635,0.03827753,0.00015775932],"about_ca_topic_score_codex":0.0013167944,"about_ca_topic_score_gemma":0.00018396792,"teacher_disagreement_score":0.14410008,"about_ca_system_score_codex":0.000115258656,"about_ca_system_score_gemma":0.00009759975,"threshold_uncertainty_score":0.965207},"labels":[],"label_agreement":null},{"id":"W4393091426","doi":"10.1136/jitc-2023-008655","title":"SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Clinical trial; Medicine; Interpretation (philosophy); Oncology; Internal medicine; Medical physics; Bioinformatics; Computer science; Biology","score_opus":0.061669252377449094,"score_gpt":0.44986434410478693,"score_spread":0.38819509172733785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393091426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9315517,0.05716415,0.0040535484,0.0019202222,0.0047800154,0.00043747172,0.00005643725,0.0000024865649,0.000033993845],"genre_scores_gemma":[0.9469603,0.05018313,0.0005300732,0.00096293184,0.0012927259,0.000026748645,0.000011790956,0.000022214434,0.0000100930065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99765766,0.00042339278,0.0014231078,0.00019648194,0.00014750211,0.00015185347],"domain_scores_gemma":[0.99862605,0.00055803015,0.00048657984,0.00013522245,0.00014675566,0.000047338275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006259814,0.000116635936,0.00050339976,0.00007055658,0.000037137277,0.000027949916,0.00012399667,0.00017664439,0.000018073986],"category_scores_gemma":[0.0002783732,0.0000982201,0.00039149795,0.000061228304,0.00013557695,0.0000066832376,0.000029090372,0.00017534212,1.879654e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022325713,0.0003643018,0.015273006,0.00007955731,0.00317025,0.0000043089267,0.00028118817,0.0007357432,0.12373713,0.00007612636,0.035162833,0.79878986],"study_design_scores_gemma":[0.031080263,0.028310187,0.06277339,0.0027374804,0.00086302945,0.00003571257,0.0003688267,0.0047219773,0.06837799,0.003638946,0.796157,0.0009352206],"about_ca_topic_score_codex":0.000078986115,"about_ca_topic_score_gemma":0.00018739265,"teacher_disagreement_score":0.7978546,"about_ca_system_score_codex":0.00007909986,"about_ca_system_score_gemma":0.00031544108,"threshold_uncertainty_score":0.40052995},"labels":[],"label_agreement":null},{"id":"W4393230681","doi":"10.1136/jitc-2023-008694","title":"Poor clinical outcomes and immunoevasive contexture in CD161<sup>+</sup>CD8<sup>+</sup> T cells barren human pancreatic cancer","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"Program of Shanghai Academic Research Leader; Shanghai Key Laboratory of Molecular Imaging; Fujian Medical University; China Postdoctoral Science Foundation; Fudan University; National Natural Science Foundation of China; Beijing Xisike Clinical Oncology Research Foundation; Shanghai Municipal Health Commission","keywords":"Pancreatic cancer; Cytotoxic T cell; Cancer; Cancer research; Medicine; Biology; Internal medicine; Biochemistry","score_opus":0.02980560795441357,"score_gpt":0.3826889662164464,"score_spread":0.3528833582620328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393230681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83109474,0.16093874,0.00008255232,0.004636214,0.0013504428,0.0013807466,0.00031270157,0.000060613078,0.00014322503],"genre_scores_gemma":[0.89655906,0.090279646,0.00042837995,0.0040296814,0.0012457867,0.00036429852,0.00003199324,0.0002138401,0.006847342],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956953,0.0002192359,0.0020473443,0.0006390974,0.0006429446,0.00075606105],"domain_scores_gemma":[0.9977259,0.00067472935,0.0005262273,0.00049159257,0.0003518791,0.00022966006],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015405554,0.0006329518,0.0017349219,0.00053228426,0.00028685288,0.00020169874,0.00038809748,0.00044845158,0.0017574632],"category_scores_gemma":[0.00007001952,0.00046988888,0.0012117204,0.00046284866,0.00048243327,0.00036510482,0.00004517873,0.001169924,0.000005838299],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031707954,0.001078538,0.18315443,0.0021648845,0.018183002,0.00021480303,0.013844646,0.00091093086,0.1435407,0.00022138236,0.049318343,0.55566037],"study_design_scores_gemma":[0.06436341,0.0058248565,0.1374088,0.01295364,0.0024802224,0.00051680533,0.0054220897,0.005213831,0.019488638,0.0011929185,0.7428388,0.0022959826],"about_ca_topic_score_codex":0.0021603745,"about_ca_topic_score_gemma":0.0002533188,"teacher_disagreement_score":0.6935205,"about_ca_system_score_codex":0.00068300474,"about_ca_system_score_gemma":0.0010754704,"threshold_uncertainty_score":0.9997753},"labels":[],"label_agreement":null},{"id":"W4393989214","doi":"10.1136/jitc-2023-006781","title":"Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Inflammasome and immune disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Guelph","funders":"Canadian Institutes of Health Research; Hospital for Sick Children; Cancer Research Society","keywords":"Pyroptosis; Cytotoxic T cell; Programmed cell death; Immunogenic cell death; CD8; T cell; Immune system; Cancer research; Biology; Acquired immune system; Priming (agriculture); Apoptosis; Cell biology; Immunology; Immunotherapy; In vitro","score_opus":0.012129554037529114,"score_gpt":0.2909093205397937,"score_spread":0.27877976650226455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393989214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96949726,0.024573026,0.0019964813,0.00081660785,0.0027686667,0.00022054775,0.00004814649,0.0000042629813,0.00007499575],"genre_scores_gemma":[0.988263,0.009033101,0.00031048272,0.00034090225,0.00042459523,0.000032932272,0.000013067937,0.00003247364,0.0015494616],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991815,0.0000256629,0.00031129326,0.00012930484,0.00018052576,0.00017168821],"domain_scores_gemma":[0.9994187,0.000046581066,0.00011762062,0.00012355439,0.00026651734,0.000027035148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022605114,0.00011179103,0.00015116649,0.00006757543,0.00009622953,0.000028549439,0.00016429316,0.00006550715,0.0002252197],"category_scores_gemma":[0.000013874922,0.00007991423,0.00022549083,0.00011465874,0.00010000836,0.000011173627,0.000020416728,0.00010154126,0.0000030960196],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064022373,0.000028536659,0.00009160365,0.000056971046,0.0004887339,2.5125226e-7,0.00015958809,0.0005194851,0.98347986,0.00008322996,0.0067523643,0.007699175],"study_design_scores_gemma":[0.00045299908,0.0002788349,0.0005072776,0.00010480236,0.00003958378,0.000002869889,0.00011855788,0.000029450655,0.8327135,0.000114158676,0.16554996,0.00008800487],"about_ca_topic_score_codex":0.000017568527,"about_ca_topic_score_gemma":0.000005178663,"teacher_disagreement_score":0.15879759,"about_ca_system_score_codex":0.000026228287,"about_ca_system_score_gemma":0.00029558424,"threshold_uncertainty_score":0.32588077},"labels":[],"label_agreement":null},{"id":"W4394690662","doi":"10.1136/jitc-2023-007675","title":"Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Université de Montréal","funders":"National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute; Eli Lilly Canada; National Institutes of Health; Bausch Health; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Galderma; Amryt Pharma; Incyte; Novocure; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre","keywords":"Medicine; CLARITY; Delphi method; Adverse effect; Grading (engineering); Usability; Medical diagnosis; Family medicine; Disease; Psoriasis; MEDLINE; Vitiligo; Alternative medicine; Dermatology; Internal medicine; Pathology; Artificial intelligence; Computer science","score_opus":0.04581985567053431,"score_gpt":0.340229610841648,"score_spread":0.2944097551711137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394690662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59782946,0.38427255,0.0022303686,0.010324257,0.00217454,0.0016487117,0.0014522551,0.00004832667,0.00001952901],"genre_scores_gemma":[0.93369454,0.060736597,0.0022100855,0.0016182375,0.00031669546,0.001169215,0.000060103946,0.00009583698,0.000098690776],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978573,0.0000711552,0.0011056648,0.00025644084,0.00037362712,0.00033582313],"domain_scores_gemma":[0.99695086,0.0016581332,0.0005601045,0.00037082928,0.00036214,0.00009789871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005849618,0.0002964111,0.00060828193,0.00020897869,0.00029497867,0.00002694808,0.00023654441,0.00012356779,0.00054583995],"category_scores_gemma":[0.000113139155,0.00019038559,0.001448618,0.0002819312,0.00027223598,0.000086718435,0.000011717974,0.00026329342,0.0000017795143],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17121848,0.0022781675,0.07314874,0.002411228,0.019476505,0.000053606844,0.003309738,0.0011571147,0.28954265,0.0012035249,0.017080927,0.4191193],"study_design_scores_gemma":[0.049577575,0.0036011885,0.09597601,0.010903757,0.002260369,0.00009498449,0.0013663894,0.004234824,0.47040263,0.0071258033,0.35340807,0.0010484052],"about_ca_topic_score_codex":0.00025816722,"about_ca_topic_score_gemma":0.000023234683,"teacher_disagreement_score":0.41807088,"about_ca_system_score_codex":0.00019606529,"about_ca_system_score_gemma":0.0010384892,"threshold_uncertainty_score":0.77636987},"labels":[],"label_agreement":null},{"id":"W4396809669","doi":"10.1136/jitc-2023-008460","title":"Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Brain Tumour Charity; Alzheimer Society; National Institute for Health and Care Research; Cancer Research UK; Brain Research UK; Linacre College, University of Oxford","keywords":"Oncolytic virus; Glioma; Virotherapy; NKG2D; Cancer research; Glioblastoma; Medicine; Stem cell; Tumor cells; Cytotoxic T cell; Biology","score_opus":0.012285022321507084,"score_gpt":0.26497405737477836,"score_spread":0.2526890350532713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396809669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92087156,0.07538253,0.0009520919,0.00017994209,0.002051858,0.00045699542,0.000020224401,0.000019751556,0.00006504581],"genre_scores_gemma":[0.9752338,0.017124338,0.00012546356,0.00017814708,0.00006808326,0.00008410251,0.000006211243,0.000057110527,0.007122768],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986601,0.000096190524,0.00061273115,0.00025451055,0.00011319734,0.00026331068],"domain_scores_gemma":[0.99905235,0.00018842088,0.00041516052,0.00012492144,0.00019999394,0.00001915764],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042732805,0.0002458794,0.00043385115,0.00040000348,0.00015472135,0.000052281313,0.00013213076,0.00013984446,0.0015939093],"category_scores_gemma":[0.0000015622531,0.000168041,0.00015069795,0.00027456155,0.0002041685,0.00026651993,0.000007588301,0.0004174361,0.0000057511784],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013034355,0.00024053527,0.00029891785,0.00010184264,0.0007973719,0.000004708783,0.001870645,0.0000496254,0.96886736,0.000028445102,0.002845465,0.011860739],"study_design_scores_gemma":[0.0065689567,0.003110966,0.00025031698,0.0006318591,0.000030853313,0.00008916262,0.0009322209,0.000069849986,0.87823766,0.00001607837,0.10987257,0.0001895076],"about_ca_topic_score_codex":0.00007473962,"about_ca_topic_score_gemma":0.000020309779,"teacher_disagreement_score":0.107027106,"about_ca_system_score_codex":0.00010094868,"about_ca_system_score_gemma":0.00021022218,"threshold_uncertainty_score":0.9993188},"labels":[],"label_agreement":null},{"id":"W4396969443","doi":"10.1136/jitc-2023-008435","title":"Therapeutic Inducers of Natural Killer cell Killing (ThINKK): preclinical assessment of safety and efficacy in allogeneic hematopoietic stem cell transplant settings","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Canadian Institutes of Health Research","keywords":"Haematopoiesis; Stem cell; Medicine; Hematopoietic stem cell; Hematopoietic stem cell transplantation; Immunology; Cancer research; Transplantation; Pharmacology; Biology; Internal medicine","score_opus":0.01718153996375349,"score_gpt":0.3227991147229518,"score_spread":0.3056175747591983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396969443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8804875,0.11121389,0.00081782474,0.0004025128,0.0065541854,0.00037547114,0.0000122324345,0.000012810891,0.00012356296],"genre_scores_gemma":[0.98201615,0.015586846,0.00009781715,0.00011197514,0.000027053125,0.000010863807,0.000010707074,0.000027721575,0.0021108505],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983386,0.00016316194,0.0010141209,0.00019166559,0.00007804115,0.00021441384],"domain_scores_gemma":[0.998855,0.000464662,0.0004441064,0.00012770927,0.00009398067,0.0000145177655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006827033,0.00017861906,0.00050696475,0.00021402969,0.000073563126,0.000014225752,0.00014650568,0.00020771161,0.0003485092],"category_scores_gemma":[0.0000028597813,0.00013837573,0.00028828776,0.00012115157,0.00012326118,0.000119457516,0.000011473398,0.0006341843,0.0000011626414],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021461013,0.00026993087,0.00085553474,0.00040763387,0.000535909,0.0000010755808,0.0039141118,0.0002087687,0.9628641,0.00008482872,0.00021158395,0.02850043],"study_design_scores_gemma":[0.010000918,0.0016482464,0.011777458,0.0019448618,0.00028348414,0.000121938996,0.0015738179,0.0005146544,0.89725333,0.000093023344,0.074396215,0.00039202377],"about_ca_topic_score_codex":0.000041606727,"about_ca_topic_score_gemma":0.000005203867,"teacher_disagreement_score":0.10152866,"about_ca_system_score_codex":0.00009686004,"about_ca_system_score_gemma":0.00018760783,"threshold_uncertainty_score":0.5642799},"labels":[],"label_agreement":null},{"id":"W4399446481","doi":"10.1136/jitc-2024-009028","title":"Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Sanofi Genzyme; Bristol-Myers Squibb Canada; Sanofi Pasteur; Sun Pharma; Regeneron Pharmaceuticals; Sanofi; Les Laboratories Pierre Fabre; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Castle Biosciences; GlaxoSmithKline","keywords":"Melanoma; Medicine; Metastatic melanoma; Term (time); Oncology; Internal medicine; Cancer research","score_opus":0.033451109223183534,"score_gpt":0.3808977893389546,"score_spread":0.34744668011577107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399446481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95172936,0.043554667,0.0007057782,0.0007301505,0.0018256132,0.0012768548,0.00006508829,0.000020671785,0.00009184612],"genre_scores_gemma":[0.9866529,0.0047060405,0.00083329214,0.0001598017,0.00025188448,0.0003408774,0.0000436525,0.000070559254,0.0069409646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988117,0.0000515502,0.0004792606,0.00018209395,0.00017600818,0.00029933645],"domain_scores_gemma":[0.9993604,0.0001775238,0.00014620797,0.00013327546,0.000114581024,0.0000680206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003917288,0.00018246265,0.00056043675,0.00021284864,0.00007470557,0.000028163658,0.000089385234,0.00008852601,0.00029968072],"category_scores_gemma":[0.000021478927,0.00013195755,0.0004509401,0.00015150134,0.00004951853,0.00011572072,0.000005709,0.0001782527,0.0000029940181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020214772,0.0010674944,0.48635095,0.0012064996,0.01101925,0.0004573965,0.0018094545,0.000019001436,0.020422569,0.0002551264,0.0014316876,0.4557458],"study_design_scores_gemma":[0.16809593,0.026493672,0.63273394,0.0066989823,0.0072172554,0.00154365,0.00042239387,0.0007700336,0.06338507,0.00387883,0.08757134,0.0011889043],"about_ca_topic_score_codex":0.000083580846,"about_ca_topic_score_gemma":0.00038868922,"teacher_disagreement_score":0.45455688,"about_ca_system_score_codex":0.00032764778,"about_ca_system_score_gemma":0.00036223512,"threshold_uncertainty_score":0.5381073},"labels":[],"label_agreement":null},{"id":"W4400892363","doi":"10.1136/jitc-2024-009427","title":"Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee","year":2024,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Kite Pharma; Moderna; EMD Serono; Ribon Therapeutics; Regeneron Pharmaceuticals; Gilead Sciences; Genentech; Society for Immunotherapy of Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Biomarker; Medicine; Immunotherapy; PD-L1; Biomarker discovery; Immune system; Oncology; Bioinformatics; Immunology; Biology","score_opus":0.08405559566590562,"score_gpt":0.3973262209989202,"score_spread":0.31327062533301453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400892363","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014602001,0.9863213,0.00031991565,0.003517127,0.0035780661,0.004532285,0.0014453373,0.00005272135,0.00008726333],"genre_scores_gemma":[0.000014705293,0.9908858,0.0029287983,0.0012655244,0.001101071,0.0015032351,0.00028727832,0.0002677524,0.0017458467],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954621,0.0001888421,0.0024988041,0.000593996,0.0006253444,0.00063091953],"domain_scores_gemma":[0.9959581,0.00112351,0.0015850622,0.0006629691,0.0005205758,0.0001498059],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016110681,0.00091919996,0.002806382,0.0003753217,0.00050628674,0.00018351561,0.00048050773,0.0005542822,0.0006912531],"category_scores_gemma":[0.00005101976,0.00053272385,0.0032507663,0.00063320954,0.00039607167,0.00006953733,0.000053234253,0.00068790663,0.000013756005],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004012865,0.000112662114,0.000005150357,0.007843366,0.016203936,0.00001609522,0.00032213578,9.017722e-8,0.0003372576,0.000016707523,0.1337627,0.83736706],"study_design_scores_gemma":[0.00494217,0.00040754277,0.00004351959,0.04903783,0.0042921226,0.00036768665,0.000119514785,0.000004463681,0.00021051298,0.00017642313,0.939813,0.0005851983],"about_ca_topic_score_codex":0.00017455402,"about_ca_topic_score_gemma":0.00010136272,"teacher_disagreement_score":0.83678186,"about_ca_system_score_codex":0.0010600421,"about_ca_system_score_gemma":0.0033058075,"threshold_uncertainty_score":0.9997124},"labels":[],"label_agreement":null},{"id":"W4400892533","doi":"10.1136/jitc-2024-009309","title":"Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?","year":2024,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Adverse effect; Medicine; Osteoporosis; Immune system; Bone remodeling; Intensive care medicine; Bioinformatics; Internal medicine; Oncology; Immunology","score_opus":0.03742799908571104,"score_gpt":0.4110232161316989,"score_spread":0.37359521704598786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400892533","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011988195,0.99093604,0.000056398694,0.00017545141,0.0046185004,0.002563199,0.00034915443,0.000031863725,0.00007059639],"genre_scores_gemma":[0.00028901285,0.9953764,0.0005113684,0.00012544944,0.0012066661,0.0002885888,0.00011253399,0.0002692971,0.0018206534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99425685,0.00016737552,0.0038705114,0.00047538176,0.0007321436,0.00049771543],"domain_scores_gemma":[0.9950271,0.00015974496,0.0033840532,0.0007252317,0.0005247322,0.00017912559],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016946028,0.0008096019,0.004053831,0.00076453417,0.00012042217,0.000040971692,0.0004688576,0.00061355205,0.0013913146],"category_scores_gemma":[0.000066591776,0.0005414472,0.0056836796,0.0005711321,0.00023550665,0.00019279595,0.000037320533,0.0010645582,0.000006939257],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049929284,0.00034713186,0.0000030162291,0.026914634,0.0067740157,0.000017175264,0.0005630652,0.0000023532643,0.0038647444,0.0000042716133,0.0012248814,0.9552918],"study_design_scores_gemma":[0.0056039793,0.0021017164,0.00003341037,0.06794796,0.0048341937,0.00038503495,0.00016737956,0.0000050678686,0.0028397553,0.00011083332,0.9154757,0.0004949438],"about_ca_topic_score_codex":0.00023712506,"about_ca_topic_score_gemma":0.00002804205,"teacher_disagreement_score":0.95479685,"about_ca_system_score_codex":0.0007706435,"about_ca_system_score_gemma":0.0026454472,"threshold_uncertainty_score":0.9997037},"labels":[],"label_agreement":null},{"id":"W4401037871","doi":"10.1136/jitc-2024-009443","title":"Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Cancer Research UK","keywords":"Oncolytic virus; Melanoma; Tumor microenvironment; Immune checkpoint; Immune system; Cytotoxic T cell; Cancer research; Immunotherapy; Biology; Priming (agriculture); Immunology; T cell; Medicine; In vitro","score_opus":0.017247862124379423,"score_gpt":0.2983928389924288,"score_spread":0.2811449768680494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401037871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95017207,0.046860483,0.0020285621,0.00017508697,0.00009382735,0.00055335165,0.0000634804,0.0000069798866,0.000046182475],"genre_scores_gemma":[0.98144764,0.014529338,0.0031093338,0.00003685994,0.000055347216,0.00012323473,0.00002354804,0.00006259972,0.0006121139],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827784,0.00009837746,0.0006531838,0.00028610823,0.00041698452,0.00026751088],"domain_scores_gemma":[0.9986833,0.000065041895,0.0004390592,0.00026653652,0.0005031012,0.000043013937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059880415,0.00022861922,0.00042464834,0.00018986511,0.00006983802,0.000027309963,0.00032295138,0.00014127065,0.000074050775],"category_scores_gemma":[0.0000094487405,0.00016853675,0.00017872555,0.00024973004,0.00018678798,0.00003684215,0.00001555378,0.00025762984,1.8212275e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060050864,0.00043035924,0.00033023438,0.000104609826,0.00040156118,0.0000013340324,0.00021775541,0.020548446,0.9126665,0.000040630148,0.000013922389,0.0051937643],"study_design_scores_gemma":[0.00630309,0.013754079,0.0006769832,0.00037553505,0.000017554536,0.0000034291706,0.00009287406,0.0012111102,0.9762621,0.00026814474,0.0008231558,0.00021197961],"about_ca_topic_score_codex":0.000031194642,"about_ca_topic_score_gemma":0.00030245856,"teacher_disagreement_score":0.06359555,"about_ca_system_score_codex":0.00013435732,"about_ca_system_score_gemma":0.0007693275,"threshold_uncertainty_score":0.6872729},"labels":[],"label_agreement":null},{"id":"W4401406952","doi":"10.1136/jitc-2024-008872","title":"Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Eisai; Department of Science and Technology, Ministry of Science and Technology, India; MacroGenics; Genentech; Actuate Therapeutics; Pfizer; Incyte; Mylan; BeiGene; Clovis Oncology; National Medical Research Council; Exelixis; Karyopharm Therapeutics; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; Astex Pharmaceuticals; Medical Research Council; Les Laboratories Pierre Fabre; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Metastatic melanoma; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.031156298007487766,"score_gpt":0.38733140100864477,"score_spread":0.356175103001157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401406952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830283,0.009431964,0.0004883254,0.00024784077,0.0006323524,0.005899199,0.0002356837,0.00001959673,0.000016746319],"genre_scores_gemma":[0.9930383,0.0019878603,0.0027277633,0.00016425406,0.00010418825,0.0006691697,0.000027345674,0.00013675596,0.0011443614],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958058,0.00023247972,0.002199579,0.0004248468,0.0009287426,0.0004085441],"domain_scores_gemma":[0.9968712,0.0005452753,0.0013580893,0.0003941681,0.00073779287,0.00009351686],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011574856,0.0004448255,0.002377942,0.0006302031,0.000113007976,0.00007260801,0.00048285152,0.00006811255,0.0013512402],"category_scores_gemma":[0.000077389595,0.00027230626,0.0002972491,0.00079585373,0.0003199609,0.00050520024,0.000030483834,0.00033464975,6.60258e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87526554,0.004210545,0.00020752805,0.0005023167,0.0051388717,0.000060945782,0.0051081153,0.0007111194,0.0053627766,0.00001834993,0.00015315064,0.10326077],"study_design_scores_gemma":[0.9519186,0.03310514,0.0012551519,0.0030976576,0.0006304051,0.00008595141,0.0025355169,0.0013804609,0.0045137154,0.00018971677,0.000887756,0.00039990642],"about_ca_topic_score_codex":0.0018654929,"about_ca_topic_score_gemma":0.00041793453,"teacher_disagreement_score":0.10286086,"about_ca_system_score_codex":0.00055725087,"about_ca_system_score_gemma":0.002232803,"threshold_uncertainty_score":0.99997294},"labels":[],"label_agreement":null},{"id":"W4404465103","doi":"10.1136/jitc-2024-009962","title":"Morphine treatment restricts response to immunotherapy in oral squamous cell carcinoma","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institute of Dental and Craniofacial Research; National Institutes of Health; Charles E. Kaufman Foundation; National Cancer Institute; University of Pittsburgh","keywords":"Medicine; CD8; Immune system; Immunotherapy; Immunosuppression; T cell; Opioid receptor; Cancer research; Opioid; Pharmacology; Immunology; Internal medicine; Receptor","score_opus":0.02187560821429628,"score_gpt":0.33495150404773705,"score_spread":0.31307589583344075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404465103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8430322,0.15003449,0.00012576592,0.0043756887,0.0012304654,0.0010081999,0.000050170947,0.000038343984,0.00010470511],"genre_scores_gemma":[0.96977866,0.015750038,0.00064707745,0.00070087425,0.00071002194,0.00027117474,0.000006743237,0.00014511427,0.011990285],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975961,0.00017610185,0.00088291726,0.00035778093,0.00042609367,0.00056104077],"domain_scores_gemma":[0.9985114,0.00045670886,0.0002017038,0.0004649027,0.00019582908,0.00016951036],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078580156,0.0003927361,0.00083670084,0.0009004738,0.00012509635,0.00009515407,0.00023064179,0.00016036668,0.00042382028],"category_scores_gemma":[0.000055727363,0.00030425703,0.00060117565,0.0006449759,0.00008437402,0.00016753573,0.000012323005,0.00032754114,0.000010877332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16410132,0.00074062764,0.004440395,0.00022110503,0.00031155383,0.00036182642,0.0043929066,0.00036123497,0.5564644,0.000012792398,0.007120873,0.261471],"study_design_scores_gemma":[0.017304365,0.010511325,0.08161465,0.0006209832,0.00013106462,0.00054473075,0.00035142654,0.00024269595,0.09725812,0.00008337319,0.7909043,0.00043296],"about_ca_topic_score_codex":0.001186449,"about_ca_topic_score_gemma":0.00011981525,"teacher_disagreement_score":0.78378344,"about_ca_system_score_codex":0.001320114,"about_ca_system_score_gemma":0.0014733884,"threshold_uncertainty_score":0.99994093},"labels":[],"label_agreement":null},{"id":"W4404567325","doi":"10.1136/jitc-2024-010143","title":"Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Alberta Health Services; Université Laval; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; CD8; Cytokine; Oncology; Response Evaluation Criteria in Solid Tumors; Melanoma; Aldesleukin; Adverse effect; Cancer; Interleukin 2; Gastroenterology; Immunotherapy; Immunology; Phases of clinical research; Toxicity; Cancer research; Immune system","score_opus":0.007401104382701864,"score_gpt":0.30071899791223383,"score_spread":0.29331789352953197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404567325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784475,0.018378196,0.0006067713,0.00084888603,0.000337177,0.0010666156,0.000067619425,0.00004000096,0.00020725073],"genre_scores_gemma":[0.9912219,0.005862959,0.00087390834,0.0006515873,0.0001490337,0.0001718052,0.000015167866,0.00012723132,0.0009263943],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99796236,0.00003677321,0.00071003725,0.00038191635,0.000469537,0.00043938137],"domain_scores_gemma":[0.9989746,0.00007457905,0.00031353583,0.00027983586,0.00024158705,0.00011583405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025674858,0.00037708436,0.00071700104,0.0003951941,0.00010456496,0.00010795991,0.00016507291,0.00011310346,0.00019302047],"category_scores_gemma":[0.000008424989,0.00025117712,0.00019281411,0.00040134016,0.00022148975,0.0003423923,0.000011139701,0.00041142895,8.111066e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30384728,0.0006473728,0.03368223,0.00066870276,0.0029258386,0.0001138298,0.0031174824,0.00042803728,0.06396857,0.00015294515,0.0007108245,0.5897369],"study_design_scores_gemma":[0.21735704,0.047501,0.51988524,0.019262819,0.00064702734,0.0015326524,0.0011391612,0.0019900638,0.06763128,0.0011813515,0.11954308,0.0023292718],"about_ca_topic_score_codex":0.00028699098,"about_ca_topic_score_gemma":0.00013951081,"teacher_disagreement_score":0.5874076,"about_ca_system_score_codex":0.00040361297,"about_ca_system_score_gemma":0.0006042251,"threshold_uncertainty_score":0.99999404},"labels":[],"label_agreement":null},{"id":"W4404926477","doi":"10.1136/jitc-2024-009462","title":"Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma","year":2024,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Cilag; Medac; Swedish Orphan Biovitrum; Else Kröner-Fresenius-Stiftung; Incyte; Eli Lilly and Company; AstraZeneca; CSL Behring; Gilead Sciences; BeiGene; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; Celgene","keywords":"Medicine; Chimeric antigen receptor; Immune system; T cell; Immunotherapy; Immunosenescence; Immunology; Multiple myeloma; Naive T cell; Senescence; Cancer research; Internal medicine; T-cell receptor","score_opus":0.03172640834317397,"score_gpt":0.38804858641614765,"score_spread":0.35632217807297367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404926477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14735994,0.85051394,0.000004481237,0.000054691776,0.00018984955,0.0016955365,0.000115000665,0.000015805794,0.000050748316],"genre_scores_gemma":[0.0122381365,0.9861202,0.00012102907,0.000028852897,0.00019275093,0.00022410303,0.000026262083,0.0001723177,0.00087632105],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973086,0.0001603894,0.001076337,0.0003926553,0.00056100346,0.000501015],"domain_scores_gemma":[0.99790627,0.0006176801,0.0007154344,0.00037451132,0.0002775835,0.00010850687],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005805246,0.0005830119,0.0025057148,0.00089406845,0.000061472885,0.00004981382,0.00027196112,0.00037135548,0.00071858073],"category_scores_gemma":[0.000039439423,0.00031671656,0.0010713483,0.0005549493,0.00025111905,0.000075881704,0.000032061223,0.0008440925,0.0000021755957],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008495297,0.0004418978,0.0009800859,0.008533251,0.0028626483,0.000051625302,0.0012951508,0.0000024891879,0.0022889578,0.0000014150482,0.000119179735,0.974928],"study_design_scores_gemma":[0.051182617,0.01919272,0.03344565,0.22686796,0.0017584178,0.00123275,0.000739387,0.000113210735,0.0011497748,0.00004440011,0.6628689,0.0014042244],"about_ca_topic_score_codex":0.0002790366,"about_ca_topic_score_gemma":0.00003127417,"teacher_disagreement_score":0.9735238,"about_ca_system_score_codex":0.0007208294,"about_ca_system_score_gemma":0.0011462194,"threshold_uncertainty_score":0.9999285},"labels":[],"label_agreement":null},{"id":"W4405012333","doi":"10.1136/jitc-2024-010094","title":"Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Alberta Cancer Foundation; Centre Hospitalier de l’Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Moncton Hospital; Trillium Health Centre; Juravinski Cancer Centre; Ottawa Hospital; Saskatchewan Cancer Agency; St. John’s Health Sciences Centre; Hôpital Charles-Le Moyne; Hôtel-Dieu de Québec; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"Eisai; Taiho Pharmaceutical; Natera; Exelixis; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Colorectal cancer; Internal medicine; Oncology; Immune system; Hazard ratio; Biomarker; Cancer; Gastroenterology; Immunology; Biology; Confidence interval","score_opus":0.018310539268710155,"score_gpt":0.3701782868469034,"score_spread":0.3518677475781932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405012333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873748,0.008735709,0.0009315627,0.0003458465,0.00030335493,0.0013360592,0.0009417832,0.0000036301458,0.000027258902],"genre_scores_gemma":[0.9963588,0.0020904865,0.00011245152,0.0000219678,0.00005206318,0.0009167272,0.000048258735,0.0000307768,0.00036843863],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885255,0.00006559386,0.00044351697,0.00019260263,0.00024003905,0.00020568936],"domain_scores_gemma":[0.9992317,0.00009804807,0.00031445595,0.00012033,0.00020037279,0.00003507267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031967578,0.00015708148,0.00042331062,0.00021836995,0.00007260804,0.000026317519,0.00009806005,0.000059118804,0.00007252817],"category_scores_gemma":[0.00004469144,0.000093117196,0.0005577454,0.00041231987,0.00013934873,0.000014621053,0.000015306681,0.000116782714,1.5783652e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36487508,0.00061975047,0.013959111,0.00014428532,0.04457666,0.000008642225,0.0013465497,0.0032893901,0.5544624,0.00004341371,0.00048040075,0.016194332],"study_design_scores_gemma":[0.0862574,0.010378505,0.045507994,0.00051530806,0.0021513302,0.000023000968,0.0004152942,0.0046490566,0.84460866,0.00035473198,0.0048391894,0.00029953494],"about_ca_topic_score_codex":0.000867106,"about_ca_topic_score_gemma":0.002029213,"teacher_disagreement_score":0.2901463,"about_ca_system_score_codex":0.00017781727,"about_ca_system_score_gemma":0.0006689714,"threshold_uncertainty_score":0.3797209},"labels":[],"label_agreement":null},{"id":"W4406093333","doi":"10.1136/jitc-2024-009435","title":"Anti-PD-1 amplifies costimulation in melanoma-infiltrating T<sub>h</sub>1-like Foxp3<sup>+</sup> regulatory T cells to alleviate local immunosuppression","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; McGill University Health Centre","funders":"Institute of Infection and Immunity; McGill University Health Centre; McGill University","keywords":"Immunosuppression; FOXP3; Melanoma; Medicine; Metastatic melanoma; Cancer research; Immunology; Immune system","score_opus":0.010074564758653613,"score_gpt":0.28256035646270344,"score_spread":0.27248579170404985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406093333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96749127,0.011230507,0.012977121,0.000602935,0.0067255483,0.00068211637,0.000017148192,0.00004009635,0.0002332632],"genre_scores_gemma":[0.9938898,0.001985146,0.00012586414,0.0009298853,0.00007115086,0.00007783856,0.000038717764,0.000039308627,0.0028422866],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99791247,0.00021281138,0.0010447722,0.00030105253,0.00009921235,0.00042967097],"domain_scores_gemma":[0.9986518,0.00025159458,0.00046949057,0.000304121,0.00029637822,0.000026608981],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058839796,0.0002940055,0.0005688492,0.0005411627,0.00037972492,0.000054399843,0.00027012153,0.00028060668,0.0004211392],"category_scores_gemma":[0.000042806903,0.00026821313,0.00029825114,0.00028993597,0.00011780511,0.00033386817,0.000042255124,0.00055680773,0.000030928564],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028633995,0.00012258998,0.00089479674,0.00004794313,0.00035515366,9.4137374e-7,0.00071694184,0.020529926,0.8973525,0.000066844164,0.015259229,0.061789718],"study_design_scores_gemma":[0.004054044,0.00038238,0.008927822,0.000711915,0.000046693247,0.000022954888,0.0007064021,0.0006877541,0.8734289,0.00014563467,0.11061808,0.00026743053],"about_ca_topic_score_codex":0.00014924217,"about_ca_topic_score_gemma":0.000029259845,"teacher_disagreement_score":0.09535885,"about_ca_system_score_codex":0.00034228043,"about_ca_system_score_gemma":0.00021040256,"threshold_uncertainty_score":0.999977},"labels":[],"label_agreement":null},{"id":"W4406487264","doi":"10.1136/jitc-2024-010579","title":"Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Blood properties and coagulation","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"Deutsche Forschungsgemeinschaft","keywords":"Secretion; Tissue transglutaminase; Cancer research; Microtubule; Cancer; Cell biology; Pancreatic cancer; Cell; T cell; Medicine; Biology; Immunology; Internal medicine; Immune system; Enzyme","score_opus":0.014144229235313381,"score_gpt":0.30323917629353736,"score_spread":0.28909494705822397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406487264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86615026,0.12867023,0.0018174673,0.000940862,0.0008590151,0.0010834045,0.0000776377,0.000016490743,0.0003846542],"genre_scores_gemma":[0.96150166,0.034005072,0.00089748896,0.00020729893,0.00018434456,0.00017077607,0.000014346564,0.000043786637,0.002975252],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983417,0.00006667107,0.0007849751,0.0002111791,0.00032833766,0.0002671455],"domain_scores_gemma":[0.99843353,0.00007317146,0.0006153879,0.00026825385,0.00056993857,0.000039732462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019743496,0.00023951606,0.0006496759,0.000103647006,0.00016649766,0.000025263786,0.00017480002,0.00016309654,0.00054559216],"category_scores_gemma":[0.000011253392,0.00017538609,0.00035493818,0.00015962833,0.00009179041,0.00023031748,0.00001739401,0.00022953398,3.966855e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055365134,0.00035903577,0.0026695626,0.0013586837,0.00047380317,0.0000017519242,0.001677359,0.00014846816,0.95136714,0.00001890804,0.0007053418,0.035683453],"study_design_scores_gemma":[0.0072955643,0.0008902724,0.0070063006,0.0024627873,0.00062030583,0.000014422398,0.00052310043,0.00018001812,0.9732644,0.00034589687,0.007228891,0.00016805751],"about_ca_topic_score_codex":0.0011880546,"about_ca_topic_score_gemma":0.00004431167,"teacher_disagreement_score":0.09535139,"about_ca_system_score_codex":0.00018345019,"about_ca_system_score_gemma":0.0004028209,"threshold_uncertainty_score":0.7152037},"labels":[],"label_agreement":null},{"id":"W4406683378","doi":"10.1136/jitc-2024-010207","title":"Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment","year":2025,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Immunotherapy; Chimeric antigen receptor; Cancer immunotherapy; Cancer; Oncology; Intensive care medicine; Internal medicine","score_opus":0.12186916104096639,"score_gpt":0.48237948766339306,"score_spread":0.36051032662242666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406683378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000056663215,0.9901503,0.0001254374,0.00045255732,0.0007030055,0.003307252,0.000371761,0.000024025581,0.0048090504],"genre_scores_gemma":[0.000012743311,0.9548177,0.00050251797,0.00019155063,0.0005502582,0.00046670248,0.000049077647,0.00017880707,0.043230634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996261,0.0002588722,0.0015996649,0.00048188234,0.00082216936,0.00057639426],"domain_scores_gemma":[0.9958547,0.00086867245,0.0014530788,0.0007714929,0.0009189429,0.00013314882],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068300584,0.0007536161,0.0042325845,0.0010588927,0.0001956101,0.000047460137,0.00047314639,0.00039608145,0.0045169955],"category_scores_gemma":[0.000067143934,0.00053332094,0.0032391842,0.00058643747,0.0002295073,0.0000651433,0.000026031235,0.0007868211,0.0000091013635],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005205721,0.0006597975,0.000008986529,0.006353831,0.0076686954,0.000012027521,0.0006231735,0.000006766334,0.004106653,0.00019829955,0.0027642143,0.97239184],"study_design_scores_gemma":[0.0066115344,0.003855916,0.00002488122,0.028659767,0.0010868458,0.0001270709,0.00016464898,0.0000073495207,0.000671918,0.00015423019,0.95829475,0.00034106875],"about_ca_topic_score_codex":0.00017695273,"about_ca_topic_score_gemma":0.000022891982,"teacher_disagreement_score":0.9720508,"about_ca_system_score_codex":0.0038404176,"about_ca_system_score_gemma":0.0032555577,"threshold_uncertainty_score":0.99998367},"labels":[],"label_agreement":null},{"id":"W4407288611","doi":"10.1136/jitc-2024-009890","title":"Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"Iovance Biotherapeutics; Janssen Research and Development; National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; bluebird bio; Pharmacyclics; Takeda Oncology; Legend Biotech; U.S. Navy; Adaptive Biotechnologies; Health Resources and Services Administration; National Institutes of Health; CytoSen Therapeutics; MorphoSys; CareDx; BeiGene; Swedish Orphan Biovitrum; Astellas Pharma; CSL Behring; Kyowa Kirin Pharmaceutical Development; Atara Biotherapeutics; Vertex Pharmaceuticals; Anthem Foundation; GlaxoSmithKline; Kiadis Pharma; Sanofi; TG Therapeutics; Medac; Jazz Pharmaceuticals; Omeros Corporation; U.S. Department of Defense; Medical College of Wisconsin; StemCyte; AbbVie; Actinium Pharmaceuticals; Gilead Sciences; Stanford University; National Marrow Donor Program; Mallinckrodt Pharmaceuticals; Merck; Bristol-Myers Squibb; AstraZeneca; Astellas Pharma US; Be The Match Foundation; Novartis Pharmaceuticals Corporation; Dana-Farber Cancer Institute; Allogene Therapeutics; Incyte; Pfizer; Amgen; Boston Children's Hospital; HistoGenetics","keywords":"Medicine; Cytokine release syndrome; Fludarabine; Internal medicine; Oncology; Hematopoietic stem cell transplantation; Diffuse large B-cell lymphoma; Salvage therapy; Cohort; Lymphoma; Transplantation; Chimeric antigen receptor; Immunotherapy; Chemotherapy; Cancer; Cyclophosphamide","score_opus":0.04027750660366552,"score_gpt":0.41093005155627,"score_spread":0.37065254495260447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407288611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96267164,0.025714718,0.0002495477,0.005086837,0.0004473518,0.00080727914,0.00006387069,0.00001776602,0.0049409796],"genre_scores_gemma":[0.86463904,0.03130359,0.0012359995,0.0022712492,0.00044438642,0.0002138238,0.00001971863,0.00010668829,0.09976552],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980328,0.00011581438,0.000626729,0.00026448167,0.00056358735,0.00039656204],"domain_scores_gemma":[0.99773777,0.0006657884,0.00060608727,0.0005993374,0.00031732876,0.00007366877],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004930022,0.00025207934,0.00072341977,0.000337913,0.00017258566,0.00007066092,0.0004312576,0.00009986465,0.0011100275],"category_scores_gemma":[0.000054760665,0.00014581127,0.00037525382,0.00069816347,0.00022114642,0.000099195524,0.000029010671,0.0003997311,0.0000014133295],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019657034,0.00088003813,0.34875613,0.00014235624,0.0034420558,0.00013150548,0.0013596656,0.00012336903,0.44678286,0.000088690846,0.014193474,0.16444282],"study_design_scores_gemma":[0.04058722,0.0007702164,0.67979735,0.001976591,0.00044179455,0.000037186703,0.0010663995,0.000140965,0.17527926,0.0013077285,0.09821535,0.00037992973],"about_ca_topic_score_codex":0.0072821504,"about_ca_topic_score_gemma":0.0041100807,"teacher_disagreement_score":0.33104122,"about_ca_system_score_codex":0.000584026,"about_ca_system_score_gemma":0.0009968546,"threshold_uncertainty_score":0.99980307},"labels":[],"label_agreement":null},{"id":"W4407302463","doi":"10.1136/jitc-2024-010584","title":"TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Healthcare KGaA","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Tolerability; TIGIT; Gastroenterology; Internal medicine; Neutropenia; Chills; Pharmacology; Antibody; Oncology; Immunology; Chemotherapy; T cell; Adverse effect; Immune system","score_opus":0.01596827262127317,"score_gpt":0.38408734006559386,"score_spread":0.3681190674443207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407302463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948017,0.0009055953,0.0000841524,0.0017267464,0.0001841832,0.0021579815,0.000017137114,0.000007794308,0.000114681076],"genre_scores_gemma":[0.9961443,0.0012277943,0.0003132079,0.00030067304,0.00011415991,0.00026315489,0.00002788872,0.000035886438,0.0015729577],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99810284,0.000057462923,0.00076966785,0.0002276077,0.00049795385,0.00034447003],"domain_scores_gemma":[0.9990607,0.00013079295,0.00031226332,0.00014218189,0.00029167614,0.000062377156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003407341,0.00021460385,0.0006010196,0.0006564722,0.00009754563,0.000035206926,0.00012789569,0.00009022167,0.00018429718],"category_scores_gemma":[0.0000325187,0.00013849858,0.00009635377,0.0005868135,0.00009325609,0.0002553189,0.000008756231,0.00038163387,6.006334e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7699155,0.0038357165,0.09869899,0.00019452513,0.00023871579,0.000028272701,0.00081338035,0.00048305746,0.0063798656,0.00011380785,0.00017747609,0.11912067],"study_design_scores_gemma":[0.64369214,0.030297037,0.29793128,0.0045846356,0.000034691788,0.0000099503395,0.00015919826,0.00075253355,0.011858373,0.0007851007,0.009541308,0.0003537446],"about_ca_topic_score_codex":0.00046976114,"about_ca_topic_score_gemma":0.0013469538,"teacher_disagreement_score":0.19923231,"about_ca_system_score_codex":0.0004098276,"about_ca_system_score_gemma":0.0005245975,"threshold_uncertainty_score":0.56478083},"labels":[],"label_agreement":null},{"id":"W4407984288","doi":"10.1136/jitc-2024-010541","title":"Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Moonshot Research and Development Program; National Center for Advancing Translational Sciences; Cancer Moonshot; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Conquer Cancer Foundation","keywords":"Medicine; Oncology; Internal medicine; Cabozantinib; Nivolumab; Endometrial cancer; Cancer; Immunotherapy; Immunology","score_opus":0.024854151554562647,"score_gpt":0.3635282175853181,"score_spread":0.33867406603075545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407984288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8811374,0.115055546,0.00004824759,0.0024691026,0.0003104382,0.00080753665,0.00007529018,0.000004717248,0.000091738606],"genre_scores_gemma":[0.94243985,0.054380905,0.0016111202,0.00016486969,0.00006231011,0.00024950498,0.0000015789807,0.000017175058,0.0010727029],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99875313,0.00008617264,0.00050535635,0.00021766753,0.00019895498,0.00023871422],"domain_scores_gemma":[0.99894327,0.00042904992,0.00022937762,0.0001377834,0.00017796547,0.000082536935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040620714,0.00017834973,0.0006854374,0.000548298,0.00006426889,0.0000143372645,0.00006723396,0.000076620636,0.00006518069],"category_scores_gemma":[0.00011903087,0.00011313102,0.00011240781,0.0007160632,0.00013338072,0.00004831251,0.000014644962,0.000105430954,5.960638e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43319622,0.0004713296,0.059176948,0.00014434734,0.0017130844,0.000011350487,0.0004556533,0.0000030729461,0.059885494,0.00006111037,0.000097145436,0.44478422],"study_design_scores_gemma":[0.13878605,0.023160418,0.6392902,0.003846537,0.00058016996,0.000033401102,0.0004935778,0.000007109301,0.07874263,0.0004396021,0.11426337,0.00035691145],"about_ca_topic_score_codex":0.0005749176,"about_ca_topic_score_gemma":0.0005652119,"teacher_disagreement_score":0.5801133,"about_ca_system_score_codex":0.00041298155,"about_ca_system_score_gemma":0.00042244905,"threshold_uncertainty_score":0.4613349},"labels":[],"label_agreement":null},{"id":"W4408099016","doi":"10.1136/jitc-2024-009364","title":"Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Internal medicine; Metastasis; Adverse effect; Retrospective cohort study; Oncology; Cancer; Cardiology; Surgery","score_opus":0.012594358853010409,"score_gpt":0.32544774661509596,"score_spread":0.31285338776208554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408099016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9560997,0.037983138,0.00059242,0.0007312559,0.00079717,0.003479813,0.00028614243,0.000004470424,0.000025921234],"genre_scores_gemma":[0.963101,0.03573225,0.00044549152,0.00006629826,0.00007643173,0.00021097866,0.000009720628,0.000025406605,0.0003323761],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986157,0.000041418738,0.0007549065,0.0001619408,0.0002812875,0.0001447561],"domain_scores_gemma":[0.99816215,0.00019967141,0.0006573067,0.00024386036,0.0007151411,0.00002184835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041357073,0.00018541352,0.0006692554,0.00014289912,0.00011220648,0.000014002085,0.00013309547,0.0000419789,0.000058717287],"category_scores_gemma":[0.000019674264,0.00009867452,0.0005179394,0.00015100007,0.0001626184,0.00006170189,0.000007570748,0.00007374239,1.7510741e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2895166,0.004364946,0.24782355,0.000066606124,0.02748209,2.651152e-7,0.0047503267,0.000020478466,0.02156751,0.000022674369,0.00006118112,0.40432376],"study_design_scores_gemma":[0.066807576,0.009458477,0.86542404,0.00023779873,0.0006100993,6.5480765e-7,0.00092093454,0.000023988798,0.027786046,0.00001627954,0.028623017,0.00009107343],"about_ca_topic_score_codex":0.00024107848,"about_ca_topic_score_gemma":0.000022247556,"teacher_disagreement_score":0.6176005,"about_ca_system_score_codex":0.000276482,"about_ca_system_score_gemma":0.00017085267,"threshold_uncertainty_score":0.402383},"labels":[],"label_agreement":null},{"id":"W4408213392","doi":"10.1136/jitc-2024-010928","title":"Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Immunotherapy; Biomarker; Clinical trial; Cancer immunotherapy; Oncology; Cancer; Immunology; Internal medicine; Biology","score_opus":0.048968913838723954,"score_gpt":0.4640198424156276,"score_spread":0.4150509285769036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408213392","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6525933,0.13039035,0.046406966,0.029835237,0.014493358,0.12095403,0.004615071,0.00023222895,0.00047943208],"genre_scores_gemma":[0.21813394,0.33039236,0.12980415,0.04867888,0.009565,0.21383682,0.00057106424,0.0023958513,0.046621922],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99382406,0.00015814208,0.0035755634,0.0007370495,0.0007467374,0.0009584209],"domain_scores_gemma":[0.9935378,0.0011674602,0.0025826185,0.0008571212,0.0017071858,0.00014781032],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032090165,0.00074694457,0.0020470796,0.0004180203,0.0005450031,0.00009838596,0.0006475257,0.0005317619,0.0005654575],"category_scores_gemma":[0.000090007845,0.0006110111,0.004340297,0.0005448534,0.00074820174,0.00014204468,0.000027937404,0.0005033403,5.885144e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20086716,0.0014855656,0.0030891458,0.0011803694,0.020071084,0.0000012570437,0.00060933054,0.00007099845,0.3783579,0.0002432016,0.064529985,0.32949403],"study_design_scores_gemma":[0.08348555,0.008057379,0.006295837,0.0031232082,0.0005867454,0.0000119148735,0.0005278224,0.00043467333,0.19845329,0.0010273558,0.6973066,0.0006896485],"about_ca_topic_score_codex":0.00041018057,"about_ca_topic_score_gemma":0.0000914853,"teacher_disagreement_score":0.6327766,"about_ca_system_score_codex":0.00090890337,"about_ca_system_score_gemma":0.0029923085,"threshold_uncertainty_score":0.99963415},"labels":[],"label_agreement":null},{"id":"W4408802828","doi":"10.1136/jitc-2024-010681","title":"Microbial Ecosystem Therapeutics 4 (MET4) elicits treatment-specific IgG responses associated with changes in gut microbiota in immune checkpoint inhibitor recipients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Conquer Cancer Foundation","keywords":"Immune system; Antibody; Immunology; Immunity; CD14; Medicine; Gut flora; Microbiome; Immunoglobulin G; Flow cytometry; FOXP3; Peripheral blood mononuclear cell; Biology; In vitro; Bioinformatics","score_opus":0.015914387534118456,"score_gpt":0.3244449996153729,"score_spread":0.30853061208125443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408802828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788344,0.019342085,0.00003368306,0.0003879869,0.00022906247,0.00088858546,0.0002542688,0.0000054408465,0.00002446739],"genre_scores_gemma":[0.9808158,0.01743271,0.00021027843,0.00008927371,0.000077873454,0.00024996995,0.000059073293,0.000050646206,0.0010143602],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838823,0.00013018235,0.0005098658,0.00032853018,0.00016531245,0.00047787733],"domain_scores_gemma":[0.99903554,0.00004368416,0.0003739169,0.0002708019,0.00022886123,0.000047187634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028255454,0.0002957901,0.0005131848,0.0003219364,0.000109672656,0.00004893274,0.0002178951,0.0001318329,0.000016823355],"category_scores_gemma":[0.000012464221,0.00021397397,0.00014171477,0.0003522361,0.00007184541,0.000014560524,0.000023807728,0.00016136839,3.359866e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023984658,0.0004908482,0.008933698,0.000025055158,0.0009141353,0.000013332149,0.00023010057,0.00013601001,0.9426759,0.0000013346307,0.000049513972,0.02254541],"study_design_scores_gemma":[0.019243788,0.0043652193,0.03345994,0.0014226559,0.000035252873,0.000021754538,0.00015313363,0.000007834595,0.9221952,0.000012963531,0.018823275,0.00025896594],"about_ca_topic_score_codex":0.00021033536,"about_ca_topic_score_gemma":0.015172814,"teacher_disagreement_score":0.02452624,"about_ca_system_score_codex":0.0007190795,"about_ca_system_score_gemma":0.0005622309,"threshold_uncertainty_score":0.8725605},"labels":[],"label_agreement":null},{"id":"W4408881986","doi":"10.1136/jitc-2024-010791","title":"Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Oxaliplatin; Cancer research; Colorectal cancer; Tumor microenvironment; Immune system; Antibody; Cancer; Immunology; Internal medicine","score_opus":0.02051684446937839,"score_gpt":0.31750323658377405,"score_spread":0.29698639211439565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408881986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85254985,0.14040127,0.00004731797,0.0044664177,0.00026707165,0.002222808,0.000015429874,0.0000078203775,0.000021985323],"genre_scores_gemma":[0.948624,0.050123774,0.00003574288,0.0008525292,0.00006387787,0.00024710866,0.0000067247893,0.000022043241,0.0000241984],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99840504,0.00021540165,0.0006391788,0.00024579107,0.00022471989,0.0002698632],"domain_scores_gemma":[0.99900717,0.0002452014,0.0004246508,0.00013462747,0.00015258197,0.000035772246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012244735,0.00024792523,0.0006834547,0.00036902537,0.00017055319,0.00006865697,0.00012145194,0.0001206697,0.000004436503],"category_scores_gemma":[0.000023557674,0.0001742968,0.00008063379,0.00029358172,0.00024829857,0.00014161294,0.000017101827,0.00034216864,3.9526856e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01116636,0.00024298215,0.03598367,0.00052174716,0.0003007997,0.0000132240575,0.0026707696,0.0000023540608,0.9052878,0.00010644712,0.000041652187,0.043662164],"study_design_scores_gemma":[0.061426997,0.0033414268,0.74042594,0.004877629,0.000085947184,0.0003311653,0.004627981,0.0003712063,0.18183367,0.0002953081,0.0019463977,0.00043630763],"about_ca_topic_score_codex":0.00046794218,"about_ca_topic_score_gemma":0.0003395255,"teacher_disagreement_score":0.7234542,"about_ca_system_score_codex":0.00018375603,"about_ca_system_score_gemma":0.00014529064,"threshold_uncertainty_score":0.7107617},"labels":[],"label_agreement":null},{"id":"W4408922776","doi":"10.1136/jitc-2024-011273","title":"Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; National Center for Advancing Translational Sciences; National Human Genome Research Institute; National Institute of Diabetes and Digestive and Kidney Diseases; NIH Office of the Director; National Heart, Lung, and Blood Institute; U.S. Food and Drug Administration; Fiona and Stanley Druckenmiller Center for Lung Cancer Research; National Cancer Institute; National Institutes of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Princess Margaret Cancer Foundation; Larry L. Hillblom Foundation","keywords":"Discontinuation; Adverse effect; Immune system; Medicine; Immune checkpoint; Immunology; Immunotherapy; Internal medicine","score_opus":0.01334862461884169,"score_gpt":0.3210786169146588,"score_spread":0.3077299922958171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408922776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9459625,0.0378329,0.007065926,0.002260632,0.0040540043,0.0023431177,0.00028706534,0.00003236945,0.00016151006],"genre_scores_gemma":[0.97990507,0.009781707,0.0017616226,0.00018244213,0.00033628548,0.00032012555,0.00009899478,0.00006605462,0.0075476873],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972458,0.000041003248,0.0019354122,0.00020319349,0.00030115806,0.00027345956],"domain_scores_gemma":[0.9975762,0.0001018296,0.0012871646,0.000295007,0.0006975284,0.000042300064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001074119,0.00023074755,0.0007016828,0.000353571,0.00016159577,0.000007838291,0.00016427756,0.00019105151,0.0002086896],"category_scores_gemma":[0.00008282791,0.0001901438,0.0011693097,0.00034711993,0.00012193144,0.00020057865,0.000014414413,0.00021595124,3.446987e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026327299,0.00046772402,0.0035529984,0.00036833406,0.0024335324,3.8713353e-7,0.00049451244,0.00006679554,0.8854724,0.00007833978,0.0005962763,0.08014138],"study_design_scores_gemma":[0.04833641,0.003082829,0.17191195,0.0041966317,0.0007302514,0.00002901671,0.00046754288,0.0009175247,0.72421515,0.0012367246,0.044592664,0.0002832975],"about_ca_topic_score_codex":0.00012099824,"about_ca_topic_score_gemma":0.00001097354,"teacher_disagreement_score":0.16835895,"about_ca_system_score_codex":0.00034147056,"about_ca_system_score_gemma":0.00049618934,"threshold_uncertainty_score":0.7753839},"labels":[],"label_agreement":null},{"id":"W4408943423","doi":"10.1136/jitc-2024-010419","title":"SITC strategic vision: prevention, premalignant immunity, host and environmental factors","year":2025,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Western University; Lawson Health Research Institute; Ontario Institute for Cancer Research","funders":"University of Texas MD Anderson Cancer Center; Society for Immunotherapy of Cancer","keywords":"Immune system; Immunotherapy; Medicine; Immunology; Cancer; Immunity; Cancer immunotherapy; Microbiome; Bioinformatics; Internal medicine; Biology","score_opus":0.047144551982480264,"score_gpt":0.3938186957324736,"score_spread":0.34667414374999334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408943423","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025650852,0.9939005,0.000040728763,0.00007913237,0.0010506052,0.0018290476,0.00036804256,0.0000163367,0.00015054981],"genre_scores_gemma":[0.00035250536,0.9931792,0.00013523185,0.000077112105,0.00022921072,0.00012727163,0.00016946945,0.00008270269,0.0056473045],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99738556,0.0001534452,0.0013621086,0.00033867703,0.00040361352,0.00035660318],"domain_scores_gemma":[0.99791837,0.00022112892,0.0012397813,0.0004248424,0.00008656252,0.00010934714],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005365209,0.0005814038,0.0021326756,0.00040234387,0.0002936977,0.000087371525,0.00029726303,0.00040383718,0.00064586796],"category_scores_gemma":[0.000011219955,0.00040399216,0.0015808087,0.00023345336,0.00022626453,0.00014235212,0.00004762517,0.0005772696,6.3706887e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015647989,0.00033826526,0.00008357645,0.013838879,0.0040658433,0.000005522354,0.00020611112,2.6555423e-7,0.0016132399,0.000020683274,0.00069119636,0.9775716],"study_design_scores_gemma":[0.0036996321,0.0016972458,0.0003017238,0.042465262,0.0018598121,0.00021061114,0.00029590796,0.0000015158224,0.000247136,0.00014210187,0.94866085,0.00041822123],"about_ca_topic_score_codex":0.000056815563,"about_ca_topic_score_gemma":0.000012272482,"teacher_disagreement_score":0.9771534,"about_ca_system_score_codex":0.00046457333,"about_ca_system_score_gemma":0.0012159022,"threshold_uncertainty_score":0.9998412},"labels":[],"label_agreement":null},{"id":"W4409252004","doi":"10.1136/jitc-2024-011049","title":"Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Project Data Sphere","keywords":"Medicine; Uveitis; Delphi method; Adverse effect; Family medicine; Disease; Usability; Ophthalmology; Internal medicine; Artificial intelligence; Computer science","score_opus":0.025072726287116723,"score_gpt":0.3355969537691115,"score_spread":0.31052422748199476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409252004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91747516,0.07263742,0.0005043221,0.0035197935,0.0029607622,0.0020474012,0.0004665713,0.000029584287,0.00035900998],"genre_scores_gemma":[0.98462635,0.0102765,0.0012966458,0.00027849124,0.00012187706,0.00030027857,0.000049431066,0.0000681942,0.0029822006],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99711823,0.000053231637,0.0019350534,0.00023175334,0.0002962163,0.00036548695],"domain_scores_gemma":[0.99744475,0.00023268162,0.0011496787,0.0003955624,0.0006749346,0.000102374295],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007336498,0.0002859204,0.00078502187,0.00041576492,0.00024443265,0.000008123684,0.00021548533,0.00015954862,0.00033656813],"category_scores_gemma":[0.00013716544,0.00024656358,0.0017737322,0.00041182528,0.00026483386,0.00008094838,0.000020095862,0.0002547786,8.719715e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06341969,0.000959314,0.0061963894,0.0010983375,0.0054630907,0.000006646085,0.00048385837,0.00015824966,0.8899759,0.0005831886,0.0015677129,0.030087616],"study_design_scores_gemma":[0.09795777,0.0036297431,0.20974962,0.011238313,0.002529563,0.00021497255,0.0013561617,0.0004805392,0.5955756,0.014841457,0.06138962,0.0010366874],"about_ca_topic_score_codex":0.00016782836,"about_ca_topic_score_gemma":0.000006586546,"teacher_disagreement_score":0.29440036,"about_ca_system_score_codex":0.00033439277,"about_ca_system_score_gemma":0.0012030365,"threshold_uncertainty_score":0.9999987},"labels":[],"label_agreement":null},{"id":"W4409535425","doi":"10.1136/jitc-2024-010684","title":"Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapy","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Flow cytometry; T cell; Cancer research; Biology; In vivo; Leukemia; Ex vivo; T-cell receptor; Cell; Single-cell analysis; Phenotype; Cancer; RNA; Jurkat cells; Molecular biology; Immunology; Gene; Immune system; Genetics","score_opus":0.055193438543429695,"score_gpt":0.3742840893308047,"score_spread":0.31909065078737503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409535425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90582204,0.08210574,0.0022445272,0.0013367666,0.0013123042,0.0040576644,0.00022213765,0.00003132579,0.0028674786],"genre_scores_gemma":[0.8158999,0.024008317,0.0035226468,0.0014575594,0.0009916214,0.00085067895,0.000024094425,0.00024931855,0.15299587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971946,0.000095568816,0.0010696191,0.00038036105,0.0006276581,0.00063219294],"domain_scores_gemma":[0.9965063,0.00039838234,0.00088757713,0.0004743529,0.0016092245,0.0001242144],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011321667,0.00037586997,0.0011373102,0.00048987014,0.00031008443,0.000059518567,0.00041063293,0.000295897,0.0025254048],"category_scores_gemma":[0.000024519091,0.00030768334,0.00083603873,0.0005480181,0.00023106912,0.00017157497,0.000024604946,0.0006480864,5.0233587e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012590591,0.00034438918,0.00021969182,0.0006922609,0.0013399991,0.0000032408072,0.001409861,0.0002784856,0.9347903,0.00007690426,0.005786248,0.04246799],"study_design_scores_gemma":[0.019467954,0.0020118388,0.000043843866,0.0011907266,0.00014380955,0.0000033341216,0.0004348495,0.000065358785,0.9170786,0.0017975827,0.057522465,0.00023963941],"about_ca_topic_score_codex":0.00079368905,"about_ca_topic_score_gemma":0.00009075858,"teacher_disagreement_score":0.1501284,"about_ca_system_score_codex":0.0010255377,"about_ca_system_score_gemma":0.0014077812,"threshold_uncertainty_score":0.99993753},"labels":[],"label_agreement":null},{"id":"W4409613957","doi":"10.1136/jitc-2025-011829","title":"MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aptose Biosciences (Canada); Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Stem Cell Network; Institute of Infection and Immunity; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Chimeric antigen receptor; Receptor; Immune system; T cell; Cancer immunotherapy; Modular design; Immunotherapy; Cancer research; Antigen; Biology; Immunology; Medicine; Computer science; Internal medicine","score_opus":0.015918664833253077,"score_gpt":0.3158186075849806,"score_spread":0.2998999427517275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409613957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.874361,0.1169912,0.0057083257,0.0010255476,0.00062661845,0.0010435521,0.00004995073,0.000026697324,0.00016713113],"genre_scores_gemma":[0.9161602,0.05024198,0.004599048,0.00068937265,0.00028835758,0.00029390055,0.00001182617,0.0001282521,0.027587028],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99779004,0.00006767242,0.00070807006,0.00038530366,0.00050044665,0.00054847467],"domain_scores_gemma":[0.9984477,0.00014629861,0.0005149879,0.00032344164,0.00046277323,0.000104776984],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007505837,0.00032716285,0.00063916825,0.0003470987,0.0003690508,0.00011446234,0.00026057064,0.0001663397,0.00092064595],"category_scores_gemma":[0.000023308497,0.00029243962,0.00039537155,0.00039605514,0.00019266957,0.0002180485,0.00002968372,0.0004955007,7.1225827e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030294661,0.00025248225,0.0037729198,0.00051739026,0.00054453145,6.846321e-7,0.00091046613,0.00008222,0.9130809,0.0000017265877,0.00047208622,0.07733517],"study_design_scores_gemma":[0.008425809,0.0008792044,0.007906012,0.0011262785,0.00013558858,0.000005995719,0.00041800857,0.0009144432,0.93682677,0.000030889,0.043033727,0.00029730293],"about_ca_topic_score_codex":0.00096384244,"about_ca_topic_score_gemma":0.000025175754,"teacher_disagreement_score":0.07703786,"about_ca_system_score_codex":0.00039312537,"about_ca_system_score_gemma":0.00068181806,"threshold_uncertainty_score":0.99999267},"labels":[],"label_agreement":null},{"id":"W4410186945","doi":"10.1136/jitc-2024-010073","title":"BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario College of Art and Design","funders":"China Postdoctoral Science Foundation; Ministry of Education; National Natural Science Foundation of China","keywords":"Venetoclax; Cancer research; Chimeric antigen receptor; Antigen; In vivo; Medicine; In vitro; Cancer; Immunology; Immunotherapy; Biology; Leukemia; Internal medicine","score_opus":0.01716655082443336,"score_gpt":0.350663301073179,"score_spread":0.33349675024874564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410186945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95285577,0.03361381,0.0056747566,0.0015384377,0.0014669687,0.0034364958,0.00013770137,0.000041273284,0.0012347987],"genre_scores_gemma":[0.6814392,0.06951649,0.02511079,0.0032164194,0.0034062774,0.005006645,0.000043119464,0.0006931689,0.21156788],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99783087,0.000054070413,0.00070990616,0.00033605407,0.00043210995,0.00063699024],"domain_scores_gemma":[0.9978214,0.00037856837,0.00046782944,0.00039319397,0.0007966824,0.00014234504],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006369873,0.00033131576,0.00083432975,0.0003335463,0.00029296035,0.00007678623,0.00030438715,0.00019899812,0.0014955876],"category_scores_gemma":[0.000023970386,0.0002451744,0.00053115806,0.0003731858,0.0001264226,0.000084844105,0.00001954325,0.0005903086,4.323326e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016296944,0.00012815968,0.0016797766,0.0006872868,0.0013465793,0.000006569909,0.0005367068,0.0006917116,0.9103865,0.000027388318,0.0016164818,0.06659591],"study_design_scores_gemma":[0.020031216,0.0011540339,0.00035273493,0.0012524583,0.00043241194,0.000023005792,0.00021622845,0.0022276633,0.823386,0.000103744256,0.15055566,0.00026482058],"about_ca_topic_score_codex":0.00058012735,"about_ca_topic_score_gemma":0.00034575642,"teacher_disagreement_score":0.27141654,"about_ca_system_score_codex":0.0009327822,"about_ca_system_score_gemma":0.0023996807,"threshold_uncertainty_score":0.9997921},"labels":[],"label_agreement":null},{"id":"W4410268064","doi":"10.1136/jitc-2024-010548","title":"The cold immunological landscape of ATM-deficient cancers","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Telesta Therapeutics (Canada)","funders":"National Cancer Institute; Starr Cancer Consortium","keywords":"Cancer research; Biology; DNA repair; Olaparib; Immune system; Immune checkpoint; Tumor-infiltrating lymphocytes; PARP inhibitor; DNA damage; Immunotherapy; Immunology; Poly ADP ribose polymerase; Gene; DNA; Polymerase; Genetics","score_opus":0.015149643538691459,"score_gpt":0.3357400251105151,"score_spread":0.3205903815718236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410268064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64894587,0.3370047,0.0008841707,0.0064591365,0.003366511,0.0010604317,0.00005965897,0.000024296045,0.0021952207],"genre_scores_gemma":[0.8853357,0.103281,0.00052724255,0.0013100124,0.00020428924,0.00016260719,0.0000032745393,0.000036576224,0.009139312],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984443,0.000044496806,0.000751404,0.00014801505,0.00030558984,0.00030615123],"domain_scores_gemma":[0.99846715,0.00025141123,0.00049751636,0.000315173,0.00043246403,0.000036266974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067822717,0.00017008382,0.00047998902,0.00013884406,0.00030243685,0.000029598368,0.00028971324,0.00011795355,0.00021564374],"category_scores_gemma":[0.000043738546,0.00010026128,0.00054130686,0.0003698029,0.00032788873,0.000048543796,0.000018615932,0.00024832334,3.8976052e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03505886,0.00022597967,0.006943918,0.00017159645,0.003208723,0.0000024033072,0.00039562624,0.00011009607,0.6304763,0.0018734204,0.01731975,0.30421332],"study_design_scores_gemma":[0.011083698,0.0015548802,0.02550656,0.0007729915,0.00020215889,0.000036451507,0.0007085785,0.00010512751,0.11889513,0.00039906727,0.84056157,0.0001737922],"about_ca_topic_score_codex":0.0002025725,"about_ca_topic_score_gemma":0.000048445214,"teacher_disagreement_score":0.82324183,"about_ca_system_score_codex":0.00033056235,"about_ca_system_score_gemma":0.0009248399,"threshold_uncertainty_score":0.40885362},"labels":[],"label_agreement":null},{"id":"W4410548822","doi":"10.1136/jitc-2024-010570","title":"Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse; National Heart, Lung, and Blood Institute; Fonds de Recherche du Québec - Santé; Institut Du Cancer de Montréal; National Institutes of Health; Université de Montréal; Fondation du cancer du sein du Québec","keywords":"Oncolytic virus; Adjuvant; Vesicular stomatitis virus; Immune system; Vaccination; Virology; Antigen; Virus; Immunology; Immunotherapy; Medicine; Biology","score_opus":0.020014269570507916,"score_gpt":0.3711631262187259,"score_spread":0.351148856648218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410548822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95846325,0.031054923,0.0066813203,0.0016498242,0.0009582152,0.0005746036,0.00005457278,0.000009365262,0.0005538993],"genre_scores_gemma":[0.9780448,0.014126118,0.0003662442,0.0006300556,0.00035955326,0.00016318349,0.000011551257,0.00003806181,0.006260415],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986837,0.000076645156,0.00044021662,0.00023204289,0.00024746402,0.00031992304],"domain_scores_gemma":[0.99883544,0.000051314175,0.00021991375,0.0003146304,0.0005316085,0.000047087313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005195577,0.0001725979,0.00029091127,0.0001459369,0.00021851186,0.000060648363,0.00033299622,0.00012745593,0.00031699493],"category_scores_gemma":[0.00006549854,0.00015238677,0.00025870925,0.00016307642,0.0001095754,0.000012643561,0.000028034525,0.000159391,0.0000012571978],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006486722,0.000078694655,0.00022947449,0.000056403114,0.0003708391,2.3027283e-7,0.00012081543,0.00027954776,0.82139814,0.000043783704,0.0026760362,0.1682593],"study_design_scores_gemma":[0.0030491797,0.002250617,0.0017195137,0.00009214487,0.00002612182,0.0000023660248,0.00010451761,0.000078527555,0.9080944,0.0011276535,0.08329647,0.00015848895],"about_ca_topic_score_codex":0.000034977376,"about_ca_topic_score_gemma":0.00024038089,"teacher_disagreement_score":0.1681008,"about_ca_system_score_codex":0.00015949801,"about_ca_system_score_gemma":0.0008919772,"threshold_uncertainty_score":0.6214152},"labels":[],"label_agreement":null},{"id":"W4410712213","doi":"10.1136/jitc-2024-011404","title":"IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Neurological Disorders and Stroke; National Institute of Mental Health; National Cancer Institute; Ludwig Institute for Cancer Research; National Foundation for Cancer Research","keywords":"Medicine; Pancreatic cancer; Oncology; FOLFIRINOX; Immune checkpoint; Internal medicine; Blockade; Cancer; Cardiotoxicity; Chemoimmunotherapy; Chemotherapy; Immunotherapy; Receptor","score_opus":0.007628141211374882,"score_gpt":0.28763999250250477,"score_spread":0.2800118512911299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410712213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9243543,0.070866294,0.00006495145,0.0030409652,0.00023595602,0.0013347889,0.000043680855,0.000009092358,0.000049956718],"genre_scores_gemma":[0.9211237,0.07701588,0.00040263592,0.0006043638,0.00009217268,0.0001196138,0.000001690334,0.000037309263,0.00060267764],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982226,0.00007632729,0.00083220174,0.00026664056,0.00028378333,0.00031848333],"domain_scores_gemma":[0.99868566,0.00019734073,0.00059051294,0.0002844851,0.0001842503,0.00005774543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075239554,0.0002910235,0.0008576682,0.00020018086,0.0001650835,0.00003131228,0.00018944395,0.00012868464,0.000028906368],"category_scores_gemma":[0.000027079977,0.00018425657,0.0002910512,0.00036753455,0.0004373741,0.0000958177,0.000024187548,0.00033632055,2.862513e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02181773,0.00027453728,0.044787597,0.00048329448,0.0027624017,0.0000021431724,0.0015464372,0.000029706918,0.77621436,0.000005907636,0.00009546423,0.15198043],"study_design_scores_gemma":[0.02354024,0.00085796835,0.58340514,0.0027911249,0.0003640763,0.000037991587,0.0005490566,0.0001457144,0.38177812,0.000083579915,0.006199053,0.0002479645],"about_ca_topic_score_codex":0.0014811687,"about_ca_topic_score_gemma":0.00021476901,"teacher_disagreement_score":0.5386175,"about_ca_system_score_codex":0.0002442642,"about_ca_system_score_gemma":0.0005088304,"threshold_uncertainty_score":0.7513765},"labels":[],"label_agreement":null},{"id":"W4410791528","doi":"10.1136/jitc-2024-011184","title":"Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Adjuvant; Stage (stratigraphy); Delphi method; Adjuvant therapy; Adverse effect; Oncology; Perioperative; Internal medicine; Neoadjuvant therapy; Cancer; Surgery; Breast cancer","score_opus":0.04205604431233636,"score_gpt":0.3922910191002602,"score_spread":0.35023497478792387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410791528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890132,0.0083494,0.000048359656,0.00038862549,0.00035574476,0.0017235478,0.00004170513,0.00001502679,0.00006437028],"genre_scores_gemma":[0.99520457,0.0026981726,0.00032128565,0.00021521207,0.00008494782,0.00026134212,0.0000017227048,0.0000389129,0.001173861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808234,0.000110012494,0.00090655085,0.00028543154,0.00028264624,0.00033302786],"domain_scores_gemma":[0.99879545,0.00018112913,0.0003780316,0.0003308965,0.0002271719,0.000087299624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037560595,0.0003080801,0.000936405,0.00028381764,0.00010676531,0.000040752555,0.00009848609,0.00010462655,0.00008868375],"category_scores_gemma":[0.000015468873,0.00018370486,0.00031914355,0.00024301292,0.0001207124,0.00006049883,0.00001016215,0.0002475045,2.95454e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015176212,0.000961191,0.9535721,0.0000389749,0.0028780068,0.00008787637,0.009491113,0.00012859148,0.0006978381,0.000018943281,0.00002205179,0.016927093],"study_design_scores_gemma":[0.023015216,0.0073094894,0.9595577,0.00068363856,0.00029566418,0.000011799582,0.0046844245,0.00004740907,0.0010762076,0.00006726982,0.003066993,0.00018415807],"about_ca_topic_score_codex":0.004860405,"about_ca_topic_score_gemma":0.0021409055,"teacher_disagreement_score":0.016742935,"about_ca_system_score_codex":0.0007985699,"about_ca_system_score_gemma":0.0008901018,"threshold_uncertainty_score":0.74912673},"labels":[],"label_agreement":null},{"id":"W4410918597","doi":"10.1136/jitc-2025-011682","title":"Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto; St. Thomas Hospital; University Health Network","funders":"Guy's and St Thomas' Charity; British Skin Foundation; Royal Society; Cancer Research UK; Wellcome Trust","keywords":"Immunology; Antibody; Medicine; Melanoma; Memory B cell; Immune system; Immunoglobulin E; B cell; Toxicity; Immunotherapy; Immune checkpoint; Cancer research; Internal medicine","score_opus":0.017328475149311004,"score_gpt":0.3499550727543015,"score_spread":0.33262659760499047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410918597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97589225,0.021044249,0.00020503752,0.00055133697,0.0005229189,0.0014695874,0.000076904675,0.0000142356575,0.00022350257],"genre_scores_gemma":[0.99328285,0.0045338725,0.0012216517,0.00020986254,0.0001002938,0.0001147997,0.00000849243,0.000035068475,0.00049309287],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982129,0.000053340485,0.000917625,0.00027180862,0.00024277173,0.00030158917],"domain_scores_gemma":[0.99881816,0.00010214884,0.0005206475,0.00025672835,0.00023447436,0.000067849214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042145376,0.0002675007,0.00081248995,0.00039762256,0.000099280245,0.00001928759,0.00011437528,0.0001312805,0.00006134329],"category_scores_gemma":[0.000025943471,0.00021375639,0.00031678323,0.00034710535,0.00013568053,0.00014094001,0.000021003581,0.0001706277,1.4432305e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009773259,0.00040152986,0.05059868,0.00029850448,0.00060609373,0.000005061211,0.0013697944,0.00006149926,0.8656253,0.000012923631,0.00006446205,0.07118288],"study_design_scores_gemma":[0.0103162555,0.0017265971,0.35152414,0.0015289371,0.00008112772,0.000018603747,0.0005120584,0.000103695136,0.6303405,0.000061040795,0.0036344663,0.00015260077],"about_ca_topic_score_codex":0.00039881625,"about_ca_topic_score_gemma":0.00004240375,"teacher_disagreement_score":0.30092546,"about_ca_system_score_codex":0.0006749621,"about_ca_system_score_gemma":0.0006499942,"threshold_uncertainty_score":0.8716732},"labels":[],"label_agreement":null},{"id":"W4411219862","doi":"10.1136/jitc-2025-011474","title":"IL-4-STAT6-induced high Siglec-G/10 expression aggravates the severe immune suppressive tumor microenvironment and impedes the efficacy of immunotherapy in head and neck squamous cell carcinoma","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Natural Science Foundation of China","keywords":"Medicine; Immunotherapy; Tumor microenvironment; Immune system; Head and neck squamous-cell carcinoma; Cancer research; Head and neck; Basal cell; T cell; Immunology; Pathology; Head and neck cancer; Internal medicine; Radiation therapy","score_opus":0.008342048639066858,"score_gpt":0.28647507645391207,"score_spread":0.2781330278148452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411219862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94553167,0.052776564,0.00004384479,0.0007653651,0.00010276152,0.0006940865,0.000037283484,0.0000015610251,0.00004684604],"genre_scores_gemma":[0.99009395,0.00866777,0.00014849367,0.0001202163,0.000048438742,0.000079054276,0.000008652061,0.000022845486,0.000810585],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878865,0.00013941598,0.00044511748,0.000207586,0.00017323409,0.00024601177],"domain_scores_gemma":[0.9991054,0.00013263106,0.00031093624,0.00031387043,0.00010636959,0.000030800715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003292816,0.00018185469,0.00026151905,0.00008152913,0.00022302833,0.000043801167,0.00028877138,0.00008928722,0.00006978645],"category_scores_gemma":[0.000037073958,0.00010881429,0.00012372877,0.00009382661,0.00018717538,0.000011115363,0.000075025804,0.00020788914,1.5527019e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036483717,0.000105017694,0.0022039346,0.000051414598,0.000064933716,9.685746e-7,0.00042542684,0.00009584492,0.9763141,0.0000078692765,0.00031235287,0.016769744],"study_design_scores_gemma":[0.006339197,0.00070370804,0.073045105,0.00011935428,0.000012039392,0.000012443094,0.00030032537,0.000027570728,0.9070431,0.000110243695,0.012171381,0.000115525436],"about_ca_topic_score_codex":0.00039590066,"about_ca_topic_score_gemma":0.000058204634,"teacher_disagreement_score":0.07084117,"about_ca_system_score_codex":0.000035136945,"about_ca_system_score_gemma":0.00013481313,"threshold_uncertainty_score":0.4437318},"labels":[],"label_agreement":null},{"id":"W4411319666","doi":"10.1136/jitc-2024-011364","title":"Blockade of colon cancer metastasis via single and double silencing of <i>PCSK7</i> / <i>PCSK9</i> : enhanced T cells cytotoxicity in mouse and human","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Montreal Clinical Research Institute","funders":"Canada Research Chairs; Québec Consortium for Drug Discovery; Cancer Research Society","keywords":"Proprotein convertase; Cancer research; T cell; Kexin; Cytotoxic T cell; Immune checkpoint; Biology; Immune system; CD8; Immunotherapy; Immunology; LDL receptor; Endocrinology; Cholesterol","score_opus":0.025767333762424804,"score_gpt":0.360806984194092,"score_spread":0.3350396504316672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411319666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803785,0.017732497,0.000341553,0.00028953518,0.00015385455,0.00084003847,0.000056851666,0.0000065219433,0.0002006394],"genre_scores_gemma":[0.9868041,0.0096083945,0.0005553902,0.00015542933,0.00006463264,0.00007772671,0.0000014293119,0.000036927424,0.00269592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820167,0.00006416936,0.00082116557,0.00022961418,0.00036491716,0.0003184806],"domain_scores_gemma":[0.99866647,0.00015737524,0.00048755805,0.00023276206,0.00037838487,0.00007746936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006812011,0.00020188792,0.00088168547,0.00039679004,0.000092290495,0.000018273211,0.00014895164,0.00012364417,0.00033323446],"category_scores_gemma":[0.000012325079,0.0001785832,0.00018619606,0.00035680368,0.00025861614,0.000107880056,0.000038872127,0.0003260867,4.7136652e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006243376,0.0003093993,0.0026481568,0.0006149041,0.00055441965,0.0000015572625,0.00097303593,0.00010341064,0.9572706,0.00001524967,0.000106362364,0.03115953],"study_design_scores_gemma":[0.010600669,0.0009937028,0.0009513117,0.00074948644,0.00011129508,0.000006811881,0.00021175013,0.000046911988,0.98401123,0.00015967184,0.0020304627,0.00012667892],"about_ca_topic_score_codex":0.0026548835,"about_ca_topic_score_gemma":0.0010521073,"teacher_disagreement_score":0.03103285,"about_ca_system_score_codex":0.0002575196,"about_ca_system_score_gemma":0.00030206188,"threshold_uncertainty_score":0.72824115},"labels":[],"label_agreement":null},{"id":"W4411417552","doi":"10.1136/jitc-2025-012391","title":"Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy","year":2025,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Glycomics Network; Canadian Institutes of Health Research; Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Mizutani Foundation for Glycoscience","keywords":"Immunotherapy; Immune system; Tumor microenvironment; Cancer immunotherapy; Cancer; Context (archaeology); Immune checkpoint; Immunology; Medicine; Cancer research; Cancer immunology; Biology; Internal medicine","score_opus":0.023587444712330544,"score_gpt":0.3899546320237682,"score_spread":0.36636718731143764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411417552","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004976662,0.9955249,0.0004623674,0.00015218105,0.0011074218,0.0016250917,0.00024319305,0.000013404797,0.00037377482],"genre_scores_gemma":[0.000036767455,0.9868445,0.00068429054,0.00018457472,0.00043425188,0.00049712835,0.000119733195,0.00012774188,0.011071059],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968467,0.00026489788,0.0013960404,0.00055482384,0.00033505674,0.00060251256],"domain_scores_gemma":[0.99739546,0.0001198073,0.0011565434,0.00074088963,0.00048760374,0.00009969325],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008317302,0.00065114273,0.0018214961,0.0004636773,0.00034190103,0.000113196365,0.00084694294,0.00060428964,0.00031531736],"category_scores_gemma":[0.0001513553,0.0005336135,0.0012149912,0.00031459698,0.00031844812,0.000016609594,0.00015160875,0.00070941716,0.000004651212],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011293145,0.000105427745,0.000009628993,0.003558228,0.002178431,0.0000038302583,0.000034717934,0.0000019302934,0.010713759,0.00006172849,0.00192383,0.98027915],"study_design_scores_gemma":[0.0028278627,0.00074743864,0.000037420763,0.004782222,0.000164125,0.00017621546,0.000023393393,0.0000026329924,0.0032864427,0.0001342594,0.98732847,0.0004895192],"about_ca_topic_score_codex":0.00007771136,"about_ca_topic_score_gemma":0.000028160619,"teacher_disagreement_score":0.9854046,"about_ca_system_score_codex":0.00013446153,"about_ca_system_score_gemma":0.0014599073,"threshold_uncertainty_score":0.9997115},"labels":[],"label_agreement":null},{"id":"W4411534009","doi":"10.1136/jitc-2024-010739","title":"SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Clinical trial; Drug development; Biomarker; Medicine; Drug; Immunotherapy; Intensive care medicine; Cancer; Oncology; Internal medicine; Pharmacology","score_opus":0.021173314319618167,"score_gpt":0.36744862160887887,"score_spread":0.3462753072892607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411534009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95771474,0.025784697,0.0034608871,0.008699095,0.002038614,0.0014651127,0.000024589648,0.000036743022,0.0007755295],"genre_scores_gemma":[0.978532,0.003240542,0.005294786,0.0072755916,0.00022518098,0.00034864465,0.0000067879146,0.000072352595,0.0050040763],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978038,0.000049524944,0.0008847486,0.00033841244,0.0004598487,0.00046366442],"domain_scores_gemma":[0.9984584,0.000070031485,0.00037568036,0.00028109673,0.00066986895,0.00014491405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053811894,0.00031268588,0.00055044907,0.0005450658,0.00035986607,0.000090190144,0.00023182674,0.00007887134,0.00039896852],"category_scores_gemma":[0.000023528131,0.00025949164,0.00040227498,0.00054934784,0.00007218648,0.0001458296,0.000032911707,0.00023676504,0.000002784453],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034581605,0.0007792042,0.0020005049,0.00012554017,0.004786877,0.000011561474,0.012930974,0.0000460132,0.3401602,0.00006079717,0.023566471,0.58095026],"study_design_scores_gemma":[0.021159803,0.0014502344,0.015097811,0.0012830618,0.00016939949,0.000027170405,0.0028131912,0.000032100485,0.31072298,0.00017369051,0.6466377,0.00043286802],"about_ca_topic_score_codex":0.00045886278,"about_ca_topic_score_gemma":0.000038340786,"teacher_disagreement_score":0.62307125,"about_ca_system_score_codex":0.0016401041,"about_ca_system_score_gemma":0.0011327125,"threshold_uncertainty_score":0.99998575},"labels":[],"label_agreement":null},{"id":"W4412940298","doi":"10.1136/jitc-2025-012659","title":"Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; London Health Sciences Centre; Lawson Health Research Institute; Western University","funders":"Canadian Cancer Society; Lotte and John Hecht Memorial Foundation; London Health Sciences Centre","keywords":"Medicine; Internal medicine; Transplantation; Melanoma; Post-hoc analysis; Oncology; Fecal bacteriotherapy; Gastroenterology; Progression-free survival; Surgery; Overall survival; Clostridium difficile; Antibiotics; Cancer research","score_opus":0.0198921299049257,"score_gpt":0.33525427973694233,"score_spread":0.3153621498320166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412940298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956546,0.0009383441,0.0002676868,0.0004985293,0.00041744622,0.0020208755,0.00018349779,0.000004627329,0.000014419345],"genre_scores_gemma":[0.9982721,0.0010244825,0.00035230213,0.00013523588,0.00002698224,0.000045593373,0.000041942476,0.000022784601,0.00007857929],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99838555,0.00011901783,0.0008562556,0.0001897466,0.00022247744,0.0002269752],"domain_scores_gemma":[0.99877334,0.00009023167,0.00068209023,0.00017082434,0.00025934508,0.000024171137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004293419,0.00018511814,0.0005181423,0.00029776833,0.00008704769,0.000014156012,0.00012355876,0.000095725765,0.000008906025],"category_scores_gemma":[0.000013559367,0.00011620493,0.0001413212,0.0005702282,0.000109093955,0.00013283348,0.000003632542,0.00022791828,1.06772955e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6826872,0.0011146617,0.02487733,0.00014470326,0.00025134787,0.0000018147808,0.00039572595,0.00010213433,0.26266533,0.0000016965874,0.000012823292,0.02774522],"study_design_scores_gemma":[0.6819404,0.011011449,0.21701494,0.0022023988,0.00015527257,0.00001581212,0.00013299643,0.00051417307,0.08640488,0.000007348073,0.0004237338,0.00017659584],"about_ca_topic_score_codex":0.0015904054,"about_ca_topic_score_gemma":0.0017404951,"teacher_disagreement_score":0.19213761,"about_ca_system_score_codex":0.00045348177,"about_ca_system_score_gemma":0.0007035941,"threshold_uncertainty_score":0.47386995},"labels":[],"label_agreement":null},{"id":"W4412940313","doi":"10.1136/jitc-2024-010777","title":"Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"American Society of Clinical Oncology","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Melanoma; Pharmacodynamics; Internal medicine; Pharmacokinetics; Clinical endpoint; Oncology; Adverse effect; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Cancer; Clinical trial; Gastroenterology; Immunotherapy; Cancer research","score_opus":0.00830114669991602,"score_gpt":0.29845379804716465,"score_spread":0.29015265134724866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412940313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774645,0.016127408,0.0005160617,0.001847106,0.0007776154,0.0028035967,0.00027706256,0.000008998822,0.00017765132],"genre_scores_gemma":[0.9914329,0.0051505924,0.000944557,0.0011162402,0.00026114224,0.00025050243,0.00005420205,0.000044792803,0.0007450881],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977364,0.00014066177,0.0011272436,0.0003218276,0.00035407627,0.00031982054],"domain_scores_gemma":[0.99796885,0.0006147589,0.0007297738,0.00039130435,0.00023277008,0.000062558014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086229644,0.00030476265,0.000978582,0.00017521449,0.00017733734,0.00005366618,0.00022125678,0.00013311715,0.00008620942],"category_scores_gemma":[0.000052155283,0.00017914923,0.00033974432,0.00029432698,0.000336013,0.00014402605,0.000013628577,0.00035262288,1.9769149e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8797854,0.0005515186,0.0028792587,0.000025186155,0.00065930287,0.0000033722117,0.00090415456,0.000016119639,0.015531855,0.0000043139953,0.0012898698,0.098349646],"study_design_scores_gemma":[0.93437696,0.003448522,0.030085826,0.0004961749,0.00020567111,0.000002420006,0.00015944595,0.00010384354,0.015617081,0.00014976054,0.015151164,0.00020315927],"about_ca_topic_score_codex":0.00089172897,"about_ca_topic_score_gemma":0.00013547952,"teacher_disagreement_score":0.09814648,"about_ca_system_score_codex":0.00021084827,"about_ca_system_score_gemma":0.0005043895,"threshold_uncertainty_score":0.73054934},"labels":[],"label_agreement":null},{"id":"W4413107688","doi":"10.1136/jitc-2025-011475","title":"First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Immunogenicity; CD8; Pharmacokinetics; Pharmacodynamics; Cytotoxic T cell; Agonist; Tolerability; Adverse effect; Pharmacology; Receptor; Antibody; CD28; T cell; Internal medicine; Immune system; Immunology; In vitro; Chemistry","score_opus":0.011388662550833616,"score_gpt":0.34751192627272615,"score_spread":0.33612326372189255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413107688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948098,0.0019075811,0.00002764095,0.00064361724,0.00057571556,0.0018018584,0.00003246819,0.000007342761,0.00019398988],"genre_scores_gemma":[0.9981919,0.00039869768,0.000046997862,0.0004972735,0.00004414401,0.00012815851,0.000002678596,0.000032172375,0.00065798644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983446,0.000047185473,0.00075173465,0.0001934483,0.0004125411,0.00025049626],"domain_scores_gemma":[0.99862266,0.00006894916,0.0005955986,0.00039519017,0.00028382576,0.000033779783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002558531,0.00021250873,0.0005756457,0.00022844756,0.0002567588,0.000018061011,0.00026526002,0.000055627046,0.00010561174],"category_scores_gemma":[0.0000175254,0.00012711635,0.00025529714,0.0004090403,0.00013909965,0.000077757635,0.0000136329345,0.00027484415,1.0826651e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26120016,0.024367196,0.32067025,0.00063583633,0.0047040684,0.000011909746,0.0061714943,0.0015304348,0.09640766,0.000104246115,0.0017952131,0.28240156],"study_design_scores_gemma":[0.18010166,0.026318397,0.7200613,0.0043430603,0.00028862222,0.000007323389,0.0015478098,0.000053379565,0.046833288,0.00014861624,0.019953396,0.00034316987],"about_ca_topic_score_codex":0.00019206913,"about_ca_topic_score_gemma":0.0003499985,"teacher_disagreement_score":0.39939103,"about_ca_system_score_codex":0.00034512047,"about_ca_system_score_gemma":0.000298699,"threshold_uncertainty_score":0.51836544},"labels":[],"label_agreement":null},{"id":"W4413112190","doi":"10.1136/jitc-2025-012478","title":"Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"EMD Serono; LEO Pharma; PharmaMar; Servier; Eisai; Fred Hutchinson Cancer Research Center; Regeneron Pharmaceuticals; Springworks Therapeutics; Advanced Accelerator Applications; Incyte; Les Laboratories Pierre Fabre; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Merkel cell carcinoma; Tolerability; Internal medicine; Clinical endpoint; Phases of clinical research; Oncology; Gastroenterology; Chemotherapy; Surgery; Carcinoma; Adverse effect; Clinical trial","score_opus":0.013898712855573774,"score_gpt":0.34620984755114265,"score_spread":0.3323111346955689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413112190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807196,0.01719739,0.00008252212,0.00011159864,0.00037099386,0.0013654584,0.00006942853,0.0000053391345,0.00007765778],"genre_scores_gemma":[0.9974457,0.0011364688,0.0003903451,0.00010607191,0.000018024795,0.000073057425,0.000006477876,0.000026614927,0.0007972204],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984835,0.000050786864,0.00071651576,0.00016825726,0.000350484,0.00023048629],"domain_scores_gemma":[0.99880993,0.00004905002,0.0004787148,0.0002200644,0.0003672803,0.000074943615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016358313,0.0001849289,0.00060289993,0.00028673402,0.00009198102,0.0000071377412,0.00013155688,0.000044116216,0.00010840996],"category_scores_gemma":[0.000023559503,0.00011170316,0.000142976,0.00032587783,0.00006326695,0.00009139679,0.000015834587,0.00022700462,1.6045857e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29816306,0.055215295,0.07746309,0.0008260596,0.0022759233,0.00004026473,0.0035645885,0.00040115774,0.01327394,0.000010035423,0.0010588702,0.54770774],"study_design_scores_gemma":[0.4944687,0.16178015,0.30917403,0.0044688233,0.0023433282,0.000009143716,0.0031755227,0.0003138577,0.017062563,0.00014896654,0.006480389,0.0005745369],"about_ca_topic_score_codex":0.00013772234,"about_ca_topic_score_gemma":0.000070105765,"teacher_disagreement_score":0.54713315,"about_ca_system_score_codex":0.00014658607,"about_ca_system_score_gemma":0.0006466873,"threshold_uncertainty_score":0.45551226},"labels":[],"label_agreement":null},{"id":"W4413863367","doi":"10.1136/jitc-2025-012083","title":"HLA Ligand Atlas DIA: extending the benign immunopeptidomics resource with increased sensitivity through data-independent acquisition mass spectrometry","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"vaccines and immunoinformatics approaches","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"German Network for Bioinformatics Infrastructure; Boehringer Ingelheim Stiftung; Deutsche Forschungsgemeinschaft; Bosch-Forschungsstiftung","keywords":"Atlas (anatomy); Mass spectrometry; Medicine; Ligand (biochemistry); Computer science; Computational biology; Information retrieval; Data mining; Internal medicine; Chemistry; Biology; Receptor; Chromatography","score_opus":0.013838170003798262,"score_gpt":0.2896823738356229,"score_spread":0.2758442038318246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413863367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91412735,0.020970417,0.062690236,0.00061944,0.00031105804,0.0005059139,0.00012520123,0.0000076781735,0.00064268],"genre_scores_gemma":[0.98309714,0.009587259,0.005581539,0.00061728526,0.0003561628,0.000031908858,0.00016316348,0.000040494542,0.00052507827],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876106,0.00008116154,0.0004518286,0.00021863874,0.0002102698,0.00027705496],"domain_scores_gemma":[0.99861175,0.00007200001,0.00043166985,0.0006917903,0.0001665524,0.000026230866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094101415,0.0002134735,0.00029937577,0.00006723977,0.0003735702,0.00012585454,0.00046462304,0.00012350977,0.000011573935],"category_scores_gemma":[0.000030704527,0.00013868915,0.00015784171,0.00016436166,0.000084051506,0.000042814827,0.00010758016,0.00024154829,3.5717048e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027387107,0.000071698116,0.0007777029,0.000054534663,0.0011793446,0.0000014917234,0.00016147266,0.00061115914,0.9834352,0.00017998242,0.0029070692,0.007881641],"study_design_scores_gemma":[0.0062966854,0.00080175046,0.007442631,0.0003197954,0.00025968745,0.0001573602,0.0012463442,0.0011440291,0.85367376,0.00069100346,0.12753662,0.00043035185],"about_ca_topic_score_codex":0.000083152205,"about_ca_topic_score_gemma":0.00003866894,"teacher_disagreement_score":0.12976146,"about_ca_system_score_codex":0.0000680984,"about_ca_system_score_gemma":0.0002101898,"threshold_uncertainty_score":0.56555796},"labels":[],"label_agreement":null},{"id":"W4413872129","doi":"10.1136/jitc-2024-011331","title":"Nanofilament immunotherapy induces potent antitumor vaccine responses","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Institute for Research in Immunology and Cancer; Université de Montréal; Université de Sherbrooke","funders":"Génome Québec","keywords":"Medicine; Immunotherapy; Immunology; Cancer research; Pharmacology; Immune system","score_opus":0.029796957230199976,"score_gpt":0.40757027692994685,"score_spread":0.37777331969974687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413872129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91512096,0.06716247,0.00038787065,0.014678232,0.0011473934,0.0006417169,0.000049851875,0.00001827618,0.00079324417],"genre_scores_gemma":[0.8210624,0.09313921,0.0031810878,0.0046885507,0.0007048264,0.0001590455,0.000012724638,0.00007075645,0.07698139],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815935,0.00007161709,0.0006904975,0.00020369134,0.00047575543,0.00039908814],"domain_scores_gemma":[0.99866533,0.00018977464,0.00027442334,0.00025953652,0.0005212655,0.00008964334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000610758,0.00022432853,0.00060253066,0.0004117641,0.00028651254,0.000049866714,0.0002660951,0.00009721251,0.000683561],"category_scores_gemma":[0.00004503873,0.00015697429,0.00046166024,0.00029442637,0.00009363171,0.0001021426,0.000029067854,0.00033227284,0.0000035386508],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027157078,0.00034368932,0.0099203875,0.00019189094,0.0014704743,0.000017901562,0.00023444033,0.000010401942,0.7420593,0.0005908106,0.01009484,0.20790881],"study_design_scores_gemma":[0.0076783006,0.0015692146,0.10140534,0.00089005014,0.00007700921,0.00011814947,0.00014937812,0.000035770016,0.32044658,0.0010517219,0.56637824,0.00020026295],"about_ca_topic_score_codex":0.00021179803,"about_ca_topic_score_gemma":0.00001226838,"teacher_disagreement_score":0.5562834,"about_ca_system_score_codex":0.00018548746,"about_ca_system_score_gemma":0.0007112791,"threshold_uncertainty_score":0.7484514},"labels":[],"label_agreement":null},{"id":"W4414257148","doi":"10.1136/jitc-2025-012496","title":"MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nuclear Laboratories; Western University","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Government of Ontario; Cancer Research Society","keywords":"Tumor microenvironment; Regulatory T cell; T cell; Bladder cancer; Tumor cells; Cell; Tumor progression; Cancer","score_opus":0.011157772161539669,"score_gpt":0.31164109957560004,"score_spread":0.30048332741406036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414257148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.934872,0.059360076,0.00029614198,0.0004946409,0.004238968,0.0005515158,0.000007894389,0.000010450538,0.00016836332],"genre_scores_gemma":[0.9606721,0.011170828,0.00025289983,0.00059989264,0.00006125319,0.00015879817,0.000011948427,0.00003070301,0.027041601],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990421,0.00007259841,0.00045802738,0.00017336597,0.000043098866,0.00021080069],"domain_scores_gemma":[0.9994062,0.000036142217,0.00034931165,0.00012541554,0.00007199962,0.000010911093],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024760852,0.00014755107,0.00024411858,0.00019988038,0.00015611696,0.000020307298,0.00009653258,0.00012444469,0.0009809057],"category_scores_gemma":[0.0000048311576,0.00012417098,0.00010207118,0.00008465906,0.00008537273,0.00015286497,0.000019560941,0.00027276503,0.0000040323384],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015037354,0.00013963039,0.0018815234,0.00005424583,0.00014805724,3.646264e-7,0.00030125436,0.00012619885,0.93015313,0.000014467933,0.0053707333,0.060306646],"study_design_scores_gemma":[0.0029569308,0.00015861432,0.016702252,0.00025222427,0.000031172316,0.0000062887802,0.00009755889,0.00004193602,0.7017996,0.0000650033,0.27778834,0.00010007753],"about_ca_topic_score_codex":0.00008119053,"about_ca_topic_score_gemma":0.000020463565,"teacher_disagreement_score":0.2724176,"about_ca_system_score_codex":0.00020280096,"about_ca_system_score_gemma":0.00010120943,"threshold_uncertainty_score":0.99993235},"labels":[],"label_agreement":null},{"id":"W4414444386","doi":"10.1136/jitc-2024-010792","title":"T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"European Regional Development Fund; Instituto de Salud Carlos III; Generalitat de Catalunya; Agència de Gestió d'Ajuts Universitaris i de Recerca; Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona; Fundación Científica Asociación Española Contra el Cáncer","keywords":"Immune system; Immunogenicity; Peripheral blood mononuclear cell; Monoclonal antibody; Antigen; Antibody; Chimeric antigen receptor; Immunotherapy","score_opus":0.0330377316831344,"score_gpt":0.38629744154714707,"score_spread":0.35325970986401267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414444386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91959614,0.06400789,0.0016296176,0.010753636,0.00078108296,0.002609964,0.0003435271,0.000053562344,0.00022454861],"genre_scores_gemma":[0.68119293,0.12615038,0.0083978055,0.005206827,0.00044045804,0.0017651793,0.00005686568,0.0003412517,0.1764483],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973352,0.00026369258,0.0010267118,0.0004073344,0.00034990482,0.00061716296],"domain_scores_gemma":[0.9961493,0.0016241452,0.00047825451,0.00070566515,0.0008747175,0.0001679228],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019237226,0.00038941312,0.00097293354,0.0006823561,0.0005177614,0.00010050996,0.00038822027,0.00023989649,0.00042419147],"category_scores_gemma":[0.00017417579,0.000316898,0.000718369,0.0004283178,0.00024282245,0.00013752539,0.000036781334,0.00045085276,0.0000013586272],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054494828,0.00033267474,0.0032383092,0.00011668359,0.0010870302,0.0000021276842,0.00048300385,0.00003095527,0.8429961,0.00004323273,0.003684439,0.09349057],"study_design_scores_gemma":[0.017799461,0.0014864145,0.086710736,0.00016595423,0.00012162219,0.000016405696,0.0001688288,0.000095168456,0.54096013,0.00052341796,0.35167468,0.00027716387],"about_ca_topic_score_codex":0.00007296849,"about_ca_topic_score_gemma":0.0000063511084,"teacher_disagreement_score":0.34799024,"about_ca_system_score_codex":0.0003766637,"about_ca_system_score_gemma":0.0014420304,"threshold_uncertainty_score":0.9999283},"labels":[],"label_agreement":null},{"id":"W4415655717","doi":"10.1136/jitc-2025-012355","title":"Acetaminophen interactions with immune checkpoint inhibitors: guilt by association?","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Acetaminophen; Immune system; Immune checkpoint; Causality (physics); Drug; Nivolumab","score_opus":0.009689728968450075,"score_gpt":0.3244373792283184,"score_spread":0.31474765025986834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415655717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8648072,0.08020848,0.0027322231,0.041995645,0.004617436,0.0016865177,0.00015551965,0.00007936285,0.0037176346],"genre_scores_gemma":[0.84095806,0.021208366,0.0042510964,0.0044388743,0.0010592205,0.0005239255,0.000052182175,0.00014771296,0.12736054],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983311,0.000037996673,0.00081032026,0.00017903907,0.00034521826,0.00029631535],"domain_scores_gemma":[0.998137,0.0001306872,0.00075073563,0.00035697882,0.0005715291,0.000053074382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000543262,0.0002099445,0.00051050686,0.00021904573,0.0002208897,0.000059283608,0.00023127197,0.000113301976,0.00058951986],"category_scores_gemma":[0.00007062474,0.0001567054,0.00046559295,0.00036160144,0.000078512174,0.00019143488,0.000019020526,0.00035373177,0.0000015086696],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013002664,0.0003618759,0.014790799,0.00011907911,0.0044281716,0.0000016318874,0.00044100865,0.00001084513,0.8116966,0.000025240734,0.095294505,0.059827592],"study_design_scores_gemma":[0.012899347,0.0010216091,0.015316847,0.001053483,0.00029429028,0.000038011578,0.00029364138,0.00002399478,0.29974768,0.00020929273,0.6688913,0.00021050463],"about_ca_topic_score_codex":0.00030093777,"about_ca_topic_score_gemma":0.000051414503,"teacher_disagreement_score":0.5735968,"about_ca_system_score_codex":0.0010539643,"about_ca_system_score_gemma":0.00053573336,"threshold_uncertainty_score":0.6454829},"labels":[],"label_agreement":null},{"id":"W4415896981","doi":"10.1136/jitc-2024-011382","title":"Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics and Genomics of Geneva; Université de Genève; Ligue Genevoise Contre le Cancer; University of Pennsylvania; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Fondation ISREC; Institut National Du Cancer; National Science Foundation; McMaster University; Fondation privée des Hôpitaux universitaires de Genève","keywords":"Bystander effect; Glioblastoma; Extracellular matrix; Cytotoxic T cell; Domain (mathematical analysis); T cell; Extracellular","score_opus":0.036324732330809476,"score_gpt":0.3776838244149533,"score_spread":0.34135909208414383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415896981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8887851,0.098922715,0.0075430903,0.0019033328,0.000909342,0.0014052079,0.00003632587,0.000015553478,0.00047931005],"genre_scores_gemma":[0.9415088,0.03285331,0.002553787,0.0001175054,0.00049622473,0.00012511965,0.000003592325,0.000113329465,0.02222831],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99740577,0.00017202216,0.0010346023,0.00025609502,0.00069526286,0.0004362445],"domain_scores_gemma":[0.99796236,0.00054464355,0.0004215759,0.00043545695,0.00056432624,0.0000716452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021484327,0.00022067696,0.0007562087,0.00033548384,0.00011794865,0.000033272212,0.0003894246,0.00014065807,0.00063907495],"category_scores_gemma":[0.000029280109,0.00013426371,0.00037043676,0.00056400686,0.00027996814,0.00011825976,0.00003033752,0.000718656,4.9665965e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018047689,0.00031604696,0.0022465796,0.00018515674,0.00062435365,0.000013540224,0.00083652604,0.008138172,0.931252,0.00038298592,0.0010434982,0.036913477],"study_design_scores_gemma":[0.042265106,0.0069470047,0.005228573,0.0036274046,0.00033394355,0.00011674947,0.0033312344,0.01913554,0.6181233,0.003530615,0.29660916,0.00075140165],"about_ca_topic_score_codex":0.00012775697,"about_ca_topic_score_gemma":0.00005511711,"teacher_disagreement_score":0.3131287,"about_ca_system_score_codex":0.00022784651,"about_ca_system_score_gemma":0.0006078823,"threshold_uncertainty_score":0.6997422},"labels":[],"label_agreement":null},{"id":"W4416135787","doi":"10.1136/jitc-2025-012138","title":"Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Helsinki Institute of Life Science, Helsingin Yliopisto; Suomen Farmaseuttinen Yhdistys; Business Finland; Biocenter Finland; Syöpäsäätiö; Sigrid Juséliuksen Säätiö; Jane ja Aatos Erkon Säätiö; Academy of Finland; Medicinska Understödsföreningen Liv och Hälsa; Helsingin Yliopisto","keywords":"Tumor microenvironment; Downregulation and upregulation; Cancer immunotherapy; Immune system; Extracellular vesicles; Immunotherapy; Cancer; Microvesicles","score_opus":0.004744796303308903,"score_gpt":0.29958771211942237,"score_spread":0.29484291581611344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416135787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8123218,0.16175902,0.024333153,0.00028126157,0.00027664195,0.000958419,0.00005848624,0.000003709927,0.0000075014323],"genre_scores_gemma":[0.9864793,0.0113287,0.0007421953,0.00016895741,0.00012293081,0.00042833574,0.000020040869,0.00005856869,0.00065097195],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859715,0.00011019733,0.0006411825,0.0002379471,0.00015659827,0.00025690603],"domain_scores_gemma":[0.99895823,0.00009368255,0.00048803468,0.0003306804,0.00010287267,0.000026524429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085234403,0.00020694964,0.00032230248,0.00007175775,0.000106348234,0.000020728574,0.00035039897,0.000102663405,0.00002059452],"category_scores_gemma":[0.000024792294,0.0001573506,0.0003349026,0.00009397406,0.00012886686,0.000012060966,0.000021215023,0.00011496912,6.961864e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069116117,0.000086129934,0.00047211116,0.00012646151,0.0002574166,1.286027e-7,0.00009668154,0.0042063016,0.9038811,0.00001790889,0.0005819037,0.083362274],"study_design_scores_gemma":[0.0056266263,0.00048695627,0.000554923,0.0002156785,0.00005683741,0.0000012489929,0.00003757129,0.0005602219,0.96534765,0.00022884803,0.026739055,0.00014435854],"about_ca_topic_score_codex":0.000056832814,"about_ca_topic_score_gemma":0.000022339938,"teacher_disagreement_score":0.1741575,"about_ca_system_score_codex":0.000108052234,"about_ca_system_score_gemma":0.00014251073,"threshold_uncertainty_score":0.6416572},"labels":[],"label_agreement":null},{"id":"W4416827100","doi":"10.1136/jitc-2025-013214","title":"JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; St Mary's Hospital Centre; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Adverse effect; Prospective cohort study; Refractory (planetary science); Immune checkpoint; Cohort study; Clinical trial; Immune system; Safety profile","score_opus":0.011013981859586493,"score_gpt":0.31381246585524136,"score_spread":0.30279848399565484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416827100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91081333,0.07951264,0.00015411907,0.0011249778,0.0016743417,0.006573477,0.00005950931,0.0000195435,0.00006804314],"genre_scores_gemma":[0.9812207,0.014599157,0.00024865326,0.00015312481,0.00022208886,0.0012484752,0.00000704905,0.000064201406,0.0022365148],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99730283,0.00006971717,0.0016120671,0.0003383348,0.00033474318,0.00034228797],"domain_scores_gemma":[0.99783665,0.00026082635,0.0008901108,0.0004103738,0.0005122899,0.00008975925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010354214,0.00036114544,0.0010196064,0.0003395942,0.00036126067,0.000018118666,0.00017502902,0.00014474077,0.00011235204],"category_scores_gemma":[0.00006423178,0.00023645669,0.0008280388,0.00039870763,0.00016672123,0.00014094057,0.000024385658,0.00024578228,3.3193908e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08666905,0.0031227537,0.26587227,0.00032813716,0.021983923,0.0000042379243,0.012684195,0.00008562171,0.37683594,0.0000129446535,0.00044996594,0.23195097],"study_design_scores_gemma":[0.04760064,0.014519282,0.7929598,0.0014900048,0.0012440031,0.00002311585,0.005018161,0.00005006012,0.1055862,0.00017347037,0.030969141,0.00036608492],"about_ca_topic_score_codex":0.00089529593,"about_ca_topic_score_gemma":0.000077347766,"teacher_disagreement_score":0.52708757,"about_ca_system_score_codex":0.0007673393,"about_ca_system_score_gemma":0.0007573205,"threshold_uncertainty_score":0.9642424},"labels":[],"label_agreement":null},{"id":"W4416910450","doi":"10.1136/jitc-2025-013420","title":"The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"School of Medicine, Emory University; National Cancer Institute; National Institutes of Health; University of Connecticut Health Center; Society for Immunotherapy of Cancer; Ohio State University; University of Pittsburgh; Emory University; Massachusetts General Hospital","keywords":"Tumor-infiltrating lymphocytes; T cell; Immunotherapy; Cancer; Immune system; Immune checkpoint; Adoptive cell transfer; Blockade; Clinical trial","score_opus":0.027962384859575633,"score_gpt":0.3661467783282843,"score_spread":0.33818439346870866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416910450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90732557,0.07966732,0.00012990828,0.010148488,0.0008324601,0.0005173015,0.0000249506,0.000010619918,0.0013433554],"genre_scores_gemma":[0.9787475,0.016766457,0.00029829287,0.00062949985,0.00043953696,0.000049830036,8.751475e-7,0.000028953895,0.0030390578],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815995,0.00009738576,0.0005555504,0.00016509171,0.00068152585,0.00034047893],"domain_scores_gemma":[0.9950985,0.0030844575,0.00039729616,0.0004459791,0.0009263206,0.00004747058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023141254,0.000137779,0.00041008342,0.00015563412,0.00075172074,0.0001049403,0.00053973903,0.00003664606,0.00044325014],"category_scores_gemma":[0.00049020903,0.00007377641,0.00039259237,0.00058858737,0.0011804077,0.000121788995,0.000037006554,0.00031494536,4.4181965e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003302473,0.00008402943,0.010541046,0.000029428918,0.0005778456,0.0000016738757,0.002781126,0.000024820014,0.79751015,0.00049449527,0.0056549036,0.178998],"study_design_scores_gemma":[0.0045719496,0.00041178684,0.069812514,0.0012822027,0.00011893261,0.00004760367,0.014181727,0.00046150995,0.76905644,0.003205481,0.13664985,0.0002000383],"about_ca_topic_score_codex":0.00068342296,"about_ca_topic_score_gemma":0.00005887805,"teacher_disagreement_score":0.17879796,"about_ca_system_score_codex":0.00042247784,"about_ca_system_score_gemma":0.0023153466,"threshold_uncertainty_score":0.5781704},"labels":[],"label_agreement":null},{"id":"W4416931943","doi":"10.1136/jitc-2025-013518","title":"Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Perelman School of Medicine, University of Pennsylvania; Children's Hospital of Philadelphia; Children's National Hospital; Universitat de Barcelona; University of Pennsylvania; Gilead Sciences; Bristol-Myers Squibb","keywords":"Transformative learning; Genetically modified organism; Cancer immunotherapy; Ethical issues; Bridge (graph theory); Translational research; Genetically engineered; Public funding","score_opus":0.15005957271258458,"score_gpt":0.39586612709767544,"score_spread":0.24580655438509086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416931943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91466,0.023053478,0.042800978,0.011199456,0.0006802414,0.0026540873,0.000025266227,0.00003354776,0.0048929485],"genre_scores_gemma":[0.8164891,0.059449248,0.028750198,0.014867945,0.0012281579,0.0010971194,0.000008676399,0.00025364727,0.077855915],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99839646,0.00004571464,0.00047280645,0.0002923322,0.0003588067,0.00043385717],"domain_scores_gemma":[0.99907255,0.00018684402,0.00012124424,0.00030617087,0.0001726229,0.00014054791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005122369,0.00021558016,0.0005016737,0.00035379597,0.00020029121,0.00021616966,0.00032249655,0.00010534606,0.00053509825],"category_scores_gemma":[0.000025938452,0.00017504282,0.00019848859,0.00026231498,0.0000657745,0.00019739683,0.000076541204,0.00030574022,0.0000012333059],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008984148,0.00011744364,0.00043722396,0.00023893167,0.00058538246,0.0000022683605,0.0013020344,0.0019490303,0.38230735,0.00007966528,0.001736858,0.6022597],"study_design_scores_gemma":[0.0038931854,0.0007285309,0.00366144,0.00039368423,0.000055352095,0.000013165141,0.0002952022,0.000090800946,0.7607763,0.0018345905,0.22806308,0.0001946682],"about_ca_topic_score_codex":0.00015283519,"about_ca_topic_score_gemma":0.000029637245,"teacher_disagreement_score":0.602065,"about_ca_system_score_codex":0.00024016759,"about_ca_system_score_gemma":0.00030428523,"threshold_uncertainty_score":0.7138039},"labels":[],"label_agreement":null},{"id":"W4417535946","doi":"10.1136/jitc-2025-012280","title":"Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI)","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Single-cell and spatial transcriptomics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Johns Hopkins University","keywords":"Checklist; Multiplex; Standardization; Best practice; Immunotherapy; Biomarker; Cluster analysis","score_opus":0.019491286129122657,"score_gpt":0.3678711952094522,"score_spread":0.34837990908032956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417535946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7542619,0.13372284,0.10646554,0.00030193728,0.0019760018,0.001549586,0.0016197267,0.000012285648,0.000090163405],"genre_scores_gemma":[0.92105764,0.047836892,0.026645012,0.00034518793,0.0005555928,0.00073602464,0.00011314824,0.00014843045,0.0025620912],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99692416,0.000023903496,0.0020595915,0.0003151845,0.00029648477,0.00038066495],"domain_scores_gemma":[0.9945194,0.00010621158,0.0029419477,0.00042826636,0.0019659488,0.00003821165],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001388607,0.00029716615,0.00079571386,0.00006910336,0.00025447144,0.000024385849,0.00049316604,0.0002915153,0.000032324577],"category_scores_gemma":[0.00025013895,0.00027701625,0.0015401832,0.00013383297,0.0002457341,0.00001599309,0.000023487728,0.00016962674,1.0918125e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065388824,0.00016479589,0.0021953026,0.0007027364,0.0017504808,8.3985014e-8,0.0003177863,0.00027738838,0.9258083,0.000034941193,0.00349118,0.05871809],"study_design_scores_gemma":[0.006253082,0.00070266885,0.00057971064,0.00050182117,0.00011678535,0.0000028676445,0.00015354421,0.0002846446,0.8863139,0.00021397173,0.10463129,0.0002456941],"about_ca_topic_score_codex":0.00040359257,"about_ca_topic_score_gemma":0.000041633775,"teacher_disagreement_score":0.16679572,"about_ca_system_score_codex":0.0002278115,"about_ca_system_score_gemma":0.001521647,"threshold_uncertainty_score":0.99996823},"labels":[],"label_agreement":null},{"id":"W4417539105","doi":"10.1136/jitc-2025-012205","title":"Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Cancer Institute; Canadian Institutes of Health Research; Foundation Medicine; EMD Serono; Genentech; National Institutes of Health; Mirati Therapeutics; Regeneron Pharmaceuticals; Gilead Sciences; GlaxoSmithKline; Amgen; Pfizer; Society for Immunotherapy of Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lung cancer; Selection (genetic algorithm); Tumor microenvironment; Smoking history; Cancer; Differential (mechanical device)","score_opus":0.013308753787749896,"score_gpt":0.3321649297811176,"score_spread":0.31885617599336774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417539105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9268314,0.059976924,0.010106307,0.00046110264,0.0010382656,0.0012913037,0.0001238748,0.000014642174,0.00015614685],"genre_scores_gemma":[0.9745899,0.015983125,0.0047744126,0.0014995387,0.000096729826,0.00042460053,0.000028621258,0.00007758702,0.0025254767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979497,0.00005702555,0.0009971955,0.00032581374,0.00031165002,0.00035857328],"domain_scores_gemma":[0.99807715,0.00015540732,0.0008565893,0.0004104467,0.00043345694,0.000066926026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025483486,0.00033534213,0.0010929252,0.0010131231,0.00010353087,0.00001589858,0.00023037208,0.00016625982,0.00048492468],"category_scores_gemma":[0.0000124798935,0.0002822207,0.00078429794,0.00059227546,0.000066418404,0.000086527485,0.000008602122,0.00030226342,1.088077e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011651395,0.0019599928,0.47300074,0.0006112032,0.010059772,0.0000032960293,0.0026509308,0.055538557,0.34377623,0.000024889796,0.0005678294,0.100155175],"study_design_scores_gemma":[0.06979379,0.0010682131,0.8155796,0.0033300046,0.0042217565,0.0000014839962,0.00022599555,0.024967369,0.074344195,0.000040609935,0.0058605354,0.0005664404],"about_ca_topic_score_codex":0.0006241251,"about_ca_topic_score_gemma":0.00043859045,"teacher_disagreement_score":0.34257886,"about_ca_system_score_codex":0.0020953573,"about_ca_system_score_gemma":0.0010677681,"threshold_uncertainty_score":0.999963},"labels":[],"label_agreement":null},{"id":"W7117233846","doi":"10.1136/jitc-2025-012235","title":"AstroID resource: a scalable, relational database structure for longitudinal biomarker discovery","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cell Image Analysis Techniques","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Genentech; National Cancer Institute; National Institutes of Health; Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Moderna; Johns Hopkins University; Division of Cancer Prevention, National Cancer Institute; Mark Foundation For Cancer Research; Regeneron Pharmaceuticals; Melanoma Research Alliance; Bristol-Myers Squibb","keywords":"Relational database; Biomarker discovery; Longitudinal data; Biomarker; Relational model; Patient data","score_opus":0.01237569453298951,"score_gpt":0.33085278266460383,"score_spread":0.3184770881316143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117233846","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4833417,0.027373414,0.48637894,0.0008715045,0.0002832978,0.0007476285,0.00064362964,0.000013585996,0.00034630558],"genre_scores_gemma":[0.9121136,0.004262343,0.05671404,0.0014761471,0.0010321431,0.00026906945,0.0011116444,0.000111865695,0.022909127],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990718,0.000027538961,0.0003590572,0.00022395879,0.00013381879,0.00018386423],"domain_scores_gemma":[0.9991223,0.00003777776,0.00025931283,0.0002859849,0.00026800903,0.000026598578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028534696,0.00014072588,0.00020796819,0.00012832192,0.00015366454,0.000052593456,0.00021312214,0.00010521152,0.000057985133],"category_scores_gemma":[0.00006354659,0.00012050457,0.00031514,0.00012291169,0.00008065705,0.000022168668,0.000028963763,0.00010198996,6.459809e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002027286,0.000046822628,0.006370607,0.00004387099,0.0007466422,3.5315514e-7,0.000008170774,0.00015461977,0.92104226,0.00010289558,0.056173496,0.013282994],"study_design_scores_gemma":[0.0020639293,0.00022494771,0.0066607334,0.00011727177,0.00013198076,0.000012136654,0.00002031524,0.0002419532,0.50470716,0.0006976333,0.48494914,0.00017280412],"about_ca_topic_score_codex":0.000021784446,"about_ca_topic_score_gemma":0.000048787097,"teacher_disagreement_score":0.4296649,"about_ca_system_score_codex":0.000046651727,"about_ca_system_score_gemma":0.00020404845,"threshold_uncertainty_score":0.49140337},"labels":[],"label_agreement":null}]}